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ABSTRACT 
Background and Aims 
Acute Pancreatitis is an inflammatol)' disorder of varied aetiology and outcome. Tumour 
necrosis factor (TNF) and interleukin-1 0 are important mediators of disease pathogenesis. 
To investigate if the TNF and IL-10 gene loci influence susceptibility to and severity of 
acute pancreatitis, 135 patients with acute pancreatitis, ethnically matched normal controls, 
and alcoholics without pancreatic disease were studied. 
Methods 
Aetiology was classified as being secondal)' to alcohol, gallstones, or idiopathic. Patients 
were stratified into groups according to disease severity by assigning an organ failure score. 
Three TNF microsatellite loci (TNFa, TNFb, and TNFc), the -308 polymorphism within the 
TNF gene, the IL-IO.G microsatellite locus, and 3 hi-allelic polymorphisms in the 5' 
flanking region of the IL-l 0 gene were typed using the polymerase chain reaction. 
Results 
There was no difference in allelic frequency of any of the cytokine gene loci between groups 
stratified according to disease severity. When patients were stratified according to aetiology 
of disease there was a decrease in the frequency of the TNFa2 allele in those patients with 
alcoholic acute pancreatitis compared to controls (14.3 vs. 35.5%, x2 =7.24, p=0.007). 
There was also a reduction in the frequency ofthe IL-IO.Gl3 allele in patients with 
alcoholic pancreatitis compared to controls (4.8 vs. 21.3%, X2 =6.46, p=O.Oll). 
Data is also presented showing that a number of haplotypes exist as well as linkage 
disequilibrium across all 4 loci of the IL-10 gene, which contrasts with findings from 
previous work. The 3 locus haplotypes GCC and AT A are in strongest linkage 
disequilibrium, as is the microsatellite allele G9 and -li17.A and G9 with the 3-locus 
haplotype AT A. 
Conclusions 
This work has identified an allele within the TNF gene locus, and an allele within the IL-
l O.G locus which have different frequencies in patients with alcohol induced acute 
pancreatitis compared to other aetiologies. This finding may in part explain individuals' 
differing susceptibility to the development of acute pancreatitis after excessive alcohol 
consumption. 
Haplotypes not previously described exist across the IL-l 0 locus. 
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I. Introduction to the pancreas and acute pancreatitis 
Human acute pancreatitis is an inflammatory disorder of the pancreas which causes 
significant morbidity and mortality. Although it was previously recognised, it was not until 
1889 that the disease was fi.1lly characterised by Reginald Fitz, the Professor of Pathological 
Anatomy at Harvard University, who published a full clinical description of acute 
pancreatitis in it's various forms of severity. He also catalogued pathological changes, both 
gross and histological, of the severe cases which died and came to postmortem (Fitz, 
1889) 
Acute pancreatitis has a varied aetiology, gallstone disease and alcohol predominating 
amongst identifiable causes, with a significant proportion being of undetermined aetiology. 
The presence of gallstones or a history of heavy alcohol consumption does not mean that 
the development of acute pancreatitis is inevitable, which indicates that there must be other 
factors involved relating to the individual or aetiological agent. 
The clinical course of the disease is often mild with only minimal associated organ 
dysfunction, but a significant proportion of patients develop severe pancreatitis which is 
associated with organ failure, systemic complications, local inflammatory and infective 
manifestations and, in up to I 0% of cases, death. 
1.1 The Normal Pancreas 
1.1.1 Gross anatomy 
The pancreas is a retroperitoneal organ situated at the level of the second lumbar vertebra. 
The gland is described as having a head, neck, body and tail (Bannister, 1995). The head, 
lying to the right ofthe midline, is closely related to the C loop of the duodenum formed by 
it's 1'1, 2"d, and 3'd parts The neck, body, and tail extend upwards to the level ofthe 12'h 
thoracic vertebra, where it is anterior to the superior pole of the left kidney and is closely 
related to the spleen. The aorta and inferior vena cava lie posterior to the gland, as do their 
branches the splenic artery and vein, which extend along the line of the body and tail. The 
I 
transverse mesocolon arises from the anterior-inferior surface. Commonly the distal bile 
duct passes through the head of the pancreas before entering the 2"d part of the duodenum. 
The pancreas is formed in the embryo from two endodermal buds arising from the second 
part of the duodenum. The smaller ventral bud forms the inferior part of the head of the 
pancreas and the uncinate process, whilst the larger dorsal bud forms the rest of the head, 
the neck, body and tail of the gland. 
This developmental process means that the pancreas has two ductal systems into which 
lobular ductules ultimately drain. The main pancreatic duct (ofWirsung) drains the ventral 
pancreas, and opens into the 2"d part of the duodenum at the ampulla of Vater, usually in 
conjunction with the common bile duct (the 'common channel') (Lankisch and Banks, 
1998b ). The duct draining the dorsal pancreas is named the accessory pancreatic duct (of 
Santorini). It communicates with the main pancreatic duct, but also opens into a separate 
minor duodenal papilla. In up to 10% of individuals the accessory duct does not fuse with 
the main pancreatic duct and may form the principal drainage of the gland; this is termed 
pancreas diviswn (Rosai, 1998). 
The blood supply of the pancreas is from multiple anastomoses formed from branches of 
the coeliac axis and superior mesenteric aiiery, whilst venous drainage is into the portal 
vein. Lymphatic drainage is extensive, draining to retroperitoneal and mesenteric nodes. 
Both divisions of the autonomic nervous system, parasympathetic and sympathetic, have 
branches supplying the gland. 
1.1.2 flistolo~ 
Both endocrine and exocrine systems are situated in the pancreas. 
The exocrine component consists of lobular units of cells called acini , formed from the cells 
which synthesise digestive enzymes, and cells that form the ductal system. Each acinus is 
formed from a single layer of acinar cells, arranged in a spherical fashion, the apex of which 
secrete enzymes into the pancreatic ductal system which originates from the centroacinar 
cells. 
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The acinar cell is a relatively large, pyramidal shaped cell with prominent microvillae on the 
luminal surface (Fig 1.1 ). [t is a highly polarised cell, the apical portion containing many 
eosinophilic zymogen granules, the basal cytoplasm being highly basophilic due to the 
presence of abundant rough endoplasmic reticulum (RER) (Stevens and Lowe, 1992). RER 
and other organelles are present in high numbers as the pancreatic acinar cell synthesises, 
stores, and secretes enzymes at a higher rate than any other cell in the body (Lankisch and 
Banks, 1998b). 
The endocrine component of the pancreas is represented by the islets of Langerhans, and a 
smaller number of endocrine cells associated with the ducts and acini. 
The islets form 1-2% ofthe adult pancreas and consist offour main cell types: 
1. P cells which secrete insulin and islet cell amyloid polypeptide (IAPP), a molecule eo-
secreted with insulin. P cells are the commonest cell type in the islet (60-70%) 
11. a cells which secrete glucagon. 
(both glucagon and insulin are involved in intermediary metabolism) 
iii. o cells which secrete somatostatin, a peptide with a broad spectmm of gastrointestinal 
activity. 
iv. PP cells are very few in number and secrete pancreatic polypeptide (PP) which reduces 
pancreatic secretion and biliary tract motility. 
The endocrine cells not contained within islets are serotonin and PP producing. 
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The acinar cell is a relatively large, pyramidal shaped cell with prominent microvillae on the 
luminal surface (Fig 2). It is a highly polarised cell, the apical portion containing many 
eosinophilic zymogen granules, the basal cytoplasm being highly basophilic due to the 
presence of abundant rough endoplasmic reticulum (RER). Mitochondria (not shown) are 
also present in large numbers due to the high activity of the cell. 
Proteins, synthesised in the RER, pass to the Golgi, where enzymes are processed and 
membrane bound into zymogen granules (pancreatic pro-enzymes) or lysosomes. 
Lysosomal enzymes are mostly segregated from the digestive pro-enzymes into their 
separate ' compar1ments' when processing occurs at the Golgi apparatus, as they can 
activate trypsinogen, and hence activate the pancreatic 'enzyme cascade'. 
In a process termed exocytosis, zymogen granules fuse with the apical cell membrane, and 
enzymes are released into the lumen. 
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1.1.3 Physiology 
As discussed the pancreas consists of exocrine and endocrine components. The endocrine 
part has little relevance to the understanding of the pathophysiology of acute pancreatitis 
and will not be discussed further. 
The exocrine portion of the gland produces a secretion which has two components: 
digestive enzymes secreted by acinar cells, and water, electrolytes and bicarbonate secreted 
by duct cells. The bicarbonate produces an alkaline pH (pH 8.0), optimum conditions for 
the function of digestive enzyme in the duodenum. 
Secretion of water, electrolytes and bicarbonate anions is stimulated by both neural and 
humoral control. Neural control is via the vagal parasympathetic nerve and humoral control 
is principally via secretin, a peptide hormone. Secretin is produced by a sub-type of mucosal 
cell, the S cell, in the crypts of Lieberkuhn of the proximal small intestine. It acts on the 
pancreatic ductal cells, via cAMP, to increase secretion. The stimulus for secretin 
production is the entry of acid into the duodenum. 
Exocrine secretion from pancreatic acinar cells is under different control. 
1.1.3.1 Acinar cell secretion 
Enzymes produced by the acinar cell include proteases, lipases, nucleases, amylase, and 
trypsin inhibitors. Some enzymes are secreted as inactive proenzymes because they are 
capable of attacking cell membranes, and require activation by trypsin, which takes place in 
the duodenal lumen. This has been termed the pancreatic enzyme cascade (Rinderknecht, 
1993) and is summarised in Figure 1.2. Trypsin is itself an enzyme produced from a 
pancreatic proenzyme, trypsinogen, by the action of enterokinase in the duodenum which 
prevents intrapancreatic activation. As well as the two endogenous protection mechanisms 
mentioned there exist a number of others to protect the pancreas from autodigestion. Some 
of these will also be mentioned in following paragraphs, but they are collectively listed here: 
1. All digestive enzymes (not lipase/amylase) are synthesised in inactive, pro-enzyme forms. 
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2. The activating enzyme (enterokinase) is physically separate from the pancreas. 
3. Digestive enzymes are compartmentalised within the acinar cell (see below). 
4. Intracellular calcium concentrations are low, inhibiting trypsinogen activation. 
5. The acinar cells secrete pancreatic secretory trypsin inhibitor (PSTI). This fits into a 
'pocket' on the trypsin molecule and inactivates it. 
6. Trypsin can autodigest itself if excessive activation occurs within the acinar cell (see 
section 3.3) 
Amylase and lipase are not harmful to the healthy pancreas, so are secreted in active form. 
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Proelastase 2 Elastase 2 
Proprotease E Protease E 
Procarboxypeptidase A Carboxypeptidase A 
Procarboxypeptidase B Carboxypeptidase B 
Prophospholipase A2 Phospholipase A2 
Procolipase Colipase 
Figure 1.2 Pancreatic enzyme cascade 
Most enzymes are secreted in pro-enzyme form., but amylase and lipase are not harmful to 
the healthy pancreas, so are secreted in active form. Trypsin activates all other pancreatic 
pro-enzymes to their active form. 
* Enterokinase or trypsin. The process is normally initiated in the brush border by 
enterokinase . Trypsin can also activate trypsinogen by the cleavage ofT AP. 
TAP - Trypsinogen activation peptide 
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1. 1.3.2 Enzyme synthesis and secretion 
Pancreatic enzymes are synthesised by the pathway common to all eukaryotic cells. RNA 
polymerase catalyses the synthesis of a complementary strand of mRNA from the startpoint 
in a gene promoter to the terminator sequence. Regulatory proteins, which can be the gene 
product acting in an autogenous fashion, interact with the RNA polymerase to control this 
step of gene expression. Ribosomes on the RER then catalyse the translation ofmRNA into 
proteins. 
Newly synthesised proteins pass through membrane enclosed compartments to the Golgi 
apparatus (Palade, 1975). Proteins that are destined for export from the cell, such as 
digestive enzymes, are packaged within a glycoprotein membrane in the form of condensing 
vacuoles. These mature into zymogen granules as they migrate towards the apex of the cell 
for subsequent release. Lysosomal enzymes such as Cathepsin B, which is capable of 
activating trypsinogen produced by the acinar cell ( Greenbaum and Hirschkowitz, 1961 ), 
are packaged in separate lysosomes during passage through the Golgi apparatus (Kornfield, 
1986; Steer and Meldolosi, 1987) which is another mechanism to prevent intracellular 
activation of damaging digestive enzymes. 
The migrated zymogen granules fuse with the acinar cell luminal membrane and contents are 
secreted into the lumen by exocytosis. This is a complex process mediated by protein kinase 
C and Ca2+ dependent protein kinase (Steer and Meldolosi, 1987). 
1.1.3.3 Control of acinar cell secretion 
Like exocrine ductal secretion, the secretion from pancreatic acinar cells is under several 
different influences. Neural control is from the parasympathetic vagal nerve, terminating in 
acetylcholine (ACh) receptors. Hormonal control is via a number of different pathways and 
the acinar cell has receptors for gastrin, cholecystokinin (CCK), secretin, and vasoactive 
intestinal polypeptide (VIP). CCK is the most potent stimulant of pancreatic enzymes. CCK 
is released by the cells of the duodenal mucosa in response to the entry of free fatty acids, 
amino acids, polypeptides, glucose, glyceride, and calcium into it's lumen (Adler et al., 
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1995). CCK acts to stimulate secretion via binding to it's own receptor (Adler et al., 1991), 
and by an interaction with the cholinergic nervous system (Nishizuka, 1984; Soudah et al., 
1992; Li and Owyang, 1994). Gastrin, a product of G cells in gastric mucosa is a weak 
stimulant of pancreatic exocrine secretion, as are secretin and VIP. 
Both CCK and ACh stimulate the breakdown of a membrane phospholipid, 
phosphatidylinositol, into diacylglycerol which activates protein kinase C , and inositol 
triphosphate which mobilises calcium to activate Ca2+ dependent protein kinase (Streb et al., 
1983). Both these kinases mediate exocytosis of digestive enzymes. 
1.2 Pancreatitis 
Inflammatory disease of the pancreas can occur in acute and chronic forms. This thesis is 
concerned with acute pancreatitis, but it will also be useful to discuss here the definition of 
chronic pancreatitis. 
1.2.1 Clinical definition of acute pancreatitis 
At a recent international symposium in Atlanta, Georgia, USA in 1992, an attempt was 
made by a group of 40 internationally recognised experts in acute pancreatic inflammatory 
disease to define and classify acute pancreatitis on a clinical basis (Bradley, 1993). The 
classification of the complications of acute pancreatitis is discussed in section I. 5. 3. 
Acute pancreatitis was defined by the Atlanta symposium as an acute inflammatmy disease 
of the pancreas, with variable involvement of other regional/issues or remote organ 
systems. Two previous symposia in Marseille, France in 1984, (Singer et al., 1985) and 
Cambridge, UK in 1983 (Sarner and Cotton, 1984) both provided a similar clinical 
definition, and recognised that the disease can occur as a single episode or be recurrent. 
1.2.2 Morphological definition of acute pancreatitis 
The Marseille consensus group also provided a morphological definition, importantly 
recognising that there was a gradation oflesions seen in acute pancreatitis. Mild pancreatitis 
is associated with interstitial oedema within the gland, and a varying degree of 
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peripancreatic fat necrosis. More severe forms of the disease are associated with extensive 
peripancreatic and intrapancreatic fat necrosis, gland necrosis and haemorrhage. Lesions can 
be localised or diffuse (Singer et al., 1985). 
Following acute pancreatitis, provided the aetiological agent and complications such as 
pseudocysts have resolved the pancreas recovers clinically, morphologically and 
functionally. 
1.2.3 Clinical definition of chronic pancreatitis 
The Marseille symposium of 1984 defined chronic pancreatitis as follows: Clinically 
characterised by recurrent or persisting abdominal pain, though chronic pancreatitis may 
present without pain. Evidence of pancreatic insufficiency e.g.: diabetes or steatorrhoea 
may be present. As with their definition of acute pancreatitis, a morphological description 
was given (Singer et al., 1985). The symposium in Cambridge, UK the previous year gives a 
more clinicopathological definition: continuing inflammatory disease of the pancreas, 
characterised by irreversible morphological change and typically causing pain and/or 
permanent loss of function (Samer and Cotton, 1984). 
1.2.4 Morphological definition of chronic pancreatitis 
The gland becomes fibrotic, areas of which may subsequently calcifY. The exocrine 
parenchyma is destroyed in a focal, segmental, or diffuse manner. Duct dilatation may be 
seen, associated with ductal strictures and/or calculi. Inflammatory cells of all different types 
are present within the substance of the gland, and there may be oedema and focal necrosis. 
Cysts and pseudocysts are often present (Singer et al., 1985). 
1.3 Epidemiology 
As the natural history of acute pancreatitis is short, incidence and prevalence rates do not 
differ. Wide variations in incidence rates are reported even within the UK, which may in 
part at least be due to methodological differences between studies. Investigators use 
differing diagnostic criteria and different methodology to identifY cases. Also, figures 
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sometimes omit cases diagnosed at autopsy, which can account for 30-40% offatal cases 
(Corfield et al., 1985) 
1.3.1 Incidence 
A study reporting cases occurring over a decade in the Bristol, UK area reported in 1985 
that the annual case rate per million was 73.0, revealing a rise in incidence over the previous 
decade from 53.8 cases per million (Corfield et al., 1985). In comparison studies in 
Scotland, UK have reported mean annual incidence rates of242 per million of the 
population (Thompson et al., 1987). Incidence rates in Scotland have also risen over the last 
twenty years (Wilson and Imrie, 1990). 
Based on these figures, there are probably up to 10,000 cases annually in the UK. 
1.3.2 Mortality rates 
Mortality rates are also subject to wide inter-study variation. The highest case mortality rate 
of20% has been reported in a study that included cases first diagnosed at autopsy. These 
accounted for 35% oftotal deaths from acute pancreatitis (Corfield et al., 1985). However 
a study also including cases diagnosed at autopsy gives an overall mortality rate of 8% 
(Mann et al., 1994). Studies from Scotland indicate that mortality rates have been falling 
over the past thirty years (Wilson and Imrie, 1990), which may reflect advances in critical 
care support and management of complications. 
It is very difficult to draw comparison between these studies due to reasons outlined above. 
Consensus opinion regards overall mortality rates to be in the region of 8-12% (Kingsnorth, 
1997). 
1.4 Aetiology of acute pancreatitis 
Although the list of aetiological factors of acute pancreatitis is long (Table I. I), many are 
rare, and there remains a significant proportion of patients in whom aetiology is unable to be 
determined and whose disease is classified as idiopathic. Recent reviews reflect general 
consensus opinion that biliary and alcoholic acute pancreatitis account for the majority 
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(approximately 80%) of cases (Kingsnorth and Sargen, 1998; Mergener and Baillie, 1998). 
1.4.1 Cholelithiasis 
In the UK the reported incidence of gallstone pancreatitis has been variable. Studies report 
that biliary stone disease accounts for 30 to 50% of cases of acute pancreatitis (Thompson 
et al., 1987; Corfield et al., 1985; Mann et al., 1994; De Beaux et al., 1995). Within a 
region the incidence of disease attributable to gallstones appears to be stable as evidenced 
by two studies reporting on the same population over 30 years (Trapnell and Duncan, 1975; 
Corfield et al., 1985). 
In the early part of this decade two groups of investigators have suggested that biliary stone 
disease accounts for a greater proportion of cases than earlier recognised. They both 
showed that the majority of cases previously labelled as idiopathic were in fact due to 
microlithiasis and 'biliary sludge' (Lee et al., 1992; Ros et al., 1991 ). 
Although the number of patients with gallstones developing acute pancreatitis is small 
(Moreau et al., 1988), it is clear that even stones less than Smm in diameter increase the risk 
of presenting with acute pancreatitis four fold (Diehl et al., 1997). Furthermore it is 
recognised that the risk of acute pancreatitis in patients with biliary stone disease is reduced 
to that of the normal population following removal of the gallbladder and it's stones 
(Moreau et al., 1988). 
1.4.2 Alcohol 
The reported incidence of alcohol induced disease is also highly variable, different studies 
estimate it accounts for between 11% and 38% of cases in the UK (Thompson et al., 1987; 
Corfield et al., 1985; De Beaux et al., 1995; Mann et al., 1994). This can be explained by 
two main factors. The first is that patterns of drinking within a local population vary, and 
these will influence the amount of cases of alcoholic pancreatitis. This is evidenced by 
studies from Finland, a country with a high per capita consumption of alcohol in which 70% 
of cases of acute pancreatitis are reported to be caused by alcohol (Puolakkainen et al., 
1987). In contrast with other European countries ethanol consumption in Finland per 
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inhabitant has been increasing to between 6-7 litres per annum since the 1970's, correlating 
with the rise in incidence of acute pancreatitis (Jaakkola and Nordback, 1993). 
Different epidemiological studies have no common defining criteria for when alcohol is 
considered the main aetiology . This may also explain variability in the reported incidence of 
alcoholic acute pancreatitis between studies. Only one published study has set an alcohol 
consumption level (consumption of;:::80 g daf1) at which subjects were defined as having 
alcoholic acute pancreatitis (Wilson et al., 1985). 
In 80% of alcoholics, neither pancreatic or liver disease develops, and in only 5% does 
pancreatitis (chronic or acute) develop (Meier, 1995). The reason for this is unclear, and 
various hypotheses have been suggested and tested. However, none of them provides an 
explanation, as alcoholics with pancreatic disease do not appear to have different drinking 
patterns or tobacco consumption compared with alcoholic controls, and conflicting data 
exists with regard to associated dietary factors (Haber et al., 1995). Genetic factors have 
also been studied, and these are discussed in section 4.3. 
1.4.3 Drug induced pancreatitis 
A recent retrospective study estimates that the incidence of drug induced pancreatitis is only 
1.4%. It seems that this form ofthe disease usually mns a benign course (Lankisch et al., 
1995). Agents known to cause acute pancreatitis include Thiazides, Azathioprine, 
Valproate, Oestrogens, Corticosteroids, Sulphonamides, and Tetracyclines. There are many 
other agents which are considered to possibly be a cause (McArthur, 1996). 
1.4.3 Idiopathic pancreatitis 
Idiopathic pancreatitis has been reported to account for between 14% and 23% of cases of 
acute pancreatitis (Mann et al., 1994; Thompson et al., 1987; De Beaux et al., 1995; 
Corfield et al., 1985). As discussed above, this figure may represent an overestimate as it 
can include unrecognised cases of both alcoholic and gallstone pancreatitis (Lee et al., 1992; 
Ros et al., 1991). It can be postulated that some cases ofidiopathic pancreatitis are 
secondary to undiagnosed viral infections. 
13 
1.4.4 Infectious pancreatitis 
Mumps virus, Coxsackie, Hepatitis B, Cytomegalovirus, and the Herpes simplex I & 11 
viruses are some of the viruses believed to initiate pancreatitis (Parenti et al., 1996). Non-
viral agents include Mycoplasma, Leptospira, Legionella, and the Ascaris worm. Some of 
these are probably very rare as only a few case reports exist in the literature. The actual 
incidence of viral and other forms of infectious acute pancreatitis is unknown. However, in 
the UK the Mumps virus, Coxsackie, Hepatitis B, Cytomegalovirus, and the Herpes simplex 
I & II viruses are very prevalent which increases the chance of cases of viral induced acute 
pancreatitis developing. 
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Aetiological factors in acute pancreatitis 
Cholelithiasis (including microlithiasis) 
Alcohol 
Trauma (Blunt and penetrating) 
ERCP 
Obstruction (Arnpullary stenosis, Duodenal diverticulum, neoplasm, parasites) 
Hypercalcaemia 
Hypertriglyceridaemia (Types I and V) 
Infection (Cocksackie, Mumps, Mycoplasma) 
Hypothermia 
Ischaemia (Vasculitis, Hypotension) 
Cardiopulmonary bypass 
Drugs 1 
Miscellaneous (Scorpion bite, hereditary, pregnancy) 
Table 1.1 Aetiological factors in acute pancreatitis 
I Thiazides, Azathioprine, Valproate, Oestrogens, Corticosteroids, Sulphonamides, 
Tetracyclines. Also many other possibles. 
ERCP - Endoscopic retrograde cholangio-pancreatography 
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1.5 Clinical acute pancreatitis 
The presenting features and natural history of human acute pancreatitis are well known and 
will be described in the following sections. 
1.5.1 Presenting features 
Patients usually present with an acute onset of upper abdominal pain (epigastric) which can 
be referred to the back in up to 50% of patients. Due to it's site and nature the pain can 
often be confused with that originating from a myocardial infarction. Other symptoms 
include anorexia, nausea, and vomiting. Some patients, especially the very ill and elderly, 
present in a confused state due to systemic hypoxia. 
Clinical signs associated with acute pancreatitis include epigastric tenderness, abdominal 
distension, small bowel ileus, dehydration, and evidence of hypovolaemia. Jaundice can be 
apparent in a case secondary to gallstone disease, and in a severe case subcutaneous 
extraperitoneal tracking of inflammatory peripancreatic exudate is manifested as abdominal 
wall staining (Cullen's sign and Grey Turner's sign). 
1.5.2 Natural history 
lt is a consistent finding in clinical series that the majority of patients with acute pancreatitis 
have mild disease, associated with minimal systemic upset or absence of local complications 
(Bradley, 1993; De Beaux et al., 1995). These patients can be managed by supportive care 
and careful monitoring for the development of complications (Banks, 1997), and require a 
relatively short hospital stay. 
However, this still leaves a significant proportion of patients who develop complicated 
disease, evident by the development of distant organ failure or local pancreatic pathology. 
Exact figures for the proportion of patients developing complications are difficult to derive 
from many studies, as widely different classification systems are used and figures quoted are 
often anecdotal. Furthermore some studies rely upon predicted severity scores which do not 
always correlate with outcome. The wide variability of the figures quoted illustrates these 
problems. 
16 
1.5.2.1 Organ failure 
The development of organ dysfunction usually occurs in the first two weeks of disease 
(Karimgani et al., 1992; Kingsnorth, 1997). Prospective series with comparable but not the 
same defining criteria of organ failure report that organ failure occurs in between 7 % and 
27% of patients (De Beaux et al., 1996; Kingsnorth et al., 1995; Larvin and McMahon, 
1989). 
The respiratory system is most commonly affected (Kingsnorth et al., 1995) and minor 
respiratory insufficiency is often seen. In one selective series as many as 22% of cases had 
respiratory insufficiency of some degree (Talvik et al., 1977). Respiratory failure is a 
significant cause of mortality, 60% of patients who die within the first week of disease die 
from respiratory failure (Guice et al., 1988). 
The development of respiratory failure can present as tachypnoea and confusion, and 
reduced arterial oxygen saturation is evident upon monitoring. In it's severe form 
respiratory failure develops into a clinical scenario labelled the Adult Respiratory Distress 
Syndrome (ARDS), in which refractory hypoxia occurs. 
Renal insufficiency can also develop, evidenced by the development of oliguria and rising 
serum creatinine. The incidence of renal dysfunction in one series, as defined by a serum 
creatinine of>2001J.g/dl, was reported to be 8.5%, and 80% ofthese required dialysis 
(Lankisch and Banks, 1998e). 
Cardiovascular insufficiency is another serious complication of acute pancreatitis, and 
manifests itself as refractory hypotension. This can be due to failure of the vasculature or 
myocardium, or both. Data on it's frequency suggests it occurs in up to 6.4% of patients 
(Satiani and Stone, 1979). 
Metabolic complications requiring intervention are a rare but serious event in acute 
pancreatitis. Hypocalcaemia is said to be common in acute pancreatitis (McFadden, 1991 ), 
and may result from the hypoalbuminaemia of disease or from fat saponification in the 
peritoneum. The requirement of treatment for hypocalcaemia is uncommon. 
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Hyperglycaemia is a poor prognostic factor in acute pancreatitis (Ranson et al., 1974), and 
is reported to be associated with high levels of glucagon and cortisol, and a corresponding 
deficiency of insulin (McFadden, 1991 ). 
Respiratory, renal, and cardiovascular failure can occur on their own or together, resulting 
in multisytem organ failure (MSOF). The development ofMSOF also puts the patient at 
risk of hepatic failure and coagulopathy. MSOF or any of it's components can result from 
acute pancreatitis without sepsis or necrosis, but is also common when sterile necrosis or 
septic complications are present (Banks et al., 1996). 
1.5.2.2 Local complications 
Local complications are those that involve the pancreas or peripancreatic area. They include 
acutefluid collections, pancreatic necrosis, acute pseudocyst, and pancreatic abscess. 
Pancreaticocutaneous fistulae can occur also, usually after surgical intervention. 
Definitions are provided in the following section (Section 1.5.3). 
Local pancreatic complications have been reported to occur in 19% of patients in a 
consecutive series (De Beaux et al., 1995). 
Acute fluid collections and pseudocysts are often asymptomatic, but are often found on 
imaging investigations (Bradley, 1993). A pseudocyst, by definition, is only classified as 
such if present four weeks from the onset of disease, and has a reported incidence of 7% 
(De Beaux et al., 1995). 
Pancreatic necrosis, occurring in 7% of cases (De Beaux et al., 1995), is often suspected in 
a patient with severe disease, or in one whose disease runs a protracted course. It can be 
relatively asymptomatic or fulminant. It is detected using contrast imaging techniques. 
There is disagreement as to whether pancreatic necrosis, whether infected or sterile, is 
predictive ofmortality (Banks et al., 1996; De Beaux et al., 1995). 
Pancreatic abscess has a reported incidence of 5% (De Beaux et al., 1995). It takes at least 
4 weeks to form, and is associated with pain and systemic upset. 
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1.5.3 Clinical classification of acute pancreatitis 
As previously mentioned, differing criteria employed by investigators has led to difficulty in 
comparing studies performed in clinical acute pancreatitis. Realisation of this led to the 
development of a clinically based classification system for acute pancreatitis, which was 
agreed by a consensus conference in Atlanta, Georgia, USA in 1992 (Bradley, 1993). 
1.5.3.1 Mild acute pancreatitis 
Defined as being associated with minimal organ dysfunction and an uneventful recovery, 
lacking the described features of severe acute pancreatitis. 
1.5.3.2 Severe acute pancreatitis 
Severe acute pancreatitis is defined as being associated with organ failure and/or local 
complications. The definitions are listed in Table 1.2. 
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·-----·--~-------------------~·--~ 
CATEGORY DEFINING CRITERIA 
·············---···················································································-·······························-·········-·································-·············································· 
Mild acute pancreatitis 
Severe acute pancreatitis: 
Predicted severe disease 
Organ failure: 
t. Cardiovascular insufficiency 
11. Respiratory insufficiency 
iii. Renal failure 
iv. Gastrointestinal bleeding 
V. DIC 
vi. Metabolic failure 
Local complications 
i. Acute fluid collection 
11. Pseudocyst 
iii. Abscess 
iv. Necrosis 
Minimal organ dysfunction 
Organ failure and I or local complications 
Apache 11 Score ;:: 8 
Systolic blood pressure < 90 mmHg 
Pa02 < 60 mmHg (8 KPa) 
Serum Creatinine> 177!J,mol r' (after rehydration) 
> SOOml ofblood loss in 24 hours 
Platelets~ 100,000 per mm3, Fibrinogen< lg r' 
Serum calcium~ I .87 mmol r' 
Located in or near the pancreas, lack a wall of 
granulation or fibrous tissue 
Collection of pancreatic secretion bounded by 
fibrous or granulation tissue wall, presenting 4 
weeks after onset of disease 
Circumscribed collection of pus 
Diffuse or focal nonviable pancreatic parenchyma 
•••~~•'""""'''"'~"""'''''""'''''''~-•••••~••"'_.""""-"'""'"~-•ao .. ,o~~------_.,._..,_.. .. _,~•••••""'''"''""'''''"''''''''''""'~~• 
Table 1.2 Atlanta Convention Classification of acute pancreatitis' 
Apache Il 
DIC 
mmHg 
Kpa 
Acute Physiology and Chronic Health Evaluation Il 
(Larvin and McMahon, 1989) 
Disseminated Intravascular Coagulation (Coagulopathy) 
millimetres of mercury 
Kilopascals 
1 (Bradley, 1993) 
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1.6 Management of clinical acute pancreatitis 
Management of acute pancreatitis is mostly supportive in nature, with initial effort directed 
towards restoring intravascular volume, ensuring adequate oxygenation, and relieving pain. 
Patients should be observed closely, to look for signs of developing organ failure and 
sepSIS. 
Investigations should monitor pulmonary, hepatic and renal function, and aim to identifY 
the aetiological agent. 
In severe cases intensive therapy may be required, including artificial ventilation, renal 
replacement therapy, and ionotropic support. The development of infected pancreatic 
necrosis warrants surgical debridement and drainage, whilst relatively asymptomatic cysts 
and sterile necrosis can be treated expectantly. Pseudocysts that do ultimately need 
drainage can often be dealt with by percutaneous techniques, not requiring open surgery. 
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2. Overview of the immune system 
Acute pancreatitis is a disorder that is characterised by inflammation and activation of 
various components of the immune system. The structure and mechanisms of the immune 
system, and the inflammatory response that it generates in conditions including acute 
pancreatitis, merit consideration to enable understanding of the pathophysiology of the 
disease. 
The immune system has two (arbitrary) functional components to deal with the presence of 
antigens (antigen; any substance that binds specifically to an antibody or T cell receptor) 
within the body, specific (acquired) immunity and non-specific (innate) immunity. Antigens 
can be exogenous, such as pathogenic organisms, or endogenous. Endogenous antigens 
include damaged cells (e.g. acinar cell in acute pancreatitis) and components of the body no 
longer recognised by the immune system as 'self. 
2.1 Non-specific (Innate) immunity 
This is the initial non-specific response to tissue injury produced by the body in response to 
mechanical, chemical or biological stimuli. Of necessity it is an early response and is capable 
of rapid amplification. 
Innate immunity has humoral and cellular components. The recruitment and activation of 
the cellular component occurs in tandem with the amplification of complement, kinin, 
coagulation and fibrinolytic cascades, a process known as the acute phase response. 
The principal cellular effectors are the endothelial cell, neutrophil, and 
monocyte/macrophage. Regulation of this inflammatory response involves many 
physiological messengers. Cytokines are key mediators of the process, but others include 
adhesion molecules, prostaglandins, kinins, nitric oxide, oxygen free radicals, and proteases. 
Various mediators are produced by the effector cells of inflammation or as a direct 
consequence of cellular injury. 
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2.2 Specific (Acquired) Immunity 
Specific immunity provides a mechanism for the body to selectively detect and eliminate 
foreign antigens. It exhibits specificity, recognising antigens that may differ by only one 
amino acid. This specificity means it has to be very diverse, recognising and responding to a 
multitude of different antigens. It also has a specific immunological memory, ensuring 
subsequent encounters with antigen are responded to quickly. As the immune system is so 
efficient at dealing with antigens it needs to be able to distinguish self from non-self, and so 
avoid the development of autoimmunity. 
The acquired immune system has humoral and cellular components. Responses described as 
humoral involve the secretion of antibody by B-lymphocytes and the involvement of various 
soluble mediators in immune response and regulation. 
The cellular component involves various types ofT lymphocytes which recognise 
expressed antigen in association with MHC molecules, and carry out cytotoxic killing of 
such cells to destroy associated antigen. T cells also secrete cytokines which mediate 
inflammatory cell activation, differentiation, and therefore function. 
Although they have been described separately, the innate and acquired immune systems do 
not function independently. Many of their cellular and soluble components have functions in 
both systems. Effector cells of the immune system, their cell membrane molecules, and the 
mediators which affect them are now described. 
2.3 Cellular effectors of the immune system 
These include the granulocytes (neutrophil, eosinophil, and basophil), the mononuclear cells 
(monocyte/macrophage), and the lymphocytes (B cells, T cells, and NK cells). Dendritic 
cells process and present antigens to subsets ofT cells. Although not from the same cell 
lineage, the endothelial cells of the vasculature can be included in the category of immune 
system cellular effectors. 
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2.3.1 Neutrophils 
The neutrophil is the characteristic cell of acute inflammation, inwardly migrating from 
blood to tissue in response to localised stimuli. It is a nucleated cell with phagocytic 
activity, and has numerous cytoplasmic granules containing substances including 
peroxidases, lysozyme, other hydrolytic enzymes, and lysozyme. Release of lysozyme and 
other reactive intermediates, such as oxygen free radicals (OFR's), nitric oxide, proteases, 
elastases, and collagenases, contribute to tissue damage and aid in the destruction of 
pathogens. 
Neutrophils exhibit chemotaxis, and express high levels ofreceptors for chemokines, a large 
family of proteins which act as chemoattractants (Premack and Schall, 1996). Chemokines 
are expressed by a variety ofleucocytes, and cells affected by inflammatory processes 
(Gerard et al., 1997; Grady et al., 1997). Some cytokines, components of the complement 
and blood clotting systems also act as chemoattractants. To get to areas of inflammatory 
activity neutrophils have to extravasate through the vascular endothelium. 
2.3.2 Endothelial cells and adhesion molecules 
The endothelial cell's immunological function is to facilitate the migration of inflammatory 
cells and proteins to sites of inflammation. This implies increased permeability to plasma 
molecules, and a mechanism for leucocyte extravasation. Leucocytes interact with the 
endothelial cell by sequential activation of families of adhesion molecules expressed on the 
surface of both types of cell (Panes and Granger, 1998). These include the select ins (L-, P-, 
and E-selectins), integrins (CDll, CD18, etc.), and the Ig supergene family (!CAM-I, 
VCAM-1, etc.). Expression ofadhesion molecules is induced by cytokines such as TNFa 
and IL-l, transcription factors (NFKB and AP-1) (Ledebur and Parks, 1995), and 
lipopolysacharride (Fries et al., 1993). Initially weak adhesive interaction involving se1ectins 
and integrins causes leucocyte rolling, margination, and pavementing along the endothelial 
cell's luminal surface. Adhesion molecules from the Ig family, and others such as the 
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integrins mediate transmigration of cellular components through the endothelial barrier, 
most probably by them squeezing between intercellular junctions (Bianchi et al., 1997). 
Adhesion molecules and their ligands not only mediate neutrophil migration, but also 
monocytes, lymphocytes, eosinophils and platelets. 
2.3.3 Mast cells 
Mast cells are located near blood vessels in all connective tissue and are cells with dense 
collections of cytoplasmic granules which release substances such as histamine, 
prostaglandins, thromboxanes, and leukotrienes. These substances have been characterised 
as being vasoactive, chemotactic for other inflammatory cells, or having the ability to 
promote platelet aggregation and increased vessel permeability. lgE mediated release occurs 
during atopic responses, but degranulation of such cells is also caused by components of the 
complement system. 
Mast cells also secrete a variety of pro-inflammatory cytokines, which serves to promote the 
inflammatory response to injury or infection. 
2.3.4 Monocyte/Macrophage 
Macrophages mature from circulating monocytes. Maturation involves an increase in size, 
number of organelles, secretory capability and phagocytic activity. They can be resident in 
tissues or migratory. They are able to secrete lysozyme and other inflammatory 
intermediates like superoxide radical and nitric oxide. Macrophages have the ability to 
secrete a wide variety of pro-inflammatory cytokines, and as such is the pivotal cell in 
eliciting and amplifying the early stages of inflammation, also called the acute phase 
response (Baumann and Gauldie, 1994) Cytokines produced by the macrophage include IL-
I, IL-6, IL-8, IL-10, IL-12, and TNFa, all ofwhich have effects upon components ofthe 
innate and adaptive immune systems (see Table 2.1). 
Macrophages are also able to present antigens to naive T cells and exhibit class I and li 
MHC expression . To avoid the development of autoimmunity this only occurs in the 
presence of inflammation or infection, and not when the macrophage is fulfilling it's normal 
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function of the phagocytosis of dead body cells. 
2.3.5 Lymphocytes 
Lymphocyte sub-populations consist of B cells, T cells, and null cells. They all have 
different cell surface/membrane components which reflect their different functions. 
Development of these different lineages from the common lymphoid progenitor cell require 
the presence of constitutively expressed transcription factors (Georgopoulos, 1997). 
2.3.5.1 8 cells 
B cells mature in the bone marrow and have membrane bound immunoglobulin on their cell 
surface B cells also express MHC class II molecules, so can act as an antigen presenting 
cell (APC). 
lmmunoglobulins act as receptors for specific antigens, and appropriate interaction between 
the two induces clonal proliferation of the antigen specific B cell. This produces plasma 
cells and memory B cells. Plasma cells have an innate capability to produce free (soluble) 
immunoglobulin, termed antibody. 
It is the formation of ligand bound immunoglobulin and related plasma antibody that forms 
the foundation of the so called humoral immune response. 
2.3.5.2 Immunoglobulins 
lmmunoglobulins are specific to antigens and as such are a very diverse family of molecules. 
The number of different antibody specificities able to be generated is estimated to be at least 
I 08, far outnumbering the estimated number of potential antigens, so enabling the 
generation of a primary response to antigens not previously encountered. 
lmmunoglobulins have a structure which consists of heavy and light polypeptide chains, 
each type having variable and constant regions (Fig 2. I). The multi-gene families encoding 
for the polypeptide chains are located on different chromosomes and consist of different 
gene segments. These are termed V (variable), D (diversity), J (joining), and C (constant). 
The light chain families have V, D, and C gene segments, the VJ segments encode the 
variable region of the light chains. The heavy chain family contains V, D, J, and C segments, 
26 
the VDJ segments encode the variable region of the heavy chains. Random mutational and 
recombinational events involving these gene segments encoding the variable regions that 
occur during the development of the immune system result in the generation of diverse 
families of polypeptides. Constitutive expression of various proteins encoded for by genes 
such as RAG-I and RAG-2 (recombination-activation-genes) are required for this 
immunoglobulin gene rearrangement (Oettinger et al., 1990). Further diversification ofthe 
immunoglobulin molecule is generated by a high rate of somatic mutation within the 
immunoglobulin V -region genes that occurs within the B cell (Kim et al., 1981 ). 
Class (isotype) switching can also occur in activated B cells. Recombination between switch 
regions ofC-region genes results in deletion of intervening coding DNA, allowing 
expression of different C-region isotypes with the same V-region (and hence same antigenic 
specificity) (Cory et al., 1980). 
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Fig. 2.1 Structure of Immunoglobulin (I g) 
H L 
Each heavy (H) and light (L) chain in an immunoglobulin molecule has a variable (V) 
region, which differs between individual Ig molecules, and a constant (C) region that has 
limited variability. In some Ig molecules there is also a hinge region. Disulphide bonds 
link the chains. The chains are in fact folded into domains, held with a disulphide bridge 
(not shown). The regions involved in antigen binding and in the mediation of biological 
activity are shown. Biological activity includes binding with cell surface receptors and 
activation of complement. This region (the Fe fragment), is also the region where joining 
(J) chains bond to form the polymeric forms oflgA (dimeric) and IgM (pentameric). 
Disulphide bond 
2.3.5.3 T cells 
T cells develop into two major subsets, expressing different cell surface markers, cluster of 
differentiation (CD)4 and CD8. The thymus is required for efficient T cell development and 
regeneration, and although extrathymic sites of differentiation (e.g. bone marrow) have been 
described in the adult (Dejbakhsh-Jones et al., 1995), these are not as efficient. 
Cells expressing CD4 recognise peptide presented with class li MHC molecules, whilst 
those with CD8 recognise peptide associated with class 1 MHC molecules. The expression 
ofCD4 and CD8 also allows differentiation ofT lymphocytes into their two major 
functional subsets. CD4+ cells function as T helper (T H) cells and CD8+ cells function as 
cytotoxic T cells (Tc). 
Following recognition of an peptide associated with a class II MHC molecule T H cells 
exhibit clonal proliferation, specific to the same antigen/MHC class II complex. The T H 
clones function as facilitators of the immune response by activating B cells, Tc cells, and 
other effector cells of the immune response by the secretion of a variety of cytokines. The 
cytokine profile that is secreted by the T H cells divides them into two populations (T HI and 
T H2) producing different effects upon the immune system (Mosmann et al., 1986). 
The T HI response consists of a cytokine profile including IL-2 and IFN-y, which results in 
the activation of a cell mediated immune response involving T c cells and macrophages. In 
contrast the TH2 response (cytokine profile includes IL-4 and IL-5) activates aB cell 
response. However, this functional division cannot be absolute, as cytokines such as TNFa, 
GM-CSF, and IL-3 are produced by both populations, and both THI and TH2 responses are 
required to deal with many antigens (Alien and Maizels, 1997). 
T c cells (CD8+) interact with an peptide/class I MHC molecule complex, and produce IL-2 
by stimulation of CD28, a molecule expressed on T cells (Fraser et al., 1991 ), which 
promotes activation into it's effector form, the cytotoxic T lymphocyte (CTL). The CTL, 
which acts to eliminate altered 'self cells, does so by activation of soluble (e.g. perforins) 
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and cell membrane effectors (e.g. Fas ligand), to induce lysis or apoptosis. Because CTL's 
are CD8+, and therefore class I MHC dependent (which is expressed on all nucleated cells), 
they can recognise and mediate the destruction of any altered body cell. 
2.3.5.4 T cell receptor 
The T cell receptor (TCR) family recognises peptide held within the groove ofMHC 
molecules (Allison et al., 1982). This results in the initiation of signal transduction events 
and cellular activation. As the T cell receptor is specific for both the peptide and an MHC 
molecule, there are significant structural differences in the TCR between different clones of 
T cells. Therefore, like the immunoglobulin family, the TCR has an enormously wide range 
of specificity for different peptides, and is probably the major determinant of response to 
antigen. 
The TCR has a similar structure to immunoglobulin (Fig 2.1 ). a and ~ chains (or y and o 
chains) are linked by disulphide bonds. The genes encoding the a and ~ chains, expressed 
only in T cells (Hendrick, 1994), have a similar arrangement to the immunoglobulin genes, 
and undergo similar rearrangement during T cell maturation to form a massively diverse 
family of antigen specific TCR' s. 
2.3.5.5 Null cells 
These are cells that do not express the T and B cell membrane markers previously 
described. Natural Killer (NK) cells belong to this group. 
NK cells have an Fe receptor for bound antibody, and can also be activated by antibody 
independent means, via certain cytokines (e.g. IL-2, lL-12, and IL-l 5). 
NK cells play an important role in immune surveillance for altered cells either not exhibiting 
constitutive expression of class I MHC molecules or expressing altered class l molecules. 
They have receptors on their surface, killer cell inhibitory receptors (KLR's), which bind to 
polymorphic class I MHC molecules (Colonna and Samaridis, 1995). If the MHC class I 
molecule acts as a KfR ligand and is so recognised as self, NK cell function is suppressed 
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As with the TCR, KIR and related molecules are diverse, as evidenced by polygenicity and 
polymorphism ofthe loci encoding them (Uhrberg et al., 1997). 
2.3.5.6 MRC Molecules (Histocompatibility antigens) 
There are three classes of major histocompatibility complex (MHC) molecule, class I, II, 
and ITI, which are also termed histocompatibility antigens. All three classes of molecule are 
encoded for by three corresponding regions in the major histocompatibility complex 
(MHC), on chromosome 6. This is discussed in Chapter 4. 
The class Ili molecules include a group of proteins involved in immune functions, but not in 
the presentation of antigen or recognition of self. Class lii molecules include components of 
the complement system and members of the tumour necrosis factor family, which will be 
discussed in section 2.4. 
Class I and ll molecules are cell surface glycoproteins. They were first characterised as the 
molecules involved in recognition of self and discrimination from non-self. Subsequently it 
was found that they play a key role in the generation of an immune response by binding with 
antigenic peptide to create a ligand for the T -cell receptor. 
Class I MHC molecules are expressed on all nucleated cells except neurones and mature 
trophoblast. Class II molecules, in contrast, are distributed only on B cells, activated T 
lymphocytes, and APC's, including macrophages and dendritic cells. 
Class l molecules bound with peptide are recognised primarily by Tc (CDS+) cells, whilst 
class II molecules bound with peptide are recognised by the T H (CD4+) subset. This 
separation of distribution and function between the two classes is also reflected in their 
manner of antigen presentation. Class I molecules generally bind and present antigenic 
peptide (originally endogenous) produced in response to cell injury or infection, or bind 
cytosolic pathogens (e.g. Virus components). Binding of peptide with MHC class I 
molecule occurs in the ER of the cell. Specific peptide transporters, named TAP I and TAP 
2 (for transporter associated with antigen presentation) span the ER membrane (Colonna 
and Samaridis, 1995), and transport peptides to the pre-Golgi region of the cell, where they 
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combine with the class I molecule, prior to migration to the cell surface. 
Class IT molecules, in comparison, present peptides which come from exogenous proteins 
(e.g. bacterial pathogen) which have been internalised and processed within the antigen 
presenting cell. 
There are a limited number of different MHC molecules within each class (e.g. class IT 
molecules identified are the HLA-DR, DQ, DP and DNA/DOB complex). MHC molecules 
are highly polymorphic and therefore diverse. But this diversity is different from that seen in 
Ig and TCR's. An individual does not express a broad diversity ofMHC molecules, rather 
the diversity occurs within a species, between individuals. This means class I and ll MHC 
molecules have broad antigenic specificity, each molecule being able to bind and present 
many different antigens. This is due to the structure of both classes ofMHC molecule, 
resulting in binding specificities to the parts of antigens which are commonly found between 
diverse antigen species. The structure of class 1 and ll molecules is reviewed elsewhere 
(Janeway and Travers, 1996). 
The diversity of MHC molecules occurring within a species is the basis of discrimination of 
self and non-self, presenting major obstacles to allogeneic tissue transplants. The reason for 
this diversity is due to the high polymorphism of the genes encoding for MHC molecules. 
The MHC is located on chromosome 6 and will be discussed in section 4.1. 
2.4 (Soluble and membrane bound) mediators and effectors of immune responses 
Various soluble mediators act in conjunction with the cellular immune response. Indeed, 
some act as important cell to cell signalling molecules. The liver produces proteins which 
help in the generation of immune responses, the acute phase proteins. Mediators present in 
normal plasma include the kinins and the complement, clotting and fibrinolytic systems. 
Histamine, nitric oxide, oxygen free radical species, and the large family of cytokines are 
secreted or produced by cellular components of the immune system. 
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2.4.1 Acute phase proteins (APP's) 
Pro-inflammatory cytokines such as IL-l, IL-6, and TNF stimulate production of acute 
phase proteins by hepatocytes (Baumann and Gauldie, 1994). Acute phase proteins include 
the complement component, C3, C-reactive protein (CRP), and mannose-binding protein 
(l\1BP). CRP and l\1BP act as opsonins and with C3 can activate the complement cascade. 
2.4.2 Plasma mediators 
Four enzymatic mediator systems are present in the normal plasma. These are the kinin, 
fibrinolytic, clotting, and complement systems. They all exist as inactive precursors in the 
plasma and are activated following tissue injury, and, in the case of complement, by 
interaction with antigen-antibody complexes. 
Activation of the kinin system results in the formation ofbradykinin which is a potent agent 
that causes vasodilatation and increased vascular permeability. A precursor of bradykinin, 
kallikrein, can also activate complement. 
Activation of the clotting system and subsequent breakdown of fibrin by the fibrinolytic 
system results in the formation of peptides chemotactic for neutrophils. 
The complement system is now discussed in more detail. 
2.4.2.1 Complement activation 
Complement is a system of plasma proteins with an important function in acquired and 
innate immune systems. Activation of complement is via classical (antigen antibody 
complex) and alternative (pathogen surfaces) pathways. Recent identification of serine 
proteases which bind to pathogen surface mannose in association with lectin (Matsushita et 
al., 1998) has helped characterise a third pathway of complement activation, the lectin 
pathway, which may be an intermediate between the classical and alternative pathways . 
In innate immunity activation is via the alternative, or related lectin pathway. 
Activation of the complement system generates C3 convertases which activate C3 to C3b 
and C3a. C3b clusters on the surface offoreign surfaces function as an opsonin, and 
activate other components of the complement system including CS. CS is split into CSa and 
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C5b which with C3a, activate mast cells and basophils, leading to the recruitment of 
additional inflammatory cells and proteins (Kanbe et al., 1996). A reaction sequence is also 
initiated which leads to the formation of a membrane attack complex (MAC) by 
complement components, which disrupts cell surface membranes, leading to cell death. 
In acquired immunity, activation of the complement system is by the classical pathway. The 
first component of this pathway, C I, is composed of three subunits which combine to bind 
to the antibody Fe receptor. This leads to the generation of a C3 convertase. The primary 
component ofthe Cl complex, Clq, has been found to be synthesised by dendritic cells 
(antigen presenting cells) and monocytes within the lymphoid compartment (Schwaeble et 
al., 1995). Activation products ofC3, bound to antigen, are known to enhance phagocytosis 
and antigen presentation, and it has recently been shown that they affect antibody 
production by B cells (Dempsey et al., 1996). 
2.4.3 Nitric oxide 
Nitric oxide (NO) is synthesised from the amino acid, L-arginine, by a family of enzymes 
named nitric oxide synthase (NOS). This was first found in endothelial cells (Palmer et al., 
1988), but is known to occur in other cell types including macrophages (Hibbs et al., 1988). 
The actions ofNO in inflammatory processes are complex (Schmidt and Waiter, 1994), 
reflecting it's effects on different tissues. 
NO can produce oxidant mediated tissue injury (Radi et al., 1991 ), which is probably the 
effect macrophages and other phagocytic cells produce by it's synthesis. NO also mediates 
vascular smooth muscle contraction (Palmer et al., 1988), and whilst it inhibits leucocyte-
vascular endothelium adhesion in vitro (Kubes et al., 1991), it has been postulated that it 
may promote leucocyte extravasation by it's effects upon microvascular dynamics and 
permeability (Mantovani et al., 1997). 
2.4.4 Oxygen free radical species 
The potential for cellular oxidative stress is from three, highly reactive, oxygen free radicals 
(OFR's), superoxide anion (02"), hydrogen peroxide (H2 02), and the hydroxyl free radical 
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(OH• ), which are produced as products of normal cell metabolism. Activated neutrophil 
polymorphs and macrophages are a potent source ofOFR's, produced during a metabolic 
process known as the 'respiratory burst'. Cellular protection against oxidative stress is from 
endogenous enzymatic pathways involving superoxide dismutase, catalase, and glutathione 
peroxidase, and endogenous free radical scavengers such as Vitamins E and C, and P-
carotene (Sweiry and Mann, 1996). Failure of these detoxification mechanisms or excess 
production of free radical species results in a disturbance in cell haemostasis, including lipid 
peroxidation. This leads to increased membrane permeability, which ultimately causes cell 
death (Slater, 1984). As well as these direct effects upon tissue, free radicals induce the 
generation of chemotactic factors which leads to accumulation of polymorphonuclear 
leucocytes in the damaged tissue (Petrone et al., 1980). Increased arachidonic acid 
metabolism is also stimulated, resulting in enhanced local production of other inflammatory 
mediators such as prostaglandins. 
2.4.5 Cytokines 
The term cytokine is used to describe low molecular weight peptides and lipids released 
from immune cells and other cells which function as mediators of inflammation, 
regeneration and remodelling. In the immune response cytokines control the intensity and 
duration of both specific and acquired components by involvement in immune cell 
activation, development, proliferation and differentiation. They can act by autocrine, 
paracrine and endocrine means. Cytokines have specific receptors, and binding of their 
ligand results in signal transduction events that alter target cell gene expression, and 
therefore function. 
Many cytokines are named Interleukins (IL), but others include the tumour necrosis factor 
(TNF) family, and the interferons (IFN). Classification is an arbitrary system, and cannot be 
done on the basis of structural similarity, as cytokines have few sequence similarities (Cohen 
and Cohen, 1996). Many cells secrete cytokines, but the two which are the main producers 
are the TH lymphocyte and the macrophage. As there are a multitude of cytokines, Table 2.1 
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summarises the origin, target cell(s), and actions of principal cytokines. In the following 
sections the pro-inflammatory cytokine, TNF, and the regulatory cytokine, IL-l 0 are 
discussed in detail as their genes have been studied in this work. Two other pro-
inflammatory cytokines, IL-l and platelet activating factor (P AF}, are also discussed as their 
role in the pathogenesis of acute pancreatitis has been extensively investigated in recent 
years. 
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------··--------···-·-------···--·····--------·-·---------------------
Cytokine 
IL-l 
IL-2 
IL-3 
IL-4 
Cell(s) of secretion 
Macrophage, Neutrophil, NK cell, T and B 
lymphocytes, APC's 
T H 1 cells, Tc cells 
T H cells, NK cells 
Mast cells 
NK cells, mast cells 
Target cell/tissue 
Macrophages/Monocytes 
T lymphocytes 
B lymphocytes 
NK cells 
Hepatocytes 
B cells 
Tc cells 
NK cells 
Stem cells 
Mast cells 
B lymphocytes 
T lymphocytes 
Macrophage 
Mast cells 
Table 2.1 Selected cytokines, source, target cell/tissue, and known effects 
Summa!)' of known effects 
Production of other cytokines, Increased migration & 
cytotoxicity. 
Production of other cytokines, Stimulation of activity, 
expression ofiL-2 receptors. 
Production of immunoglobulin, activation, growth, 
development. 
Production of other cytokines, activation. 
Production of acute phase proteins 
Production of Immunoglobulin, growth 
Activation, cytokine production (IFN-y) 
Growth, cytokine production (IFN-y) 
Growth and differentiation 
Growth and histamine secretion 
Activation, proliferation, differentiation, increase class 11 
MHC expression, IgE production 
Proliferation 
Increase class 11 MHC expression, reduce secretion of pro-
inflammatory cytokines 
Growth 
continued ..... . 
IL- Interleukin GM-CSF Granulocyte-macrophage colony stimulating factor 
TNF Tumour necrosis factor TGF Transforming growth factor 
IFN Interferon P AF Platelet activating factor 
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~--~--------------- -············--·---------------------------
Cytokine Principal immune cell(s) of secretion 
---··--···--··-·----------,-,-------
IL-5 T H2 cells, mast cells 
IL-6 Monocytes, macro phages, T H2 cells 
IL-9 TH cell 
IL-10 T H 2 cell, macrophage, B cells 
IL-12 Macrophages, B cells 
IL-13 TH cells 
IL-15 T cells 
IL-16 Tc cells 
Target cell/tissue 
B cells 
Eosinophils 
B cells 
Plasma cells 
Stem cells 
Hepatocytes 
TH cell 
Macrophage 
------
T c cell siNK cells 
B cell/Mast cell 
T c cell siNK cells 
Macrophage 
T cells/NK cells 
B cells 
T H cells 
Table 2.1 Selected cytokines, source, target cell/tissue, and known effects 
Summary of known effects 
- ·-------
Proliferation and differentiation, IgA production 
Growth and development 
Differentiation to plasma cells 
Antibody secretion 
Differentiation 
Acute phase protein production 
Proliferation 
Suppresses activation and cytokine release 
Suppress function and cytokine release 
Proliferation and differentiation 
Activation 
Suppresses activation and cytokine release 
Proliferation 
Proliferation and differentiation 
Chemotaxis, increased expression of class ll MHC, 
cytokine synthesis, suppress antigen induced proliferation 
continued ..... . 
IL- Interleukin GM-CSF Granulocyte-macrophage colony stimulating factor 
TNF Tumour necrosis factor TGF Transforming growth factor 
IFN Interferon P AF Platelet activating factor 
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Cytokine 
TNF-a. 
TNF-~ 
IFN-a 
IFN-y 
GM-CSF 
TGF-~ 
PAF 
-----,~------ -------,------~---~---··--·-····~-------
Principal immune cell(s) of secretion 
Macrophages/Monocytes, T H cells 
T cells 
T cells and viral infected cells 
T cells/NK cells 
T cells 
Macrophages, T and B cells, platelets 
Endothelial cells, macrophages, platelets 
Target cell/tissue Summary of known effects 
-----···-----------
Macro phages Stimulation 
T cells Activation and cytokine release 
B cells Antibody production 
Endothelial cells Expression of cytokines and adhesion molecules 
As TNF-a 
All cells 
NK cells 
Normal cells 
Macrophages 
APC's, T and B cells 
Macrophage, Granulocytes 
Macro phages 
Macrophages 
Platelets 
Neutrophils 
Endothelial cell 
As TNF-a 
Induce MHC class I expression and antigen presentation 
Induce killing of viral infected cells 
Inhibit viral replication 
Induce class II MHC expression 
Increase activity 
Increase MHC class I & II expression 
Activation and proliferation 
Attract, Increase IL-l production 
Activation and attraction 
Activation 
Activation and attraction 
Leucocyte adherence, increased permeability 
Table 2.1 Selected cytokines, source, target cell/tissue, and known effects 
IL- Interleukin GM-CSF Granulocyte-macrophage colony stimulating factor 
TNF Tumour necrosis factor TGF Transforming growth factor 
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IFN 
PAF 
Interferon 
Platelet activating factor 
2.4.5.1 Tumour necrosis factor (TNF) 
Tumour necrosis factor (TNF) is the name given synonymously to TNFa, one of the 
members of the TNF family. Others are TNFJ3 (also known as lymphotoxin a, L Ta ), and 
L TJ3, which share similar effects. 7 other related ligands, including the Fas ligand and nerve 
growth factor, have been identified, and are reviewed elsewhere (Bazzoni and Beutler, 
1996). 
TNF and LTa were first isolated in 1975, when their ability to kill tumour cells in vitro and 
in mice transplanted with tumours was noted (Carswell et al., 1975). A decade later the 
genes encoding the two proteins were cloned, and their homology was noted (Pennica et al., 
1984). Studies also demonstrated the stimulatory effects ofTNF in leucocyte adherence to 
endothelial cells (Gamble et al., 1985), and it's role as a central mediator of systemic shock 
(Tracey et al., 1986; Beutler et al., 1985). 
TNF is considered to be predominantly secreted by the macrophage/monocyte lineage, 
although other immune cell sources include T and B lymphocytes, neutrophils, activated NK 
cells, and endothelial cells (Jones et al., 1989; Cohen and Cohen, 1996). Furthermore it is 
becoming apparent that TNF is expressed by many non-immune cells, both in health and 
disease. For example, normal pancreatic acinar cells (Gukovskaya et al., 1997), muscle cells 
(Saghizadeh et al., 1996), fibrocytes (Chesney et al., 1998), and adipose tissue cells 
(Hotamisligil et al., 1995) all express TNF. 
It is unclear whether TNF is detectable in the plasma of normal healthy humans , as 
conflicting data has been produced (McLaughlin and Davies, 1990; Eigler et al., 1997) 
Likewise, although it is often detectable in acute inflammatory conditions such as sepsis and 
acute pancreatitis (Exley et al., 1992), this is by no means a consistent finding, probably 
reflecting the short halflife (14-18 minutes) ofTNF, difficulties with it's measurement in 
serum, and the fact that TNF can function both via autocrine and paracrine routes. 
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2.4.5.1.1 Structure 
TNF is a heterotrimer, consisting of three identical polypeptide chains (Jones et al., 1989). 
Likewise LTa is a heterotrimer ofthree LTa molecules, but one of the three molecules of 
the LT~ heterotrimer is a LTa subunit (Bazzoni and Beutler, 1996). 
TNF is synthesised as a membrane bound precursor protein, and cleavage by a specific 
metalloprotease (TNFa converting enzyme, T ACE) produces a molecule I 57 amino acids 
(AA) in length (Rink and Kirchner, 1996). The mature molecule forms into the heterotrimer 
after membrane cleavage. TNF and L Ta are predominantly secreted in soluble form, 
although TNF does exist in a membrane bound active form which is also capable ofTNF 
receptor (p75) binding (Grell et al., 1995). LT~ and the other members of the TNF ligand 
family are transmembrane proteins and do not exist in free (soluble) form (Crowe et al., 
1994; Bazzoni and Beutler, 1996). 
The genes for TNFa, L Ta, and LT~ are tandemly arranged within the MHC on 
chromosome 6. The TNF gene complex will be discussed in section 4.1.4. 
2.4.5.1.2 Receptors 
TNF has two receptors, a 55 kDa receptor, and a 75 kDa receptor. They have been 
designated p55 (or TNFR55, or TNFRI, now called CDI20a), and p75 (or TNFR75, or 
TNFRII, now called CDI20b) (Bazzoni and Beutler, 1996). It shares these with the LTa 
heterotrimer, explaining the similar effects of the different proteins. LT~ has it's own 
specific receptor (Crowe et al., 1994). 
The TNF receptor family are transmembrane proteins consisting of two identical subunits. 
As two different proteins share two different receptors, the extracellular domains are 
similar, variation being in the cytoplasmic domain. Crystallisation studies of the extracellular 
domain ofthe pSS receptor reveal that it is dimeric (Bazzoni et al., 1995). 
The exact mechanism of interactions between heterotrimer ligand and dimeric receptor are 
unknown, and theories are reviewed elsewhere (Rink and Kirchner, 1996; Bazzoni and 
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Beutler, 1996). 
The TNF receptors p55 and p75 are expressed on nearly all nucleated cell types. Both types 
ofTNF receptor are shed from the cell membrane and exist in soluble form as biologically 
active receptors, binding free TNF and thereby limiting it's action (Hale et al., 1995). 
The p55 receptor binding with soluble TNF ligand was regarded as the dominant functional 
receptor/ligand unit in TNF responses. However, it has been shown that activation of the 
p75 receptor is maximal when binding membrane bound TNF, and this is more important in 
T cell activation and proliferation than the receptor binding of soluble TNF ( Grell et al., 
1995). This suggests that the p75 receptor has an important physiological role in local 
inflammatory responses. 
Different functions of the two TNF receptors are also suggested by 'gene knockout' studies 
in mice subsequently challenged with lipopolysaccharide (LPS) and soluble TNF. 
Deletion of the p55 receptor results in resistance to the lethal effect of low doses ofLPS in 
D-galactosamine sensitised animals, but not to high doses in unsensitised groups. Animals 
also become highly susceptible to infection by Listeria monocytogenes, which is an 
intracellular bacterium that requires both initial non-specific resistance and later specific T 
cell mediated immunity for resolution of infection. The same p55 knockout mice also 
showed no systemic effects on the administration of (soluble) TNF compared to controls in 
whom high lethality was observed (Rothe et al., 1993). 
Studies of deletion of the p75 receptor did not show the same protection from the effects of 
LPS, but showed decreased lethality {<10% of animals) to the effects ofTNF administration 
compared to controls (100% of animals died) (Erickson et al., 1994). 
The cytoplasmic proteins used by the TNF receptors for signal transduction are an ever 
increasing group, and are reviewed elsewhere (Bazzoni and Beutler, 1996). Expression of 
transcription factors such as NFKB results from TNF receptor signal transduction. 
Expression ofNFKB has many known effects in the immune system, including increasing the 
42 
transcription rate of various cytokine genes (Baeuerle and Henkel, 1994). 
The multiple functions ofTNF (and LTa) are summarised in Fig. 2.2. Effects upon immune 
functions are now discussed. 
2.4.5.1.3 Functions ofTNF in immune and inflammatory responses 
As TNF and L Ta function through the same receptors, they are generally considered to 
have the same effects in acute immune responses. However studies on mice rendered 
deficient in LTa by gene targeting of immune stem cells, show that LTa may have a 
function separate from TNF, as it is necessary for the development of lymph nodes and 
Peyer's patches (De Togni et al., 1994). This may, however, only reflect the fact that an 
LTa molecule is required for the formation ofthe LT~ heterotrimer, which has it's own 
specific receptor that is thought to be important in lymphoid organ development (Crowe et 
al., 1994). 
TNF (and L Ta) is regarded as an initiator of the cytokine network, causing other pro-
inflammatory cytokines such as IL-l (Tracey et al., 1989), lL-6, (Van der Poll et al., 1992), 
and IL-8 (Van Deventer et al., 1993) to be released from and expressed by many immune 
cell types including macrophages, monocytes, T cells, and endothelium. This will result in a 
generalised upregulation of the inflammatory response (Cohen and Cohen, 1996), but it is 
interesting to note that TNF is also known to increase the secretion of IL-l 0 from 
monocytes (Platzer et al., 1995). The transcription of genes encoding for such cytokines is 
thought to be via the activation of the transcription factor NFKB (NFKBIREL unit), which 
can itself be activated by TNF (Baeuerle and Henkel, 1994) 
The endothelial cell is affected in many ways by TNF, which explains early observations of 
the effect ofTNF on leucocyte adherence to endothelial cells (Gamble et al., 1985). 
As previously mentioned TNF induces release of other pro-inflammatory cytokines from the 
endothelial cell, which with TNF affect endothelial cell-leucocyte interaction by different 
pathways (Mantovani et al., 1997). Expression of members of adhesion molecule families 
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such as the selectins are transcriptionally upregulated by TNF (also IL-l) (Panes and 
Granger, 1998) as is the expression ofMHC molecules (Pober et al., 1987). Nitric oxide 
(NO) also has effects upon endothelial cell-leucocyte interaction (see section 2.4.4) . TNF 
affects the production of NO by increasing the activity of NOS (Mantovani et al., 1997). 
The endothelial cell is also a site for TNF induced activation of thrombus forming pathways, 
causing activation of pro-coagulant activity, and inhibiting anticoagulant and fibrin 
pathways (Mantovani et al., 1997). 
TNF activates many other inflammatory cells such as the neutrophil (Van der Poll et al., 
1992), and induces T cell mediated cytotoxicity as well as T cell proliferation(Grell et al., 
1995) B cells are also affected, production of immunoglobulin and cellular proliferation are 
both enhanced . 
The expression of MHC class I (Pober et al., 1987) and IT (Pujol-Borrell et al., 1987) 
molecules are induced by TNF in association with lFNy. This not only occurs on cellular 
components of the immune response, but also on non immune cells such as pancreatic islet 
cells (Pujol-Borrell et al., 1987). 
As well as affecting cellular effectors of the innate immune response, TNF has been 
identified as having effects upon other soluble mediators of the non-specific immune 
reaction. The expression of APP's and components of the complement system (e.g. CRP 
and C3) are enhanced by TNF (Baumann and Gauldie, 1994). Although the effect is thought 
to be by direct action upon hepatocytes, TNF could induce APP's through it's effect as an 
endogenous pyrogen (Selby et al., 1987). Glucocorticoids, released in response to fever can 
stimulate APP production. 
2.4.5.1.4 Involvement ofTNF in cell death 
There are two forms of cell death, necrosis and apoptosis. Necrosis is the type of cell death 
that occurs with hypoxia, or cell membrane damage caused by complement and antibody. [t 
is characterised by ballooning of the cell membrane and lack of nuclear disintegration. 
Apoptosis is characterised by nuclear disintegration and shrinking. Apoptosis is important in 
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CTL mediated cytotoxicity and also in tissue development. 
As expected from it's activating and stimulatory effects upon T and NK cells, TNF plays a 
major role in the mediation of cell death. However TNF can induce both types of cell death 
without the help of cellular mediators in many cell types (Gukovskaya et al., 1997; Laster et 
al., 1988). 
This involvement ofTNF in cell death has relevance to it's inflammatory effects, and 
evidence indicates a physiologic role for TNF induced apoptosis in different tissues. These 
include pancreatic acinar cells (Gukovskaya et al., 1997), adipose cells (Prins et al., 1997), 
and myocytes (Meldrum, 1998). Indeed TNF receptors and ligands are related to the Fas 
receptor and ligand, and their signal transduction proteins and receptor intracellular domains 
have structural homology (Bazzoni and Beutler, 1996). Fas is known to be associated with 
physiological apoptosis occurring in developmental cell lineages such as haemopoetic stem 
cells and gut endothelium. 
2.4.5.1.4 Other effects of TNF 
Some ofthe earliest studies on the functions ofTNF showed that when administered in 
quantities similar to those produced endogenously in response to LPS, TNF induces 
tachypnoea, hypotension, metabolic acidosis, and acute tubular necrosis in the kidney 
(Tracey et al., 1986). This led to it being identified as a central mediator of shock. 
As well as mediating apoptosis in adipocytes (Prins et al., 1997), TNF is known to suppress 
the synthesis oflipoprotein lipase in adipocytes, which may partly explain it's effects in 
producing cachexia (Tracey et al., 1989). TNF is also involved in glucose haemostasis in 
adipocytes, stimulating glucose uptake by itself, whilst inhibiting insulin dependent uptake 
(Wang et al., 1998). 
TNF is also known to have a role in the regulation of connective tissue and bone 
remodelling and has been suggested to have a pathophysiologic role in related disorders. 
TNF suppresses collagen production from fibroblasts (Sato et al., 1998), and induces 
osteoblasts to stimulate osteoclastic bone resorption (Thomson et al., 1987). Recent 
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evidence indicates that TNF plays an important role in the bone resorption that accompanies 
periodontal disease (Assuma et al., 1998). 
The evaluation ofTNF in the circulatory system has grown apace in recent years. It is 
produced by cardiac myocytes as well as cardiac macrophages. It's exact role in the 
pathogenesis of cardiac disease is not clear at present. TNF has been found to depress 
myocyte and left ventricular contractility (Meldrum, 1998), whilst recent evidence from 
studies upon isolated myocytes indicates that it protects the heart from hypoxic injury 
(Nanako et al., 1998). 
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Fig. 2.2 Summary of biological effects of TNF on immune cells, selected organs, and 
cells of the body. 
Although many cell types produce TNF, the main source ofthe cytokine is the macrophage. 
Many of the cell types illustrated express TNF themselves, where it may act in an autocrine 
or paracrine fashion. TNF also mediates apoptosis in some cell types illustrated, e.g. 
Adipocyte, Myocyte. 
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2.4.5.2 Interleukin-1 (IL-l) 
IL-l is the name given to two structurally related molecules, IL-l a, and IL-l P. The two 
molecules are 26% homologous at the amino acid level, and share common receptors (IL-
l RI and IL-l RII) , so display identical biological properties (Platanias and Vogelzang, 
1990) There exists a naturally occurring antagonist to IL-l, the IL-l receptor antagonist 
(IL-l ra), which also is a ligand for both IL-l receptors. Both IL-l molecules, IL-l ra, and the 
two receptors are encoded for on the long arm of chromosome 2 (Copekland et al., 1991; 
Nicklin et al., 1994). 
Like TNF, the major cell of production is the macrophage, but it is also produced by other 
immune cells, connective tissue cells, and many other nucleated cells of the body (Piatanias 
and Vogelzang, 1990). 
IL-l a and IL-l P are synthesised as precursor molecules, and in a similar fashion to the TNF 
ligands are cleaved by specific proteases to produce their active forms. 
The IL-l receptors are located on many cell types, and share 28% homology in their ligand 
domains, the main structural differences being within their cytoplasmic domains. As is the 
case with TNF, the transcription factor NFKB is an important mediator ofiL-1 induced 
gene transcription (Baeuerle and Henkel, 1994 ). 
Functionally, IL-l shares many functions with TNF (Cohen and Cohen, 1996). In the 
immune system resultant macrophage activation results in the release of more pro-
inflammatory cytokines such as TNF and IL-6. Phagocytic cell activity is enhanced, T cells 
are activated, and B cells are stimulated to produce immunoglobulin (Piatanias and 
Vogelzang, 1990). Endothelial cells are activated (in conjunction with TNF) by IL-1. This 
results in MHC expression on endothelial cells (Pober et al., 1987), activation of 
coagulation pathways, induction ofNO production (Mantovani et al., 1997), and expression 
of adhesion molecules (Panes and Granger, 1998). IL-l is also an endogenous pyrogen and 
increases the production of APP and complement components from the liver (Baumann and 
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Gauldie, 1994). 
As previously described, TNF is an important mediator of cell death in normal states and 
disease. lL-1 also plays a role in such events. As well as the activation of cells which have a 
cytotoxic role, lL-1 has direct cytolytic effects, first demonstrated on tumour cells (Onozaki 
et al., 1985). 
lL-1 is also involved in connective tissue and bone biology. lL-1 decreases collagen 
secretion in fibroblasts (Chesney et al., 1998), and stimulates bone resorptive activity, both 
similar to effects seen with TNF. 
2.4.5.3 Platelet activating factor (PAF) 
Platelet Activating Factor (P AF) is a potent phospholipid mediator which is involved in a 
wide range of physiological and pathological events. 
Whilst it's name implies a specific role (as does TNF), P AF is synthesised and released in 
numerous cell types and tissues upon which it also exerts it's multiple effects. P AF is 
synthesised by similar immune cell types that secrete lL-1 and TNF. Endothelial cells, 
neutrophil polymorphs, monocytes and macrophages all produce P AF (Braquet et al., 
1987), and it is also produced by other tissue cells such as the pancreatic acinar cell (Soiling 
and Fest, 1986). 
In spite of the fact that P AF is a phospholipid and can simply be incorporated into the 
membrane, in common with other cytokines it does act upon specific receptors which exist 
upon the surface of responsive cells (Chao and Olson, 1993). The receptor has been cloned 
and evidence seems to indicate that GTP-binding proteins are involved in signal 
transduction (Honda, 1991 ). 
P AF functions in normal physiological processes including haemostasis, inflammation, 
pressor activity and reproduction (V enable et al., 1993). PAF in vitro causes activation of 
platelets, polymorphonuclear leucocytes, monocytes and macrophages, and in vivo P AF 
causes hypotension, increased vascular permeability, decreased cardiac output , acute 
bronchoconstriction, and increased leucocyte adherence to endothelial cells (Braquet et al., 
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1987), presumably by similar mechanisms to the effects produced by IL-l and TNF 
(Mantovani et al., 1997). 
It is through this enhancement of transmigration of activated polymorphonuclear leucocytes 
from postcapillary venules into the interstitium of organs such as the lung, kidney, 
myocardium and liver that is believed to be one of the principal mechanisms through which 
PAF exerts it's pathobiological effect. Once within the tissue spaces of these organs the 
activated polymorphs release proteolytic enzymes, elastases and superoxide ions, and other 
tissue damaging substances such as Cathepsin B. This results in the release of potent tissue 
damaging substances such as proteolytic enzymes, elastases and superoxide ions(Braquet et 
al., 1987). 
2.4.5.4 lnterleukin 10 (IL-10) 
Interleukin-1 0 (IL-l 0) is a cytokine that plays an important role in the regulation of 
inflammatory and immune responses through it's influence on several cells of the immune 
system It was first identified a decade ago as a mediator secreted by T H2 cells that inhibited 
cytokine production and subsequent effector functions ofTH 1 cells (Fiorentino et al., 1989). 
Subsequent studies of the IL-l 0 ligand and receptor have revealed that IL-l 0 is secreted 
and has effects on many more immune cell types. It mediates suppression of cell mediated 
immunity (CMI) and inflammation, and promotes the humoral response by playing a 
supporting role in the development ofTH2 responses. 
The ability to secrete IL-10 has been demonstrated in T11 cells (CD4+), Tc cells (CD8+) (Ho 
and Moore, 1994), B cells (O'Garra et al., 1992), the monocyte/macrophage lineage (Moore 
et al., 1993), neutrophils (Cassatella and Meda, 1994), NK cells (Mehrota et al., 1998), and 
keratinocytes (Enk and Katz, 1992). As can be expected immune cells within tissues also 
secrete IL-10. Kupffer cells in the liver (Knolle et al., 1995)and T cells of the intestinal 
mucosa (Braunstein et al., 1997) are such examples. However non-immune cells 
(hepatocytes and intestinal epithelial cells) of these organs have also been shown to express 
and secrete IL-10 (Napolitano et al., 1997; Ishizaka et al., 1996). 
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2.4.5.4.1 Structure 
Human IL-10 is a homodimer with a molecular weight of39kD (de Waal Malefyt et al., 
1992). The protein structures were derived from cDNA clone sequences and indicate a 178 
amino acid polypeptide (Ho and Moore, 1994). Unlike the TNF ligand it does not have a 
transmembrane domain precursor (Gallea-Robache et al., 1997), so may be produced in 
active form. Recent evidence seems to indicate that the IL-l 0 molecule has two functional 
domains. One region activates the anti-inflammatory properties of IL-l 0, inhibiting release 
of pro-inflammatory cytokines (including TNFa and IL-l) and chemokine and MHC class Il 
expression on mononuclear cells, whilst the other domain seems to be involved in regulation 
of mast cell proliferation (Gesser et al., 1997). 
The gene for IL-10 is located on chromosome 1, and will be discussed in section 4.2. 
2.4.5.4.2 Receptor 
IL-10 has one receptor, designated IL-IOR, which is ofthe size 90-120kD. lt is a trans-
membrane protein, and in solution interacts with it's ligand by forming a complex of two 
IL-l 0 dimers and four receptor monomers (Tan et al., 1995). The mechanism of interaction 
between ligand and receptor on the cell surface is unknown. 
IL-l OR has been identified on a number of haemopoetic cells, including 
monocytes/macrophages and T cells (Liu et al., 1994). In stark contrast to the situation with 
TNF receptors (see section 2.4.5.1.2), expression has mainly been identified on the 
haemopoetic cell lineage 
IL-l OR is structurally related to the IFN-y receptor (IFNR). As IL-l 0 inhibits IFN-y 
activation of macro phages, and inhibits release of pro-inflammatory cytokines (e.g. IL-12) 
that are induced by IFN-y (Trinchieri, 1997), this has raised the possibility that IFN-y and 
IL-l 0 share a receptor or components of signal transduction pathways. 
Pathways of IL-l OR signal transduction are under investigation at present. Present 
evidence seems to indicate two different pathways of signal transduction, involving separate 
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series of different cytoplasmic proteins, for the proliferative and inflammatory effects of IL-
10 (Crawley et al., 1996; O'Farrell et al., 1998). 
2.4.5.4.3 Functions ofiL-10 
The functions of IL-l 0 are summarised in figure 2. 3. 
IL-l 0 was first identified as a mediator secreted by TH2 cells that inhibited cytokine 
production from T HI cells (Fiorentino et al., 1989). Subsequent investigations have 
confirmed similar effects upon other cell types including monocytes/macrophages and 
neutrophils, and NK cells. 
T ~d cells show diminished secretion of cytokines including IFN-y . TH I production of other 
pro-inflammatory cytokines such as TNF is also slightly affected (Gesser et al., 1997). 
In contrast, macrophage secretion of TNF is profoundly suppressed by IL-l 0 (Hart et al., 
1995; Fiorentino et al., 1991 ). The same is true for other pro-inflammatory cytokines such 
as IL-l (Schreiber et al., 1995; Fiorentino et al., 1991), IL-6 (Fiorentino et al., 1991), and 
IL-12 (Trinchieri, 1997). Interestingly, in line with the general anti-inflammatory effect, 
macrophage production ofthe endogenous IL-l antagonist (IL-lra) is increased by IL-10 
(Gesser et al., 1997). 
TNF receptor expression on macrophages in response to IL-l 0 has also been studied. The 
most recent evidence indicates that cell surface levels of the TNF receptor (p75 ) increase 
initially on the cell surface (Dickensheets et al., 1997; Hart et al., 1996). This however is 
accompanied by an increase in the levels of soluble TNF receptor, shed from cell 
membranes, seen in supernatants of cultured macrophages (Hart et al., 1996). This may 
indicate that IL-l 0 promotes limitation of the activity of TNF on other cells by the binding 
of free TNF with the shed (soluble) receptor. The significance of these findings is not clear, 
as the same cells subsequently cultured with TNFa increase their IL-Ia production, which 
would be expected to have the same pro-inflammatory effects as TNF. Studies of the effect 
of IL-l 0 upon p55 (TNF) receptor expression on mononuclear cells have produced 
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conflicting data, so limiting interpretation. 
PAF production from monocytes and neutrophils is also affected by IL-10. 
Lipopolysaccharide (LPS) stimulates an early release ofP AF from these cell types, but 
sustained production is dependent upon stimulation by pro-inflammatory cytokines {TNF, 
IL-l). TL-1 0 blocks this cytokine-dependent sustained release of P AF in mononuclear cell 
cultures, but conversely it increases early production ofPAF in the presence ofLPS 
(Bussolati et al., 1997). The unexpected finding may be due to the fact that initial 
production ofP AF does not require protein synthesis, only cleavage from a membrane 
precursor (Braquet et al., 1987), and IL-l 0 acts only to reduce protein synthesis by effects 
upon gene transcription. 
Similar effects upon OFR production by the same cell types were seen in the same series of 
investigations. The authors postulated that the superoxide production was secondary to 
PAF release, as it was blocked by a P AF antagonist (Bussolati et al., 1997). 
NK cells also show reduced pro-inflammatory cytokine (IFN-y) secretion upon incubation 
with IL-10 (de Waal Malefyt et al., 1992). This effect is not seen in the presence ofthe pro-
inflammatory cytokine IL-2, indicating that suppression of cytokine production by IL-l 0 in 
NK cells may require other cellular or soluble effectors . It also serves to remind us that 
regulation of immune responses by cytokines is a complex affair, and in vitro studies do not 
necessarily relate to the in vivo situation. 
As well as affecting cytokine synthesis by T cells and producing effects upon them through 
the reduction in macrophage derived cytokines, IL-l 0 inhibits antigen specific T cell 
proliferation. This appears to be due to the diminished function of APC' s, as IL-l 0 reduces 
MHC class Il expression on monocytes (de Waal Malefyt et al., 1992; Gesser et al., 1997; 
de Waal Malefyt et al., 1991). 
Expression of other cell surface molecules involved in immune responses is also affected by 
IL-l 0. The expression of chemokines (e.g. IL-8) on macrophages is suppressed, resulting in 
reduced chemotactic activity ( Gesser et al., 1997). 
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IL- 10, in conjunction with it's modulation of T H cell cytokine production, which results in 
reduction of the T H 1 response, encouraging a T H2 mediated antibody response (see section 
2.3.5.3}, also directly affects B cell function by working as a co-stimulator of proliferation 
and antibody production, and a eo-regulator ofB cell apoptosis. 
Memory B cells are stimulated to develop into functional plasma cells by IL-l 0 when acting 
in conjunction with IL-2 and IL-3, but this effect requires that the cell surface molecule 
CD40, expressed on the B cell, is ligated (Kindler and zubler, 1997; Rousset et al., 1992). 
CD40 and it's ligand, which is expressed on the surface ofTH cells, are members of the 
TNF family ofligands and receptors (Bazzoni and Beutler, 1996). Immunoglobulin 
production is also seen to be increased upon ligation ofCD40. This effect is also enhanced 
by the presence of IL-l 0 (Ho and Moore, 1994). CD27 is another cell surface molecule 
which when ligated promotes the differentiation ofB cells into plasma cells. IL-l 0 is again 
seen as a co-stimulator of this process. When CD27ligation occurs in the presence ofiL-
10, increased numbers ofplasma cells are seen (Agematsu et al., 1998). 
Proliferation of the B cell and plasma cell is in part controlled by the rate of apoptosis. lL-
10 has been shown to act as a modulator of this process. This appears to be a bi-phasic 
phenomenon, as studies show that when IL-l 0 is present upon initial activation of the B cell 
in response to antigen, apoptosis is facilitated. However when IL-l 0 doesn't appear until 72 
hours after the initial activation, perhaps a more accurate reflection of the in vitro situation, 
B cell apoptosis is seen to be reduced (ltoh and Hirohata, 1995). 
IL-l 0 also acts to reduce apoptosis in T cells, so allowing proliferation in response to IL-2. 
Similar effects are also seen on neutrophil and macrophage apoptosis (Arai et al., 1995; 
Keel et al., 1997). The effect in T cells may be due to IL-10 mediated upregulation of Bcl-2 
expression (Cohen et al., 1997). Bel is an oncogene with an established role in the 
regulation of lymphoid cell apoptosis. 
There has also been interest in the role of IL-l 0 in allergic inflammation. IL-l 0 is known to 
act upon mast cells to reduce the secretion of pro-inflammatory cytokines and eosinophilic 
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As can be seen, the overall effect of IL-l 0 is to mediate suppression of cell mediated 
immunity (CMI) and inflammation, and promote the humoral response by playing a 
supporting role in the development of T112 responses. 
* These effects are by facilitating effects of other cytok:ines and CD cell surface molecule 
ligation upon the B cell (see text for details). 
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2.4.5.5 Chemokines 
The chemokines are a group of chemoattractant cytokines involved in the activation and 
trafficking of inflammatory cells. They are a very large family, to date around fifty related 
proteins are known, classified into 2 broad groups, a (C-X-C) or p (C-C) chemokines 
depending upon their structure (Premack and Schall, 1996). The a (C-X-C) group has two 
cysteine residues separated by another amino acid, whilst the p (C-C) group has two 
adjacent cysteine residues. Most a chemokines are chemoattractant for neutrophils but not 
monocytes, and most p chemokines are chemoattractant for monocytes and lymphocytes, 
but not neutrophils. Chemokine ligands and receptors are expressed by many cells involved 
in migration towards inflammation (monocytes/macrophages, neutrophils, T cells) and by 
platelets and endothelial cells (Mantovani et al., 1997). Evidence is emerging that 
chemokines are also expressed by other cells involved in inflammatory processes, such as 
the pancreatic acinar cell in acute pancreatitis (Grady et al., 1997). 
IL-8 is a well characterised (a) chemokine. lt is known to affect endothelial cell-leucocyte 
interaction, mediating the adherence ofleucocyte to the endothelial cell, and promoting 
their subsequent extravasation. This is via activation of adhesion molecules such as the 
integrins (Panes and Granger, 1998). Chemokines not only mediate cellular extravasation, 
but are also able to attract inflammatory cells to exact sites of inflammation by the 
mediation of binding not only to inflammatory and endothelial cells but also to the 
extracellular matrix (Lioyd et al., 1996). 
2.5 Upregulation of the Inflammatory response: progression to the systemic 
inflammatory response syndrome (SIRS) 
Inflammation is a complex, initial, non specific response produced by the body in response 
to tissue injury produced by mechanical, physical, or infectious stimuli. By it's nature 
inflammation is rapid in onset and is highly amplified, mediated and effected by humoral and 
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cellular components of the immune system previously described. The inflammatory response 
is at first a local response, but may become more widespread, with distant organ systems 
becoming involved by inflammatory processes. 
2.5.1 Inflammation 
Inflammation traditionally consists of four classical symptoms, rubor (erythema). tumor 
(swelling/oedema), calor (heat), and do/or (pain). These reflect major events in the 
inflammatory process; vasodilatation, increased microvascular permeability, cellular 
activation/adhesion, and activation of complement, coagulation, fibrinolytic, and kinin 
systems. As previously described, the cells activated in the initial phase are the endothelial 
cell, neutrophil and macrophage. Activation results in their increased metabolism, with 
consequent release of inflammatory (e.g. TNF, IL-l) and regulatory cytokines (e.g. IL-lra, 
IL-l 0). Adhesion molecules and receptors are expressed, and secondary inflammatory 
mediators and effectors including prostaglandins, OFR's, nitric oxide, and proteases are also 
released. Mediators trigger release of APP's from the liver, recruit T cells and increase class 
II MHC expression, resulting in the involvement and activation ofT cells in the 
inflammatory process. 
The local inflammatory response is physiologically protective, promoting healing and repair 
of damaged tissue. However, if inflammation is not controlled locally or is exaggerated, 
systemic inflammation ensues. 
2.5.2 Systemic inflammatory response 
The upgrading of inflammation to involve systemic organ systems is well recognised. The 
clinical picture produced is called the systemic inflammatory response syndrome (SIRS), the 
sequelae of which is multiple organ dysfunction syndrome (MODS). 
It has been proposed that there are three stages in the development of SIRS (Bone, 1998). 
Stage I involves initiation of the local inflammatory response. Stage li is either a controlled 
amplification of the process, or a loss of homeostatic control. Stage Ill is the development 
of SIRS with the advent of MODS. It is summarised in Figure 2.4. 
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The reason for this loss of local control is not fully understood. One might hypothesise that 
persistence or increased severity of the initial insult would cause SIRS, but this cannot 
always be the case, as infection is not always found to persist in patients with MODS after 
sepsis (Goris et al., 1985), and severity of pancreatic damage does not always correlate with 
the development ofMSOF in acute pancreatitis (Banks et al., 1996). 
Although it does not explain the precise mechanism of the development of SIRS, it is 
commonly thought that the process occurs due to the (inappropriate) systemic release of 
locally produced cytokines (specifically pro-inflammatory cytokines such as TNF and IL-l) 
which initiate inflammatory processes in other organs (Kusske et al., 1996b; Kingsnorth, 
1997b; Davies and Hagen, 1997b). 
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Figure 2.4 Stages in the development of SIRS 
Stage I involves initiation and propagation of the local inflammatory response. Stage II is 
either a controlled amplification of the process, or a loss of homeostatic control. Stage Ill is 
the development of SIRS with the advent ofMODS. 
SIRS Systemic inflammatory response 
MODS Multiple organ dysfunction syndrome 
Adapted from (Davies and Hagen, 1 997) and (Bone, 1998) 
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The involvement of TNF and IL-10, the cytokines studied in this work, in the development 
of SIRS can be inferred from the multiple functions of both these cytokines which have 
already been discussed in this chapter. However, their role in the development of SIRS will 
briefly be summarised with discussion of evidence resulting from clinically based studies. 
2.5.3 TNF and IL-10 in the development ofSffiS 
As previously discussed TNF ( along with IL-l) is heavily implicated as a pivotal cytokine 
in the regulation of inflammation. Administration ofTNF to animal models results in the 
pathophysiological events associated with SIRS (Van der Poll et al., I 992; Tracey et al., 
1986), and passive immunisation with anti-TNF antibody confers protection against 
manifestations of SIRS and death seen in bacterial sepsis (Tracey et al., 1987) or endotoxin 
administration (Beutler et al., 1985). 
There is however evidence in animal models that TNF is also required for normal 
functioning of immune responses, and is indeed protective against bacterial infection. Mice 
show increased early resistance to Listeria infection when pre-treated with TNF (Havell, 
1989), and recombinant TNF administration has been shown to ameliorate systemic effects 
of peritoneal gram negative sepsis (Echtenacher et al., I 990; Alexander et al., I 991 ), when 
given early in the disease process. Similar results have already been described for models 
studying the effect ofTNFR p55 deletion in mice (Rothe et al., 1993) in section 2.4. 5.1.2. 
These results confirm that the functions ofTNF are complex, for as well as having 
deleterious effects, TNF seems to be required for normal immune system functioning. 
Studies measuring serum levels ofTNF have been done in septic patients. However, results 
vary widely. The measurement of serum cytokine levels can be problematic (McLaughlin 
and Davies, 1990), and studies have used different anti-TNF antibodies in their varied 
immunoassays Also TNF has a short halflife in serum of 14-18 minutes (Davies and 
Hagen, 1997), and many effects are by paracrine and autocrine routes. Correlation has been 
made between higher median plasma TNF measurements and mortality in heterogeneous 
groups of septic patients (Damas et al., 1989; Debets et al., 1989), but conclusions are 
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based on evidence which is subject to some criticism. For example, serum TNF was 
detected in only 25% of patients in one study (total =43), but presence of detectable TNF 
did correlate with mortality (Debets et al., 1989). In contrast, in a smaller group of patients 
with comparable severity of sepsis (both studies used the same scoring system) serum TNF 
was detectable in all patients. This study also correlated mortality with mean TNF levels, the 
mean being raised by 17% (n=3) of patients with levels up to ten times higher than in others 
who died. The opposite conclusion has been arrived at by a recent study, which suggests 
that survival, not mortality, correlates with high serum TNF levels. Studying a slightly less 
heterogeneous group of patients with abdominal sepsis, no association in serum TNF levels 
was seen between survivors and non-survivors. Again, wide variability in levels was seen, 
and a significantly higher number of survivors did have a serum TNF level greater than 
200pg mr 1 (Riche et al., 1996). 
Evidence reviewed in section 2.4 6.4 implicates IL-l 0 as a key regulatory cytokine, 
modulating release and effects of pro-inflammatory cytokine release. Animal models show 
that IL-l 0 confers protection against pro-inflammatory cytokine release and the lethal 
effects of SIRS (Gerard et al., 1993; Howard et al., 1993; Bean et al., 1993). One group of 
investigators noted, however, that IL-1 0 did not diminish activation of components of the 
coagulation or fibrinolytic systems and only modestly affected neutrophil recruitment and 
degranulation (Van der Poll et al., 1997). Serum IL-10 is noted to be raised in 57% of 
patients with septicaemia, whilst only being present in 12% of patients without sepsis or 
inflammatory disease (post-surgical, cancer, and cirrhotic patients). Also, levels are 
significantly higher in septic patients with circulatory failure (Systolic BP<90 mmHg) than 
in septic patients without (Marchant et al., 1994). 
In the clinical situation, although it is generally believed that TNF up-regulates systemic 
inflammation, and IL-l 0 functions to modify it's release and effects, evidence has been 
produced that indicates that high levels of serum IL-1 0, and a higher IL-l 0 to TNF ratio 
(both serum measurements) are associated with death a in large, n=464, group of febrile 
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patients (mostly, 86%, due to varied causes oflocal and systemic sepsis) (van Dissel et al., 
1998). In the study, no significant differences were seen in mean serum TNF levels on their 
own. This is interesting data, and although it is possible that the cytokine profile detected in 
this study may indicate the body's (unsuccessful) attempts to deal with the inflammation, the 
same authors have produced evidence with comparable conclusions in studies of relatives of 
patients with meningococcal disease (Westendorp et al., 1996). This study first 
demonstrated a strong genetic influence upon TNF and IL-l 0 production, and showed that 
low TNF production in first degree relatives of patients increased the risk of death from 
meningococcal sepsis I 0-fold. Similarly high IL-l 0 production in relatives increased the risk 
of death in patients 20-fold. This study will be discussed further in chapter 4. 
2.6 Important concepts of immune system function 
Previous sections have described cells and their surface molecules involved in immune 
responses and the mediators that affect those responses. The basis of an immune response is 
recognition of exogenous and endogenous antigens, recognition of self and discrimination 
from non self, and subsequent response. To be able to discriminate between self and non 
self(foreign cells/tissues or altered self), and protect itself from it's own potentially self 
reactive effector cells, the immune system has to develop tolerance to the body's own 
antigenic determinants. The ability to produce a highly effective immune response to re-
challenge with non-self antigens depends upon the immune system being capable of 
memory. Breakdown of tolerance to self antigenic detenninants is the basis of 
autoimmunity. A detailed description of the mechanisms of these concepts is outside the 
scope of this work; however, a general overview is given. 
2.6. L Memory 
As previously discussed both B cells, through immunoglobulin diversity, and T cells, via 
TCR diversity, can recognise and react to the enormous range of potential antigens. Naive 
B and T cells, already induced with tolerance during foetal development, bind with 
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previously unencountered (presented) antigen, and mount a response after a lag phase 
during which clonal expansion oflymphocytes specific to the antigen occurs. This clonal 
expansion results in the formation of effector and memory lymphocytes. Memory cells have 
a long life, possibly due to the fact that exposure to antigen has somehow programmed 
them for long life, so are able to persist in lymphoid tissues, and because they are already 
clonally expanded are able to mount an effective and rapid secondary response. 
2.6.2 Tolerance 
Tolerance to self is acquired by clonal deletion of developing B and T lymphocytes. Their 
natural diversity to antigen recognition includes ability to recognise self antigens, whether 
they are bound (in the case ofT lymphocytes) to MHC molecules, or not (B cell 
recognition). In the developing foetus selection oflymphocytes non-reactive to self antigens 
occurs. In this stage of immune system development the exposure of lymphocytes to 
abundant self antigen results in clonal deletion of the cells recognising that particular 
antigen. The MHC molecules themselves act as antigens, and clonal deletion of cells 
reactive to selfMHC molecules without bound antigen also occurs. Once the immune 
system has developed, before birth in the human, further tolerance cannot develop. 
2.6.3 Autoimmunity (Inappropriate immunity) 
Autoimmunity, which should perhaps be best called inappropriate immunity, can be 
considered as a dysfunction of the immune system. It has been regarded as break down of 
tolerance to self, but may be due to the alteration of self by pathogenic organisms or agents, 
resulting in body cells recognised as foreign, to which a response is mounted. 
Autoimmunity can be organ specific, where response is directed against a specific cellular 
component of an organ ( e g. type I, insulin dependant, diabetes mellitus ), or systemic, 
where autoantibodies are produced against a wide range of antigenic determinants in 
multiple organs or tissues and/or immune complexes produce damage in a number of organs 
(e.g. systemic lupus erythematosus, SLE). Antibody or effector T cells can cause the 
damage seen in autoimmune disease. 
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There are a number of possibilities as to how autoimmunity can arise: 
a) Antigenic similarities may occur between antigenic components of pathogens and self 
antigens. This is termed molecular mimicry. A good example is rheumatic fever, where 
antibodies to group A streptococci react with cardiac myosin (Dale and Beachey, 1985). 
Viral T cell epitopes also have similarities to selfpeptides (Wucherpfennig and 
Strominger, 1995), and could lead to an autoantigen directed T cell response. 
b) Self antigens not previously encountered by the immune system, could be released 
following damage to cells by toxic influences. This cannot be regarded as a break down 
of tolerance, but rather an immune response to an antigen recognised as foreign. 
c) The MHC has been found to be associated with the development ofautoimmune disease. 
A good example is the association between HLA-DRJ and DR4 and type I diabetes 
(Wolf et al., 1983 ). Presumably such associations occur because different MHC 
molecules may vary in their affinity for antigenic peptides, be they self or exogenous. 
Indeed one single variation (polymorphism) in an amino acid residue of the HLA-DQ 
molecule jj chain confers susceptibility to type I diabetes (Morel et al., 1988; Todd et al., 
1987). These associations, however, are not by themselves causative, and imply the 
presence of other (environmental) factors in the development of autoimmunity. 
d) MHC molecules may be aberrantly expressed on non-APC tissue cells, allowing antigen 
from internal cellular components to be combined with and presented by the secreted 
MHC molecule. There is evidence for aberrant MHC expression in both thyroid 
autoimmune disease and type I diabetes (Pujol-Borrell et al ., 1986). IFN-y is known to 
induce expression of class U MHC molecules on a number of non immune cells (Janeway 
and Travers, 1996), including pancreatic jj cells, thyroid acinar cells and intestinal 
epithelial cells. It has been hypothesised that infection and trauma, both resulting in local 
IFN-y production, cause MHC expression on non APC cells, resulting in inappropriate T 
cell activation. IFN-y would also induce the production of other pro-inflammatory 
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3 Pathogenesis of acute pancreatitis 
3.1 Pathological features in acute pancreatitis 
3.1.1 Pancreas 
The gross and microscopic appearance of the pancreas is variable depending upon the 
severity of the disease. When the local inflammatory process is only mild the pancreas 
appears swollen and oedematous. If the local inflammation is severe the gland structure 
appears very disordered, with varying degrees of necrosis and haemorrhage. Fat necrosis 
appears as yellow plaques and nodules in the pancreas, throughout the mesentery, and 
dotted around the peritoneal fat. Ascites is often an accompanying feature, being turbid or 
haemorrhagic if the gland is severely diseased (Rosai, 1998). 
Microscopic appearances in the early stages of human acute pancreatitis are assumed to be 
similar to those seen in experimental animals. Acinar cells lose their polarity and zymogen 
granules accumulate. Vacuoles form after fusion of these granules with lysosomes (Steer 
and Meldolosi, 1987). Other early changes involve interstitial oedema and intravascular 
margination ofleucocytes. An inflammatory cell infiltrate of neutrophil polymorphs and 
monocytes is also seen (Formela et al., 1994; Schoenberg et al., 1990), being especially 
evident at areas of acinar cell necrosis. Haemorrhage appears and is associated with fat and 
parenchyma! necrosis (Lerch et al., 1992). The Islets of Langerhans appear to be more 
resistant to damage, although most become necrotic (Senninger et al., 1986). 
3.1.2 Other organs 
The lung, often the first systemic organ to be affected in severe acute pancreatitis, is 
affected by a diffuse alveolar injury, the clinically defined Adult Respiratory Distress 
Syndrome (ARDS). Oedema, intra-alveolar haemorrhage and fibrin deposition occur early, 
and macrophages and polymorphs accumulate in the interstitial space (Murakami et al., 
1995). Hyaline membranes form to line alveolar ducts and alveoli. 
Damage to the kidney can also occur, often occurring secondary to hypotension and 
vascular depletion. The kidneys become pale and enlarged as cellular components become 
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ischaemic, swell, and die. The tubular epithelial cells and interstitium are most susceptible to 
ischaemic damage, and inflammatory cells infiltrate the interstitium. 
Cardiovascular failure is also common. Failure is secondary to physiological events, so no 
gross pathological changes are seen acutely. 
3.2 Pathogenesis of acute pancreatitis 
Following the initiation of the disease, resulting in acinar cell damage, the 
pathophysiological process is understood to progress in three phases. Local inflammation is 
followed by a varying degree of systemic inflammatory response, which can progress to 
overwhelming sepsis with the translocation of bacteria from the gastrointestinal tract. 
In spite of decades of investigation, elucidation of the pathogenic mechanism of acute 
pancreatitis remains a difficult challenge. Major obstacles include the inaccessibility of the 
human pancreatic gland, technical difficulties in experimentation with pancreatic enzymes 
and tissues, and the lack of correlation between experimental animal models of acute 
pancreatitis and human disease which may limit the clinical application of laboratory 
research (Bane~ee et al., 1994; Steinberg and Schlesselmann, 1987). 
3.2.1 Experimental models used to study the pathogenesis of acute pancreatitis 
Various animal models of acute pancreatitis have been used to study the pathogenesis of 
acute pancreatitis. In this chapter, evidence is presented which has been produced in models 
which differ from each other in mode of disease initiation and severity, both at 
morphological levels in the pancreas and in effects on systemic organ function and animal 
mortality. Basic methodological details of the five in vivo animal models used in studies 
described in this work are presented in Table 3.1, which also gives information on the 
severity of disease produced, both local and systemic. A more comprehensive review has 
been published in recent years (Bane~ee et al., 1994). 
In view of the different pathophysiological mechanisms which must exist in the development 
of acute pancreatitis, no single experimental method produces the ideal model, and this must 
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Type Agent 
Secretagogue Caerulein 
(CCK analogue) 
Diet-induced CDE Diet 
Duct injection Bile!Taurochlorate 
Duct ligation NI A 
Microvascular Microspheres 
Administration 
Intraperitoneal 
Intravenous or 
subcutaneous 
Oral 
Pancreatic duct 
NIA 
Artery supplying 
pancreas (branch of 
splenic) 
Animal Effects on pancreas 
Rat Oedema 
Mouse Necrosis 
Mouse (female) Haemorrhage and 
peripancreatic fat necrosis 
Rat, Dog, Cat Oedema and necrosis 
Rat, Oppossum Necrosis and haemorrhage 
Rat Oedema, haemorrhage, 
and fat necrosis 
Systemic effects 
Lung injury (ARDS like) 
Lung injury (ARDS like) 
Acidosis, hypoxia, and 
hypovolaemia 
Low systemic complication rate 
Lung, kidney failure 
High mortality 
Lung injury 
------··---·-----------------------
Table 3.1 Animal models of acute pancreatitis: Overview of methodology and local and systemic effects 
CDE Choline-deficient ethionine-supplemented 
CCK Cholecystokinin 
ARDS Adult respiratory distress syndrome 
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3.2.2 Disease Initiation 
The precise mechanisms which lead to initial acinar cell damage are not fully understood. As 
already outlined, acute pancreatitis is a disease with multiple different aetiologies, so 
different mechanisms may operate to initiate damage and subsequent inflammation in the 
acinar cell. This first phase in the pathogenesis of the disease has been most investigated in 
relation to the two main aetiologies, alcohol and gallstones, but other mechanisms of 
initiation are apparent with other less common aetiologies and will also be discussed. 
3.2.2.1 Alcohol 
Clinically, pancreatitis caused by excessive consumption of alcohol occurs in both acute and 
chronic forms. Acute alcoholic disease can be defined as an episode of acute 
pancreatic inflammation occurring without evidence of chronic pancreatitis (e.g. 
calcifications and cysts). The first attack of alcoholic acute pancreatitis is often considered 
to be a step in the development of chronic pancreatitis (Lankisch and Banks, 1998c), and a 
recent epidemiological study provides evidence to support this view (Lankisch et al., 1998). 
Therefore evidence supporting hypotheses relating to the pathogenic mechanism of alcohol 
in acute and chronic pancreatitis will be discussed. 
3.2.2.1.1 Ethanol as an acinar cell toxin 
Ethanol has been postulated to have a direct damaging effect upon the acinar cell (Meier, 
1995). The evidence supporting this is provided by a number of observations describing 
different effects of ethanol or it's metabolites. 
Chronic ethanol ingestion by rats causes fatty changes in the acinar cell, which may be a 
result of disordered intracellular lipid metabolism, as cells have an increased cholesteryl 
ester content. Ethanol exposure was also shown to decrease secretory capacity of acinar 
cells and increase their lipase content (Wilson et al., 1988), which may lead to intracellular 
damage. 
This leads to the theory that increased acinar cell enzyme production and accumulation may 
override endogenous protection mechanisms and has been supported by the recent 
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demonstration of increased intrapancreatic mRNA levels for digestive enzymes (lipase, 
trypsinogen, chymotrypsinogen) in rats fed ethanol for four weeks (Apte et al., 1998). 
Metabolites of ethanol have also been shown to injure pancreatic acinar cells. Fatty acid 
ethyl esters (F AEEs), non-oxidative products of ethanol metabolism found in high levels in 
the pancreas in intoxicated humans, infused into rats at levels comparable to that found in 
the human, produce pancreatic oedema, trypsinogen activation, and vacuolisation of acinar 
cells (Werner et al., 1997a). 
3.2.2.1.2 Effects on ducts and ductules 
Precipitates of proteins or 'plugs' have been demonstrated at high levels compared to 
controls in pancreatic juice of alcoholics with pancreatitis (Guy et al., 1983). These are 
hypothesised to cause obstruction and subsequent damage. Formation of these will depend 
upon concentration of proteins within the ducts. Lithostathine, a pancreatic secretory 
protein, is a major component of protein plugs. In the rat pancreas mRNA levels for 
lithostathnine increase after four weeks of ethanol exposure in the diet (Apte et al., 1996). 
Direct measurement of the same protein, previously called pancreatic stone protein (PSP), 
in the pancreatic juice of alcoholics with chronic pancreatitis has however produced 
conflicting results (Schmiegel et al., 1990; Multigener et aL, 1985). 
Duct permeability is also altered by ethanol exposure in a cat model, which may trigger 
autodigestion of the gland by allowing macromolecules including digestive enzymes to 
escape into the interstitium (Wedgwood et aL, 1986). 
3.2.2.1.3 Effect upon Sphincter of Oddi tone 
Alcohol may interfere with Sphincter of Oddi motor activity, causing reflux of duodenal 
contents culminating in acinar cell damage (Gotf, 1993). In the presence of a common 
channel (see Section 1.1. 1) bile could also reflux into the pancreatic duct. However, the 
application of the common channel theory to explain human disease pathogenesis has been 
questioned, as a common channel does not always exist (Singh and Simsek, 1990). 
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3.2.2.1.4 Other effects of ethanol 
Intragastric ethanol given to cats has been shown to cause a reduction in pancreatic blood 
flow and interstitial pH, an index of pancreatic ischaemia. This effect was also seen in 
animals with induced chronic pancreatitis (Toyama et al., 1997). The ethanol was given to 
produce levels in the cat similar to the seen in intoxicated humans. Ischaemia is postulated 
by the same authors to explain bouts of acute pancreatic inflammation. 
Recently, expression oftranscription factors NF-KB and AP-1, both involved in regulation 
of cytokine expression, have been demonstrated in acinar cells treated with ethanol in vitro 
(Gukovsky et al., 1998). Metabolites of ethanol, not ethanol itself, caused this expression, 
and while it is a finding which deserves further investigation, the effect may of course be 
non specific. 
Oxygen free radicals (OFR's) are postulated by many to be involved in the initial cellular 
damage seen in acute pancreatitis, and there is some supporting circumstantial evidence 
(discussed in section 3 .2.4.3 .1 ). Proponents of this theory (Braganza, 1991 ), have not 
attempted to explain how aetiological agents such as ethanol could cause generation of 
OFR species. One study has however provided evidence that this is the case. Rats enterally 
fed ethanol for a period of 4 weeks not only had evidence of scattered pancreatic necrosis, 
but also had evidence of OFR species generation in the pancreas, stimulated specifically by 
ethanol (Iimuro et al., 1996). 
In chronic pancreatitis, including disease caused by excessive ethanol production, a 
consistent pathological finding is some degree of lymphocytic infiltrate (Lankisch and 
Banks, 1998d). T cells, a lymphocyte sub-population, require antigen presentation in 
conjunction with MHC molecule expression on target cells. Whilst MHC expression on p 
cells in the pancreatic islets has been extensively investigated (van Dissel et al., 1998), only 
one group of investigators have explored the question of MHC expression upon pancreatic 
cells in pancreatitis. In pancreatic specimens from patients requiring operation for chronic 
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pancreatitis, MHC class I and 11 expression was found in 57% of patients. llhese included 
patients with alcohol induced disease. Interestingly expression was confined to ductal and 
ductular epithelium (Jalleh et al., 1993). One could postulate .that MHC expression may also 
be increased in acute pancreatitis initiated by alcohol. This, however has not been 
investigated. Even so, cell mediated cytotoxicity is undoubtedly a factor in the pathogenesis 
of alcoholic chronic pancreatitis. Perforin mRNA, an activation marker for cytotoxic cells, is 
expressed by cells with a high frequency in the pancreata of human subjects with alcoholic 
chronic pancreatitis compared to controls (Hunger et al, 1997). The relevance of these 
findings to the pathogenesis of the acute form of the disease is unable to be tested in 
humans due to the unavailability of tissue specimens. 
As can be seen from the large number of hypotheses concerning the early pathogenesis of 
alcohol induced pancreatitis, each supported by some evidence, the exact mechanism is not 
yet defined. It may be that several mechanisms act in synergy. 
3.2.2.2 Cholelithiasis 
The early pathogenesis of acute pancreatitis caused by cholelithiasis is generally thought to 
be due to hypertension in the pancreaticobiliary duct system, secondary to the passage of a 
gallstone or obstruction (Steer and Meldolosi, 1987) The first description of acute 
pancreatitis caused by an obstructing stone at the duodenal papilla was by Opie in 190 I. He 
provided a full pathological description of a case of severe acute pancreatitis where a biliary 
calculus was found lodged at the duodenal papilla occluding the termination of both the 
biliary and main pancreatic duct ('common channel'). He also described a series of 
experiments upon dogs where bile had been injected into the pancreatic duct. All the seven 
dogs so treated developed differing degrees of pancreatitis evident upon pathological 
examination after one to seven days (Opie, 190 I). He developed two theories, the first that 
obstruction so caused resulted in impaired flow from the pancreas which initiated damage, 
the second that obstruction in the presence of a common channel would allow reflux of bile 
into the pancreatic duct, so causing pancreatitis. 
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Gallstones are not often found impacted at the. ampulla, either at operation or autopsy 
(Wilson et al., 1988) The opposite viewpoint is often quoted, supported by evidence that 
states that impaction occurs in 63% of patients with biliary pancreatitis (A costa et al., 
1980). However this data is heavily biased as it only included patients with clinical evidence 
of biliary obstruction. 
As impaction is uncommon, the transient passage of gallstones past the confluence of 
pancreatic and bile ducts and the ampulla may initiate pancreatitis. This is supported by 
evidence demonstrating that 95% of patients with acute biliary pancreatitis have gallstones 
present in their faeces (Acosta and Ledesma, 1974) 
Whether the passage of stones·causes bile reflux into the pancreatic duct depends upon 
whether there is a 'common channel' formed by the confluence of pancreatic and biliary 
duct. This is not always the case (Lankisch and Banks, 1998b). Also the pancreatic duct is 
known to have a higher physiological pressure, so precluding the theoretical reflux of bile 
into the pancreas (Lerch et al., 1994 ). Therefore it may be that the initiation of inflammation 
in the pancreas is by obstructed pancreatic flow. This view is supported by an animal study 
where pancreatitis occurred on concomitant obstruction of the pancreatic and bile duct, 
whet her or not bile reflux was present ( Senninger et al., 1986) 
Whatever the exact mechanism of disease initiation in the presence of total or partial 
obstruction, the acinar cell shows early signs of injury in experimental models (Lerch et al., 
1992). 
3.2.2.3 Viral infections 
Mumps virus, Coxsackie, Hepatitis 8, Cytomegalovims, and the Herpes simplex I & 11 
viruses are some ofthe agents believed to initiate pancreatitis (Parenti et al., 1996). 
Although the pathogenesis of viral acute pancreatitis is not discussed in standard texts and 
reviews, the pathogenic mechanism can be presumed to be similar to that observed in viral 
infection of any cell in the body. 
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Viruses increase MHC class I expression and initiate inappropriate class ll expression on 
cells (Maudsley, 1995), resulting in the presentation of viral or previously unencountered 
self antigen, stimulating immune mediated damage to the host cell Viruses can also directly 
injure cells, and infection of adjacent cells (of same or different type) may cause damage via 
increased local cytokine production, mediating MHC independent and/or dependent cell 
damage. 
3.2.2.4 Drugs 
llhere are a number of drugs associated with the development of acute pancreatitis. The 
reader is referred to other texts for a comprehensive list (McArthur, 1996), and the most 
well known are listed in the footnotes to table I. I. The mechanism of action is thought to 
be direct cytotoxicity upon the pancreatic acinar cell or individual hypersensitivity 
(McArthur, 1996). There is no experimental evidence regarding this. 
3.2.3 Events in the acinar cell 
Irrespective of the nature of the aetiologic agent or it's exact mechanism of promoting 
disease initiation, the acinar cell is now believed to be the site of the early steps in the 
pathogenesis ofacute pancreatitis (Lerch et al, 1992). Disruption ofthe mechanism of 
acinar cell secretion is believed to occur, leading to intracellular activation of pancreatic 
enzymes, and subsequent autodigestion. Evidence supporting this theory has recently been 
published. Trypsinogen activation, assessed by measurements ofTAP, is known to occur 
prior to the appearance of detectable morphological or functional damage to the acinar cell 
(Frick et al, 1997). 
Previous belief that pancreatitis was associated with acinar cell hypersecretion led to 
unsuccessful clinical trials with agents known to reduce output from the exocrine portion of 
the gland (Gjrup et al, 1992). However, animal models show that pancreatic exocrine 
secretion is reduced early in the course of acute pancreatitis, and recovers on resolution of 
disease (Neiderau et at, 1990). 
In both in vivo and in vitro models of acute pancreatitis, it has been shown that an apparent 
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blockade to zymogen granule exocytosis occurs (Leach et al., 1990; Steer and Meldolosi, 
1987). Zymogen granules accumulate within the acinar cell, and undergo abnormal fusion 
with lysosomes. This results in the formation of large vacuoles which contain both digestive 
enzymes and lysosomal hydrolases, an event termed 'eo-localisation' (Steer and Meldolosi, 
1987). 
In the normal acinar cell, lysosomal enzymes are mostly segregated when processing occurs 
at the Golgi apparatus. The segregation is not complete as a considerable fraction of 
lysosomal enzymes escape processing in the Golgi (Hirano et al., 1991). However, studies 
evaluating the subcellular fractionation of the lysosomal enzyme Cathepsin B (known to 
activate trypsinogen ( Greenbaum and Hirschkowitz, 1961) ), indicate that in the early stages 
of acute pancreatitis the already incomplete segregation becomes more pronounced; half of 
the total cellular free Cathepsin B is recovered from the zymogen granule fraction of the 
cell (Watanebe et al., 1984; Saito et al., 1987). 
Both incomplete segregation of enzymes and eo-localisation are thought to lead to the 
activation ofproenzymes, an event which may account for the fragility of the cytoplasmic 
vacuoles observed in animal models at the time that eo-localisation occurs (Saluja et al., 
1987; Saluja et al., 1989). 
How the aetiologic agent causes this disruption within the acinar cell is the subject of 
ongoing investigation. Recently, increased levels of cytoplasmic calcium have been 
implicated as a mediating factor that may lead to zymogen granule activation (Ward et al., 
1995). This does seem to occur prior to trypsinogen activation, as studies in animal models 
of acute pancreatitis show that therapeutic blockade of calcium influx reduces TAP release 
(Frick et al., 1997). 
As described, disruption of intracellular trafficking and processing and resulting 
autodigestion are the events that are first detectable in the pathogenesis of acute 
pancreatitis. This initiation of disease leads to the generation of local inflammation. 
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3.2.4 Local inflammation~ The role of'leucocytes, cytokines, and other:inflammatory 
mediators 
"Phe onset of local inflammation is seen morphologically as oedema, haemorrhage, necrosis, 
and further disruption of acinar cell architecture. Cellular infiltrates of inwardly migrated 
leucocytes are seen in the tissue interstitium. Inflammation is followed by death. of acinar 
cells. This can occur by necrosis or apoptosis, mediated by cellular and soluble effectors. 
Chemoattraction of macro phages and neutrophils and propagation of a macrophage derived 
cytokine response are subjects covered in depth in this work, however, as a number of other 
factors may also play important roles in the propagation of local inflammation, they will also 
be discussed here. These include generation of oxygen free radicals (Sweiry and Mann, 
1996)~ changes in microvascular perfusion mediated by the kallikrein-kinin system 
(Weidenbach et al., 1995 ), and complement activation (Weiser et al., 1996). 
Most experimental studies evaluate the role of individual cellular infiltrates, cytokines, and 
other mediators of inflammation as key mediators playing the predominant role in the 
disease pathogenesis. It is important to realise that as all may play some part in 
upregulating local inflammation, it is likely that to some degree they all act in synergy. 
Early in the course of disease there is inward migration of neutrophils and macrophages. 
The mechanisms of inflammatory cell recruitment and activation, including the role of 
cytokines in this process will now be discussed. 
3. 2.4.1 Leucocytes 
Neutrophils migrate into the pancreas early in the course of the disease process. In 
experimental pancreatitis in rats, intravascular margination and tissue infiltration is seen as 
early as 3-3 5 hours after the induction of disease (Folsch et al., 1998; Schoenberg et al., 
1990), and interstitial tissues are heavily infiltrated when assessed at 12 hours (Schoenberg 
et al., 1990). Neutrophils are shown to predominate over mononuclear cells in the 
inflammatory cell infiltrate early in the course of disease (Sandoval et al., 1996). The effect 
of neutrophil depletion in has been assessed in models of mild experimental pancreatitis. In 
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one study neutrophil depleted animals demonstrated a reduced inflammatory cell infiltrate 
and pancreatic oedema (Fink and Norman, 1996), whilst two other studies demonstrated 
both these aforementioned effects plus a reduction in acinar cell vacuolisation (Sandoval et 
al., 1996; Fujimoto et al., 1997), and acinar cell necrosis (Sandoval et al., 1996). A 
corresponding increase in the number of acinar cells undergoing apoptosis is also seen 
(Sandoval etal., 1996; Fujimoto et al, 1997), which suggests that neutrophils and their 
released products (e,g. NO, OFR's) are capable of regulating cell death response, playing a 
key role in the development of necrosis. 
Macro phages are also seen in the inflammatory cell infiltrate in the course of acute 
pancreatitis, although they are not the most predominant cell early in the course-of disease 
(Sandoval et al, 1996). Using immunohistochemical techniques it has been demonstrated 
that although macrophage infiltration starts soon after the induction of acute pancreatitis, 
maximal proliferation occurs 2 days after induction of disease (Goto et al, 1993) 
Intraperitoneal injections of a specific macrophage activating agent have been used to 
evaluate the effect of macrophage activation on the pancreas in rats. The experiments 
showed that macrophages alone can induce pancreatic damage. Although it is a cmde 
estimate of damage, pancreatic water content was shown to be increased. Unfo11unately the 
authors did not rep011 histological effects (Andersson et al, 1997). Macrophage depletion 
in mice with mild pancreatitis results in significant attenuation of oedema, but no reduction 
in acinar cell vacuolisation, necrosis, or inflammatory infiltrate (Fink and Norman, 1996). 
Whilst not being the most prominent cell type in the inflammatory cell infiltrate seen in acute 
pancreatitis, macrophages are considered to play a cmcial role in the pathogenesis of acute 
pancreatitis by their production of pro-inflammatory and regulatory cytokines ~Kusske et 
a!, 1996b; Kingsnorth, 1997b ). This is based upon evidence evaluating the effects of 
cytokines (considered to be predominantly produced by the macrophage) in disease 
pathogenesis (see section 3 24.2) 
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It is pertinent to point out atthis point that depletion of cellular components·ofthe immune 
system will also cause depletion of the products of those cells, e.g. cytokines, chemokines, 
OFR's. 
Lymphocytes are not considered to be a,predominantpancreatic infiltrating cell in acute 
pancreatitis, being seen in chronic pancreatitis (Lankisch and Banks, 1998d). However, 
recently the effect of acute pancreatitis upon lymphocyte proliferation has been assessed. 
Studies indicate that lymphocytes, T lymphocytes, and CD4 and CBS subsets are reduced in 
the early course of acute pancreatitis (Widdison and Cunningham, 1996; Pezzilli et al., 
1997). This will be discussed in section 3.2.5.1. 
3.2.4.2 Cytokines 
Cytokines play a central role in the mediation of both the local and systemic inflammatory 
response seen in acute pancreatitis, causing activation of polymorphonuclear leucocytes, 
monocytes and macrophages and promoting their migration into tissue interstitium. Many of 
the recent advances in the understanding of the pathophysiology of acute pancreatitis have 
come from a greater understanding of the role of cytokines in the local and systemic 
manifestations ofthe inflammatory process. 
This section will discuss the role of specific cytokines in the local inflammatory disease 
process in acute pancreatitis , and review evidence that suggests that certain cytokines are 
pivotal mediators of disease progression. 
3.2.4.2.1 Tumour necrosis factor (TNF) 
As discussed in section 2.4.5, TNF is a key cytokine with many pro-inflammatory effects of 
it's own. It also induces the release of other pro-inflammatory cytokines. 
In rats, TNFa mRNA is expressed, and TNFa protein is expressed, produced, and released 
by pancreatic acinar cells in health. Both the pSS and p75 TNF receptor are expressed 
(Gukovskaya et al., 1997). The same series of investigations revealed that one of the effects 
that TNF has upon normal acinar cells is the activation of NFKB, so it is possible that the 
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effects of'fNF are·mediated, at least partially, by the activation ofthis transcription factor. 
As well as this possible role in the mediation of the effects ofTNF, the blocking ofNFKB 
activation is also shown to prevent increased expression ofTNF mRNA in whole pancreatic 
mRNA extracts from rats with pancreatitis (Dunn et al, 1997), illustrating that NFKB may 
be a regulator of the production as well as effects of TNF. Controlled experiments also 
indicate that an effect ofTNF upon normal pancreatic acinar cells in vitro is to mediate 
apoptosis, and this effect is also seen in vivo during experimental acute pancreatitis 
(Gukovskaya et al, 1997). 
In contrast to the investigations of Gukovskaya et a/, TNFa mRNA or protein could not be 
detected in healthy mouse pancreas (Norman et al, 1995a). 
However, investigators agree that TNF expression in the pancreas is induced by (Fu et al, 
1997; Norman et al, 1995), or increased by (Gukovskaya et al, 1997) the onset of 
experimental pancreatitis This occurs as soon as 30 minutes after the induction of disease. 
It seems that increased TNFa is produced by both acinar cell and infiltrating macrophage 
(Gukovskaya et al, 1997). Markedly increased serum levels ofTNFa have also been 
detected after the onset of acute pancreatitis (Hughes et al, 1995). These investigators also 
observed similar results in confirmed 'sterile' germ -free rats, so that the rise in TNF could 
be attributed to the pancreatitis, rather than the presence of endotoxin, as had been 
previously postulated. 
To assess whether TNF has a pivotal role in the generation of local inflammation, 
antagonism of TNF by administration of anti-TNF polyclonal antibody has been investigated 
in animal models of acute pancreatitis. Studies demonstrate that prophylactic administration 
significantly reduces gross and microscopic pathology associated with pancreatitis including 
a reduction in inflammatory cell infiltrate(Gukovskaya et al, 1997; Hughes et al, 1996), 
whilst another study demonstrated minimal effect upon markers of local inflammation 
(Grewal et al, 1994) Treatment using TNF antiserum raised in rabbits increased rather 
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that attenuated pancreatic oedema in one rat model (Guice et al., 1991), however evidence 
that the antiserum used contains a blocking antibody to TNF is lacking. 
Whilst there is no evidence that treatment using anti-TNF antibody after the initiation of the 
disease process is beneficial, the antagonism ofTNF by recombinant soluble TNF receptor 
has been tested therapeutically and prophylactically in an animal model. Reductions in 
pancreatic oedema and serum markers of inflammation were noted, but no effects were seen 
upon the degree of necrosis, vacuolisation or inflammatory cell infiltrate in histological 
specimens of pancreas (Norman et al., 1996b). TNFRl (p55) receptor knockout mice also 
show reduced pancreatic damage in necrotising acute pancreatitis (Denham et al., 1997b) 
Similar effects are seen with IL-l receptor deficient animals, but no additive effect is seen 
with loss of both TNF and IL-l receptor. 
Recently, the effect of blocking macrophage production ofTNF has been assessed using a 
specific synthetically produced molecule (CNI-1493) that inhibits TNFa mRNA translation 
(Denham et al., 1997a). This approach significantly reduces pancreatic necrosis in mice with 
mild and severe experimental disease. It must be noted that these effects may also be due to 
the reduction in IL-l, as both TNF and IL-l mRNA levels were significantly reduced in 
treated animals, compared to diseased controls. 
On the basis of the experimental evidence reviewed, it can be seen that as TNF is produced 
in the pancreas by both acinar cell and macrophage, and seems to contribute in no small part 
to the development of acute pancreatitis, it is possible to conclude that TNF plays a major 
role in the induction and propagation oflocal injury. 
3.2.4.2.2 lnterleukin-1 (IL-l) 
IL-l has many similar effects to TNF and as such is also a key cytokine in the regulation of 
immune responses (section 2.4.5). Although IL-l can be produced by many non-immune 
cells, it's constitutive expression in the pancreas has not been shown (Fink and Norman, 
1996; Fink and Norman, 1997). Conversely it appears that IL-l receptors, IL-l ra, and IL-l 
converting enzyme (ICE) are all expressed by normal healthy pancreatic tissue (Fink and 
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Norman, 1997). Studies show that IL-l is produced in the pancreas early in the course of 
acute pancreatitis (Fu et al., 1997; Fink and Norman, 1997; Norman et al., 1997), and that 
the cells of origin are the infiltrating macro phages and neutrophil (Fink and Norman, 1996). 
By using fL-1 receptor gene 'knockout' mice that were unable to recognise or respond to 
fL-1, it has'been shown that the presence oflL-1 receptor is required for maximal 
progression of acute pancreatitis, as evidenced by a reduction in acinar cell vacuolisation 
and necrosis, and reduction in parenchyma! oedema and inflammatory cell infiltrate 
(Norman et al., 1996a). As already discussed, similar effects are seen with TNFRI (p55) 
knockout animals, but the effect is not additive when both receptors are absent (Denham et 
al., 1997b). 
An endogenous method of lL-1 regulation occurs as part of molecular interaction in the lL-
1 system by a naturally occurring IL-l receptor antagonist (IL-l ra) (Dower et al., 1994) 
Down regulation of IL-l can also be produced by inhibition of ICE. Both these methods of 
IL-l blockade have been tested in models of acute experimental pancreatitis, mostly from 
the same group of investigators. 
In models of mild and severe acute pancreatitis administration ofiL-1 ra reduced serum 
amylase levels, pancreatic oedema, inflammatory cell infiltrate, and histological severity of 
necrosis in a dose dependant manner (Fink et al., 1997; Norman et al., 1995; Norman et al., 
1995). Treatment also reduced serum levels ofTNFa and fL-6 (Norman et al., 1995c). The 
development of disease seems not to be by a direct action of IL-l on pancreatic acinar cells, 
as in vitro viability of acinar cells was not affected by incubation with fL-1 (Fink et al., 
1997). These beneficial effects were seen when fL-1 ra was given as prophylaxis and 
treatment. In contrast another group of investigators using a different model of experimental 
pancreatitis showed that administration of IL-l ra had no effect upon local consequences of 
inflammation. However, both the initial dose of IL-l ra used, and subsequent maintenance 
infusion dosage were below those shown to have beneficial effect in the previously 
described experiments (Tanaka et al., 1995). 
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Irreversible inhibition oHL-1 synthesis by administration of a novel ICE ·inhibitor, YE-
13045, has been shown to have similar beneficial effects upon experimental disease. Again, 
cytokine production and amylase levels were reduced, whilst morphological changes in the 
pancreas were also significantly improved (Norman et al., 1997). 
As discussed in the previous section, reduction in IL-l (and TNF) production by blockade 
of mRNA processing reduces severity of pancreatic necrosis (Den ham et al., 1997a). 
It can be seen from the presented evidence that IL-l, like 1NF, plays a major role in the 
upregulation of the local inflammation seen in the pathogenesis of acute pancreatitis. 
3.2.4.2.3 Platelet activating factor (PAF) 
In 1986 it was shown that the mammalian pancreas could synthesise P AF, by demonstrating 
the incorporation of radiolabelled acetate into the P AF molecule by isolated Guinea pig 
pancreatic lobules stimulated by the CCK analogue, cerulein. P AF released into the culture 
medium was shown to have incorporated radioactivity, indicating that the isolated lobules 
were synthesising P AF rather than releasing the stored form (Soiling and Fest, 1986). 
involvement of P AF in acute pancreatitis was demonstrated in vivo in 1989 by injection of 
P AF into the superior pancreatoduodenal artery of rabbits. It resulted in dose dependent 
elevations of serum amylase and morphologic changes associated with acute pancreatitis, 
including oedema, neutrophil infiltration, and acinar cell vacuolisation and necrosis 
Electron microscopy showed the damage at ultrastructural level, first zymogen granules 
accumulating at the acinar portion of the cell, then vacuoles developing containing cellular 
debris. The damage induced progressed over the studied time, from 3-72 hours (Emmanuelli 
et al., 1989). In the same series of investigations it was also shown that the administration 
of a P AF antagonist inhibited these effects, demonstrating that the changes were due to the 
specific effect ofP AF. While this may suggest that the local inflammatory response induced 
may be dependant upon a direct effect of P AF upon the acinar cells, it is also possible that 
secondary mediators released by activated inflammatory cells within the pancreas could play 
a key role. 
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Systemically administered P AF .has also been shown to have an aggravating effect upon 
established experimental disease. Animals treated with P AF show an increase in 
inflammatory cell infiltrate and development ofintrapancreatic haemorrhage.as compared to 
those with animals with· acute pancreatitis treated with placebo (Yotsumoto et al., 1994). 
Intraperitoneal injection of exogenous P AF also causes biochemical and morphological 
changes similar to that seen in acute pancreatitis. The same study demonstrated that a P AF 
antagonist given prophylactically gave a protective effect, reducing tissue damage 
(Tomaszwska et al., 1992). 
It has also been shown that therapeutic P AF antagonism reduces histological pancreatic 
damage The antagonist was given 30 minutes after the induction of pancreatitis; when early 
histological changes in the pancreas are already occurring (Formela et al., 1994) . 
P AF is therefore also considered to have a major role in the mediation of local pancreatic 
damage (Kingsnorth et al, 1995). 
3.2.4.2.4 Interleukin 10 (IL-10) 
As discussed in section 2.4.5, IL-l 0 plays an important role in regulating immune and 
inflammatory responses though it's effect upon several cellular components of the immune 
system. I L-1 0 is known to be secreted by many immune cells, and hepatocytes and intestinal 
epithelial cells (Napolitano et al, 1997; lshizaka et al, 1996). However it's expression by 
any healthy constituent cells of the pancreas has not been assessed. As previously discussed, 
macrophages infiltrate the pancreas in acute pancreatitis, and macrophages are a 
predominant secret or of IL-l 0. 
Recently there have been well designed experimental studies which have assessed the role of 
[L-1 0 in the pathogenesis of acute pancreatitis and evaluated it's potential as a therapeutic 
agent. 
Pre-treatment with intraperitoneal IL-10 in mice with caerulein induced pancreatitis caused 
reduction of serum amylase rise and the extent of acinar necrosis (Van La et hem et al, 
1995). Other histological parameters were not affected. Both effects were seen after a delay 
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of 6 hours. In another study treatment after the,induction of caerulein induced pancreatitis 
in rats produced similar effects, significantly reducing pancreatic oedema compared with 
controls (Rongione et al., 1997). Both studies also looked at TNFa mRNA and protein 
within pancreatic tissue and found their expression to be significantly attenuated in treated 
animals, consistent with the assumption that lL-1 0 down-regulates the inflammatory 
response.at least in part by reducing expression ofTNFa. 
A beneficial effect of IL-l 0 was also demonstrated in a model of severe necrotising 
pancreatitis induced with a CDE dietin mice (Kusske et al., 1996a). Again serum enzymes 
and local pancreatic damage were seen to be attenuated, when assessed at 54 and 80 hours 
post disease onset. Oedema, inflammation, necrosis, and haemorrhage were all significantly 
reduced in treated animals compared to controls. Again, although significant effects were 
seen earlier in the course of disease, a greater reduction was seen after a delay. These 
effects were regardless of whether lL-1 0 was given as pre-treatment or after disease 
commenced. 
These results suggest that lL-1 0 plays an important role in the down regulation of the local 
inflammatory response in acute pancreatitis as revealed by the attenuation of it's deleterious 
effects upon the pancreas. 
3.2.4.2.5 Chemokines 
As discussed in section 2.4.5.5 chemokines are a group ofchemoattractant cytokines 
involved in the activation and trafficking of inflammatory cells. As the inflammatory cell 
infiltrate is a predominant feature of local inflammation in acute pancreatitis, chemokines 
must be involved in disease pathogenesis. To date, there has been a limited amount of useful 
experimental work in this area. Serum IL-8, a C-X-C or a-chemokine (chemoattractant for 
neutrophils), has been measured in patients with acute pancreatitis, and is found to be 
significantly higher in patients with complicated and uncomplicated disease compared to 
healthy controls (Gross et al, 1992; De Beaux et al., 1997). Whilst this implicates the 
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involvement of IL-8 in disease pathogenesis it gives little detailed insight into it's exact role, 
which can only be inferred. Recently two chemokines, mob-1 (a C-X-C, a-chemokine), and 
mcp-1, (a C-C, 13-chemokine, chemoattractant for macrophages) have been identified as 
being involved in acute pancreatitis. mRNA from both chemokines was identified in rat 
pancreas after induction of acute pancreatitis by caerulein. The source of both was identified 
by immunocytochemistry as the acinar cell (Grady et al., 1997). Acinar cells did not express 
these two chemokines in healthy animals, although some expression in ductular cells was 
identified. The same investigators provided some evidence that mob-1 and mcp-1 were 
important in disease pathogenesis by showing that blockade of their expression in vivo 
prevented the increases in pancreatic oedema seen with this model. However, this may not 
have been a direct effect, as the agent used to block their expression (Pyrrolidine 
dithiocarbamate, PDTC) is a potent inhibitor ofNFK.B activation, so expression of other 
cytokines known to be important in inflammation could also have been affected . The 
expression ofTNF, for example, is known to be reduced by blockade ofNFKB activation 
(Dunn et al., 1997). PDTC also an antioxidant, so reduction ofOFR's may have reduced 
inflammation also (see section 3.2.4.3.1). If blockade of chemokine expression is shown to 
be the main factor in reducing the pancreatic inflammation, then this may be due to reduced 
chemoattraction for neutrophil and macrophage produced by both chemokines. 
Another study, using mice with deleted 13-chemokine receptors, showed that although no 
effects on diseased pancreas morphology were seen, reduced neutrophil influx occurred, as 
reflected by decreased levels of the leucocyte enzyme, myeloperoxidase (Gerard et al., 
1997). 
Both these studies, as could be expected from the known functions of chemokines, 
demonstrate that chemokines may play an important role in the pathogenesis of acute 
pancreatitis. 
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3,2.4,3 Other inflammatory mediators/effectors 
3.2.4.3.1 Oxygen free radicals (OFR's) 
The exact source ofOFR species in acute pancreatitis is considered to be varied. Different 
pathological mechanisms have been hypothesised. These include the activation of the 
xanthine oxidase system by disease, production by daniaged mitochondria, cytochrome 
P450 oxidation of products of cell damage, and production by activated PMN leucocytes 
(Schoenberg et al, 1995). The latter must be a major source ofOFR's as production by 
neutrophils is well known, and there is always a heavy infiltrate of these cells in the pancreas 
allected by inflammation. 
Evidence for the involvement of oxidative stress in the early pathogenesis of AP has been 
provided by numerous studies, mostly producing indirect evidence of free radical excess by 
the detection of depleted glutathione or increased products of lipid peroxidation in animal 
(Dabrowski and Chwiecko, 1992; Schoenberg et al, 1990; Nonaka et al., 1989), and human 
disease (Braganza et al, 1995). 
In attempts to provide further evidence regarding the role of OFR species in disease 
pathogenesis, and to assess possible therapeutic benefits, agents have been used in 
experimental models to inhibit the formation of free radicals, or reduce their tissue levels. 
Some agents show beneficial effects as evidenced by a reduction in histological damage, 
gland oedema, and serum pancreatic enzymes (Wang et al, 1995; Wisner et al, 1988; 
Neiderau et al, 1992; Wisner and Renner, 1988; Nonaka et al, 1991; Schoenberg et al, 
1994), while others show minimal or no benefit (Hotter et al, 1995; Furukawa et al, 1994; 
Lankisch et al., 1989; Steer et al, 1991 ). 
The evidence that oxidative stress is a key step in local disease pathogenesis is indirect and 
conflicting, although this area of investigation is at an early stage. 
3.2.4.3.2 Kallikrein-kinin system 
Kallikrein is normally present in the pancreas in it's active precursor form Once activated it 
produces active bradykinin and Lys-bradykinin by cleaving them fi·om their inactivating a.-2 
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macroglobulin, to which they are physiologically bound'. Kinins are known to increase 
microvascula~ permeability and vasodilatation , as well as.causing the release of a number of 
other mediators of inflammation, including leukotrienes, prostaglandins, and thromboxanes. 
Kinins are released during experimental acute pancreatitis (R yan et al., 1964 ), and are 
known to -aggravate biochemical and histological markers of local disease progression when 
infused into animals with pancreatitis.(Yotsumoto et al., 1993). This type of evidence led to 
the hypothesis that kinins play a key role in disease pathogenesis. 
However, evidence from studies using kinin inhibitors in experimental acute pancreatitis is 
less conclusive In a study where disease is induced by an ischaemia-reperfusion type injury 
administration of a kinin antagonist has shown a beneficial effect on the pancreatic 
microcirculation (Hoffmann et al., 1996a). In other studies the effect upon oedem!l and 
histological damage has not been consistent. Reduction in oedema by blocking bradykinin 
has been seen ( Griesbacher et al., 1993 ), although most studies indicate that kinins do not 
play a large role in disease pathogenesis as local oedema and injury are either not affected 
(Lerch et al., 1995), or are worsened by kinin antagonism (Weidenbach et al., 1995) 
The evidence for the involvement of kinins in the pathogenesis of acute pancreatitis is 
conflicting and at best, circumstantial. Earlier interest in kinins as key mediators of 
pancreatic inflammation doesn't seem to have been sustained. 
3.2.4.3.3 Complement activation 
Complement is an important component of immune responses, in particular, components of 
non-specific immunity (see section 2.4.2.1) Several investigators have suggested a key role 
for various components of the complement system as pivotal mediators of local 
inflammation in acute pancreatitis. This has led to the testing of complement inhibition in 
experimental acute pancreatitis, and one study in mice deficient in the complement 
component CS. 
However, in a model of mild disease, administration of soluble complement receptor type I 
(sCRI), a potent inhibitor of the classical and alternate complement pathways, failed to 
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ameliorate pancreatic oedema or serum markers of disease (Weiser et al., 1996). Another 
inhibitor of the complement cascade, plasma C I esterase inhibitor (on it's own or in 
combination with Antithrombin Ill) also had no effect in mild or severe models of disease 
(Yamaguchi et al., 1997). 
In a recent study in mice with pancreatitis indLtced by duct ligation the authors compared 
mice with mutations in the He gene on chromosome 2 with wild type mice. Mice with He 
mutations lack circulating levels of CS Although the authors demonstrated a significant 
decrease in pancreatic oedema and in leucocyte infiltration in the mutant animals, 
differences were not striking, and the mutant animals still has significantly higher levels of 
oedema and histologically evaluated leucocyte infiltration in their pancreata than sham 
operated animals . 
There is no strong evidence that complement, by itself, is a key factor in disease 
pathogenesis, but components of the complement system have effects on neutrophil 
migration and induction of other inflammatory mediators such as Interleukin-1 (Frank and 
Fries, 1991 ), so the complement system must be involved to some degree in the 
development of local inflammation. 
3.2.5 Systemic Innammation -The role of leucocytes, cytokines, and other 
innammatory mediators 
In the natural course of acute pancreatitis the disease may progress no further than a local 
inflammatory process of the pancreas. However in cases of severe acute pancreatitis, a 
systemic inflammatory response can occur, resulting in distant organ dysfunction and 
failure This process appears to be much the same process as seen in severe sepsis and burns 
and has been termed the Systemic Inflammatory Response Syndrome (SIRS). Dysfunction 
and failure of the respiratory system, renal system, cardiovascular system, and coagulation 
system can occur. 
A number of mechanisms of this upregulation of the inflammatory response have been 
proposed and investigated These include cellular activation and pro-inflammatory cytokine 
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release, regulated by anti-infla1nmatory cytokines released ;by the macrophage and T-cells 
(Kusske et al, 1996b; Kingsnorth, 1997b). However, as with the mediation of local 
inflammation, a number of other mediators may also play a role in the generation of 
systemic inflammation, and· these warrant mention here, as they are likely to act in 
conjunction with other inflammatory pathways, and have been investigated as having key 
roles in the pathogenesis of the systemic inflammation that occurs with severe acute 
pancreatitis. 
3.2.5.1 Leucocytes 
Neutrophil infiltration and activation in organs distant from the pancreas is considered to be 
an important mediating step in the development of pathological damage on those organs. 
The metabolic activity of circulating neutrophils is demonstrated to be increased in both 
mild and especially in severe acute pancreatitis (Widdison and Cunningham, 1996). 
Neutrophils are also known to infiltrate the lung in models of acute lung injury which are 
similar to ARDS (Takahashi et al, 1990). indeed in the lung injury produced secondary to 
necrotising pancreatitis in rats, neutrophils are found heavily infiltrating the lung tissue, as 
soon as three hours after induction of disease (Folsch et al, 1998; Murakami et al, 1995). 
ln 1982 it was shown that depletion of neutrophils prevented the increased permeability 
normally seen in sheep lung vasculature after the induction of experimental pancreatitis 
(Barie et al, 1982). Rats depleted ofneutrophils by anti-neutrophil serum (ANS) have no 
histologically detectable lung injury and demonstrate reduced lung. surface 
chemolumninescence attributable to OFR production by activated neutrophils (Murakami 
et al, 1995). Another study using polyclonal and monoclonal anti-neutrophil Ab has shown 
similar results upon the lung injury, and in addition demonstrated a significant improvement 
in survival rate·oftreated animals, evident in rats treated prophylactically and 
therapeutically (lnoue et al, 1995). Reduction in lung neutrophil sequestration following 
experimental acute pancreatitis has been demonstrated using prostaglandin (Yamanaka et 
al, 1997). This also results in reduced lung injury as demonstrated by a reduction in lung 
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oedema. It was postulated by the authors that the effect of the prostaglandin treatment was 
due to it's depletion ofneutrophils, although of course; it may be via another mechanism of 
action of prostaglandin, such as affecting the permeability of pulmonary vasculature. 
Indirect evidence of the involvement of neutrophil activation in severe acute pancreatitis 
complicated by systemic inflammatory injury is provided by studies of serum markers of 
neutrophil activation in patients One such marker, polymorphonuclear elastase, is found to 
be increased in patients with severe disease associated with lung injury and sepsis (Mora et 
al., 1997). 
This study also provided indirect evidence of macrophage activation in pancreatitis 
associated with systemic complications, by the measurement of a marker of macrophage 
activation, Neopterin, which was found to be increased in patients with severe disease. 
Although there is some evidence that blood monocytes, precursors of macro phages, have 
impaired phagocytic activity in patients with acute pancreatitis associated with organ failure 
(Larvin et al., 1993 ), it is difficult to reconcile this with other evidence indicating that other 
aspects of macrophage function are enhanced and that immune function is increased early 
in acute pancreatitis (Widdison and Cunningham, 1996). It could be that the capacity of 
phagocytic cells, which remove particles including bacteria and protease-antiprotease 
complexes, becomes saturated during severe acute pancreatitis. 
Alveolar macrophages isolated from the lungs of animals induced with experimental 
pancreatitis show a strong cytotoxic effect .upon endothelial cells in vitro, an effect thought 
to be due to macrophage NO production (Tsukahara et al., 1996). Also, bronchoalveolar 
macrophages from rats with lung damage following acute pancreatitis show increased 
expression of cytokine induced neutrophil chemoattractant (CINC), indicating 
macrophages are activated systemically during severe acute pancreatitis. 
The main role of the macrophage in the development of a systemic inflammatory response 
is considered to be it's release of pro-inflammatory and regulatory cytokines (Kusske et al., 
1996b; Kingsnorth, 1997b). Isolated peripheral blood mononuclear cells (PBMC's), a 
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mixed cell population comprised largely of monocytes and lymphocytes have been shown 
to increase their in vitro release of pro-inflammatory cytokines in patients with severe 
disease (McKay et al., 1996; De Beaux et aL, 1997). Evaluation oft he evidence indicates 
that PBMC production ofTNFa and lL-6 are both increased in patients with systemic 
complications. One of the studies.did not actually find that levels ofTNFa were increased 
in their patients with severe disease, but the patients they characterised as severe were a 
mixed group consisting of patients with local complications and reversible renal impairment 
(De Beaux et al., 1997), rather than with properly defined organ failure as in the other 
study (McKay et al, 1996). 
Lymphocyte subsets are shown to be altered in patients with severe acute pancreatitis. 
Significant reductions in CD4 and CD8 counts are seen (Widdison and Cunningham, 1996; 
Curley, 1996), which return to normal after resolution of disease (Curley, 1996) Similar 
results have been noted with the SIRS associated with burns, sepsis, and trauma. The 
significance of these findings is unclear, as circulating lymphocytes are only a small 
proportion of the totallymphocyte population, and redistribution to lymphoid and other 
tissues would reduce the circulating fraction measured in these studies. This could though 
be taken as evidence of immune compromise during the systemic inflammatory response, 
especially as further evidence of reduced T cell function is provided by the demonstration 
of reduced IL-2 production by T cells in vitro from mice with severe, CDE diet induced 
acute pancreatitis (Curley et aL, 1996). However, a study in patients with acute pancreatitis 
shows that the CD4 CD8 ratios in both severe and mild acute pancreatitis are unchanged, 
indicating that host immunity may not be impaired; in immunosuppressed patients CD4 
lymphocytes are depleted and the CD4:CD8 ratio increases. In addition the same study 
(Widdison and Cunningham, 1996) demonstrates that IL-2 receptor expression is increased 
on lymphocytes, indicating that lymphocytes are activated and undergoing clonal 
proliferation, a normal immune response to (processed) antigen. 
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3.2.5.2 Cytokines 
The pro-inflammatory and regulatory role of the cytokines TNF, IL-'1, P AF, and lL-1 0 in 
the pathogenesis of systemic complications associated with acute pancreatitis are now 
discussed. 
3.2.5.2.1 Tumour necrosis factor (TNF) 
As discussed above PBMC secretion ofTNFa is increased in patients with organ failure 
associated with acute pancreatitis(McKay et al., 1996). Levels of the two soluble TNF 
receptors, shed from cell membranes, are also shown to be increased in patients with 
manifestations of organ failure(De Beaux et al., 1996), implicating TNF as having a central 
role in the pathogenesis of the systemic complications of acute pancreatitis. 
TNF is known to increase pulmonary vascular permeability, oedema, and decrease oxygen 
diffusion across the alveolar basement membrane (Stephens et al., 1988). ft may do this by 
decreasing gene transcription of lung surfactant C (Rink and Kirchner, 1996), reduction of 
which will increase lung compliance and reduce oxygen transfer. When administered in 
quantities similar to those produced endogenously in response to LPS, TNF is also known 
to induce tachypnoea, hypotension, metabolic acidosis, and acute tubular necrosis in the 
kidney (Tracey et al., 1986) 
The data outlined above serves to implicate TNF as a central mediator of severe systemic 
disease in humans. More direct evidence is supplied by animal studies. Reducing 
endogenous TNF production or using TNF antagonists is shown to improve clinical 
recovery and survival rates, which can be regarded as crude indicators of the severity of 
systemic complications. 
Confirmed blockade ofTNFa expression at the gene level by inhibiting NFKB is shown to 
improve (unspecified by authors) clinical recovery of experimental animals with severe 
acute pancreatitis (Dunn et al., 1997). 
Antagonism ofTNF by using polyclonal anti-TNF antibody also improves survival of 
94 
experimental animals, prophylactic administration improving survival from 15 to 85% 
(Hughes et al., 1996). Similar improvements in mortality rates are observed using a 
recombinant form of the type l receptor to decrease TNF levels (Norman et al., 1996b), 
and using mice devoid of the type I receptor gene (Den ham et al., 1997b). 
One study in the literature has supplied evidence to contradict some of the above. 
Antagonism using rabbit derived antimurine TNF antiserum was shown to increase rather 
than attenuate pulmonary oedema in rats with caerulein induced acute pancreatitis (Guice 
et al., 1991 ). Although the anti-serum was shown to neutralise TNF and cross react with 
rat TNF it cannot be excluded that the other elements of the antiserum had some effect, 
calling into question the interpretation of the data. 
3.2.5.2.2 lnterleuk.in-1 (IL-l) 
IL-l antagonism produces similar results in experimental animals. Prophylactic and 
therapeutic administration of IL-l ra to mice with severe (CDE diet induced) acute 
pancreatitis, results in significant reductions in mortality (Norman et al., 1995b). 
Experiments in rats have confirmed this finding (Tanaka et al., 1995). Interestingly both 
investigations demonstrated an improvement in histological parameters of lung damage 
normally seen in the models studied, and an improved urine output was also seen with 
treatment in the studies in rats, indicating that haemodynamic shock was ameliorated. 
Levels of other pro-inflammatory cytokines, TNF and IL-6, were also seen to be reduced. 
Blockade of IL-l synthesis by the TL-1 Converting enzyme (ICE), and deficiency of the IL-
I receptor also improves mortality and reduces associated cytokine levels in rats with severe 
pancreatitis (Fu et al., 1997; Norman et al., 1997). 
3.2.5.2.3 Platelet activating factor (P AF) 
The involvement ofP AF in the pathogenesis of the systemic sequelae of severe acute 
pancreatitis has also been assessed using specific P AF antagonists in animals and in humans. 
In experimental animals a modest but significant improvement in survival rates were seen on 
treatment with a PAF antagonist. A 66% improvement in a low survival rate (30%) was 
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noted at 48 ·hours in rats with severe acute pancreatitis .(Babrowski et aL, 1995). •Lung 
injury is also ameliorated by treatment with a PAF antagonist given before (Zhou et aL, 
1992) and after the induction of disease (Galloway and Kingsnorth, 1996). 
A platelet activating factor antagonist, Lexipafant ®,which was the only PAF antagonist 
that had been shown to be effective after induction of acute pancreatitis has been tested in 
two phase £1 trials in human disease (McKay et aL, 1997; Kingsnorth et aL, 1995). 
In both studies clinical outcome measures and inflammatory markers were used to assess 
effect upon the disease. Organ failure scores were used to assess the effect of the P AF 
antagonist in downregulating the systemic inflammatoryresponse. 
Both studies were double blind and placebo controlled, and both showed that the P AF 
antagonist reduced incidence and severity of organ failure-in the treated groups. Levels of 
serum lL-8 and IL-6 were also reduced in the treated cohort (Kingsnorth et al., 1995). 
Numbers however were relatively small, only 60 patients in the studies combined having 
organ failure. Nevertheless, results were deemed encouraging and a Phase Ill trial was 
undertaken (Kingsnorth for the British Acute Pancreatitis Study Group, 1997). Patients 
with predicted severe acute pancreatitis, received an infusion ofP AF antagonist for up to 7 
days after study entry 
Again, effects upon organ failure score were seen. Mortality was reduced in the treated 
cohort, especially in the group of patients (n=205) treated within 48 hours of the onset of 
their disease, it being reduced ITom 20.4% to 9.3% (p<0.04) These results are subject to 
confirmation by a further Phase lii trial which is at present ongoing 
3.2.5.2.4 lnterleukin-10 (IL-10) 
IL-l 0 is postulated to have an important role as a regulatory mediator in the systemic 
complications associated with severe acute pancreatitis through it's ability to affect various 
components of the inflammatory response (see section 24.5.4). 
Levels of serum IL-l 0, when measured. in patients with acute pancreatitis, have been shown 
to be,different in patients with severe as opposed to mild disease. In a group of 45 patients 
admitted witlucute pancreatitis (mostly studied from the onset of the disease), levels were 
shown to be significantly lower on day l in those with severe disease as compared to those 
with mild disease, and whilst levels in those with mild disease rapidly decreased over the 
next 3 days of their illness, levels in the patients with severe disease did not change 
significantly until the 4th and s'h days (Pezzilli et al., 1997b). 
Work in animal models has provided limited data on the effect IL-10 therapy has upon the 
development of systemic complications Only one of the ,three published studies has used an 
animal model of sufficient disease severity to study mortality. In mice with CDE diet acute 
pancreatitis both prophylactic and therapeutic administration of IL-l 0 reduced mortality to 
zero in study animals, compared to 40% in control animals (Kusske et al., 1996a). 
This data suggests that IL-10 plays a key role in the regulation of the inflammatory 
response seen in severe acute pancreatitis. 
3.2.5.2.5 Chemokines 
Serum levels·ofthe C-X-C (a) chemokine, IL-8, have been compared in patients with 
severe disease associated with systemic complications and patients with mild disease. The 
one study with sufficient numbers and patient characterisation reported that levels ofiL-8 
were raised in those with systemic complications compared to those with mild disease 
(McKay et al., 1996) 
Only one study has assessed the role chemokine expression has upon the systemic 
inflammatory response in severe acute pancreatitis. In mice with caerulein induced acute 
pancreatitis, genetic deletion of the ~-chemokine receptor (CCR I) is associated with 
protection from the pulmonary damage associated with the disease, as assessed by lung 
oedema, tissue myeloperoxidase activity, and alveolar membrane thickening and 
permeability (Gerard et al., 1997). 
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3.2.5.3 Other inflammatory mediators/effectors 
3.2.5.3.1 Oxygen free radical species 
As well as having effects upon local disease, OFR's are postulated to be involved in the 
pathogenesis of the systemic inflammatory response ~Braganza et al., 1995; Sweiry and 
Mann, 1996). The mechanisms are presumed to be the same as discussed in section 
3.2.4.3.1. Superoxide radicals have been detected in the lung of rats with experimental 
acute pancreatitis, and this evidence seems to indicate that they are produced, at least in 
part, by neutrophils (Murakami et al., 1995). Lung injury can be ameliorated by reducing 
OFR species during the course of experimental disease (Guice et al., 1989). Data in other 
experimental models has shown that mortality rate, a crude indicator of multiple organ 
failure resulting from SIRS, is reduced in some experimental models by the administration 
of similar therapy (Schoenberg et al., 1994; Nonaka et al., 1991 ). 
Evidence that this situation is applicable to the pathogenesis of the human form of the 
disease is also scanty. There has been no evidence produced to indicate OFR excess in 
severe forms of the disease, and one report that experimental treatment with detoxifYing 
enzymes reduces severity of disease (Braganza, 1991) Patient numbers were very small, 
limiting the conclusions that could be drawn. 
3.2.5.3.2 Kallikrein-kinin system 
The involvement ofkinins in the upregulation to a systemic inflammatory response has been 
suggested for many years, and Trysalol, an inhibitor of Kallikrein, the precursor ofkinins, 
was tested as a therapeutic agent in the 1950's (Kellermeyer and Graham, 1968). Recent 
evidence has not confirmed thatkinins play a major role in the development of systemic 
complications of acute pancreatitis. However, animals induced with a severe form of 
experimental pancreatitis do show maintenance of haemodynamic function (Kanbe et al., 
1996), and improved survival rate (Hotfmann et al., 1996b; Frank and Fries, 1991b) on 
administration of a kinin antagonist. This effect of kinin antagonism can be predicted as it is 
known that kinins cause systemic vasodilatation. Inhibition of Kallikrein by a Cl esterase 
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inhibitor is discussed below (section 3.2.5.3.5). 
3.2.5.3.3 Nitric oxide 
Endogenous nitric oxide.~O) is· involved in immunomodulation, mediation of endothelium-
dependent relaxation of blood vessels, and· functions as a neurotransmitter (Schmidt and 
Waiter, 1994). The first tWo of these three classic functions ofNO are probably imp011ant 
in the pathogenesis ofacute pancreatitis, but it's precise role is at an early stage of 
investigation. In the local inflammation produced by acute pancreatitis, NO treatment seems 
to mostly improve markers of disease severity (Werner et al., 1997b; Molero et al., 1995b) 
However, it has been advocated that NO functions as a mediator to worsen the systemic 
inflammation associated with acute pancreatitis (Tsukahara et al., 1996) In animals induced 
with severe pancreatitis, alveolar macrophages expressed high levels of NO synthase (NOS) 
mRNA, high levels of NO, and demonstrated NO mediated cytotoxicity (Tsukahara et al., 
1996) Conflicting evidence has been produced by other investigators (O'Donovan et al., 
1995), and it seems unlikely that NO functions as a mediator to upregulate systemic 
inflammation when NO has excited considerable interest as an adjuvant treatment for the 
adult respiratory distress syndrome (ARDS) (Joillet et al., 1997) 
3.2.5.3.4 Proteolytic enzymes 
Since it was first advocated by Chiari in 1896 that the systemic complications of acute 
pancreatitis could be explained by systemic spillage of pancreas-derived proteolytic enzymes 
(Chiari, 1896), this theory has maintained considerable interest, and is still quoted in 
textbooks and authoritative reviews upon the subject (Mergener and Baillie, 1998). 
However therapies based upon this theory have had little success, and it is clear that 
pancreatic enzyme secretion is diminished during acute pancreatitis (Neiderau et al., 1990). 
Evidence that an aberrant leucocyte response occurs ~Larvin et al., 1993; Barie et al., 
1982), has led to the more attractive suggestion that activated macrophages, and 
inflammatory mediators play the major role in systemic complications of acute pancreatitis 
(Kusske etal., 1996b; Kingsnorth, 1997b; Rinderknechl, 1994b; Rinderknecht, 1988b). 
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Recently, the role of the pancreatic enzyme trypsin in the development of the systemic 
inflammatory response, has again been investigated (Acioli et al., 1997) It relates to it's 
ability to cleave components of the complement system, CJ and CS, resulting in the 
generation ofthe chemotactic chemokines CJa and CSa (Frank and Fries, 1991). Serum 
trypsin levels were seen to increase as complement activity reduced, producing a negative 
correlation. This was taken as evidence that trypsin plays an important role in complement 
mediated neutrophil.accumulation in the lungs-see below (Acioli et al., 1997). This only 
suggests a relationship, a point acceded to by the authors. 
3.2.5.3 .. 5 Complement activation 
As with the mediation of local inflammation, it would be surprising if complement didn't 
have some role to play in the development of the systemic inflammation seen in severe acute 
pancreatitis, due to it's multiple effects such as those involving neutrophil chemotaxis. 
The only data regarding it's function in the systemic inflammation seen in severe acute 
pancreatitis is when complement inhibitors have been used in animal models of the disease. 
Complement inhibition fails to affect the pulmonary damage of experimental acute 
pancreatitis as assessed by oedema and vascular permeability (Acioli et al., 1997; Weiser et 
al., 1996), although it does reduce myeloperoxidase levels and neutrophil sequestration in 
the lung (Acioli et aL, 1997). This latter effect conforms with the known function of 
complement as a neutrophil chemotactic agent 
Complement inhibition by inhibiting the function of C I esterase is shown not to affect 
survival oftaurochlorate induced pancreatitis in the rat, however when used in combination 
with Antithrombin III, survival is increased when measured at 72 hours (Yamaguchi et aL, 
1997). No difference was seen in the pathological damage to lungs, kidneys or livers, and 
the reason for this effect is unknown, although the authors speculate that it is due to 
inhibition of kallikrein by the inhibitor (C I INH). 
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3.2.5.3.6 Endotoxaemia 
Endotoxin, the lipopolysaccharide associated with the cell membranes of gram negative 
organisms, causes hypotension and organ failure similar to that seen in acute pancreatitis 
when injected into animals (Parillo, 1993 ). Endotoxaemia can be. detected in the serum of 
patients with acute pancreatitis (Curley, 1996; Exley et aL, 1992), and is present in higher 
levels in those with severe disease, which is associated with organ failure. Endotoxaemia 
without bacteraemia is well recognised in acute pancreatitis (Foulis et aL, 1992), and may 
result from local sepsis or translocation of gut derived endotoxin (see below). 
3.2.6 Sepsis 
The SIRS in severe acute pancreatitis can in itself cause significant morbidity and mortality, 
but progression of the disease to involve sepsis often heralds irreversible organ failure and 
death (lsenmann and Buchler, 1994). 
Infectious complications occur in patients who have SIRS (Runkel, 1996), and are most 
common in patients who have developed pancreatic necrosis {lsenmann and Buchler, 
1994). 
3.2.6.1 Bacterial translocation 
The bacterial spectrum of colonising organisms is similar to that of gut flora, and it is widely 
accepted that the gastrointestinal tract is the source of infection (Banks, 1997; lsenmann 
and Buchler, 1994~. 
Various investigators have studied sepsis occurring in animal models of severe acute 
pancreatitis All confirm that pathogens are intestinal in origin. Severe acute pancreatitis 
has been shown to increase the rate of bacterial contamination of intestinal lymph nodes 
and pancreas (Runkel et aL, 1995; Runkel et al., 1990). Pancreatitis also promotes bacterial 
translocation into mesenteric lymph nodes (Widdison et al., 1994; Runkel et aL, 1991) 
This evidence suggests that sepsis in acute pancreatitis is due to bacterial translocation 
from the gut, occurring via haematogenous or lymphatic routes. 
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The exact mechanism of bacterial translocation may be due to disruption of the intestinal 
tlora, loss of gut-barrier function; impairment of host defence, or a combination of all three. 
3.2.6.2 Disruption of intestinal flora 
Studies in animal models show that the intestinal tlora is altered following the onset of 
acute pancreatitis. The bacterial tlora changes in as little as two days following the onset of 
acute pancreatitis. A greater proportion of pathogenic gram negative aerobic bacteria are 
noted first in the large'bowel , then the jejunum and ileum (Widdison et al., 1994). This 
change in enteric tlora is followed by bacterial translocation (Muncy et al., 1993). 
Pancreatitis also significantly reduces gut transit time (Muncy et al., 1993; Runkel et al., 
1991) This may promote the alteration of bacterial tlora and subsequent translocation, as 
pharmacological depression of gut motility produces a similar sequence of events (Runkel 
et al., 1993,). 
3.2.6.3 Gut-barrier function 
Loss of the physical gut barrier function provided by the mucosa is suggested by 
experiments demonstrating that intestinal permeability to both fluorescent beads (Medich et 
al., 1993) and enteric bacteria (Widdison et al., 1994; Kazantse et al., 1994) is increased 
during acute pancreatitis. The mechanism of this is unclear, but it may be secondary to 
impaired gut wall blood supply which is impaired by acute pancreatitis, or the fact that 
reduced gut motility provides increased contact time between luminal contents and mucosa, 
thus increasing the chance of permeation 
3.2.6.4 Impairment of host defence 
The reduction in the ability of the host immune system to deal with bacteria may also play a 
role in the development of sepsis. The evidence that this is important is circumstantial, but 
it is an attractive concept. CD3, CD4, and COS positive lymphocytes are reduced (Curley, 
1996), and monocyte phagocytosis is impaired (Larvin et al., 1993) in patients with severe 
acute pancreatitis, with restoration of normal levels oflymphocytes on recovery. 
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Impairment of the local clearance of bacteria frorillhe pancreas has been noted in,an animal 
model of acute pancreatitis, this could be countered by the administration of levimasol, 
indicating that the ,impairment of clearance was due to impaired phagocytic activity 
(Widdison et al., 1992). 
3.3 Hereditary pancreatitis (HP) 
To complete the discussion on the pathogenesis of acute pancreatitis, recent developments 
in the understanding of hereditary pancreatitis will be reviewed. The suggested molecular 
mechanism involved in the development of HP may have relevance to the pathogenesis of 
acute pancreatitis. 
HP is a rare disorder, as only about 400 patients in 95 kindreds around the world have been 
reported . lt is an autosomal dominant disorder with 80% penetrance and is characterised by 
recurrent acute attacks of pancreatitis, and subsequent progression to complicated chronic 
pancreatitis. Many patients with chronic HP will ultimately develop pancreatic cancer. 
The gene for HP has recently been mapped to chromosome 7q3 5 (Whitcomb et al., 1996b ). 
Trypsinogen genes have been located at this position, as the surrounding region has been 
entirely sequenced due to the presence in the area of the TCRI3 locus. Screening revealed 
that there existed a mutation (G-A transition) in the third exon of the cationic trypsinogen 
gene. This was, confirmed to be present in all individuals affected by, and known to be 
obligate carriers of HP (Whitcomb et al., 1996a). This mutation produces a amino acid 
difference in the trypsin molecule, as the arginine (CGC) at codon 117 (Argl17) is replaced 
by a histine (CAC) Trypsin is central to the pancreatic enzyme cascade. Trypsinogen is 
activated to trypsin by the cleavage of an octapeptide (trypsinogen activation peptide; 
TAP). The process is normally initiated in the duodenum by brush border enterokinase, but 
trypsin can also activate trypsinogen by the cleavage ofT AP 
The trypsin molecule consists of two globular domains connected by a single polypeptide 
chain and although the position of Arg 117 is opposite the catalytic site and trypsin inhibitor 
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binding site (PSTI), it is in the middle ofthe connecting chain. Arginine is the recognition 
site for trypsin-like enzymes and studies suggest that Arg 117 is the initial hydrolysis site in 
the trypsin degradation of·the trypsin.molecule itself, which ·renders it inactive.(Whitcomb et 
al., 1996a). 
Figure 3.1 details the proposed mechanism of HP. 
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Fig 3.1 Proposed mechanism for the development of hereditary pancreatitis (BP) 
In HP, the normal inhibitory influence of trypsin upon trypsinogen/trypsin activation are 
not functioning as the Arg 117 mutation prevents hydrolysis, and therefore inactivation of 
trypsin and trypsinogen by trypsin. 
Trypsin inactivation of the trypsin molecule is only one of the endogenous protective 
mechanisms preventing uncontrolled trypsinogen/trypsin activation. The trypsin inhibitor, 
PSTI fits into a pocket on the trypsin molecule and inhibits it's action. Normally PSTI and 
trypsin hydrolysis of trypsin will prevent trypsin activation in the pancreas. However, when 
the Arg117 mutation of HP is present and trypsin hydrolysis of trypsin is absent, the 
function ofPSTI can be overridden as it can only activate up to 20% of potential trypsin. It 
is hypothesised this mechanism explains why attacks of HP are intermittent, an attack only 
occurs when more trypsin is active than can be inhibited by PSTI. 
PSTI - Pancreatic secretory trypsin inhibitor 
HP - Hereditary pancreatitis 
Negative influences upon trypsin activation are shown in red ---
+ inhibitory influence doesn't function due to HP mutation at in trypsin molecule 
(Adapted from Whitcomb et al, Nature Genetics 1996) 
As discussed in section 1.1.3, trypsin inactivation ofthe trypsin molecule is-only one of the 
endogenous protective mechanisms preventing uncontrolled trypsinogen/trypsin activation, 
The trypsin inhibitor, PSTI fits into a pocket on the trypsin molecule and inhibits it's action. 
Normally PSTT and trypsin hydrolysis of trypsin will prevent trypsin activation in the 
par1creas. However, when the Arg,Jl7 mutation is present and trypsin hydrolysis of trypsin 
is absent, the function of PSTI can be overridden as it can only activate up to 20% of 
potential trypsin. It is hypothesised this mechanism explains why attacks of HP are 
intermittent, attack only occurs when more trypsin is active than can be inhibited by PSTI 
(Whitcomb et al, 1996a). 
This proposed mechanism demonstrates the importance of premature trypsin activation in 
the development of acute attacks ofHP. Whitcomb et al (1996) claim it also demonstrates 
the importance of premature trypsin activation in the development of (non-HP) acute 
pancreatitis As can be seen from the abundance of evidence presented in this chapter 
concerning other proposed mechanisms of the early pathogenesis of acute pancreatitis, it is 
unlikely that this is the whole story. 
3.4 Alcohol and the liver 
As well as being an aetiological factor for acute and chronic pancreatitis, prolonged 
excessive alcohol consumption can cause a variety of other diseases affecting other organs 
of the body. Liver disease is the most common, but an alcoholic may also develop alcoholic 
cardiomyopathy. 
It will be helpful to briefly discuss alcoholic liver disease in relation to it's pathogenesis as a 
group of alcoholics with liver disease (alcoholic hepatitis and cirrhosis), but without a 
history of pancreatic disease, have been used as a 'control' group in this work. It is also 
useful to be able to compare it with alcoholic pancreatitis 
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3.4.1 Alcohol induced liver injury 
As with pancreatic disease, severe liver disease develops in only a minority of heavy 
drinkers. For example; biopsy studies show that established cirrhosis occurs in less than 
20% (Derr et al., 1990). It appears the level at which liver disease starts to occur is the daily 
consumption of> 80 g da/, and that consumption has to be, consistent over five years 
(Sherlock and Dooley, 1993). Morphological changes in the liver, and the clinical 
syndromes they produce are of three different types: 
I. Fatty liver. 
Diffuse fatty change occurs, with fat accumulating towards the central zone of the liver's 
functional and anatomical unit, the acinus. Patients are usually asymptomatic, and 
clinically may show a slightly enlarged liver. Fatty liver is not regarded as a precursor of 
the other types of alcoholic liver disease, and is present in the majority of chronic, heavy 
alcohol abusers. 
2. Alcoholic hepatitis (Steatohepatitis). 
Hepatocytes are swollen and steatosis usually occurs With increasing severity of disease, 
necrosis becomes more conspicuous, and some collagen deposition occurs. Clinical 
presentation varies from those with anorexia, fatigue, and weight loss to those with 
pyrexia, anorexia, jaundice, and repeated vomiting with pain from an acutely enlarged 
liver. Alcoholic hepatitis is regarded as a precursor of cirrhosis, with which it may co-
exist 
3. Cirrhosis 
Fibrous bands divide the liver into 'nodules'. Necrotic areas become replaced by fibrosis, 
and the amount of steatosis reduces as cirrhosis progresses Symptoms are those of end 
stage liver disease; ascites, oedema, malabsorption etc. 
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3.4.2 Pathogenesis of alcoholic liver disease 
Many of the effects of alcohol upon the liver are thought to be related to the toxic effects of 
alcohol or it's metabolites. Alcohol cannot be stored so oxidation, predominantly in the 
liver, is obligatory. The main ethanol oxidation pathway is via conversion to acetaldehyde 
catalysed by alcohol dehydrogenase (Crabb, 1995). Acetaldehyde causes membrane damage 
to mitochondria and cell necrosis. The acetaldehyde is converted to acetate by aldehyde 
dehydrogenase. Both these processes of oxidation, by nature of their process, produce 
hydrogen, carried by nicotinamide adenine dinucleotide (NAD), as NAI!>H. The excess 
hydrogen generated inhibits protein synthesis and increases lipid peroxidation, both 
ultimately injurious to the liver (Situnayake et al., 1990). This increased NADH:NAD ratio 
is also termed 'increased redox potential' It is also thought to be responsible, at least in 
part, for the formation of fatty liver, collagen deposition, and impaired gluconeogenesis seen 
in alcoholic liver disease (Sherlock and Dooley, 1993). The reoxidation of NADH also 
results in an increased oxygen requirement, possibly causing hypoxic necrosis of liver cells. 
Alcohol is also metabolised by the mitochrondrial oxidising system, using cytochrome 
oxidising enzymes such as Cytochrome P450. Oxidation by this pathway also produces 
acetaldehyde and generates OFR's (Crabb, 1995), which have the potential to cause cellular 
damage. 
Cytokines are also implicated in the pathogenesis of alcoholic liver disease. In alcoholic 
hepatitis monocyte TNF secretion is increased and serum levels have been found to 
correlate with severity ofliver injury (Bird et al., 1990). Furthermore, reversible hepatitis is 
a consequence ofTNFa administration (Schilling et al., 1992). IL-l and IL-6 are also found 
to be raised in chronic alcoholics with liver disease(Sherlock and Dooley, 1993). 
3.4.3 Alcohol-induced liver and pancreatic disease: do they co-exist? 
lt is unknown whether an alcoholic is more likely to develop alcohol-induced acute or 
chronic pancreatitis, liver cirrhosis, or both conditions. Whatever the relationship, it is 
certainly true that both conditions do not by nature always co-exist. Reports have produced 
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data that suggests that alcoholic hepatitis or cirrhosis occurs in from 5 to 20%.of patients 
with chronic alcoholic pancreatitis (Lankisch.and Banks, 1998a). There is no data on 
patients with acute pancreatitis, but as acute and chronic pancreatitic disease due to alcohol 
are·probably a spectrum of disease (see section 3.2.2.l)the same.figures can probably be 
applied, 
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41mmunogenetic considerations 
This chapter will first consider the gene structure, polymorphism and disease associations of 
the MHC, the TNF locus within it, and the lL-1 0 gene located on chromosome I. Some 
other cytokine gene polymorphisms will also be discussed, as will the evidence for a genetic 
component in susceptibility to alcohol related liver and pancreatic disease. 
4.1 Major Histocompatibility Complex (MHC) 
'J;he major histocompatibility complex (MHC) extends over 4Mb of DNA on the shol't arm 
of chromosome·6 in band 21.3. 0ver 200 genes have been located within the MHC 
(Trowsdale and Campbell, 1998), mapped within three major gene clusters, the class I, class 
II, and class lil genes (Fig. 4.1 ). 
The class I and II gene products are central to the functioning of the immune system, being 
the molecules that present processed antigen to T cells, so causing their activation The 
class I genes encode for the classical and non-classical class l antigens. The class Il region 
encodes for the HLA-D antigens and other immune response proteins involved in antigen 
processing. The class Ill region generally encodes secreted proteins involved in the 
generation of an immune response, including complement components, TNF, and heat 
shock proteins (HSP). 
The MHC is highly polymorphic, being one of the most variable genetic complexes known. 
The region is remarkable not only because of the number of polymorphic loci it contains 
within it's relatively short length of DNA, but for the extraordinary large number of 
different alleles at many of the loci. The diversity thus generated creates major obstacles to 
successful organ transplantation. 
In addition, alleles at loci within the MHC associate in non-random fashion. This is called 
linkage disequilibrium, and results in the generation of allelic associations, termed 
haplotypes. The strength of this phenomenon within the MHC is illustrated by the fact that 
linkage can occur between alleles which are geographically close, such as alleles within a 
110 
12Kb region in the TNF gene cluster (Crouau-Roy et aL, 1993), and alleles separated by up 
to 2Mb of Ji)NA (Jongeneel et aL, 1991; Wilson et aL, 1993). 
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Fig. 4.1a Gene Structure of the MHC 
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Fig 4.1. Map of MHC; class I and ll regions 
The classical and non-classical class I loci, the HLA-D loci, and other genes of interest, mentioned in the text, are depicted. 
The class ill region is shown in figure 4.2. 
I Classical class I antigen locus Ja HLA-D locus 
I Non-classical class I locus • Loci of other genes of note 
• 
J A H G F I 
Olfactory receptor gene loci 
4. 1.1 Class 1 region 
The class I region is approximately 2Mb in length, lies telomeric to class lii (see Fig. 4. I), 
and contains the polymorphic classical transplantation antigen genes, HLA-A, HLA-B, and 
HLA-C, and the non-classical class I genes. The non-classical genes include HLA-E, HLA-
F, and HLA-G, and a number of pseudogenes, HLA-J and HLA-X, which do not encode 
protein products. As described in section 2.3.5, HLA•A, B, and Care expressed on almost 
all nucleated cell types and present peptides from intracellularly degraded proteins to CD8+ 
(lie) cells This provides. a mechanism for immune recognition of intracellular proteins. 
The non-classical class 1 genes show limited expression of their class-I like ,products. Their 
function is not well established, and some are thought functionless, representing remnants of 
gene duplication events. HLA-H, for example, is related structurally to HLA-A, but shows 
limited diversity and alleles with mutations that render the heavy chain of the molecule 
unable to function in antigen presentation (Zemmour et al., 1990). However, it has recently 
been shown that HLA-E is the predominant ligand for certain NK cell inhibitory receptors 
~KIR), implying it has an important role in mediating the lysis of cells by some NK cell 
subsets (Braud et al., 1998). 
The class I region also contains other, structurally unrelated genes. The first to be mapped 
was the P-tubulin gene (TUBB), telemetric to HLA-C, and others include the S gene (for 
skin), which is expressed at high levels in differentiating keratinocytes in the epidermis, so 
may have a function related to skin differentiation and structure (Zhou and Chaplin, 1998). 
A group of olfactory-receptor-like genes, which exhibit some polymorphism, are situated 
telemetric to HLA-F (Trowsdale and Campbell, 1998). 
As previously mentioned, the class I region is highly polymorphic. Polymorphism of the 
HLA-A,B and C molecules is well characterised (Parham et al., 1988), and amino acid 
variations at positions in the MHC molecule chains correspond with genetic variation at the 
individual loci, producing multiple alleles. The number of sites at which there is nucleotide 
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variation can be extensive between different alleles, as many as eighty-eight can occur (Le 
Boutellier, 1994). The HLA-E locus also has well characterised polymorphism (Grimsley 
and Ober, 1997), and within the class I region are a number ofdinucleotide repeat 
polymorphisms, or microsatellites (Le Boutellier, 1994) 
4.1.2 Class II region 
l:hree subregions; DP, DQ, and DR, make up the class Il region which spans approximately 
1Mb of DNA, located centrometric to the class I and III regions (see Fig4.1). Each ofthe 
subregions. has at least one a- and one ~-chain pair of genes, whose protein products form 
the class 11 molecule heterodimers. Therefore, each subregion, DP~ DQ, and DR, contains at 
least two functional genes, but can have more, which is often dependent upon the 
haplotype. For instance, the DR region contains between one and' four expressed ORB 
genes, which can associate with the a-chain encoded by the single DRA gene (Ragoussis, 
1995). The DQ region in contrast, has only a pair of functional genes, as the additional 
genes DQA2, DQB2, and DQB3 are not expressed This is due to the presence of altered 
gene promoter sequences. 
There are also additional separate a and ~ genes within the class 11 region. They encode for 
chains which are similar to the classical class 11 molecule a and ~ chains. The DNA and 
DMA genes encode class 11 a chains, whilst the DMB and DOB genes encode ~ chains 
The DMA and B genes lie within the same locus (DM) (Ragoussis, 1995). The DM genes 
are expressed in the same tissues as the classical class Il genes and are also inducible by 
IFN-y. Although not in the same gene locus it is possible that the DNA and DOB gene 
products also form a similar heterodimer, as their mouse homologues have been shown to 
do (Karlson et al, 1992) 
There are also a number of other genes within the class 11 region which encode entirely 
different classes of protein, but never1heless have impor1ant functions in immune system 
functioning. The (antigenic) peptide transporter genes TAP 1 and T AP2 , also called RING4 
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and RING 11 ~for really interesting new gene) are situated within the·class U region (Spies 
et al., 1990) although they have effects upon class I molecule functions. They encode 
proteins that span the ERand transport degraded intracellular peptide to the pre-Golgi 
regions (Kieijmeer et al., 1992) where association with class I molecules takes place prior to 
transport to the cell surface. Defects in these genes result in unstable class I molecules and 
the loss of presentation of intracellular antigens (Parham, 1990). 
The LMP (large multifunctional protease) genes, LMP2 and LMP7 are also situated within 
the class TI region. lihey encode proteins homologous to a large cytoplasmic protease which 
degrades intracellular proteins. It has been suggested that LMP2 and 7 gene products bind 
to this complex, leading to production of peptides suitable for class I and U presentation 
(Ragoussis, 1995). 
Several other genes, including the collagen type II gene, COL !I A2, the RING I gene 
(which encodes a transcription factor) and RING3 (encodes a nuclear kinase involved in cell 
cycle control), and other expressed genes of unknown function (e.g. RING9) also map to 
the class I! region (Trowsdale and Campbell, 1998). 
As with the class I, the class Il region is highly polymorphic, variations in the class II 
molecule chains being produced by amino acid differences. These correspond with the 
different alleles caused by polymorphism in the nucleotide sequence, which like the class I 
region, can be extensive It is also of interest that polymorphism exists in the TAP genes 
(Powis et al., 1992), and the LMP2 gene (Ragoussis, 1995). ln the rat, polymorphism of the 
TAP genes affects the repertoire of pep tides available for class I binding (Monaco, 1992). 
4.1.2.1 Class I and class 11 disease associations 
Several diseases have been found to have associations with certain HLA alleles. Table 4. I 
details some of the better known disease associations. It is not surprising that the 
pathophysiology of all the HLA linked diseases involves immunological processes, with the 
exception of idiopathic haemochromatosis, which must have an HLA association by virtue 
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of linkage with it's gene locus. 
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Disease RLA~IIele Relative Risk 
Class l Associations 
Idiopathic haemochromatosis A3 8.2 
Myaesthenia gravis 88 4.4 
Ankylosing spondylitis 827 87.4 
Reiter's disease 827 37.0 
Post-salmonella arthritis 827 29.7 
Post-yersinia arthritis 827 17.6 
Postcgonococcal arthritis 827 14.0 
Uveitis 827 14.6 
Amyloidosis (in Rheumatoid Arthritis) 827 8.2 
Subacute thyroiditis 835 13.7 
Class I I associations 
Tuberculoid leprosy DR2 8.1 
Good pasture's syndrome DR2 13.1 
Thyrotoxicosis (Graves' disease) DR3 3.7 
Chronic active hepatitis DR3 13.9 
Dermatitis herpetiformis DR3 56.4 
Rheumatoid arthritis DR4 5.8 
Multiple sclerosis DR2,DR6 12 
Crohn's Disease DQ2 250 
Coeliac disease DQ8 14 
Insulin dependent diabetes mellitus DQ2/8 20 
DR3 6.3 
DRJ/4 14.3 
Narcolepsy DQ6 38 
Table 4.1 RLA class I and 11 disease associations 
Relative risk - Risk of developing disease relative to general population if carry that 
particular allele 
Where allele is given as x/x, e.g. DR3/4 it denotes heterozygocity 
The gene for idiopathic haemochromatosis has been mapped within the class I region. It's 
exact locus has not been determined, but it is situated telometric to HLA-A (Ragoussis, 
1995). 
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4.1.3 Class Ill region 
The·class Ill regions spans approximately I. I Mb of DNA between the class I and class ll 
regions (fig 4. I and 4.2). It contains the "PNF gene loci which will be discussed in. section 
4.1.4. It also contains the genes for the-complement components C4, C2 (classical pathway) 
and Bf (alternative pathway) (Ragoussis, 1995). The C2 and Bf genes are less than 2 kb 
apart and lie approximately 30 kb telometricto the C4 genes, C4\'\ and B, which are 
separated by about I Okb. The 21-hydroxylase gene, CYP21 B, involved in mineralocorticoid 
and glucocorticoid synthesis, and a pseudogene CYP21 A are immediately centrometric to 
the C4 genes (Dunham et al., 1987). A duplicated locus, lying telometric to the C2 and Bf 
genes, encodes the major heat (inducible) shock proteins·(HSP70) (Trowsdale and 
Campbell, 1998). These are stress proteins expressed in response to heat, oxygen free 
radicals, toxic metals and other stress stimuli. They bind to denatured or inappropriately 
folded proteins and are said to act as chaperones in the recovery of cells from stress. Other 
genes mapped within the class Ill region include G 1-11 (some of which were previously 
called BAT genes; for HLA-B associated transcripts), and other genes of unknown or 
speculated function (Trowsdale and Campbell, 1998). It has been suggested various genes 
within the region encode for protein kinases, transcription factor (REL family) inhibitors; 
which influence TNF signalling, and a protein like a TNF receptor-associated-protein 
(Trowsdale and Campbell, 1998) 
The class Ill region, as expected, is also highly polymorphic. TNF polymorphisms will be 
discussed in section 4.1.4, but it is also known that the C4A and C4B loci are highly 
polymorphic; 13 alleles are recognised at the C4A locus and 13 at the C4B locus. The 
HSP70 locus is also known to be polymorphic (Chouchane et al., 1997). 
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Figure 4.2 MHC Class m region 
The TNF region is depicted in more detail in figure 4. 3 
CYP - 21-hydroxylase gene, CYP21B 
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TNF - Tumour necrosis factor region 
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4.1.4 TNF region 
The TNF region (Fig.4.3) maps at the telomeric end of the class lli region in the middle of 
the MHC gene cluster (Carroll et al., 1987; Dunham et al., 1987). The TNF locus is usually 
designated as the 7kb region encompassing the TNFa and TNFP (LTa) genes, which are 
tandemly arranged, and separated by about 1.2kb (Udalova et al., 1993; Jongeneel et al., 
1991). The LTP gene also maps 4kb centromeric to these two genes (Trowsdale and 
Campbell, 1998), as illustrated in Fig. 4.3. Further upstream (4kb) of the LTP gene is LST-
I (for leucocyte specific transcript). The function of it's protein product is unknown. 
Likewise the gene mapped telomeric to TNFP, the NB6 gene, also has no known function. 
The gene further downstream from this, IkBL, produces lkP I, which is speculated to be an 
inhibitor ofthe Rei family oftranscription factors (Trowsdale and Campbell, 1998). In 
contrast functions of TNFa and p, and that of L TP are well described, as discussed in 
section 2.4.5. 
Regulation ofTNF production is complex, having been shown to occur at the 
transcriptional and post-transcriptional (translational) levels. Sequences within the TNFa 
promoter region control the rate of it's transcription (Goldfield et al., 1990), and it has been 
shown that there are binding sites for the transcription factors NFKB and AP-1 within this 
region (Rink and Kirchner, 1996). NFKB binding is known to increase TNF expression 
(Baeuerle and Henkel, 1994). The effect ofLPS upon TNF mRNA processing appears to be 
to upregulate gene expression, suggesting that TNF production can also be affected at the 
translational level (Rink and Kirchner, 1996). 
121 
C~ss D., Centromeric 
LST-1 LTf3 
<4kb> 
-8-HHI!"" 
I \ 
TNFa 
< 4 kb > < 1.2 kb > 
* ** * 
~ 
TNFe TNFd TNFa promoter region 
Figure 4.3 TNF region within MHC class ID 
This shows the intron/exon structure of the four genes in the TNF region. All have 4 exons. 
Microsatellites TNFb-e are (CT)n repeats, TNFa is a (CA)n repeat. 
The TNFa promoter region contains the hi-allelic base substitution polymorphisms at -308, -244, and -238. 
Within the first exon of the TNFa gene is the hi-allelic C-insertion site polymorphism. 
Within the first intron of the TNFa gene is the hi-allelic base substitution polymorphism at +488. 
Within the first intron of the TNFI3 gene are the Asplll ( + 365) and Ncol RFLP ( + 249) polymorphisms. 
Within the third exon of the TNFI3 gene is a hi-allelic base substitution polymorphism, and there is an EcoRJ 
restriction site within it's fourth exon. 
The LST-1 and LTI3 gene structures are unknown. 
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4.1.4.1 Polymorphism of the TNF loci 
Polymorphism ofthe TNF region is well recognised and is illustrated in Fig 4.3. 
Single base substitutions at occur at positions -376, -308, -244, -238, and -163 (G-A 
transitions) in the TNFa promoter region (Fanning et al., 1997; D'Aifonso and Momigliano 
Richiardi, 1994; Wilson et al., 1993). There is also a C insertion site at position + 70 (within 
first exon) and a base substitution polymorphism (G-A transition) at position +488 within 
the first intron of the TNFa. gene (Fanning et al., 1997; D'Aifonso and Momigliano, 1994; 
Messer et al., 1991 ). All positions are relative to the transcription initiation stari site of the 
TNFa gene. The polymorphisms at positions -308 and -238 were the first described and are 
the most extensively investigated. 
In the region of the TNFP gene, there are four base substitution polymorphisms, three of 
which create a restriction site. An Ncol site (A-G transition) is at position +249 from the 
TNFP transcription start site, and an AspH1 site (C-G transition) is at position +365. Both 
these are situated in the first intron (Bouma et al., 1996). The gene also contains an EcoR I 
restriction site in it's fourth exon (Rink and Kirchner, 1996), and a C-A transition at 
position +720 (also called AA26), within it's third exon (Fanning et al., 1997). As they are 
base transition polymorphisms, all are biallelic, again illustrating the low degree of sequence 
polymorphism actually within the TNF gene loci. 
Around the TNF region exist five polymorphic microsatellite loci (Fig. 4.3). Microsatellites 
are tandemly repeated arrays of sequence elements (usually a CA or CT dinucleotide) 
occurring at unique sites within the genome, and are often highly polymorphic, differing in 
the number of repeats. They are inherited in a normal eo-dominant fashion (Weber and 
May, 1989). The microsatellites within the TNF region are denoted TNFa-e. TNFc is 
situated within the first intron of the TNFP gene, in close proximity to the Ncol 
polymorphism at position +249, and is bi-allelic. However the other TNF microsatellites 
exhibit a greater degree of polymorphism. TNFa and TNFb are located 3.5 kb telometric of 
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the TNFI3 gene and have at least I 3 and 7 alleles respectively (Nedaspasov et al., 199 I; 
Jongeneel et al., 1991 ). TNFd and TNFe are located circa 4kb upstream of the LTP gene, 
within intron 3 ofthe LST-1 (also called B144) gene and have 3 and 7 alleles respectively 
(Udalova et al., 1993). All except TNFa, which is a (CA). repeat, are (CT)n repeats. 
4.1.4.2 Nomenclature 
Individual TNF microsatellite loci and alleles are named in this work as proposed by 
Nedaspasov and colleagues (1991 ). The allele with the least number of dinucleotide repeats 
(n=x) is designated allele I, and subsequent alleles are numbered according to the number of 
repeats (n=x+ 1,allele 2; n=x+2, allele 3; etc.). 
For the bi-allelic polymorphisms in and around the TNF loci there is no agreed international 
nomenclature, and individual studies have used different systems. This has the potential to 
cause confusion, as investigators have named the respective common and uncommon alleles 
of individual loci typed by PCR-SSP and PCR-SSOP as allele 1 (common) and allele 2 
(uncommon), whereas for loci typed by PCR-RFLP alleles I and 2 are sometimes named 
according to whether the fragment is digested (allele I) or undigested (allele 2). This does 
not always correspond; for example the undigested fragment of the Ncol polymorphism in 
the TNFI3 gene is the most common in Caucasian populations (Stuber et al., 1996b; Stuber 
et al., 1996b). Therefore in this work the alleles will be named according to the nucleotide 
present. 
Furthermore, loci will be named according to their position from the gene's transcriptional 
start site, using TNF for the TNFa. gene and TNFB for the TNFP gene. 
E.g. -308 TNF.G and -308 TNF.A; +249 TNFB.A and +249 TNFB.G (Ncol site) 
Where the work referred to has typed the polymorphism by PCR-RFLP and have used 
nomenclature based upon presence or absence of digestion the allelic nomenclature used by 
that study will also be put in parentheses as shown: 
(TNFB*I) = digested fragment 
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(TNFB*2) = undigested fragment 
4.1.4.3 TNF region linkage and extended MHC haplotypes 
As expected, there is evidence of much linkage within the TNF region, and between the 
TNF region alleles and other MHC alleles. Linkage between the microsatellites, producing 
distinct three locus haplotypes, has been characterised by maximum likelihood estimates in 
previous population based and family studies (Jongeneel et al., 1991; Nedaspasov et al., 
199I; Crouau-Roy et al., I993) and their existence has been confirmed in homozygous cell 
lines(Weissensteiner and Lanchbury, 1997; Udalova et al., 1993). Table 4.2 details known 3 
locus TNF microsatellite haplotypes so confirmed in North European Caucasian 
populations. Five locus haplotypes have also been characterised and confirmed in 
comparable populations (Weissensteiner and Lanchbury, 1997). 
An association between individual TNFa, b, and c alleles is also seen with alleles at other 
loci within the MHC, including class I, IT, and Ill alleles (Weissensteiner and Lanchbury, 
1997; Udal ova et al., 1993; Jongeneel et al., 199I; Abraham et al., 1993), and three and five 
locus microsatellite haplotypes associate with HLA class I and Il extended haplotypes 
(Garcia-Merino et al., I996; Crouau-Roy et al., 1996; Jongeneel et al., I99l; PLevy et al., 
1996) Table 4.3 details known TNF microsatellite and HLA class I and II associations in 
populations of Caucasians. 
Likewise, bi-allelic polymorphisms in the region of the TNFa promoter and TNFI3 gene also 
produce distinct haplotypes (Fanning et al., 1997; Bouma et al., I996), which have been 
shown to have certain HLA associations (Fanning et al., I997). Individual alleles of the bi-
allelic polymorphisms are also seen to be in linkage with certain HLA alleles and haplotypes. 
One of the first detected was allele -308 TNF.A of the TNFa promoter which was shown 
to be linked with HLA-A I, -88, and -DR3 alleles, and the HLA-A I ,88,DR3 haplotype 
(Wilson et al., 1993 ). Many other HLA class I and li associations have since been 
described, including those between haplotypes produced by 6 of the bi-allelic 
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polymorphisms (fanning et a I.! 1997.). TableA.3! also details known classil ai\d-ll 
associations:ot:ihe -308' polymorphism. 
,-
2-1-2' 
:6-5-1 
7A=l 
Table 4:2. 3ilocusimicrosatellite haplotypes oft he ifNF region 
·:rhese haplcitypes have!been characterised by allele!segregaiion and· maximum 11ikelihood! 
•estimates in previous 
1
population !based I and farriily studies ~Jongeneel.et:aL, 1991; 
Nedaspasov etaL, 199:1; :Crouau~Roy et all., 1993) and their existence has been-confirme<l fin 
homozygous celllines(Weissensteiner and 'Lanclibury, ]997·; •UdaJova et al!, 1993). 
HLA Association -308 allele TNFa allele TNFb allele TNFc allele TNFd allele TNFe allele Reference 
Class I 
AI TNF2 (Fanning et al., 1997; Wilson et al., 1993) 
AI a2 (Abraham et al., 1993) 
A3 TNFl (Fanningctal., 1997) 
B7 TNFl (Fanning ct al., 1997) 
B8 TNF2 (Fanning et al., 1997; Wilson et al., 1993) 
B8 a2 b3 (Abraham et al., 1993) 
Cw*070l TNF2 (Fanning et al., 1997) 
Cw*0702 TNF1 (Fanning et al., 1997) 
Table 4.3 Class I and ll associations with TNF-308 and microsatellite polymorphic alleles reported in Caucasians continued ....... . 
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HLA Association -308 allele TNFa allele TNFb allele TNFc allele TNFd allele TNFe allele Reference 
Class II 
DRl TNFl a2 bl c2 d4 ti (Weissensteiner and Lanchbury, 1997) 
DR2 TNFl a 11 b4 £1 d3 e3 (Weissensteiner and Lanchbury, 1997) 
DR2 TNFl alO b4 £1 d3 e3 (Weissensteiner and Lanchbury, 1997) 
DRJ,DQBl *0201 TNF2 (Deng et al., 1996) 
DR4,B62 a2 hl (Monos et al., 1995) 
DR4,B44 a6 b5 (Monos et al., 1995) 
DRJ TNF2 (Wilson et al., 1993) 
DRJ TNF2 a2 b3 £1 dl e3 (Weissensteiner and Lanchbury, 1997) 
DRJ TNFl al bS c2 d4 e3 (Weissensteiner and Lanchbury, 1997) 
DR4 TNF! a2 bl c2 d4 ti (Weissensteiner and Lanchbury, 1997; 
DR4 all b4 £1 d3 e3 Wilson et al., 1993) 
(Weissensteiner and Lanchbury, 1997) 
Table 4.3 Class I and Il associations with TNF-308 and microsatellite J:!OI:ymorJ:!hic alleles reJ:!orted in Caucasians continued ........ 
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HLA Association -308 allele TNFa allele TNFb allele TNFc allele TNFd allele TNFe allele Reference 
DR5 alO b4 £1. d3 e3 (Weissensteiner & Lanchbury, 1997) 
DR5 a6 bS tl d3 d3 (Weissensteiner & Lanchbury, 1997) 
DR5 a5 b5 c2 d5 e3 (Weissensteiner & Lanchbury, 1997) 
DR6 TNF1 (Wilson et al., 1993) 
DR6 a6 bS £1. d3 eS (Weissensteiner & Lancbbury, 1997) 
DR6 a2 !ll c2 d4 .tl (Weissensteiner & Lancbbury, 1997) 
DR7 TNFI a7 b4 cl d3 e3 (Weissensteiner & Lanchbury, 1997) 
DR7 TNFI a2 bS c2 d4 e3 (W eissensteiner & Lancbbury, 1997) 
DR8 a2 hl c2 d4 .tl (Weissensteiner & Lanchbury, 1997) 
DQBI *06 TNF1 (Fanning et al., 1997) 
A1,B8,DR3 TNF2 a2 b3 (Gallagher et al., 1997a; Wilson et 
al., 1993a) 
A2,B44,Cw5,DRB I *0401 a6 b5 d4 (Hajeer et al., 1996) 
A1,B8,CW7,DRB1 *0301 a2 b3 d2 (Hajeer et aL, 1996) 
Table 4.3 Class I and U associations with TNF-308 .and microsatellite (!ol:rmor(!hic alleles re(!orted in Caucasians continued ........ 
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HLA Association -308 allele TNFa allele TNFb allele TNFc allele TNFd allele TNFe allele Reference 
A3,B7,DR2 TNFI all b6 tl el (Gallagher et al., 1997a) 
Al,B8,C4AQO,C4Bl,DR3 a2 b3 (Abraharn et al., 1993) 
B27,Cl,DRl,DQ5 a6 b5 tl d3 e3 (Udalova et al., 1993) 
Bl8,DR3 al b5 c2 (Crouau-Roy et al., 1996) 
B18,C5,DR3,DQ2 al b5 c2 d4 e3 (Udal ova et al., 1993) 
B7,SC31,DR2 all b4 tl (Garcia-Merino et al., 1996) 
B8,SC01,DR3 a2 b3 tl (Garcia-Merino et al., 1996) 
B62,Cw3 a2 hl c2 d5 (Hajeer et al., 1996) 
DRI, DQS a2 hl c2 d4 tl (PLevy et al., 1996) 
DR3,B8 a2 b3 (Monas et al., 1995) 
DR3,DQB1 *0201 TNF2 ODengetal., 1996) 
DR4,B62 a2 hl (Monas et al., 1995) 
DR4,B44 a6 b5 (Monas et al., 1995) 
Table 4.3 Class I and II associations with TNF-308 and microsatellite polymorphic alleles reported in Caucasians (Footnotes on next page) 
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Table 4.3 Class I and ll associations with TNF-308 and microsatellite polymorphic alleles reported in Caucasians (Footnotes) 
Where a class I or II association with TNF polymorphic alleles occurring as a haplotype is shown, the TNF alleles are underlined 
In a Japanese population, TNFa9 and TNFd4 showed strong associations with HLA-835 and 844, respectively (Asano et al., 1997). 
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4.1.4.4 Involvement ofMHC and TNF alleles in TNF protein production? 
Evidence has recently been produced that concludes that approximately 60% of the inter-
individual variation in TNF secretion is genetically determined. This is based on a pedigree-
based maximum likelihood model, using data on TNF production by whole blood samples 
after in vivo endotoxin stimulation in 190 first degree relatives of61 families and 26 
monozygotic twins (Westendorp et al., 1996). 
Evidence that MHC molecules were involved in the secretion of TNF came shortly after the 
TNF genes were mapped to the MHC gene complex. Anti-class II MHC molecule mAb 
(anti-OR and -DQ) were shown to inhibit, in a dose dependent manner, the secretion of 
TNFa and IL-l by cultured monocytes stimulated with LPS (Santamaria et al., 1989). 
Importantly, the same series of experiments also demonstrated that certain HLA-DR 
haplotypes secreted more TNF and IL-l than others. The results from this study indicated 
that in their North American study population, DR2 and DR4 +ve cells were low secretors 
of both cytokines, whilst DR3 +ve cells secreted high levels. This association has been 
investigated in other studies, and partially confirmed. HLA-DR2 was confirmed to be 
associated with low levels ofTNFa secretion, and DR3 was confirmed as being associated 
with high levels ofTNF production in North American and European populations (Garcia-
Merino et al., 1996; Poicot et al., 1993; Jacob et al., 1990), but DR4 was found to be 
associated with high not low levels of production (Poicot et al., 1993; Jacob et al., 1990). 
An association with TNF secretion has also been observed with TNF microsatellite alleles 
(Poicot et al., 1993). The study shows significantly higher TNFa secretion by stimulated 
monocytes in subjects with TNFa2 (-3.4 ng/ml) and TNFc2 alleles, whilst the TNFa6 allele 
correlated with low TNF secretion (-2.4 ng/ml). The level of secretion was compared with 
a baseline of 3 ng/ml. Data for the TNF c2 allele was not shown in the paper. 
Another study reported that individuals homozygous for the TNFa2 allele have a higher in 
vitro PBMC TNFa secretion than individuals homozygous for the TNFall allele (Garcia-
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Merino et al., 1996). The difference did not reach statistical significance however (p<O.l ). 
Using data inferred from the associations of individual markers in the MHC, which have 
been shown to be linked to TNF microsatellite alleles and TNF microsatellite haplotypes, it 
has been suggested that haplotypes containing the alleles TNFa2, TNFb I, TNFb3, and 
TNFc2 are all associated with higher levels ofTNF secretion by LPS stimulated monocytes 
in vitro (Weissensteiner and Lanchbury, 1997). This work classifies many of the known 
haplotypes as having, 'high', 'low', or 'intermediate' secretor status. 
There is disagreement as to whether the hi-allelic polymorphism at position -308 in the 
TNFa promoter influences TNFa production. Evidence that the -308 TNF.A allele has 
effects upon TNF levels was largely circumstantial, based on the fact that it is linked with 
HLA-DR3 (Wilson et al., 1993) and that DR3 typed mononuclear cells exhibit higher 
production ofTNF upon stimulation in vitro (Jacob et al., 1990). However, differences in 
TNF production between individuals could not be explained by the -308 polymorphism in a 
study which also found no correlation between genotype of the -238 and -376 
polymorphisms (Huizinga et al., 1997). Inserted gene constructs with deletion of the 
promoter region containing the -308 polymorphism and constructs with the -308 variation 
have no effect upon LPS stimulated TNF secretion in macrophages (Stuber et al., 1996b), 
and allele specific transcript quantification and reporter gene studies, again using TNFa 
promoter constructs also did not detect any effect of the G-A transition (Brinkman et al., 
1996). Conversely, -308 variation is claimed to have effects upon TNFa production (Wilson 
et al., 1997). This is based upon more circumstantial evidence produced by these authors, 
showing that the polymorphism has significant effect upon transcriptional activity as 
detected by a reporter gene assay. This study did not show any difference in the specific 
affinity of ON A-binding protein for the polymorphic promoter site with or without the -308 
variation, leaving open the question of how the detected alteration in transcription is 
affected by the polymorphism. 
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The Ncol restriction site (A-G transition) at +249 in the first intron of the TNFP gene has 
also been linked with levels ofTNFa and p secretion in vitro by stimulated monocytes. 
+249 TNFB.A (called TNFB*2 in study) homozygotes are shown to have a significantly 
higher secretion ofTNFa than +249 TNFB.G (TNFB* I) homozygotes. Heterozygotes for 
this gene have an intermediate level ofTNFa secretion. This correlates with the finding of 
higher mean TNFa levels in sera of patients with sepsis homozygous for the +249 TNFB.A 
(TNFB*2) allele (Stuber et al., 1996a). Another study has reported higher levels ofTNFP 
secretion in +249 TNFB.G (TNFB* I) homozygotes, compared to +249 TNFBA (TNFB*2) 
homozygotes (Biragyn and Nedaspasov, 1995). 
4.1.4.5 TNF allele disease associations 
On the basis of the hypothesis that TNF alleles have important influence upon TNF 
secretion, TNF alleles have been characterised in populations of patients with various 
diseases or pathophysiological states in which TNF is thought to play a key developmental 
role. 
4.1.4.5.1 Base substitution and RFLP biallelic polymorphisms 
Details of many studies that have been carried out in this regard are detailed in Table 4.4. 
Some are further discussed below. 
The -308 and -238 polymorphisms in the TNFa promoter are the loci that have been most 
extensively studied in attempts to find association with disease. Neither allele of the -308 
locus has been found to be associated with susceptibility to ankylosing spondylitis (Vejans 
et al., 1994), alcoholic liver disease (Grove et al., 1997), insulin resistance (Day et al., 
1998), or rheumatoid arthritis (RA) (Vinasco et al., 1997c). Nor has association been found 
with either susceptibility to, or severity of, post-operative sepsis (Stuber et al., 1996b) or 
multiple sclerosis (MS) (Huizinga et al., 1997). Susceptibility to systemic lupus 
erythamatosus (SLE) is reported to be associated with the -308 TNF.A allele, although, as 
detailed in the table, the two studies conclude differently as to whether the association is 
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independent of known 1-ll..A associations (Rudlaweit et al., 1996; Sullivan et al., 1997). 
Although no association has been found with disease susceptibility, allele TNF.A of the-
308 polymorphism is reported to be increased in frequency in patients with fatal 
meningococcal disease compared to survivors (Nadel et al., 1996}, and those with 
mucocutaneous as opposed to milder forms of leishmaniasis (Cabrera et al., 1995). In 
Western African patients with malaria, subjects who were homozygotes for -308 TNF.A 
had an increased risk of the more severe, cerebral form of the disease (McGuire et al., 
1994). A study from North Africa reports that -308 TNF.A is more common in patients 
with various forms of malignant disease, including breast carcinoma and lymphoma, 
compared to a group of healthy controls with similar ages (Chouchane et al., 1997). 
On the other hand a negative association has been reported between this allele of the -308 
locus (TNFA) and Ulcerative colitis (UC) in a population of Dutch patients with 
inflammatory bowel disease (IBD) (Bouma et al., 1996). In UC patients it is present at a 
frequency of0.15, compared with 0.25 in healthy controls (p=0.44). The same study reports 
no difference in allelic distribution of the -238 TNFa polymorphism, or the AspHI (+365) 
and Ncol (+249) restriction polymorphisms of the TNF~ gene, in the same group of 
patients with lBD. 
The -238 TNFa promoter polymorphism has been investigated in populations of patients 
with other diseases. Investigators have reported increased frequency of the -238 TNF.A 
allele with reduced insulin resistance in relatives of patients with insulin-dependent diabetes 
mellitus (IDDM) (Day et al., 1998}, and alcoholic steatohepatits (Grove et al., 1997). 
Although their respective studies did not report an association between the -238 locus and 
susceptibility to either RA or MS, TNF.A at -238 is reported to be more common in RA 
patients with an earlier age of onset of disease (Vinasco et al., 1997) (the difference 
between mean ages being a decade) and in MS patients with more severe, progressive 
disease. This was assessed by their being confined to nursing homes (Huizinga et al., 1997). 
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The Ncol restriction site polymorphism in the TNFJ3 gene has also been investigated in 
patients with post-operative sepsis and rheumatoid arthritis. No association between either 
allele and susceptibility to RA was found (Vinasco et al., 1997), but two studies report 
associations between this locus and severity ofpostoperative sepsis (Stuber et al., 1996b; 
Stuber et al., l996b). Although the same group of authors report both studies, no mention 
is made that the groups of patients are the same. The authors report that the more common 
allele TNFB.A (they called TNFB*2), was reduced in frequency in survivors compared to 
non survivors, and TNFB.A (they call TNFB*2) homozygotes had a significantly higher 
mortality rate. This meant heterozygotes had a significantly higher rate of survival, as did 
TNFB.G (they call TNFB* I) homozygotes. One of the studies reports that the group of 
patients homozygous for TNFB.A (they call TNFB*2) had significantly higher median 
plasma TNF measurements (Stuber et al., 1996a). 
A recent study that characterised 6 of the bi-allelic polymorphisms associated with the 
TNFa. (-308, -238, +488) and TNFJ3 (+249, +365, +720) genes in patients with common 
variable immune deficiency (CVID) found that the +488 TNF.A allele was strongly 
associated with a subgroup with granulomatous disease (p=O 0005), and that this was 
independent ofknown class [and 11 associations (Mullighan et al., 1997). This subgroup of 
patients are known to have high serum TNF levels, but it is pre-emptive to reason that the 
+488 polymorphism is the cause of this as it's fi.mctional relevance is unknown. 
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-308 locus -238 locus Ncol locus 
Disease Susceptibility Severity Susceptibility Severity Susceptibility Severity Reference 
·········-··-------------------------
Rheumatoid arthritis No Yes 1 No Yes 1 No No (Vinasco et al., 1997) 
No No No Yes2 (Brinkman et al., 1997) 
No3 No3 (Field et al., 1997) 
No No (Wilson et al., 1995) 
Ankylosing spondylitis No No (Vejans et al., 1994) 
Wegener' s granulomatosis No No No (Mascher et al., 1996) 
Systemic lupus erythematosus Yes4 (Sullivan et al., 1997) 
Yes5 No (Rudlaweit et al., 1996) 
Psoriasis (types I and 11) No Yes6 (Sullivan et al., 1997) 
No Yes7 (Arias et al., 1997) 
Sarcoidosis No Yes8 No No (Seitzer et al., 1997) 
Table 4.4 Studies of the TNFn -3082 -2382 and TNF~ Ncol biaUelic [!Oil:mornhisms in immune linked2 inflammatoa2 infective2 metabolic and 
malignant disorders Continued ............ 
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-308 locus -238 locus Ncoi locus 
Disease Susceptibility Severity Susceptibility Severity Susceptibility Severity Reference 
·-c;;-~li~~-CiT~~~~~---·--·-··-········---·-···--v~s9--·-········-·-···-------------------·····-·--·---·-··· -------------------------· (Manus et al., 1996) 
Liver disease (alcoholic) No (Grove et al., 1997) 
Coronary heart disease No No (Hermann et al., 1998) 
Multiple sclerosis No No No (Huizinga et al., 1997) 
Ulcerative colitis Yes (-ve)12 No No (Bouma et al., 1996) 
Crohn's disease Yes (-ve) 13 (Louis et al., 1996) 
Obesity Yes14 No (Hermann et al., 1998) 
Insulin resistance Yes 15 (Day et al., 1998)* 
IDDM Yes 16 (Deng et al., 1996) 
Asthma Yes 17 (Moffatt and Cookson, 1997) 
Malignant disease Yes 18 (Chouchane et al., 1997) 
Chronic hepatitis B No (Hohler et aL, 1997) 
Table 4.4 Studies of the TNFa -308, -238, and TNFB Ncol biallelic polymorphisms in immune linked, inflammatory, infective, metabolic and 
malignant disorders Continued ........... . 
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-308locus -238 locus Ncoi locus 
Disease Susceptibility Severity Susceptibility Severity Susceptibility Severity Reference 
AIDS No2o No (Knuchel et al., 1998) 
Post-operative sepsis No No No Yes21 (Stuber et al., 1996a) 
Meningococcal disease No Yes22 (Nadel et al , 1996) 
No No23 No No (Westendorp et al., 1996)* 
Leishmaniasis No Yes24 No Yes23 (Cabrera et al., 1995) 
Malaria No Yes25 (McGuire et al., 1994) 
Table 4.4 Studies ofthe TNFa -308,-238, and TNFB Ncol biallelic polymorphisms in immune linked, inflammatory, infective, metabolic and 
malignant disorders 
TNF is thought to be important in the pathogenesis of all disorders studied * study in relatives of patients 
The study populations are all N European Caucasians unless otherwise specified IDDM Insulin dependent diabetes mellitus 
If an association is claimed by the study, details are given in footnotes, below: AIDS Acquired immune deficiency syndrome 
1. -308 TNF.G/G genotype associated with increased presence of nodular disease compared with TNF.G/A genotype (25.5 vs. 0%, p=0.03); -238 TNF.A/A 
genotype associated with lower mean age of onset compared with -238 TNF.G/A genotype (49±14.2 vs. 59±8.8, p=0.02). Study population Spanish. 
2. -238 TNF.G/A genotype associated with a slightly less frequent occurrence of erosions, although this was not statistically significant (82 vs. 94%). Study 
also looked at other TNFa bi-allelic polymorphisms at positions -376, -163, and +70 and found no associations. 
3. Study also looked at the bi-allelic polymorphism at +365 in TNF~ locus-no association. Likewise with microsatelite alleles. 
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4. -308 TNF.A allele associated with Systemic lupus erythematosus (SLE) in African-Americans. Association reported to be independent ofHLA-DR alleles 
5. -308 TNF.A allele increased in incidence in (UK) Caucasians (p=0.04). -308 TNF.A allele strongly linked with DR3 in the Caucasians, so association due to 
DR3. In native South African patients, DR2 but not DR3 was increased, and the frequency of -308 TNF.A was actually reduced rather than increased. This 
contrasts with later study (see note 4). 
6. -238TNF.A allele associated with juvenile onset psoriasis and psoriatic arthritis compared with controls (38 vs. 7%, p<0.01and 32 vs. 7%, p<0.03 
respectively). 
7. -238 TNF.G/A genotype associated with type I psoriasis compared to controls (41 vs. 8%, p<10-5). N American Caucasians. 
8. -308 TNF.A allele associated with subtype of disease with acute onset and spontaneous remission compared with controls (41 vs. 23%, p=0.02). 
9. -308 TNF.A allele associated with susceptibility to coeliac disease (CD) compared to controls (50 vs.16%, p<10-6). However the association was not 
independent ofthe association of CD with HLAB1 *0201. Study inN American Caucasians and Taiwanese Chinese. 
10. -238 TNF.G/A genotype associated with alcoholic steatohepatitis (ASH) compared with controls or patients with other lesions of alcoholic liver disease 
(ASH vs. non-ASH 16%vs 4%, p=0.036). No difference in age between patients, therefore total cumulative alcohol consumption claimed likely to be 
similar. 
11.-238 genotypes differently distributed in patients 'hospitalised' in a nursing home compared to those attending outpatient clinic x2=6.9, p<0.01). Difference 
attributed to absence of -238 TNF.A in 'hospitalised cohort. Numbers, however, were small; -238 TNF.A allele frequency in controls/clinic 
patients/'hospitalised' patients was 0.1/0.03/0.0. 
12.-308 TNF.A allele decreased in patients with ulcerative colitis (UC) compared to controls (15 vs.25%, p=0.044). Crohn's disease (CD) and UC patients 
studied. Study also looked at AspiD RFLP polymorphism within TNFP gene, no association was found. Haplotypes across the four loci (-308, -238, Ncol, 
AspiD) also were not significantly differently distributed between patient groups (UC and CD) and controls. -308 association with UC not confirmed by 
larger study, see note 13. 
13. -308 TNF.A allele decreased in patients with CD compared to controls (13.2 vs.21.3%, p=0.044). CD and UC patients studied. Did not confirm -308 
association with UC, see note 12. 
14. -308 TNF.A allele carriers were more frequently obese than non-carriers (40 vs. 30%, p<0.004). This finding not confirmed in study ofDay et a! (1998), 
see note 15. 
15. Non-diabetic relatives of non-insulin dependent diabetes mellitus patients carrying -308 TNF.A allele had reduced mean insulin resistance (p=0.03) and 
increased mean insulin sensitivity (p=0.04) compared with those with only -308 TNF.G allele. 
16. IDDM subjects have increased allelic frequency of -308 TNF.A compared to controls. However this association was due to linkage disequilibrium with 
141 
ID..,A-DR3, DQB1 *0201 haplotype, and not independent of it. 
17. Asthma significantly more common compared to controls in subjects with -308 TNF.A allele (p=0.004), and (Ncol) +249 TNFB.G allele (p=0.005). 
18. Significantly increased carriage of -308 TNF.A allele in patients with malignant disease (lymphoma, breast carcinoma, other tumours) compared to age 
matched controls (35 vs. 16%, p<0.005). Differences confirmed between individual tumour groups. Study also associated hsp70 polymorphism (MHC class 
Ill) with same groups. No linkage between 2 loci detected. Study in population ofNorth Africans. 
19. -238 TNF.A allele significantly more common in patients with chronic hepatitis B infection compared to controls and those with acute infection (25 vs. 6 
and 7% respectively, p<0.04 and p<0.003). 
20. Study inN American Caucasians. 
21. (Ncol) +249 TNFB.A (called TNFB*2 in study) heterozygotes had significantly higher survival than homozygotes (p=0.007). Also see text, section 
4.1.4.2.1. 
22. -308 TNF.A allele carriage associated with higher risk of death in childhood meningococcal disease compared with patients surviving (30 vs. 12%, 
p=0.03). 
23. -308 and -238 allele frequencies no different in relatives of survivors and non-survivors with adult meningococcal disease 
24. -308 TNF.A allele present at significantly higher frequency in mucocutaneous leishmaniasis (MCL) patients compared with healthy control subjects (18 
vs.6.9%, p<0.05). +249 TNFB.G (TNFB*2) allele also higher in MCL compared to controls. Population of Venezuelan subjects. 
25. In Gambian population cerebral malaria associated with increased frequency of -308 TNF.A/A homozygotes vs. mild malaria, 4.5% vs.l.S% (p=0.04). In 
cases of cerebral malaria, those who died or had severe neurological sequelae (99/376) had even higher frequency ofhomozygotes, 8.1 vs. 1.8% (p=0.005). 
found to be independent offfi.,A class I and II alleles. 
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4.1.4.5.2 TNF microsatellite polymorphisms 
The TNF microsatellite polymorphisms have also been investigated as regards their possible 
association with selected diseases. Table 4.5 details many of these studies, and some are 
now discussed. 
In a group of Caucasian IDDM subjects who were DR3/DR4 positive, the allele TNFa2 
was significantly more frequent compared to DR3/DR4 controls (Poicot et al., 1993). The 
same study demonstrates that the allele TNFa6 is correspondingly reduced in frequency in 
their DR3/DR4 patients compared to controls. 
Although differences in allele distribution could not be assigned to any particular allele, 
another study in a population of South Indians with Non-IDDM (NIDDM) and IDDM 
noted significant differences in the distribution ofTNFa and TNFb microsatellite alleles 
between IDDM patients and controls and between NIDDM patients with retinopathy as 
opposed to NIDDM patients with no associated eye disease (Hawrami et al., 1996). This 
latter association was found to be caused exclusively by NIDDM patients with proliferative 
retinopathy. 
Further characterisation ofTNF microsatellite alleles and 3 locus (TNFabc) haplotypes has 
been carried out in populations ofNorth American patients with IDDM and multiple 
sclerosis (MS) (Garcia-Merino et al., 1996). The authors also related their TNF 
microsatellite haplotypes to extended I-ll-A haplotypes. Individual allelic data is not 
presented, but the haplotype TNFa2b3cl was found to be significantly increased in patients 
with IDDM, compared to controls. Also, the TNFa11b4cl haplotype was found to be 
significantly increased in frequency in the patients with MS. These associations were not 
found to be independent of the already identified I-ll-A haplotype associations. The 
TNFa2b3c I haplotype was found to be carried exclusively by 1-ll.-A-88, SC03, DR3 
subjects, a haplotype already identified as being associated with IDDM. Likewise the 
TNFa 11 b4c I haplotype association was 80% attributable to it's 1-ll.-A-87, SC31, DR2 
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linkage, already known to be associated with MS. 
Another North American study has studied TNF microsatellite alleles in Caucasians with 
IBD (Pievy et al., 1996). Characterisation of3 (TNFabc) and S locus (TNFabcde) 
haplotypes was carried out. They found the 3 locus haplotype TNFa2b I c2 to be 
significantly increased in patients with Crohn's disease (CD) compared to ulcerative colitis 
(UC). It was also more frequent in CD patients compared to controls, but this figure did not 
reach statistical significance. The frequency of the S locus haplotype TNFa2b I c2d4e I was 
also found to be significantly increased in patients with CD compared to those with UC and 
the healthy controls. The authors showed that the TNFa2b I c2d4e I haplotype was 
associated in SO% of subjects with HLA-DRI/DQS, an HLA combination they had 
previously found to be associated with CD. The TNF S locus haplotype gave a more 
significant association with CD than the HLA-DRIIDQS association (Odds Ratio 4.4 vs. 
2.5). 
As can be seen, many of the reported associations ofTNF alleles and haplotypes have not 
been confirmed by similar studies in comparable populations_ Furthermore, it is apparent 
that associations reported are often secondary to, or linked to, known HLA associations. 
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··········-··-·-··----·------····---···-·······-·····-.. ·---·-···------
·---·--··--·· .............. __ , _____ .. ,_,_, ........ _____ _ 
Disease 
IDDM 
Details ofTNF microsatellite allele or haplotype association 
TNFa2 increased in DR3/4 +ve (p=0.047), a6 decreased in DR3/4 +ve vs. controls (p=0.051) 
Distribution ofTNFa and b alleles different vs. controls (p=0.016) 1 
TNFa2b3c1 haplotype frequency patients vs. controls, 24.5 vs. 8.2% ( p<0.004)2 
TNFalb5 haplotype frequency patient vs. controls, (p<0.005)3 
Reference 
(Poicot et al., 1993) 
(Hawrami et al., 1996) 
(Garcia-Merino et al., 1996) 
(Monos et al., 1995) 
NIDDM Distribution ofTNFa and b alleles different in patients with retinopathy vs. those without (p=0.006) 1 (Hawrami et al., 1996) 
Multiple sclerosis TNFallb4c1 haplotype frequency patients vs. controls 30.2 vs. 16.5% ( p<0.04)t (Garcia-Merino et al., 1996) 
IBD TNFa2b1c2d4el haplotype frequency in Crohn's Disease vs. controls 24 vs. 6.7% (p=0.01)5 (PLevy et al., 1996) 
Rheumatoid arthritis TNFa and TNFe 6 (Field et al., 1997) 
SLE 
Coeliac disease 
TNFa6 allele frequency in patients vs. controls (p=0.0019f 
No association; TNFa microsatellite only tested 
TNFa2 allele frequency in patients vs. controls 61.2 vs. 26.3% (p<O.OOl). Also TNFb3 association8 
(Hajeer et al., 1996) 
(Mascher et al., 199) 
(McManus et al., 1996) 
....... --····--------.. --·-------· ----·-·----~-------·-----·--...... , _______ _ 
Table 4.5 Studies of the TNF microsatellite polymorph isms in immune linked, inflammatory, infective, and malignant disorders (continued ... ) 
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---·---·-----···---·-··---··---- ----··-·-----·-·-·-··-·----
Disease Details ofTNF microsatellite allele or haplotype association Reference 
Renal allograft rejection TNFa9 and TNFd4 alleles increased in rejection vs. rejection free9 (Asano et al., 1997) 
Colorectal cancer TNFa2 allele frequency in patients vs. controls (3 5 vs. 20%,p=O. 01 )10 (Gallagher et al., 1997b) 
AIDS TNFa2 allele associated with faster disease progression vs. Controls (15 vs. 46%, p=O 006) 11 (Khoo et al., 1997) 
·--------··---·---------·-.. ·- ----------··--·····----·-···-·· 
Table 4.5 Studies of the TNF microsatellite polymorph isms in immune linked, inflammatory, infective, and malignant disorders 
TNF is thought to be important in the pathogenesis of all disorders studied 
The study populations are all N European Caucasians unless otherwise specified 
details and additional information of studies are given in footnotes, below: 
1. Study in Southern Indian subjects 
- denotes relationship not tested 
IDDM Insulin dependent diabetes mellitus 
AIDS Acquired immune deficiency syndrome 
NIDDM Non-insulin dependent diabetes mellitus 
2. TNFa2b3c2 association not independent ofHLA-B8,SCo1,DR3 association. Study inN American Caucasians 
3. Only TNFab microsatellites tested. In linkage with HLA-DR3,B18, a haplotype known to be associated with IDDM. This association not tested in patient 
cohort 
4. TNFa 11 b4c1 association 80% attributable to known HLA-B7,SC31,DR2 association. Study inN American Caucasians 
5. TNFa2b1c2d4e1 (and 3 locus TNFa2b1c2) association greater than HLA class I and II haplotype association that is in linkage with TNFa2b1c2d4e1 (HLA-
DR1, DQ5). No association with ulcerative colitis found. Study inN American Caucasians 
6. TNFa and TNFe only tested. Differences observed consistent with extended MHC haplotypes, therefore no independent contribution of the TNF locus 
7. TNFa6 association due to linkage with DRB 1 *0401. Not an independent marker. 
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8. TNFb3 also increased in Coeliac patients vs. controls (53.9 vs. 13%, p<O.OOI ). This association due to linkage with HLA-DQB I *0201. TNFa2 association 
was independent of HLA class I or II association 
9. TNFa9 and TNFd4 showed strong associations with HLA-B35 and B44, respectively. However the TNF microsatellite loci were more closely related to 
acute rejection than HLA-B. Japanese population 
I 0. Two independent populations confirmed this association. 
I LTNFa,b,c, and d microsatellite characterisation. The 2 subgroup numbers were~ 24. 
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4.2 lnterleukin-10 (IL-10) locus 
The gene encoding IL-l 0 has been mapped to chromosome 1 (Kim et al, 1992). It's exact 
location has yet to be confirmed, but it is probably in the region of 1 q31 and 1 q3 2 (Eskdale 
et al, 1997a). Other genes in this region include genes encoding proteins with functions 
within the immune system; for example the CD21 (lymphocyte cell surface molecule) locus 
is nearby, as are genes encoding complement system components (decay accelerating factor, 
complement receptor 1, complement receptor 2). 
The intron/exon structure of human IL 10 has yet to be determined. The mouse IL-l 0 gene, 
which has considerable homology to the human form (Kube et al., 1995), also maps to 
chromosome 1 and is composed of five exons arrayed over c. 5.5kb of DNA (Kim et al., 
1992). The IL-10 region is shown in Fig. 4.4. 
The human IL-10 promoter region (5' region) has been investigated in some depth. Kube 
and eo-workers (1995) isolated the promoter region and produced deletion mutants of it by 
partially digesting the fragment with a selection of restriction enzymes, and then re-ligating. 
Subsequently a chemoluminescent reporter gene assay was constructed in lymphoma cell 
lines (Kube et al, 1995). This work showed that areas of the promoter had different effects 
upon reporter gene activity, identifying elements within the promoter region that could alter 
the constitutive expression of IL-l 0. Elements that upregulated gene expression were 
identified between -1 l 00 and -900, and sequences that reduced gene expression were 
located between -800 and -300. All positions are relative to the transcription initiation start 
site of the IL-l 0 gene. 
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Figure 4.4 IL-10 gene and promoter region on chromosome 1 
IL-l 0 Gene, intron/exon structure unknown 
A TG - Transcription start site 
A - region of promoter reported to reduce gene expression1 
B - region of promoter reported to increase gene expression 1 
ILlO.G - rnicrosatellite (CA)n repeat, 16 alleles 
ILlO.R - rnicrosatellite (CA)n repeat, 5 alleles 
4000bp 
ILlO.G 
BialleLic (base substitution) polymorphisms at -1117, -854, and -627 from transcription start site 
1 (Kube et al 1995) 
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ILlO.R 
• microsatellite 
gene locus, intron/exon structure unknown 
(not to scale) 
4.2.1 Polymorphisms in the ILIO locus 
Polymorphic sites have subsequently been identified within the promoter region. These 
consist oftwo polymorphic dinucleotide repeats (microsatellites), named IL10.G and 
IL10.R, and a number of base substitution polymorphisms (point mutations). These are 
shown in Figure 4.4. 
The first to be described was the IL lO.G microsatellite, a (CA)n repeat located between 
positions -1193 and -115 I (Eskdale and Gallagher, 1995). IL I O.R, another (CA)n repeat, 
was subsequently reported to be c. 2.8kb upstream of this (Eskdale et al., 1996). They have 
sixteen and five alleles respectively. 
Three single (biallelic) base substitution polymorphisms have also been characterised. They 
are named according to position from transcription initiation start site, which causes some 
confusion, as the two sets of investigators involved seem to have named and identified the 
polymorphisms using different sequences deposited at the GenEMBL database. In this 
work, the sequence with accession number X78437 will be used to name the biallelic 
polymorphisms by position, with their other published nomenclature put in parentheses 
Turner et at (1997) characterised three sites at -1117 (they called -I 082), -854 (they called 
-819), and -627 (they called -592). -1117 is a C-A transition, -854 is aC-T transition, and 
-627 is a C-A transition (Turner et al., 1997). The sites at -854 and -627 have been 
confirmed by Eskdale et at , who did not analyse the region beyond -I 002 (Eskdale et al., 
1997a). They found the two sites ( -854 and -627) to be in complete linkage disequilibrium 
in their population, -854.1 was always linked with -627. 2 and vice versa. 
4.2.2 Nomenclature 
Alleles ofthe two microsatellites (ILIO G and lLIO.R) are named according to the common 
system for this type of polymorphism. The allele with the least number of dinucleotide 
repeats (n=x) is designated allele I, and subsequent alleles are numbered according to the 
number of repeats (n=x+ I ,allele2; n=x+2, allele 3; etc.). 
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With regard to the biallelic polymorphisms at positions -1117, -854, -627, as well as having 
two different names (in this work the sequence with accession number X78437 will be used 
to name the biallelic polymorphisms by position, with their other published nomenclature 
put in parentheses), they are in possession of two different systems of allelic nomenclature 
Eskdale et al ( 1997) typed the -854 and -627 loci by PCR-RFLP, and name alleles 
according to whether the fragment is undigested (allele 1) or digested (allele 2). Turner et al 
( 1997) name alleles according to the nucleotide. This work will follow the convention 
outlined for the alleles of the TNF locus (see section 4.1.4.2), and will name alleles 
according to the nucleotide. 
e.g. -1117.G, -854.T, -627.A 
4.2.2 Effects of polymorph isms upon IL 10 production? 
As discussed above, comparable with genetic influences upon secretion ofTNF, a high 
proportion (75%) ofthe variation in IL-10 production between individuals is estimated to 
be genetically influenced (Westendorp et al., 1996). 
It is important to note that (as detailed in fig. 4.4) the three biallelic polymorphisms and the 
IL I O.G microsatellite are all either within or close to the regions identified as having effects 
upon gene transcription, -I I 00 to -900, and -800 to -300 (Kube et al., 1995), leading to 
speculation that the polymorphisms may play a functional role in lL I 0 gene transcription 
and subsequent protein expression. 
To date, there have been no studies to determine ifthe ILIO.G or ILIO.R microsatellites 
have any functional relevance upon IL-l 0 production. However, all three of the biallelic 
polymorphisms have been investigated to see if they have any effect upon IL-l 0 protein 
production (Turner et al., 1997). Mean IL-l 0 production, as measured by in vitro 
stimulation of peripheral blood leucocytes, has been shown to be significantly higher in 
healthy controls typed for -1117.G (called -I 082*G in study) compared to those typed for 
-1117.A (called -1 082* A in study), 1720 pg ml 1- vs. 1297 pg mr1 (p=0.035, t-test). 
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Sequencing ofthe ILlO 5'flanking region has also revealed that close to all the 
polymorphisms so far characterised there are numerous and varied transcription factor 
binding sites (Eskdale et al., l997a). These include NKKB/REL sites known to mediate 
TNF signalling (Baeuerle and Henkel, 1994), STAT. I sites known to mediate interferon and 
interleukin signalling, and the NF-IL-6 recognition sequence. A concentration of such sites 
are situated downstream ofthe ILIO.R polymorphism (and this is described by the authors 
as being the putative cytokine responsive area), but there also are many located in close 
proximity to the IL I O.G polymorphism and the three biallelic polymorphisms. For example 
there are two of the nine potential NFKBIREL sites 60 and 80bp immediately upstream of 
lLlO.G (Eskdale et al., 1997a) It can be speculated that the known ability ofTNF to 
influence lL I 0 transcription (Platzer et al., 1995) is mediated through these sites, and the 
other transcription factor binding sites may be involved in a similar way in cytokine 
mediated modulation of IL I 0 gene expression. Further conjecture could lead one to 
suppose the polymorphisms in this region may be functional through their associated 
alteration of an important transcription factor binding site. 
4.2.3 IL-10 allele associations with disease 
As polymorphisms around the IL-l 0 locus have been characterised relatively recently, there 
are a limited number of studies utilising their potential role as tools to detennine the 
conceivable role ofiL-10 in genetic susceptibility to inflammatory and (auto)immune 
disorders. 
Systemic lupus erythematosus (SLE) is a disorder in which elevated IL-l 0 levels are found, 
particularly in association with the presence of pathogenic autoantibodies Both the 
microsatellite polymorphisms and the three biallelic loci have been characterised in several 
patient populations with SLE. 
No differences have been noted in the distribution of ILl O.R alleles between SLE patients 
and controls, however, the two populations differed significantly in the distribution of 
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ILIO.G alleles (p=0.028). In particular allele 9 was decreased whilst allele 13 was increased 
in frequency (Eskdale et al., 1997b). Differences were confirmed by examining the genotype 
distribution. The data suggested that those subgroups of patients without renal disease or 
with anti-DNA antibodies accounted for this, as the other subgroups (with renal disease or 
with anti-ENA antibodies) had allele 9 and 13 frequencies comparable with the control 
population. This is a tentative interpretation of the observation, as subgroup numbers and 
the total were relatively small (total=56). 
Two other studies have looked at the biallelic polymorphisms in SLE patients. One also 
looked at a larger group ofUK Caucasian SLE patients and found no significant change in 
-1117, -854, and -62 7 allele frequency compared with controls (Lazarus et al., 1997). The 
authors did note, within the SLE population, a significant difference in the distribution of 
their (three) putative haplotype frequencies according to positive Ro antibody status 
(p=O.OOS). The other published study is in a population of Chinese (n=88). In this 
population of SLE patients, a significantly different IL-l 0 allelic distribution was not noted 
between patients and controls, however an association seen between alleles -854.T and 
-627.A and the development of lupus nephritis was seen in this small subgroup of patients 
(Mok et al., 1998). 
ln another autoimmune associated disease, rheumatoid arthritis (RA), the allelic frequency 
of -1117, -854, and -627 was found to be the same in Caucasian patients and controls 
(Hajeer et al., 1998). To assess whether there was any association with disease severity the 
patients were subdivided on the basis of whether their rheumatoid factor (RF) was IgG, IgA 
or lgM (IgA associated with worse prognosis). The patients with lgA+IlgG- RF were found 
to have a higher frequency of the -1117.A allele and the ( -1117.A I -854. C I -627.C) 
haplotype than controls, (28 vs. 50% p=0003). However, as this is a haplotype the authors 
had previously associated with low IL-l 0 production (Turner et al., 1997), the significance 
of this finding is unclear, as IL-l 0 is known to induce B cells to switch to IgA production 
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(in combination with TGF~). The same group of investigators have also characterised the 
same three polymorphic loci in heart transplant patients, in association with the -308 TNF 
polymorphism. They found that the patients typed as 'low secretors' of IL-l 0 ( -1117.A 
homozygotes) and 'high secretors' ofTNF ( -308.A allele present) were more likely to have 
high levels of rejection (5-8 episodes). 5 of 19 patients with high levels of rejection had this 
combination, as compared to 4 of96 patients with low levels of rejection. (Yates' <0.005). 
These findings are very interesting and worthy of further study, but the numbers are 
relatively small. 
4.3 Other cytokine genes and inflammatory diseases 
Polymorphisms have also been characterised at other cytokine loci within the genome. 
Three of the most interesting are polymorphisms in the IL-l ra, IL-l, and IL-4 genes. 
IL-l ra, the natural antagonist to IL-l, has a well characterised variable number tandem 
repeat (VNTR) polymorphism in the second intron of it's gene on chromosome 2 (Tarlow 
et al., 1993). The repeat unit is an 86 bp sequence The polymorphism has 5 alleles, the four-
repeat (allele I) and the two-repeat (allele 2) being the most common, whilst the other 
alleles have a combined frequency of less than 5%. A relationship has been shown to exist 
between allele 2 and increased IL-lra production, and decreased IL-l production by 
stimulated monocytes in vitro (Danis et al., \995). 
Investigations have suggested that allele 2 of the IL-l ra VNTR is a marker of disease 
severity in a number of inflammatory diseases and processes. These include Juvenile RA 
(Me Dowell et al., 1995), nephropathy in NIDDM and IDDM (Blakemore et al., \996), and 
ulcerative colitis (Mansfield et al., 1994). The association between severity of UC and allele 
2 has been a disputed finding as other studies with increased (and perhaps more adequate) 
numbers of patients have partially confirmed (Heresbach et al., 1997; Roussomoustakaki et 
al., 1997) and refuted the finding (Hacker et al., 1997). Nevertheless, especially as the 
!54 
VNTR has been shown to have functional relevance, testing for associations between the 
polymorphism and severity of inflammatory disease is a very attractive hypothesis which 
warrants testing. There are also identified biallelic (RFLP) polymorphisms in the IL-l gene 
itself on the same chromosome. These have also been investigated with the IL-l ra 
polymorphisms as markers of disease susceptibility and severity in IDDM and mo 
(Heresbach et al., 1997). 
IL-4 is an interesting cytokine that is produced by and has effects upon mast cells and 
stimulates increased production of IgE. Therefore it has an important role in atopic 
responses. The TL-4 gene and IL-4 receptor (IL-4R) genes both have identified biallelic 
(base substitution) polymorphisms. These have been characterised in groups of patients with 
asthma and atopy. No association has been found with the IL-4 promoter polymorphism, 
but an allele, termed R576, of the IL-4R gene (which causes an amino acid change in the 
cytoplasmic domain of the receptor), has been reported to be associated with atopy. 
Furthermore, carriers of this allele seem to have enhanced expression ofCD23 in response 
to TL-4, indicating that the mutant allele may have effects upon receptor signalling (Hershey 
et al., 1997). 
4.4 Genetic association studies in alcoholism and alcohol related diseases 
Because of the significant number of patients with alcohol-induced pancreatic disease, and 
in view of the nature of the immunogenetic studies being undertaken in them in this work, 
consideration will be given to possible HLA associations with alcoholism and alcohol 
related diseases, and to genetic studies on alcohol-metabolising enzyme genes. 
4.4.1 Inherited susceptibility to alcoholism 
Alcoholism is well known to run in families, but the important question is whether this is 
due to the influence of genes or the environment. 
Twin studies indicate that alcoholism is more concordant in monozygotic (MZ) than 
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dizygotic (DZ) twins, and also this does not completely rule out the influence of 
environment it is suggestive that alcoholism is in part inherited. Adoption studies, which go 
some way towards separating environmental and genetic influences upon behaviour and 
disease, confirm this. Animal studies support the concept of a genetic influence on 
alcoholism; it is possible to selectively breed rats for high and low voluntary alcohol intake 
(Lumeng and Crabb, 1994). 
A recent American study, while confirming that concordance rates for alcoholism are higher 
in MZ compared to DZ twins, claims that there exists little additional genetic liability to the 
cirrhotic or psychotic complications of alcoholism, beyond that already seen in relation to 
alcoholism. Studies that have used different variance modelling methodology are, however, 
in direct contradiction to this finding (Reed et al., 1996). 
4.4.2 HLA associations with alcoholism and alcohol related liver disease 
There have been a large number of studies looking at the association between HLA 
antigens, encoded by the MHC, and alcoholism and alcohol-related liver disease in a number 
of different races. All published studies used serological methods to perform HLA typing 
and used healthy control subjects from the same geographical area. 
In Caucasian populations there is no consistent HLA type which is associated with 
alcoholism or alcohol-related liver disease. However, HLA-8 IS, 840, DR2, and DR4 have 
all been reported of an increased frequency in groups of such patients in Northern European 
and Australian Caucasians populations, but a meta-analysis of all the studies done in this 
area concludes that there is no HLA association (List and Gluuid, 1994). 
4.4.3 HLA associations with alcohol related pancreatitis 
Studies have also been undertaken regarding serological HLA types and association with 
alcohol-induced pancreatic disease. Although many of the studies are poorly controlled 
certain HLA types have been found to have a significant association with the development 
of alcoholic chronic pancreatitis in certain Caucasian populations: 
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French: 
UK: 
Italian: 
Australian: 
840 (Fauchet et al., 1979) 
CS (Forbes et al., 1987) 
813 (Gullo et al., 1982) 
839 (Wilson et al., 1984) 
Again, the HLA type in question differed between studies, and only one used a control 
group of alcoholics without pancreatic disease (Wilson et al., 1984). Other studies in similar 
Caucasian populations have found no associations (Haber et al., 1995). 
4.4.4 Alcohol metabolising enzyme genes, alcoholism, and alcohol-related liver disease 
As previously discussed there are three main families of alcohol metabolising enzymes; 
alcohol dehydrogenase (ADH), aldehyde dehydrogenase (ALDH), and the cytochrome 
P450 2E1 enzyme (CYP450 2E1). 
Although hepatic ADH is the major pathway for ethanol oxidation in the liver, there are 
over 20 different ADH isoenzymes grouped in five classes. They have diverse tissue 
distribution, including stomach mucosa. The five classes (I to V) are encoded by seven gene 
loci, which encode for subunits of ADH isozymes. The genes ADH I, ADH2, and ADH3 
encode for the subunits which make up the isoenzyme class found predominantly and 
extensively in the liver. ADH2 and ADH3 are polymorphic, biallelic base substitution 
polymorphisms result in amino acid residue changes in the subunits. The ADH2 residue 
changes are in the coenzyme binding site, so directly affect the kinetic properties of the 
enzyme. The same is postulated for ADH3 (reviewed by (Arnon et al., 1995)). 
The ALDH enzyme has two classes, but it seems that only the ALDH2 isozyme, encoded by 
the ALDH2 gene, is a major participant in ethanol metabolism (reviewed by (Arnon et al., 
1995)). It too exhibits biallelic polymorphism. 
The CYP450 2E I gene has four polymorphic RFLP sites, indicating biallelic base 
substitution changes (Savolainen et al., 1997). 
In Caucasian populations the ADH2 and ALDH2 allelic variations do not occur or are very 
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rare, however, they exist in Far Eastern populations (Suzuki et al., 1994). Associations 
with ADH2* I and ALDH2* I alleles are claimed in Japanese alcoholic subjects, but 
conflicting results have been obtained as to whether any allele is associated with the 
development of alcoholic liver disease (Tanaka et al., 1996; Yamaguchi et al., 1995). 
Interestingly possession of the ALDH2* 1 allele protects Far Eastern individuals from the 
severe facial flushing commonly seen with alcohol in these populations. 
ln Caucasian alcoholics with liver disease the ADHJ* I allele is reported to be increased in 
frequency compared to controls, but the (weak, and non-significant by standard tests) 
association seen by the authors could be due to an association with alcoholism as a non-
alcoholic control group was used (Day et al., 1991). 
CYP450 2E I polymorphisms have been characterised in subjects with heavy alcohol intakes 
and in patents with alcoholic liver disease. Again, markedly different allele frequencies are 
seen in different racial groups, the Japanese population (Tsutsumi et al., 1994) exhibiting 
more variability than Caucasians (Savolainen et al., 1997) Unsurprisingly therefore, only in 
the Japanese has an association between alcoholic liver disease and polymorphism of 
CYP450 2E I been claimed. lt does not seem to be associated with alcoholism per se. 
4.4.5 Alcohol metabolising enzyme genes and alcohol-related pancreatic disease 
There have only been a few studies that have characterised alcohol metabolising gene 
polymorphisms in pancreatitis patients. These have been in subjects with alcohol-induced 
chronic pancreatitis. 
Studies in Caucasians have been ofthe ADH2, ADHJ, and ALDH21oci. Unsurprisingly, 
little or no allelic variation of the ADH2 and ALDH2 loci was detected. An increased 
frequency of the ADHJ* I allele is reported to be found in Caucasian alcoholics with 
chronic pancreatitis compared to normal healthy controls (Day et al., 1991 ), however the 
association is very weak and does not achieve significance with standard statistical 
methodology. Furthermore, only 13 patients were studied. A similarly sized study reports 
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no ADHJ association (Couzigou et al., 1990). 
Larger studies, also characterising and the CYP450 2E I locus, have been carried out in 
Japanese patients with chronic pancreatitis, comparing them with alcoholic patients with no 
chronic pancreatitis (Matsumoto et al., 1996). No differences in allele distribution between 
patients and controls were seen for the ADHJ, ALDH2, or CYP450 2E 1 loci. The authors 
noted that the frequency of the ADH2*2/*2 genotype was increased in the group with 
pancreatic disease (42 vs. 30%), and in fact the genotype distribution is significantly 
different (p<O.OS). 
AJI in all, this is scanty evidence that polymorphisms of the alcohol metabolising enzyme 
genes are associated with susceptibility to alcoholic chronic pancreatitis or alcohol-induced 
liver disease, especially in Caucasian populations. To do more than suggest an association, 
more studies are needed. 
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4.5 Aims of this study 
The clinical course of acute pancreatitis is often mild with only minimal associated organ 
dysfunction, but a significant proportion of patients develop severe pancreatitis which is 
associated with organ failure, systemic complications, local inflammatory and infective 
manifestations and, in up to I 0% of cases, death. The aetiology of acute pancreatitis is also 
diverse, gallstones and heavy consumption of alcohol accounting for the majority of cases. 
The reason for the development of alcoholic acute pancreatitis is unclear, but does not 
appear to be related to the amount or type of alcohol consumed, implying that factors 
relating to the host account for why only a proportion of patients with heavy alcohol 
consumption develop the disease. 
Pro-inflammatory and regulatory cytokines play a fundamental role in the local and systemic 
inflammatory response in the initial stages of disease and in the development of severe acute 
pancreatitis. As has been discussed, polymorphisms of cytokine genes may influence protein 
production, so influencing regulation of the inflammatory response. 
This study aimed to characterise TNF and IL-l 0 polymorphisms in a population of normal 
Europids, and patients with acute pancreatitis. This enabled analysis to determine if any of 
the polymorphisms studied were determinants of disease severity or susceptibility. 
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5 Materials and Methods 
5.1 Study Subjects 
5.1.1 Patients 
One hundred and thirty five Europid patients admitted with a diagnosis of acute pancreatitis 
were identified shortly after admission to Derriford Hospital, Plymouth. Ethical committee 
approval had been obtained. The criteria for diagnosis of acute pancreatitis were: 
1. a clinical history and examination consistent with the disease (Table 5.1) 
11. a serum amylase level greater than 660units/1 (Hitachi 911, Hitachi Corporation, Japan; 
normal level <220 units). 
iii. appropriate radiological evidence (Table 5.1) 
Patients who had clinical or radiological evidence suggestive of a diagnosis of chronic 
pancreatitis were excluded (Table 5.2) as were patients who subsequently proven to have 
radiological or ERCP evidence of chronic pancreatitis. CT or ERCP was performed if there 
was a clinical suspicion of chronic pancreatitis in those patients with alcohol induced 
disease 71% (IS of 21) patients classified as having acute alcohol-induced acute 
pancreatitis underwent CT or ERCP. The other 19% (6 of21) had an adequate ultrasound 
scan (pancreas clearly visualised), with no evidence of chronic pancreatitis in this imaging 
modality. 
Venupuncture was performed using a Vacutainer@ blood collection system (Becton 
Dickinson, Meylan, Cedex-France). Blood was collected into 5% disodium ethylenediamine 
tetra-acetic acid (Na2EDT A), and stored at -20°C in sterile polypropylene containers prior 
to subsequent DNA extraction. 
Patients who had received a blood transfusion within the previous three months were not 
included in the study as donor white cells still may have been present in peripheral blood, so 
contaminating subsequent DNA preparation. 
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5.1.2 Determination of aetiology of disease 
Aetiology of acute pancreatitis was classified as being due to gallstones in the presence of 
appropriate radiological or ERCP findings, due to alcohol if subjects admitted on 
questioning to being consistent consumers of greater than 80g of alcohol per day (Wilson et 
al., 1985), or idiopathic if no other identifiable cause could be discovered. 
Patients were classified as having idiopathic pancreatitis following an optimal ultrasound or 
CT scan reporting the absence of gallstones in the biliary tree and gallbladder. Patients who 
had an inadequate initial examination underwent repeat ultrasound scan. 
Consistent consumption of alcohol was defined as daily consumption of greater than 80g of 
alcohol per day over a time period exceeding six months. No subject who had acute 
pancreatitis secondary to excessive 'binge' consumption of alcohol was encountered during 
recruitment for this study. Any history of alcohol consumption recorded in the medical 
notes was confirmed by interviews with individual patients. 
5.1.3 Severity of disease episode 
The progress of individuals with regard to development of complications was monitored 
during their disease episode. The recording of physiological, biochemical, and 
haematological parameters enabled patients to be classified as having mild disease or severe 
local or systemic disease according to criteria defined by the Atlanta convention (Bradley, 
1993). This is summarised in Table 5.3. 
The occurrence of a local pancreatic complication was defined as described in the Atlanta 
classification, except an acute fluid collection was not included in this category for the 
purposes of this study. 
Maximal organ failure scores according to the method ofBernard (Kingsnorth et al., 1995) 
were also calculated to provide another means of patient stratification (Table 5.4). 
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Clinical history and examination 
Abdominal pain 
Referred pain to back 
Anorexia 
Nausea 
Vomiting 
Epigastric tenderness 
Dehydration 
Hypovolaemia 
Confusion secondary to hypoxia 
Jaundice (10-20%) 
Grey-Turner/Cullen sign ( <5%) 
Radiological evidence 
Plain X-rays: 
Intestinal ileus 
Gallstones 
Absence of free sub-diaphragmatic air1 
Absence of pancreatic calcification2 
Ultrasound Scan: (may be normal) 
Pancreatic oedema 
Free intraperitoneal fluid 
Fluid collection (pseulfocyst, abscess) 
CT Scan: (may be normal) 
Pancreatic oedema 
Free intraperitoneal fluid 
Fluid collection (pseudocyst, abscess) 
Area of necrosis 
Table 5.1 Clinical and radiological criteria consistent with diagnosis of 
acute pancreatitis 
CT = computerised tomography 
1 Indicates perforated viscus 
2 Indicates probability of chronic pancreatic inflammation 
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Clinical 
History: 
Chronic epigastric pain 
Steatorrhoea 
Weight loss 
Diabetes 
Pancreatic function test 
Evidence of pancreatic insufficiency 
Radiological 
Plain Radiographs. USS. CT Scan: 
Calcification 
Ductal stones 
Pseudocysts 
ERCP: 
Calcification 
Ductal stones 
Pseudocysts 
Ductal stricture 
Table 5.2 Clinical and Radiological evidence suggestive of Chronic Pancreatitis 
CT = computerised tomography 
USS = ultrasound scan 
ERCP = endoscopic retrograde cholangiopancreatography 
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CATEGORY DEFINING CRITERIA 
·················--·········································································------···························································································-·····························---
Mild acute pancreatitis 
Severe acute pancreatitis: 
Predicted severe disease 
Organ failure: 
1. Cardiovascular insufficiency 
11 Respiratory insufficiency 
iii. Renal failure 
iv. Gastrointestinal bleeding 
V. DIC 
vi. Metabolic failure 
Local complications 
i. Acute fluid collection 
n. Pseudocyst 
iii. Abscess 
iv. Necrosis 
Minimal organ dysfunction 
Organ failure and I or local complications 
Apache II Score ~ 8 
Systolic blood pressure < 90 mmHg 
Pa02 < 60 mmHg (8 KPa) 
Semm Creatinine> 177~-tmol 1"1 (after rehydration) 
> SOOml ofblood loss in 24 hours 
Platelets s 100,000 per mm3, Fibrinogen< lg 1" 1 
Semm calcium s 1.87 mmol r• 
Located in or near the pancreas, lack a wall of 
granulation or fibrous tissue 
Collection of pancreatic secretion bounded by 
fibrous or granulation tissue wall 
Circumscribed collection of pus 
Diffuse or focal nonviable pancreatic parenchyma 
Table 5.3 Atlanta Convention Classification of acute pancreatitis 1 
Apache II 
DIC 
mmHg 
Kpa 
Acute Physiology and Chronic Health Evaluation II 
(Larvin and McMahon, 1989) 
Disseminated Intravascular Coagulation 
millimetres of mercury 
Kilopascals 
1 (Bradley, 1993) 
165 
cvs RS CNS COAG. RENAL 
OFS SBP(mmHg) Pa02/Fi02 Glasgow Platelets Creatinine 
Lactate (mmoll1) (mmHg) Coma Score (xl09 1'1) (Ill 1'1) 
0 ~90 2:400 15 2: 120 ~ 133 
<90 2:300- <400 13-14 2:80- <120 >133- ~169 
responsive to fluid 
2 <90 2:200- <300 10-12 2:50- <80 >169- ~310 
unresponsive to fluid 
3 2-5 2:100- <200 6-9 2:20- <50 >310- ~440 
4 >5 <100 ~5 <20 >440 
Table 5.4 Organ failure score system used in this study 
OFS Organ failure score 
CVS Cardiovascular system 
RS Respiratory system 
CNS Central nervous system 
COAG. Coagulation system 
RENAL Renal system 
SBP Systolic blood pressure 
Pa02 Arterial partial pressure of oxygen 
Fi02 Fraction of inspired oxygen 
Organ failure score was the sum of the score obtained in each system 
Modified from (Kingsnorth et al., 1995) 
5.1.4 Control subjects 
Two sets of control subjects were used for this study: 
5.1.4.1 Normal healthy controls Cord blood samples from 134 Europids following a 
normal healthy obstetric delivery at Derriford Hospital, Plymouth were used to obtain 
control allele and genotype frequencies. 
5.1.4.2 Alcohol related disease 'controls' Due to methodological difficulties in recruiting 
alcoholics who are definitely free of organ specific alcohol related disease, a group of33 
Europids with alcohol induced liver disease was used as an extra 'control' group for the 
group of alcoholic pancreatitis patients. 
49 alcoholics admitted to Derriford Hospital, Plymouth with acute alcoholic hepatitis or 
alcohol-induced cirrhosis were screened for inclusion in the 'control' group. Diagnosis was 
by clinical history and examination, liver enzyme estimation, and ultrasonography in all, but 
further confirmed by post mortem in I, and liver biopsy in 13 patients. 4 patients (8 2%) 
with a history of pancreatic disease were excluded. Of the remainder, DNA was available 
for analysis in 33 subjects. 
All subjects admitted to the consumption of>80g alcohol day" 1 for a minimum period of2 
years. 
5.2 Materials 
5.2.1 Water 
Double distilled tap water was used to make up all stock, general purpose and specialist 
solutions. Sterile water (Baxter Healthcare, Thetford, UK) was used to dilute amplimer and 
probe solutions, and used for PCR. 
5.2.2 Reagents 
All reagents used were analytical or molecular biology grade or equivalent 
Acetic acid, Disodium ethylene diamine tetra-acetic acid, Glycerol, Hydrochloric acid, 
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Magnesium chloride, Maleic acid, Orthoboric acid, Sodium chloride, Sodium citrate, 
Sodium dodecyl sulphate, Sodium hydroxide, Sucrose, Tris (hydroxymethyl) aminomethane 
and Tween 20 were purchased from BDH Laboratory Supplies-Merck Limited (Poole,UK). 
Chloroform, Ethanol, and Methanol were purchased from Rathbums Limited (Walkerburn, 
UK). Ammonium persulphate, Ethidium bromide, N-Lauroylsarcosine, Tetra-methyl-
ammonium-chloride, Triton-X-100 and Xylene cyanol were purchased from Sigma 
Chemicals (Poole, UK) and Orange G from Fisher Scientific (Loughborough, UK). 
5.2.3 Specialised reagents, enzymes and materials 
Agarose and the DIG luminescent detection system was purchased from Boehringer 
Mannheim GrnbH, (Germany). Taq polymerase and PCR buffer was purchased from HT 
Biotechnology, (Cambridge, UK). Deoxynucleoside 5 '-triphosphates (dNTP's) and T4 
Polynucleotide kinase (T4 PNK) were purchased from Pharmacia Biotech (Sweden). 
3MM Whatman paper (Whatman International, Maidstone, UK) was used in the Southern 
blotting station and SO x 30cm filter paper from Heto Laboratory Equipment (Surrey, UK) 
was used for polyacrylamide gel support and drying. 
5.2.4 Stock solutions 
i. Sodium chloride/sodium citrate (SSC) 
20x solution: 3 MNaCI, 0.3M trisodium citrate, pH 7.0 
ii. Tris/borate electrophoresis buffer (TBE) 
I Ox solution: 0.89mM Tris base, 0.89M Boric acid, 2mM EDTA(pH 8.0) 
iii. Ethidium bromide 
10 mg ml" 1 in H20 
iv. Xylene cyanol track dye I loading buffer 
0 25% w/v Xylene cyanol, 10% v/v Glycerol in 10 x TBE 
v. Orange G track dye I loading buffer 
0.25% Orange G, 10% v/v Glycerol in 10 x TBE 
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5.2.5 Autoclaving 
All solutions, and all glassware and plasticware used in the techniques ofDNA analysis 
were autoclaved at a temperature of 121 oc , and pressure of 15 p.s i for 30 minutes in a 
steam autoclave (Rodwell Instruments, UK). 
5.3 Preparation of high molecular weight DNA 
I 0 to 15 ml of peripheral venous blood was collected into 5% disodium ethylene diamine 
tetra-acetic acid (Na£DT A), and stored at -20°C in sterile polypropylene containers prior 
to subsequent DNA extraction. 
The method utilised for DNA extraction used a Nucleon® BACC (blood and cell culture) 
genomic DNA extraction kit (Scotlab Ltd, Coatbridge, Lanarkshire, UK). The 
manufacturer's protocol was followed with only slight modification, described below. The 
kit reagents supplied (reagents A & B, sodium perchlorate, Nucleon® resin) were used, 
other and additional reagents were supplied and made up in house as described in section 
5.2. 
5.3.1 Cell preparation 
Stored blood was thawed at room temperature, and an aliquot of7.5 mls transferred to a 50 
ml Falcon tube (Becton Dickinson, New Jersey, USA) To the sample a 4x volume of 
Reagent A (lOmM Tris-HCI, 320mM Sucrose, SmM MgCb, 1% Triton X-100, pH 8.0) 
was added and mixed on a Luckham R100/TW Rotates! shaker for 4 minutes. After 
centrifugation at 1300 g for 4 minutes on a MSE Mistral 1000, supernatant containing lysed 
red cells was separated from the pellet and discarded. 
5.3.2 Cell lysis and deproteinisation of solution 
The pellet was resuspended in 2mls Reagent 8 (400mM Tris-HCI pH 8.0, 60mM EDT A, 
ISOmM NaCI, I% SDS) and incubated at 37°C for 10-15 minutes, enabling nuclear 
membrane disruption to occur. Then the suspension was transferred to a 15 ml Falcon tube 
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and 500J.ll of sodium perchlorate added and mixed by inversion. 
5.3.3 DNA extraction and precipitation 
2mls of chloroform ( -20°C) was added and mixed to emulsify the 2 phases, which were the 
separated by centrifugation at 1300g for 3 minutes. 200J.ll ofNucleon® silica resin was 
added prior to another centrifugation at 1300g for 3 minutes. The aqueous phase containing 
the DNA was carefully transferred to a fresh tube, ensuring the interphase with silica resin 
and the underlying organic phase were not disturbed. The solution was re-spun at 1300g for 
I minute to pellet any residual silica and transferred to another fresh tube. Precipitation of 
DNA was by inverting gently with 2x volume 100% ethanol (-20°C). A sterilised glass 
pipette with a sealed tip was used to hook out the precipitated DNA which was washed in 
70% ethanol prior to dilution in 500J.ll of sterile water over 24 hours. 
5.3.4 Quantification and dilution 
The quantity of DNA was estimated by eye after precipitation, and this information used to 
guide dilution. Generally a 1 in 5 dilution of concentrated DNA was used which gave I 00-
500ng of DNA per J.l( of dilute solution. This was confirmed on a sample of specimens by 
estimation of concentration using a Cecil spectrophotometer. 
5.4 Polymorphism detection 
All assays used for the detection of polymorphisms at gene loci were PCR based. Specific 
assays for the different polymorphisms studied will be described in following sections. 
5.4.1 Polymerase Chain Reaction (PCR) 
The principle ofPCR is shown in Fig 5.1. Thermostable DNA polymerase copies DNA, 
using a template and priming DNA molecules (amplimers) complementary to sequences on 
either side of the sequence targeted for amplification. 
100-500ng of genomic DNA was used in each reaction with 0.5J.lM of each amplimer pair 
I OmM Tris-HCL(pH 9.0), 50mM KC I, 2-2.5mM MgCh, 0.1% Triton X-1 00, 300JJ.M of 
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each dNTP, and 0.8 units ofTaq DNA polymerase. All PCR reactions were performed in 
20111 volumes in 0.2ml thin walled microtubes (Advanced Biotechnology, Epsom, UK) in a 
PTC-200 Thermal Cycler (MJ Research, Essex, UK) or a Cyclogene thermocycler (Techne, 
Cambridge, UK) under the following conditions. 
Denaturation 
the11 30 cycles of 
Denaturation 
Annealing 
Extension 
the11 
Extension 
95°C for 3 minutes 
95°C for 30 seconds 
55-62°C for 1 minute 
72°C for 1 minute 
72°C for 3 minutes 
Samples were cooled at 4°C until further use. 
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5' ------------------- -- 3' Double 
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5'--- --------------- --3' 
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----------------~11111 
5'---------------------------------------------3' 
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5' 
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Figure 5.1 The polymerase chain reaction (PCR) 
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of DNA 
molecules 
DNA amplification. Denaturation of the DNA separates the strands, allowing sequence 
specific amplimers to anneal. A new strand of DNA is made from dNTP' s using the 
template DNA, catalysed by Taq DNA polymerase. Subsequent cycles of amplification 
give rise to exponential increase of product. 
11111 
Sequence for amplification 
Amplimer 
5.4.2 Agarose gel electrophoresis 
Amplification efficiency and product size was checked by electrophoresis of an aliquot of 
the product mixed with track dye on a I% agarose gel (I% w/v agarose in 0.5 x TBE 
buffer) containing 0.01% v/v ethidium bromide. The tank contained O.Sx TBE. A 123 bp 
ladder (Life Technologies, Paisley, UK) was used as a size marker. 
Gels were electrophoresed for 30 minutes at 180V. The gels were then photographed under 
UV light (320nm). 
5.4.3 Amplimer design and production 
Amplimers were designed with reference to sequences deposited in Genbank. All amplimers 
were 18-21 bases in length with an approximate GC content of 50%. Amplimers used were 
commercially produced on an oligonucleotide synthesiser (Pharmacia Biotech, Sweden), 
and diluted for use to concentrations of I Opmol 111 -I , so 1111 of diluted amplimer in a 20 111 
volume was at O.SM concentration. 
5.5 Microsatellite markers 
Three microsatellite markers of the TNF gene (TNFa, TNFb, and TNFc) and one marker 
associated with the IL-l 0 gene (IL-l OG) were studied. These have been described in 
sections 4.1 and 4.2. Alleles were detected by separation on denaturing polyacrylamide gels. 
5.5.1 Amplimers for microsatellite amplification 
Amplimers used for the assays are listed in Table 5.5 The forward amplimer in each 
reaction was 5 '-end labelled with [ y 32P] ATP (Amersham International, Amersham, UK) 
using T4 Polynucleotide kinase (T4 PNK). 
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Microsatellite 
TNFa Forward 5' -GCACTCCAGCCT AGGCCACAGA-3' 
Reverse S '-GCCTCT AGATTTCATCCAGCCACAG-3' 
TNFb Forward S '-CCTCTCTCCCCTGCAACACACA-3' 
Reverse S '-TGTGTGTTGCAGGGGAGAGAGG-3' 
TNFc Forward S'-GGGAGGTCTGTCTTCCGCCG-3' 
Reverse S '-CGTTCAGGTGGTGTCA TGGG-3' 
ILIO.G Forward S '-TCCTTCCCCAGGT AGAGCAACACTCC-3' 
Reverse S '-TCCCAAAGAAGCCTT AGT AGTGTTG-3' 
Table 5.5 Amplimer pairs used to amplify microsatellite polymorphisms 
The TNF-a microsatellite is a (CA). dinucleotide repeat 
The TNF-b & TNF-c microsatellites are (CT). dinucleotide repeats 
The IL-l 0. G microsatellite is a (CA). dinucleotide repeat 
Their position and significance is described in section 4.1 and 4.2. 
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5.5.2 5'-end labelling of amplimers 
T4 PNK was bought in kit form (Pharmacia Biotech, Sweden). 2SJll of sterile H20 was 
added to the tube containing the T4 PNK, incubated at room re forS minutes, then mixed. 
SO pmol of amplimer, I Ill of[y 32P] ATP (I OJlCi/Jll), and sterile HzO to make the volume 
up to SO Ill were added prior to brief centrifugation then incubation at 3 7°C for 4S minutes. 
The reaction was stopped by placing on ice. 
5.5.3 Precipitation of labelled amplimer 
0.1 volumes of SM NaCI, 2J..!I ofQuick-Precip@ (Advanced Genetic Technologies Corp. 
USA), and 3 volumes of Ethanol ( -20°C) were added to the reaction tube to precipitate the 
DNA. Centrifugation at 1300 rpm in Biofuge 13 microcentrifuge (Heraeus Sepatech, 
Germany) pelleted the DNA, from which supernatant was pipetted off. A wash of the pellet 
in 70% Ethanol was performed prior to dissolution in SOJll of sterile H20. 
5.5.4 Assessment of efficacy of amplimer labelling 
IJll of the labelled amplimer was counted in a Beck man scintillation counter. This gave a 
count per minute (cpm) reading. Knowing the cpm ofthe whole sample allowed calculation 
of the volume of labelled amplimer for each reaction when the desired amount of 
radioactivity is 2S,OOO cpm. 
5.5.5 PCR of microsatellite markers 
PCR was carried out as previously described. 2S,000cpm of the labelled amplimer was 
added to the reaction mixture in addition. 
Annealing temperatures for each assay were: 
TNFa & TNFb 62°C 
TNFc S8°C 
lL-IO.G 6S°C 
An extension temperature of 68°C was employed for all rnicrosatellite amplifications. 
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5.5.6 Polyacrylamide gel electrophoresis 
A 6% polyacrylamide gel with 8M Urea was cast in a 30 x 50 cm Sequi-Gen GT 
Electrophoresis cell (Biorad Laboratories, Hemel Hempstead, UK). Sequagel™ sequencing 
system gel reagents were used (National Diagnostics, Atlanta, USA) and made up to the 
manufacturers instructions. The gel was equilibrated in 1 x TBE buffer. 
Amplification products (6Jll) mixed with 3 J.1L of Stop solution containing Formamide 
(Amersham Life Science, Buckinghamshire, UK) were then separated on a 6% 
polyacrylamide gel with 8M urea at 1700V for 2.5 hours (TNFa and TNFc, IL-l OR), or 3 
hours (TNFb, IL-l OG). 
The gel was fixed in 10% Methanol and Acetic Acid and removed from the cell plate onto 
filter paper. 
5.5. 7 Exposure of gel 
After drying the gels were exposed to Kodak XLS5 X-ray film (Scientific Imaging Systems, 
Cambridge, UK) with intensifying screens at -80°C for 18 hours. Film was developed in 
Kodak developing and fixing agents. 
5.5.8 Scoring of microsatellite alleles 
An example ofmicrosatellite alleles revealed by this method is shown in Fig 6.1. 
Allele scoring was by two independent observers. Description of how alleles were assigned 
for each microsatellite is given in the results section. 
5.6 PCR-Sequence specific primer reaction (PCR-SSP) 
This method was used to type the bi-allelic -308 polymorphism of the TNF promoter 
region previously described in section 4.1.4.1. Amplification of an 836 base pair (bp) 
fragment of the TNF promoter region was performed in two PCR-SSP reactions. PCR-SSP 
is commonly used for HLA typing (Bunce et al., 1995). It was described as the 
'Amplification refractory mutation system' (ARMS) (Newton et al., 1989), and is 
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dependent upon the fact that Taq polymerase lacks 3' exonuclease activity. Therefore 
amplimers (primers) employing allele specific nucleotides at their 3' end will amplify only 
those alleles ifPCR conditions are exacting and stringently applied. 
5.6.1 PCR-SSP Amplimers 
Allele specific amplimers employed are detailed in Table 5.6. A common forward amplimer 
and one oftwo reverse amplimers with a 3' mismatch corresponding to a G or an A at 
position -308 were used. Amplimers for a 256 bp control amplicon from exon 15 of the 
adenomatous polyposis coli gene was included in the same reaction (Table 5.6). The assay 
had an annealing roof 55°C. 
5.6.2 PCR and electrophoresis 
As described in sections 5.4.1 and 5.4.2. Loading dye used was Orange-Gas this migrates 
with the amplimer enabling simplified reading of gels. 
5.6.3 Scoring of alleles detected by PCR-SSP 
Gels were scored for the presence or absence of an allele specific band providing a PCR 
control band was present. 
Amplimer 
Common Forward 5 '-CTGCATCCCCGTCTTTCTCC-3' 
Allele specific for 'G' Reverse 5 '-AT AGGTTTTGAGGGGCA TCG-3' 
Allele specific for 'A' Reverse 5' -AT AGGTTTTGAGGGGCATCA-3' 
Control amplicon Forward 5' -ATGATGTTGACCTTTCCAGGG-3' 
Reverse 5 '-TTCTGT AACTTTTCATCAGTTGC-3' 
Table 5.6 Amplimers used in PCR-SSP assay for TNF promoter (-308) polymorphism 
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5. 7 PCR-Sequence-specific oligonucleotide probing (PCR-SSOP) 
This method was employed to type the three hi-allelic polymorphisms of the lL-1 0 promoter 
region as described in section 4.2. The method relies on the hybridisation of sequence-
specific oligonucleotide probes to an amplified fragment of the gene locus. Detection of 
bound probe was by non-radioactive detection of 5' -digoxygenin labelled probe. 
5. 7.1 Amplification of DNA 
PCR to amplify a 626 bp fragment of the IL-l 0 promoter was carried out as described in 
section 5.4.1 using the amplimers: 
Forward 
Reverse 
5'-ATCCAAGCAAC ACTACTAA-3' 
5 '-T AAA T ATCCTCAAAGTCCC-3' 
An annealing temperature of 56°C was employed 
5. 7.2 Southern Blotting 
Following electrophoresis on a 1% agarose gel DNA was transferred to Hybond-N+ nucleic 
acid transfer membrane (Amersham Life Science, Buckinghamshire, UK), using the capillary 
transfer method described by Southern ( 1975) using 0.4M NaOH as the solvent. Transfer 
took place overnight following which the membranes were washed thoroughly in 3x SSC 
Storage of membranes wrapped in cling film was at 4°C 
5. 7.3 Oligonucleotide probes 
Hybridisation was initially performed using oligonucleotide probes previously described 
(Turner et al., 1997). However, non-specific binding of probes occurred in spite of variation 
of wash stringency. Therefore probes for 2 of the loci ( -1117 and -627) were redesigned by 
shortening the length of the probe or placing the allele-specific oligonucleotide at the 3' 
end. it was determined that the probes which bound with specificity to these two loci were 
those with the allele-specific oligonucleotide at the 3' end, and these were subsequently 
used. Sequences of oligonucleotide probes are given in Table 5. 7. Probes were purchased 
from the usual commercial supplier labelled at the 5 '-end with digoxygenin (DIG). 
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5. 7.4 Pre-hybridisation and hybridisation 
This was performed in glass roller tubes in a HB-1D oven (Techne, Cambridge, UK). The 
membranes were pre-hybridised for 1 hour in 20ml of hybridisation solution per I 00cm2 of 
membrane (Sx SSC, 1% Blocking agent, 1% N-Lauroylsarcosine, 0.02% SDS). Subsequent 
hybridisation was at 42°C in 6 ml of hybridisation buffer per 100cm2 membrane for I hour. 
DIG-labelled probes were used at a concentration of Spmol ml -t ·. 
Allele Nucleotide Probe sequence Wash T0 
1117*G G TAAGGCTTCTTTGGGAGG 60°C 
1117*A A TAAGGCTTCTTTGGGAAG 60°C 
854*C c CAGGTGATGTAACATCTCTGTCG 70°C 
854*T T GCACAGAGATATTACATCACCTGT 70°C 
627*C c CTGTGACCCCGCCTGCC 62°C 
627*A A CTGTGACCCCGCCTGAC 62°C 
Table 5. 7 Oligonucleotide probes used for PCR-SSOP typing of the three 
polymorphisms in the IL-10 promoter 
Nucleotide differences in the probes for the two alleles at each polymorphism are underlined 
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5. 7.5 Post hybridisation washing 
Initial washing was performed in the hybridisation oven and roller tubes. Washing was with 
3.2M Tetra-methyl-ammonium chloride (TMAC} solution (3.2M TMAC, 0.02M EDTA, 
0.1% SDS, and 0.05M Tris-HCI, pH 8.0). TMAC is a reagent which binds AT-rich DNA 
polymers, and abolishes the preferential melting of AT compared to GC base pairs. This 
means hybridisation of probes is only a function ofthe length of the probe. 
The washing protocol was: 
5x SSC at 42°C for 10 minutes, then 5x SSC at specific probe temperature* for 10 minutes, 
then 3.2M TMAC solution at specific probe temperature* for 20 minutes. 
Filters were then transferred to 'sandwich boxes' and washed twice at room T0 for 10 
minutes. 
* Specific probe washing T0 in Table 5. 7. 
5.7.6 Detection of bound probe 
A commercially available DIG luminescent detection system was used (Boehringer 
Mannheim GmbH, Germany ) and the manufacturers protocol was followed with slight 
modifications. 
Buffers used: 
Buffer I: 0.15M NaCI, 0 I M Maleic acid, pH 7. 5 
Blocking reagent: 10% w/v Marvel TM skimmed milk in Buffer I 
Buffer 2: Blocking reagent 1 : 1 0 in Buffer I 
Buffer 3: 0 1M Tris-HCl (pH 9.5), O.lM NaCI 
Wash Buffer: 0.3% Tween 20@ in Buffer I 
Filters placed in 'sandwich boxes' were washed briefly in Wash buffer, then blocked for 30 
minutes in Buffer 2. After transfer to roller tubes in the hybridisation oven, filters were 
incubated at room T 0 in IOmls per 100cm2 of anti-DIG ab solution (1:10,000 in Buffer 2). 
Excess ab was washed off with Wash buffer x2 for I5 minutes. The filters were then 
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equilibrated in Buffer 3 for 5 minutes, prior to exposure in the roller tube to 2ml per I 00cm2 
of a 1:100 solution (in Buffer 3) of the chemoluminescence substrate, CSPD®. Filters were 
then briefly blotted on filter paper (DNA side up) prior to being wrapped in cling-film. The 
filters were then incubated at 37°C for 15 minutes prior to exposure against Kodak XLS5 
X-ray film (Scientific Imaging Systems, Cambridge, UK) in a cassette with intensifying 
screens for 2hours. 
Films were then developed and scored by 2 independent observers (Fig. 6. 7) 
5. 7. 7 Stripping bound probe from filters 
To enable re-use of filters, they were first rinsed briefly in H20. This was followed by two 
15 minute washes at 37°C in 0.2 M Na OH, SDS 0.1% to remove the DIG-labelled probe, 
and a thorough wash in 2x SSC. 
5.8 Analysis of data 
All data was entered into a computerised spreadsheet (Microsoft ® Excel 7.0) registered 
with and subject to the Data Protection Act 1988. This enabled statistical analysis to be 
performed within the same application, or in applications that could import Excel ® 
spreadsheets. 
5.8.1 Patient and control subject demographics 
Comparison was made between control subjects and patient groups with regard to sex 
distribution using the x2 test. 
Distribution of age in patient groups was tested for normality using Statgraphics software 
(Statistical Graphics Corp. USA. 1996). Distribution in subject groups was tested for 
normality using the Chi-square goodness-of-fit statistic, the Shapiro-Wilkes W statistic, the 
Z score for skewness, and the Z score for kurtosis. 
If distribution was normal, variances of each group were compared by the F-test, with 
subsequent comparison of means using the t-test. Ifthe distribution in any group being 
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compared was not normal a non-parametric test (Kolmogorov-Smirnov) was used to 
compare age distribution. 
P values of~ 0.05 were considered significant. 
5.8.2 Allele and gene frequencies 
Allele frequencies, expressed as decimals, were calculated from the number of copies of an 
allele out of the total number of chromosomes in the population, counting homozygotes as 
two copies. Gene frequencies in control subject and patient groups were calculated as the 
percentage of subjects positive for each gene. 
5.8.3 Hardy-Weinberg equilibrium 
This was used to determine whether a bi-allelic polymorphism is conforming to normal 
distribution within a population. Expected gene frequencies are calculated by the formula: 
1 = p2 x q2 x 2(pq). p and q are the frequencies of the two alleles within the population. 
The observed gene frequencies are the compared using 2 x n tables and the Chi-square test. 
Hardy-Weinberg equilibrium is established if the expected frequencies do not differ 
significantly (p ~ 0.05) from the observed. 
5.8.4 Haplotype analysis 
In the absence of family studies haplotypes were assigned dependant upon observed 
possibilities. As long as the subject was not heterozygous at more than one locus used to 
create the haplotype, the possible haplotypes can be determined and the frequency 
calculated. If the subject was heterozygous at more than one locus, the two different 
haplotypes were possible on each chromosome, so the information was disregarded. Using 
this method a bias may be introduced ifthere is a large number of double heterozygotes. 
Where haplotypes and their frequency are shown, the number excluded from the analysis is 
shown. As such bias is likely to be systematic it should be the same for the two populations 
being compared. 
Linkage across the TNFabc microsatellite loci, producing distinct three locus haplotypes, 
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has been characterised by maximum likelihood estimates in previous population based and 
family studies (Jongeneel et al., 1991; Nedaspasov et al., 1991; Crouau-Roy et al., 1993) 
and their existence has been confirmed in homozygous celllines(Weissensteiner and 
Lanchbury, 1997; Udalova et al., 1993). The eleven putative haplotypes previously 
described in Caucasian populations were used for haplotype analysis. 
5.8.5 Linkage analysis 
Linkage of alleles at two loci occurs when they combine more frequently than could be 
expected by random association. Expected frequency of an allelic association between two 
loci was calculated by multiplying the frequency of one of the alleles with the other. 
Expected and observed frequencies were compared using the Chi squared statistic [ ( 0-E )2 
I E]. Linkage was considered to occur if the associated p value was :s; 0.05. 
5.8.6 Comparison of allelic, gene, and haplotype frequencies 
Comparisons of allelic, gene, and haplotype frequencies between the control group and 
patient groups were made in 2 x 2 contingency tables using the Chi-squared test. If any cell 
value was <5 Fisher's exact test was used. Both were performed on the Statcalc program of 
the computer software package Epi lnjo 6 (World Health Organisation, Geneva, 
Switzerland). P values were corrected (Pc) for multiple comparisons made using the 
Bonferroni inequality method(Tiwari and Terasaki, 1985). This involves multiplying the p 
value by the number of comparisons made. 
The Bonferroni correction is considered a conservative procedure as it assumes that in 
making multiple comparisons one is testing multiple independent hypotheses. In testing n 
independent hypotheses, Bonferroni assumes a significance level of 0. 5 + n. 
Statistical significance was achieved when the corrected p value (pc) was :s; 0.05 
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6 Results 
6.1 Study subjects 
6.1.1 Normal control subjects 
The normal control group was taken from a bank of cord bloods collected at the time of 
normal healthy deliveries at Derriford Hospital, Plymouth. I 07 controls were used for the 
TNF locus typing, and 136 were used for the ll..-1 0 typing. The sex distribution within the 
normal control group is shown in Table 6. 1. 
6.1.2 Alcoholic 'control' subjects 
Of the 49 patients with alcoholic liver disease (Cirrhosis or alcoholic hepatitis), 4 (8.2%) 
had a history of pancreatic disease (episodes of acute/chronic pancreatitis), so were 
excluded. Of the remainder, DNA was available from 33 patients for DNA typing Basic 
demographic characteristics are shown in Table 6.3. 
6.1.3 Acute pancreatitis patients 
135 patients were included in this study. A total of 144 patients were initially thought to fit 
inclusion criteria during the recruitment period. However, 8 were subsequently excluded. 3 
of these were alcoholic patients who were subsequently proven over a time period of3-6 
months from screening to have chronic pancreatitis on ERCP. 4 patients were excluded as 
insufficient data was available, and in 2 subjects DNA preparation was inadequate. Basic 
demographic characteristics of the patient group are shown in Table 6.1. 
Of the 135 patients in this study, 97 (71.9%) had mild disease as defined by the Atlanta 
criteria Of the 38 patients (28.1%) with severe disease, 30 (22.2%) had systemic 
complications defined by at least one organ dysfi.mction, 21 (15.5%) had a local pancreatic 
collection (fluid, necrosis, or pseudocyst), of whom only 8 did not have concurrent systemic 
complications. 35 (25 9%) patients had maximal organ failure scores of2 or more during 
their disease episode and 18 (13.3%) patients had organ failure scores of3 or more, the 
respiratory system always accounting for at least 3 of the score. 12 (8.9%) patients had 
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organ failure scores of 4 or more, and in only 5 patients (3. 7%) did death occur. The reason 
for the difference in the numbers having systemic complications as defined by the Atlanta 
classification and those having organ dysfunction as evidenced by OFS of2 or more is due 
to the different criteria in the two classification systems. Basic demographic characteristics 
of the patient groups stratified according to disease severity are shown in Table 6.1 and 6.2. 
In 21 patients (15.6%) the episode of acute pancreatitis was caused by alcohol (280g per 
day), in 77 (57.0%) the cause was cholelithiasis, and in 37 patients (27.4%) no cause could 
be identified following adequate radiological (USS or CT) visualisation of the gallbladder 
and biliary tree (classified as idiopathic). 
Basic demographic characteristics of the patient groups stratified according to aetiology of 
disease are shown in Table 6.3. 
6.1.4 Age and sex distribution in subjects 
Age is not applicable to the normal controls as they were from a bank of cord bloods. 
Although mean age and standard deviation are shown in Tables 6.1-6.3 to allow 
approximate comparison between groups, derivation of these statistics is not strictly 
applicable as the study population or study groups do not fit normal distribution for age. 
Distribution in subject groups was tested for normality using the Chi-square goodness-of-fit 
statistic, the Shapiro-Wilkes W statistic, the Z score for skewness, and the Z score for 
kurtosis. 
As no group fitted normal distribution this tends to invalidate comparison of means and 
standard deviations using the F-test and t-test. Therefore, a non-parametric test 
(Kolmogorov-Smimov) was used to compare whether there is a statistically significant 
difference in distribution of age between study groups. Distribution of age in the group of 
patients with severe disease was significantly different compared to the group with mild 
disease (p=0.007), the patients with mild disease having a younger age distribution. The 
same was true for those with a local complication vs. mild disease (p=O.OOl ), and those 
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with an OFS:?: 2 (p=0.008). However, using the Kolmogorov-Smirnov test, there was not a 
significant difference in distribution of age between those with mild disease vs. OFS :?: 3 
(p=O.II) or vs. OFS :?: 4 (p=0.27). 
With patients stratified according to aetiology, there was a significant difference in the 
distribution of age between: 
Alcoholic pancreatitis and idiopathic pancreatitis groups (p=0.003), alcoholic pancreatitis 
and gallstone pancreatitis groups (p=0.0002), and alcoholic pancreatitis and idiopathic and 
gallstone groups combined (p=O.OOO I). As indicated by the age range shown in table 6.3, 
the alcoholic pancreatitis group were younger. Also the alcoholic pancreatitis group were 
younger than the alcoholic 'controls', as distribution of age was again significantly different 
(p=0.006). However, as indicated by their age ranges, using the Kolmogorov-Smirnov test, 
there was not a significant difference in distribution of age between gallstone and idiopathic 
groups (p=0.68). 
Male to female ratio was comparable between the normal controls and acute pancreatitis 
patients as a whole (57 vs. 51% female, x2=0.84, p=0.4), and between patient groups 
stratified according to disease severity. However, only I of21 patients (4.8%) in the 
alcoholic pancreatitis group was female, meaning that there was a significant difference in 
sex distribution between alcoholic pancreatitis patients and the normal control group and 
the other aetiological groups. 
Normal controls and alcoholic pancreatitis (X2 =19.2, p<O.OOOI ), idiopathic pancreatitis 
(female=47.4%) and alcoholic pancreatitis (X2 = 11. 7, p<O.OO I), gallstone pancreatitis 
(female=66 2%) and alcoholic pancreatitis (X2 =25.0, p<I0-6). 
The alcoholic 'control' group were 33 J% female, meaning that there was also a significant 
difference in sex distribution between the alcoholic 'controls' and the normal controls (33.3 
vs. 57%, x2=5. 7, p=O.Ol7), and the alcoholic 'controls' and the alcoholic pancreatitis group 
(Fisher's exact test, p=O.Ol3). 
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· Iil spite. oJther(! being !lJmost twice:as manyfemalescthan males' wlth!gailstone 1pancreatitis; 
no statistically significant.difference iin sex distribution was seen ibet'W_een gallstOne aM 
idiopathic!pancreatitis,groups,. ()~between the g<illstone pan<:r~atitis group and the ,normal 
controls. 
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Study Local 
Controls 1 patients Mild Severe complication 
n=107 n=135 n=97 n=38 n=21 
mean age n/a2 56.1 3 53.5 3 62.6 3 64.5 3 
(years) 
age range n/a 21-86 21-86 26-78 35-78 
(years) 
S.D n/a 15.4 16.0 11.6 10.7 
M:F 46:61 66 69 4 49:48 17:21 10: I I 
Table 6.1 Demographic characteristics of normal control and study subjects, and 
patient subgroups according to (local and systemic) disease severity 
Age and sex characteristics of normal control and study subjects, and patient subgroups of 
those with mild or severe pancreatitis, and those with a local (pancreatic) complication. 
n represents the number of subjects in each group 
S.D standard deviation 
M Male 
F Female 
Mild and severe disease severity groups are according to the Atlanta convention 
classification (Bradley, 1993), described in section 5.1.4. 
Local complication is defined as occurrence of pancreatic necrosis, abscess or pseudocyst 
I. For the studies involving the IL-10 polymorphisms, a larger group of controls (up to 
136) was used. The male: female ratio is comparable for this group (55:71 ). 
2. Age not applicable to controls as taken from a bank of cord bloods 
3. Although mean age and standard deviation are shown to allow approximate comparison, 
derivation of these statistics is not strictly applicable as the study population or study 
groups shown do not fit normal distribution for age. Distribution in subject groups was 
tested for normality using the Chi-square goodness-of-fit statistic, the Shapiro-Wilkes 
W statistic, the Z score for skewness, and the Z score for kurtosis. 
As no group fitted normal distribution this tends to invalidate comparison of means and 
standard deviations using the F-test and t-test. Therefore, a non-parametric test 
(Kolmogorov-Smimov) was used to compare whether there is a statistically significant 
difference in distribution of age between study groups. 
As indicated by the means in the table there were significant differences between 
distribution of age in 
Mild vs. Severe, p=0.007 
Mild vs. Local complication, p=O.OOI 
3. Comparison of sex distribution using x2 test, no significant difference in sex 
distribution between normal control and study patient groups (X2 =0.84, p=0.4) 
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Controls Mild OFS~2 OFS~3 OFS~4 
n=107 n=97 n=35 n=18 n=12 
mean age n/a • 53.5 2 63.4 2 62.1 2 61.3 2 
(years) 
age range n/a 21-86 26-84 26-78 26-76 
(years) 
S.D n/a 15.4 11.4 13.7 14.9 
sex M:F 46:61 3 4948 17:18 10:8 7:5 
Table 6.2 Demographic characteristics of normal control and study subjects, and 
patient subgroups according to (systemic) disease severity as assessed 
by organ failure score 
Age and sex characteristics of normal control and study subjects, and patient subgroups as 
defined by organ failure score 
n represents the number of subjects in each group 
S. D standard deviation 
M Male 
F Female 
OFS Organ failure score 
OFS calculated according to method described in section 5 .1.4 (Kingsnorth et al, 1995) 
I. Age not applicable to controls as taken from a bank of cord bloods 
2. Although mean age and standard deviation are shown to allow approximate comparison, 
derivation of these statistics is not strictly applicable as the study population or study 
groups shown do not fit normal distribution for age. Distribution in subject groups was 
tested for normality using the Chi-square goodness-of-fit statistic, the Shapiro-Wilkes 
W statistic, the Z score for skewness, and the Z score for kurtosis. 
As no group fitted normal distribution this tends to invalidate comparison of means and 
standard deviations using the F-test and t-test. Therefore, a non-parametric test 
(Kolmogorov-Smimov) was used to compare whether there is a statistically significant 
difference in distribution of age between study groups. 
As indicated by the means in the table there was a significant difference between 
distribution of age in: 
Mild VS. OFS ~ 2, p=0.008 
However, using the Kolmogorov-Smirnov test, there was not a significant difference in 
distribution of age between: 
Mild VS. OFS ~ 3, p=O.ll 
Mild vs. OFS ~ 4, p=0.27 
3. Comparison of sex distribution using x2 test, no significant difference in sex 
distribution between normal control and study patient groups. 
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'Alcoholic' 
Controls Alcohol Idiopathic Gallstones controls 
n=l07 n=21 n=37 n=77 n=33 
mean age n/a I 43.8 2 57.4 2 58.5 2 51.0 
(years) 
age range n/a 28-64 23-84 21-86 37-71 
(years) 
S.D n/a 11.6 17.2 14.3 9.0 
sex M:F 46:61 3 20:1 3 19 18 3 26:51 3 22: 11 3 
Table 6.3 Demographic characteristics of normal and 'alcoholic' control and 
study subjects grouped according to aetiology of acute pancreatitis 
Age and sex characteristics of normal and 'alcoholic' control and study subjects grouped 
according to aetiology of disease 
n represents the number of subjects in each group 
S.D standard deviation 
M Male 
F Female 
Alcoholic pancreatitis if daily consumption of~ 80g alcohol da/ 
Gallstones if radiological or ERCP evidence of cholelithiasis 
Idiopathic if no identifiable aetiology 
1. Age not applicable to controls as taken from a bank of cord bloods 
2. Although mean age and standard deviation are shown to allow approximate comparison, 
derivation of these statistics is not strictly applicable as the study population or study 
groups shown do not fit normal distribution for age. Distribution in subject groups was 
tested for normality using the Chi-square goodness-of-fit statistic, the Shapiro-Wilkes 
W statistic, the Z score for skewness, and the Z score for kurtosis. 
As no group fitted normal distribution this tends to invalidate comparison of means and 
standard deviations using the F-test and t-test. Therefore, a non-parametric test 
(Kolmogorov-Smimov) was used to compare whether there is a statistically significant 
difference in distribution of age between study groups. 
As indicated by the means in the table there was a significant difference between 
distribution of age in: 
Alcoholic pancreatitis vs. Idiopathic, p=0.003 
Alcoholic pancreatitis vs. Gallstones, p=0.0002 
Alcoholic pancreatitis vs. Idiopathic & Gallstone combined, p=O.OOO I 
Alcoholic pancreatitis vs. alcoholic 'controls', p=0.0056 
Alcoholic 'controls' vs. Idiopathic & Gallstone combined, p=0.00005 
Alcoholic 'controls' vs. all acute pancreatitis patients, p=0.0006 
However, as indicated by their means, using the Kolmogorov-Smimov test, there was 
not a significant difference in distribution of age between: 
Gallstone and Idiopathic groups, p=0.68 
3. Comparison of sex distribution using x2 test or Fisher's exact test. Significant differences 
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in sex distribution between: 
Normal controls and alcoholic pancreatitis, x2 =19.2, p<0.0001 
Idiopathic and alcoholic pancreatitis, X2 =11.7, p<O.OOl 
Gallstone and alcoholic pancreatitis, x2 =25.0, p<l o-6 
'Alcoholic controls' and normal controls, l=S.7, p=O.Ol7 
'Alcoholic controls' and alcoholic pancreatitis, Fisher's exact test, p=O.OI3 
'Alcoholic controls' and gallstone pancreatitis, x2=10.2, p=O.OOI4 
In spite of there being almost twice as many females than males with gallstone 
pancreatitis, no statistically significant difference in sex distribution was seen between 
gallstone and idiopathic pancreatitis groups, or between the gallstone pancreatitis group 
and the normal controls: 
Normal controls and gallstone pancreatitis, l =1.6, p=0.2 
Idiopathic and gallstone pancreatitis, X2 =3.2, p=0.07 
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6.2 Severity of disease according to aetiology 
Severe disease, according to the Atlanta classification, occurred in 38 of 135 patients 
(28. 1 %). 17 of those had idiopathic disease, a group which accounts for only 27.4% of 
patients. This apparent excess of those with severe disease (Atlanta) in the idiopathic group 
is non significant however when compared to the expected number (x2=4.2, p=0.12, 2 d f). 
Likewise, there is an apparent excess of patients ( 11 of 18) with an OFS of3 or more in the 
group classified as having idiopathic disease. When compared to the expected number this 
approaches significance (x2=7.2, p=0.027, 2 d.f). However, as the expected number is less 
than 5 (4.9), the x2 test is not valid Testing with Fisher's exact test gives a p value of 
0.074. There is no variation from expected numbers in patients with a pancreatic collection 
in the aetiological groups. 
6.3 TNF microsatellite alleles 
Allelic frequencies of the 3-locus TNFabc microsatellite system were measured in 100% of 
patients. 13 of 14 known alleles ofTNFa (Fig. 6.1) were observed in the population studied. 
Six of the seven known alleles ofTNFb (Fig. 6.2) were found in the patient and control 
groups. TNFc (Fig. 6.3) is biallelic. Tables 6.4 and 6.5 show the allelic frequencies at the 
three loci in normal control and acute pancreatitis subjects. Tables 6.6 and 6. 7 show allelic 
frequencies at the 3 loci in patient groups stratified according to disease severity classified 
according to the Atlanta classification and the occurrence of a local complication Tables 
6.8 and 6. 9 show patient groups stratified according to organ failure score. 
There are no statistically significant differences in the allelic frequencies of the TNF-a, TNF-
b, or TNF-c loci when comparing all acute pancreatitis patients with controls or when 
patients grouped according to disease course (mild vs. severe, mild vs. OFS;::2, mild vs 
OFS;::3, mild vs. OFS;::4) were compared. The distribution of all TNFabc alleles between 
controls and patients was also not different (TNFa, X2 =14.99, Pc=0.31, 13 d.f; TNFb, x2 
=6.21, Pc=0.4, 6 d.f; TNFc, l =0.02). 
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When patients were grouped according to the aetiology of their disease there was a 
decrease in the frequency of the TNFa2 allele (Tables 6.10 and 6.11) in those patients with 
alcoholic acute pancreatitis compared to normal controls (X2 =7.24, p=0.007, Pc=0.098), 
those with pancreatitis of other aetiology (X2 =4.51, p= 0.034, pc=0.4), and alcoholic 
'controls' (x2=8.57, p=0.0034, Pc=0.048). However this was only significant in comparison 
with the group of alcoholic 'controls' after correction of p-values. 
The reduction in the a2 allele in the alcoholic group was not accounted for by an increase in 
any one allele, but both a6 and a 11 were increased in frequency, although again this was not 
statistically significant. For allele a6, alcoholic pancreatitis vs. normal controls (28.6 vs. 
15.4%, x2= 1.5, p=0.2), alcoholic pancreatitis vs. non-alcoholic pancreatitis group (28.6 vs. 
16.2%, x2 =3.64, p= 0.056, Pc>O.S), alcoholic pancreatitis vs. alcohol 'controls' (28.6 VS. 
12.1 %, x2=4.6, p=0.032, Pc=0.44). For allele all, alcoholic pancreatitis vs. normal controls 
(26.2 vs. 16 8%, x2=2.1, p=O.IS), alcoholic pancreatitis vs. non-alcoholic pancreatitis (26.2 
vs. 16. 7%, x2 =2.17, p= 0.14), alcoholic pancreatitis vs. alcohol 'controls' (26.2 vs. 13.6%, 
x2=2. 7, p=O.I ). 
It is unlikely that the difference in TNFa allelic frequencies could be accounted for by 
gender (20 of the 21 alcoholic patients were male) as the control population had an equal 
distribution of all alleles in the males and females. 
There was a trend towards reduced frequency of the TNFb 1 allele in the alcoholic 
pancreatitis group, although this did not achieve statistical significance (Table 6.12). 
Alcoholic pancreatitis vs. controls (4.8 vs. 14.0%, X2 =2.75, p=0.097, Pc>O 5), alcoholic 
pancreatitis vs. non-alcoholic pancreatitis ( 4.8 VS. 15.8%, X2 =3 .57, p= 0.059, Pc>0.5). 
In the group of 'alcoholic controls' the b 1 allele was very slightly reduced in frequency 
compared to the normal controls, so the difference in b I frequencies between the alcoholic 
pancreatitis group and alcoholic 'controls' was much reduced. Alcoholic pancreatitis vs. 
alcohol 'controls' (4.8 vs. 10.6%, x2=1.2, p=0.28), normal controls vs. alcohol 'controls' 
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('1'4\0!Vs 10!6%; ?(=o,s, p=O.S). 
l'NF:c allelic frequencies were comparable between1 contrcii groups and aetiological j:latieiit 
groups (Table 6'.,13J)i. 
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Figure 6.1 TNFa microsatellite autoradiograph 
Amplification of a region containing the microsatellite was performed as described in 
section 5.5. Amplification products (6!11) mixed with 3!11 of Stop solution containing 
Formamide (Amersham Life Science, Buckinghamshire, UK) are separated on a 6% 
polyacrylamide gel with 8M urea at 1700V for 2.5 hours, and alleles revealed with 
autoradiography. 
TNFa has 14 known alleles. Alleles were assigned as proposed by Nedaspasov et al ( 1991 ). 
Allele I denotes the allele with the least number of repeats. For TNFa, this is (AC/GTk 
Allele 2 (TNFa2) is the most common allele in Europids. Each subsequent allele differs by 
one base pair repeat. 
Alleles TNFa2, TNFa6, and TNFa 10 are labelled in this figure. Genotypes for each of the 
samples shown in lanes 1-9 are as follows: 
Lane! : a4,7 
Lane2: a2,2 
Lane3: null 
Lane4 : a2, I 0 
LaneS : a5 , 11 
Lane6: a2,2 
Lane7: a2, 11 
Lane8: a6, 11 
Lane9: a2,2 
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Figure 6.2 TNFb microsatellite autoradiograph 
TNFb7 
TNFb l 
7 8 9 10 ll 
Amplification of a region containing the microsatellite was performed as described in 
section 5.5. Amplification products (6~1) mixed with 3~1 of Stop solution containing 
Formamide (Amersham Life Science, Buckinghamshire, UK) are separated on a 6% 
polyacrylamide gel with 8M urea at 1700V for 3.5 hours, and alleles revealed with 
autoradiography. 
TNFb has 7 known alleles. Alleles were assigned as proposed by Nedaspasov et al (1991). 
Al lele 1 denotes the allele with the least number of repeats. For TNFb, this is (TC/GA)8. 
Each subsequent allele differs by one base pair repeat. Allele 4 (TNFb4) is the most 
common allele in Europids. 
Alleles TNFb 1 and TNFb7 are labelled in this figure. Genotypes for each of the samples 
shown in lanes 1-9 are as fo llows: 
Lanel : b3 ,5 
Lane2: b4,5 
Lane3 : bl ,4 
Lane4: b3 ,5 
LaneS : b4,5 
Lane6: bl ,7 
Lane?: b5,5 
LaneS: b4,5 
Lane9: b 1,4 
Lane 10: b4,7 
Lane 11: b 1 ,7 
196 
Direction of 
migration 
Lane 2 3 4 
Figure 6.3 TNFc microsatellite autoradiograph 
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Amplification of a region containing the microsatellite was performed as described in 
section 5.5. Amplification products (61 .. tl) mixed with 3~tl of Stop solution containing 
Formamide (Amersham Life Science, Buckinghamshire, UK) are separated on a 6% 
polyacrylamide gel with 8M urea at 1700V for 2.5 hours, and alleles revealed with 
autoradiography. 
TNFc is biallelic. Alleles were assigned as proposed by Nedaspasov et al ( 199 1 ). 
Allele I denotes the allele with the least number of repeats. For TNFc, this is (TC/GA)g. 
Allele 2 is (TC/GA) 10. Genotypes for each of the samples shown in lanes 1-7 are as follows : 
Lanel : cl , I 
Lane2: cl , l 
Lane3 : c2,2 
Lane4: cl , l 
LaneS: c l,2 
Lane6: c l,2 
Lane7: c 1,2 
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TNFa allele 
Controls Study patients 
n=107 n=l35 
% % 
--------·---·--
al 0.5 0.7 
(1) (2) 
a2 35.5 27.4 1 
(76) (74) 
a3 0.9 0.0 
(2) (0) 
a4 8.4 9.3 
(18) (25) 
a5 1.9 4.8 2 
(4) (13) 
a6 15.4 18.1 
(43) (49) 
a7 7.5 7.4 
(16) (20) 
aS 1.4 2.6 
(3) (7) 
a9 0.9 0.7 
(2) (2) 
a10 9.3 9.6 
(20) (26) 
all 16.8 18.1 
(36) (49) 
a12 0.0 0.7 
(0) (2) 
al3 0.9 0.0 
(2) (0) 
al4 0.5 0.4 
(1) (1) 
Total alleles(n) 214 270 
Table 6.4 TNFa microsatellite allele frequencies in normal controls and 
acute pancreatitis patients 
This table displays TNFa microsatellite allele frequencies in control and patient 
subjects. For each allele the % frequency and the actual number of alleles (in 
brackets) is given. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the l test. P values were corrected for the number of 
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comparisons made. 
I Control vs. patient "l =3.67, p=O.OSS, Pc=0.77. 
2 Control vs. patient X2 =3.06, p=0.08, Pc>O.S. 
No statistically different differences in individual TNFa alleles are seen between the 
control and patient subjects. 
The distribution of all TNFa alleles between controls and patients was also not 
different 
(x,2 =14.99, Pc=0.31, 13 d.f.). 
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TNFb allele 
Controls Study patients 
n=107 n=135 
o;o 0/o 
bl 14.0 14.4 
(30) (39) 
b2 0.0 0.4 
(0) (1) 
b3 18.2 12.2 1 
(39) (33) 
b4 35.5 36.3 
(76) (98) 
b5 30.4 32.6 
(65) (88) 
b6 0.0 0.7 
(0) (2) 
b7 1.9 3.3 
(4) (4) 
Total alleles (n) 214 270 
TNFc allele 
cl 73.4 73.0 
( 157) (197) 
c2 26.6 27.0 
(57) (73) 
Total alleles (n) 214 270 
Table 6.5 TNFb and TNFc microsatellite allele frequencies in normal 
controls and acute pancreatitis patients 
This table displays TNFb and TNFc microsatellite allele frequencies in control and 
patient subjects. For each allele the % frequency and the actual number of alleles (in 
brackets) is given. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the r! test. P values were corrected for the number of 
comparisons made. 
1 Control vs. patient X2 =3.4, p=0.065, Pc>O.S. 
No statistically different differences in individual TNFb or TNFc alleles are seen 
between the control and patient subjects. 
Distribution ofTNFb alleles (X2 =6.21, Pc=0.4, 6 d.f.), and TNFc alleles (X2 =0.02) 
between controls and patients was also not different 
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Controls Mild Severe Local 
TNFa allele 
complication 
n=107 n=97 n=38 n=21 
% % % % 
al 0.5 0.5 1.3 2.4 
(I) (1) (1) (1) 
a2 35.5 25.8 31.6 28.6 
(76) (50) (24) (12) 
a3 0.9 0.0 0.0 0.0 
(2) (0) (0) (0) 
a4 8.4 9.3 9.2 9.5 
(18) (18) (7) (4) 
a5 1.9 4.6 5.3 7.1 
(4) (9) (4) (3) 
a6 15.4 18.6 17.1 21.4 
(43) (36) (13) (9) 
a7 7.5 7.7 6.6 4.8 
(16) (15) (5) (2) 
aS 1.4 2.1 3.9 4.8 
(3) (4) (3) (2) 
a9 0.9 l.O 0.0 0.0 
(2) (2) (0) (0) 
a10 9.3 8.2 13.2 7.1 
(20) (16) (1 0) (3) 
all 16.8 20.6 11.8 14.3 
(36) (40) (9) (6) 
a12 0.0 l.O 0.0 0.0 
(0) (2) (0) (0) 
a13 0.9 0.0 0.0 0.0 
(2) (0) (0) (0) 
a14 0.5 0.5 0.0 0.0 
(1) (1) (0) (0) 
Total alleles ( n) 214 194 76 42 
Table 6.6 TNFa microsatellite allele frequencies in normal controls and acute 
pancreatitis patients grouped according to (local and systemic) disease 
severity 
This table displays TNFa microsatellite allele frequencies in control and patient group 
subjects. For each allele the % frequency and the actual number of alleles (in brackets) is 
g1ven. 
n 
(n) 
represents the number of subjects in each group 
represents the number of alleles in each group. 
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(continued ...... ) 
Mild and severe disease severity groups are according to the Atlanta convention 
classification (Bradley, 1993), described in section 5.1.4. 
Local complication is defined as occurrence of pancreatic necrosis, abscess or pseudocyst. 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the .. l test. P values were corrected for the number of comparisons 
made. 
No differences are seen in the frequency of individual alleles between patient groups or 
between patient groups and controls. 
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Controls Mild Severe Local 
TNFb allele 
complication 
n=107 n=97 n=38 n=21 
o/o 0/o % 0/o 
b1 14.0 13.9 15.8 11.9 
(30) (27) (12) (5) 
b2 0.0 0.5 0.0 0.0 
(0) (1) (0) (0) 
b3 18.2 12.4 11.8 9.5 
(39) (24) (9) (4) 
b4 35.5 37.6 32.9 33.3 
(76) (73) (25) (14) 
b5 30.4 32.0 34.2 42.9 
(65) (62) (26) (18) 
b6 0.0 1.0 0.0 0.0 
(0) (2) (0) (0) 
b7 1.9 2.6 5.3 2.4 
(4) (5) (4) (I) 
Total alleles (n) 214 194 76 42 
TNFc allele 
cl 73.4 75.3 67.1 69.0 
( 157) (146) (51) (29) 
c2 26.6 24.7 32.9 31.0 
(57) (48) (25) (13) 
Total alleles (n) 214 194 76 42 
Table 6.7 TNFb and TNFc microsatellite allele frequencies in normal controls and 
acute pancreatitis patients grouped according to (local and systemic) 
disease severity 
This table displays TNFb and TNFc microsatellite allele frequencies in control and patient 
group subjects. For each allele the % frequency and the actual number of alleles (in 
brackets) is given. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
Mild and severe disease severity groups are according to the Atlanta convention 
classification (Bradley, 1993), described in section 5.1.4. 
Local complication is defined as occurrence of pancreatic necrosis, abscess or pseudocyst. 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. 
No differences are seen in the frequency of individual alleles between patient groups or 
between patient groups and controls. 
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TNFa allele 
Controls OFS~2 OFS~3 OFS~4 
n=l07 n=35 n=l8 n=l2 
0/o 0/o 0/o 0/o 
----------------·-- ------------
al 0.5 0.0 0.0 0.0 
(I) (0) (0) (0) 
a2 35.5 32.9 36.1 37.5 
(76) (23) ( 13) (9) 
a3 0.9 0.0 0.0 0.0 
(2) (0) (0) (0) 
a4 8.4 8.6 8.3 8.3 
(18) (6) (3) (2) 
a5 1.9 7.1 5.6 8.3 
(4) (5) (2) (2) 
a6 15.4 15.7 16.7 20.8 
(43) ( 11) (6) (5) 
a7 7.5 5.7 11.1 4.2 
(16) (4) (4) (1) 
aS 1.4 4.3 0.0 0.0 
(3) (3) (0) (0) 
a9 0.9 0.0 0.0 0.0 
(2) (0) (0) (0) 
alO 9.3 12.9 16.7 12.5 
(20) (9) (6) (3) 
all 16.8 12.9 5.6 8.3 
(36) (9) (2) (2) 
a12 0.0 0.0 0.0 0.0 
(0) (0) (0) (0) 
a13 0.9 0.0 0.0 0.0 
(2) (0) (0) (0) 
a14 0.5 0.0 0.0 0.0 
(1) (0) (0) (0) 
Total alleles (n) 214 70 36 24 
Table 6.8 TNFa microsatellite allele frequencies in normal controls and acute 
pancreatitis patients grouped according to (systemic) disease severity as 
assessed by organ failure score 
This table displays TNFa microsatellite allele frequencies in control and patient group 
subjects. For each allele the% frequency and the actual number of alleles (in brackets) is 
g1ven. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
OFS Organ failure score (continued ...... ) 
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0FS c(llcul(lted,acc;ording to :method,described !in section.5. 1.4 (Kif"!gsnorth: et al, !).995). 
Comparisons Were made for ea"ch allele! between ,patient and controLgroups,using 2x2: 
c;ontinge11<:Y tab.les (lnd the;x2 test. P\rah.ies were corrected for, the,numberot: comparisons 
made,· 
No: differences ·are:seeniin ,the frequency of individual alleies.ti:letween patient groups,<ir 
between patient;groups,and controls. 
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TNFb allele 
Controls OFS~2 OFS~3 OFS ~4 
n=l07 n=35 n=18 n=l2 
% % 0/o % 
------------ -----
b1 14.0 15.7 19.4 20.8 
(30) (11) (7) (5) 
b2 0.0 0.0 0.0 0.0 
(0) (0) (0) (0) 
b3 18.2 12.9 13.9 12.5 
(39) (9) (5) (3) 
b4 35.5 34.3 33.3 25.0 
(76) (24) (12) (6) 
b5 30.4 32.9 33.3 41.7 
(65) (23) {12) ( 1 0) 
b6 0.0 0.0 0.0 0.0 
{0) {0) (0) (0) 
b7 1.9 4.3 0.0 0.0 
(4) (3) (0) (0) 
Total alleles (n) 214 70 36 24 
TNFc allele 
cl 73.4 67.1 66.7 58.3 
(1 57) (47) (24) {14) 
c2 26.6 32.9 33.3 41.7 
(57) (23) (12) ( 1 0) 
Total alleles (n) 214 70 36 24 
Table 6.9 TNFab and TNFc microsatellite allele frequencies in normal controls 
and acute pancreatitis patients grouped according to (systemic) disease 
severity as assessed by organ failure score 
This table displays TNFb and TNFc microsatellite allele frequencies in control and patient 
group subjects. For each allele the % frequency and the actual number of alleles (in 
brackets) is given. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
OFS Organ failure score 
OFS calculated according to method described in section 5.1.4 (Kingsnorth et al, 1995). 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. 
No differences are seen in the frequency of individual alleles between patient groups or 
between patient groups and controls. 
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TNFa allele Controls 
Alcohol Idiopathic Gallstones 
n=107 n=21 n=37 n=77 
o;o % % % 
a1 0.5 2.4 1.4 0.0 
(1) (I) (I) (0) 
a2 35.5 14.3 I 27.0 31.8 
(76) (6) (20) (49) 
a3 0.9 0.0 0.0 0.0 
(2) (0) (0) (0) 
a4 8.4 0.0 12.2 10.4 
(18) (0) (9) (16) 
a5 1.9 2.4 4.1 5.8 
(4) (I) (3) (9) 
a6 15.4 28.6 2 16.2 16.2 
(43) (12) (12) (25) 
a7 7.5 9.5 10.8 4.5 
(16) (4) (8) (7) 
aS 1.4 4.8 1.4 2.6 
(3) (2) (I) (4) 
a9 0.9 2.4 1.4 0.0 
(2) (1) (I) (0) 
a10 9.3 7.1 9.5 10.4 
(20) (3) (7) ( 16) 
all 16.8 26.2 3 14.9 17.5 
(36) (11) ( 11) (27) 
a12 0.0 2.4 0.0 0.6 
(0) (1) (0) (1) 
a13 0.9 0.0 0.0 0.0 
(2) (0) (0) (0) 
a14 0.5 0.0 1.4 0.0 
(I) (0) (1) (0) 
Total alleles (n) 214 42 74 154 
Table 6.10 TNFa microsatellite allele frequencies in normal controls and acute 
pancreatitis patients grouped according to aetiology of acute 
pancreatitis 
This table displays TNFa microsatellite allele frequencies in control and patient group 
subjects. For each allele the %frequency and the actual number of alleles (in brackets) is 
g1ven. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
Alcoholic pancreatitis if daily consumption of~ 80g alcohol day" 1 
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Gallstones if radiological or ERCP evidence of cholelithiasis 
Idiopathic if no identifiable aetiology 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the x.2 test. P values were corrected for the number of comparisons 
made. 
I. There was a trend towards reduced frequency of the TNFa2 allele in patients with 
alcohol induced acute pancreatitis, although this did not achieve statistical significance. 
Controls vs. alcohol group, l =7.24, p=0.007, Pc=0.098 
Alcohol vs. idiopathic and gallstone groups combined, x.2 =4.51, p= 0.034, Pc=0.4 
The reduction in the a2 allele in the alcoholic group was not accounted for by an 
increase in any one allele, but both a6 and all were increased in frequency, especially 
when compared to patients with non-alcoholic aetiology, although again this was not 
statistically significant. 
2. Alcohol VS. idiopathic and gallstone groups combined, x2 =3.64, p= 0.056, Pc=>0.5. 
Alcohol vs. normal controls, l=I.5, p=0.2. 
3. Alcohol vs. idiopathic and gallstone groups combined, x.2 =2.17, p= 0.14. 
Alcohol vs. normal controls, l=2.1, p=O.l5. 
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TNFb allele 
Controls Alcohol Idiopathic Gallstones 
n=l07 n=21 n=37 n=77 
0/o 0/o % 0/o 
bl 14.0 4.8 I 20.3 13.6 
(30) (2) (I 5) (21) 
b2 0.0 0.0 0.0 0.0 
(0} (0) (0) (0) 
b3 18.2 16.7 12.2 13.0 
(39) (7) (9) (20) 
b4 35.5 38.1 36.5 33.8 
(76) (16) (27) (52) 
b5 30.4 38.1 29.7 33.8 
(65) (16) (22) (52) 
b6 0.0 2.4 0.0 0.6 
(0) {I) (0) {l) 
b7 1.9 0.0 1.4 5.2 
(4) (0) (I) (8) 
Total alleles (n) 214 42 72 154 
TNFc allele 
cl 73.4 88.1 68.9 70.8 
(I 57) (37) (5 I) (109) 
c2 26.6 11.9 31.1 29.2 
(57) (5) (23) (45) 
Total alleles (n) 214 42 74 154 
Table 6.11 TNFb and TNFc microsatellite allele frequencies in normal controls and 
acute pancreatitis patients grouped according to aetiology of acute 
pancreatitis 
This table displays TNFa microsatellite allele frequencies in control and patient group 
subjects. For each allele the % frequency and the actual number of alleles (in brackets) is 
g1ven. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
Alcoholic pancreatitis if daily consumption of~ 80g alcohol day"1 
Gallstones if radiological or ERCP evidence of cholelithiasis 
Idiopathic if no identifiable aetiology 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for number of comparisons. 
I. There was a slight trend towards reduced frequency of the TNFb I allele in patients with 
alcohol induced acute pancreatitis, although this did not achieve statistical significance 
Controls vs. alcohol group, X2 =2.75, p=0.097, Pc>0.5. 
Alcohol vs. idiopathic and gallstone groups combined, X2 =3.57, p= 0.059, Pc>0.5 
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Controls Alcohol Alcohol Not alcohol 
TNFa allele 'controls' 
n=107 n=33 n=21 n=ll4 
o;o o;o o;o % 
a1 0.5 0.0 2.4 0.4 
(I) (0) (!) (I) 
a2 35.5 40.9 14.3 1 30.3 
(76) (27) (6) (69) 
a3 0.9 l.S 0.0 0.0 
(2) (I) (0) (0) 
a4 8.4 7.6 0.0 11.0 
(18) (5) (0) (25) 
aS 1.9 3.0 2.4 5.3 
(4) (2) (1) (12) 
a6 15.4 12.1 28.6 2 16.2 
(43) (8) (12) (37) 
a7 7.5 7.6 9.5 6.6 
(16) (5) (4) (15) 
aS 1.4 1.5 4.8 2.2 
(3) (I) (2) (5) 
a9 0.9 0.0 2.4 0.4 
(2) (0) (I) (I) 
alO 9.3 12.1 7.1 I 0.1 
(20) (8) (3) (23) 
all 16.8 13.6 26.2 3 16.7 
(36) (9) ( 11) (38) 
a12 0.0 0.0 2.4 0.4 
(0) (0) (1) (I) 
a13 0.9 0.0 0.0 0.0 
(2) (0) (0) (0) 
a14 0.5 0.0 0.0 0.4 
(I) (0) (0) (I) 
Total alleles (n) 214 66 42 228 
Table 6.12 TNFa microsatellite allele frequencies in normal controls, alcohol-
induced and non alcohol-induced acute pancreatitis patients, and 
alcoholic 'controls' 
This table displays TNFa microsatellite allele frequencies in both control and patient group 
subjects. For each allele the % frequency and the actual number of alleles (in brackets) is 
gtven. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
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Alcoholic pancreatitis if daily consumption of~ 80g alcohol dai1 
Non-alcohol induced pancreatitis includes: 
• Gallstones if radiological or ERCP evidence of cholelithiasis 
• Idiopathic if no identifiable aetiology 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. 
I. There was a trend towards reduced frequency of the TNFa2 allele in patients with 
alcohol induced acute pancreatitis, although this achieved statistical significance only 
when comparing with the group of'alcoholic controls'. 
Controls vs. alcoholic pancreatitis group, X2 =7.24, p=0.007, Pc=0.098 
Alcoholic pancreatitis VS. non-alcoholic group, X2 =4.5 1, p= 0.034, Pc=0.4 
Alcoholic pancreatitis vs. alcohol 'controls', x2=8.6, p=0.0034, Pc=0.048 
The reduction in the a2 allele in the alcoholic group was not accounted for by an 
increase in any one allele, but both a6 and a 11 were increased in frequency, although 
again this was not statistically significant. 
2. Alcohol vs. non-alcoholic group, X2 =3.64, p= 0.056, Pc>0.5. 
Alcohol vs. alcohol 'controls', x2=4.6, p=0.032, Pc=0.44. 
3. Alcohol vs. non-alcoholic group, l =2.17, p= 0.14. 
Alcohol vs. alcohol 'controls', l=2. 7, p=O.I. 
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Controls Alcohol Alcohol Not alcohol 
TNFb allele 'controls' 
n=107 n=33 n=21 n=114 
o;o o;o % o;o 
b1 14.0 10.6 4.8 I 15.8 
(30) (7) (2) (36) 
b2 0.0 0.0 0.0 0.0 
(0) (0) (0) (0) 
b3 18.2 19.7 16.7 12.7 
(39) (13) (7) (29) 
b4 35.5 31.8 38.1 34.6 
(76) (21) (16) (79) 
b5 30.4 36.4 38.1 32.5 
(65) (24) (16) (74) 
b6 0.0 0.0 2.4 0.4 
(0) (0) (1) (1) 
b7 1.9 1.5 0.0 3.9 
(4) (I) (0) (9) 
Total alleles ( n) 214 66 70 228 
TNFc allele 
cl 73.4 66.7 88.1 70.2 
(157) (44) (37) (160) 
c2 26.6 33.3 ll.9 29.8 
(57) (22) (5) (68) 
Total alleles (n) 214 66 42 228 
Table 6.13 TNFb and c microsatellite allele frequencies in normal controls, alcohol-
induced and non alcohol-induced acute pancreatitis patients, and 
alcoholic 'controls' 
This table displays TNFb and c microsatellite allele frequencies in both control and patient 
group subjects. For each allele the % frequency and the actual number of alleles (in 
brackets) is given. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
Alcoholic pancreatitis if daily consumption of~ 80g alcohol da/ 
Non-alcohol induced pancreatitis includes: 
• Gallstones if radiological or ERCP evidence of cholelithiasis 
• Idiopathic if no identifiable aetiology 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. 
I . There was a trend towards reduced frequency of the TNFb 1 allele in patients with 
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alcohol induced acute pancreatitis, although this did not achieve statistical significance. 
Controls vs. alcoholic pancreatitis group, X2 =2.75, p=0.097, Pc>0.5. 
Alcoholic pancreatitis VS. non-alcohol group, x2 =3.57, p= 0.059, Pc>0.5. 
In the group of 'alcoholic controls' the b 1 allele was very slightly reduced in frequency 
compared to the normal controls. 
Alcoholic pancreatitis vs. alcohol 'controls', x2=1.2, p=0.28. 
Controls vs. alcohol 'controls', x2=0.5, p=O.S. 
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6.4 TNF microsatellite genotypes 
Due to the number of alleles, there are many possible TNFa and TNFb microsatellite 
genotypes. This limits analysis of genotype distribution because of very small numbers. The 
TNFc locus has only 2 alleles, so only 3 genotypes are possible. TNFa, b, and c genotypes 
in normal control and patients are displayed in Tables 6.14, 6.15, and 6.16. Genotypes in 
patient groups stratified according to disease severity classified according to the Atlanta 
classification and the occurrence of a local complication are shown in Tables 6.17, 6.18, and 
6.19. No significant differences were seen between controls and patient groups or between 
patient groups. 
Tables 6.20, 6.21 and 6.22 show genotypes in patient groups stratified according to organ 
failure score. No significant differences were seen between controls and patient groups or 
between patient groups. Tables 6.23, 6.24, 6.25, 6.26, 6.27, and 6.28 show genotypes in 
patient groups stratified according aetiology of acute pancreatitis, and alcoholic 'controls'. 
No significant differences were seen between controls and patient groups or between patient 
groups. 
214 
TNFa genotype Controls Study patients 
n=107 n=135 
0/o o/o 
1,2 0.9 0.0 
(I) (0) 
1,7 0.0 0.7 
(0) (I) 
1,11 0.0 0.7 
(0) (I) 
2,2 13.1 5.9 
(14) (8) 
2,3 0.9 0.0 
(I) (0) 
2,4 5.6 6.7 
(6) (9) 
2,5 0.9 3.7 
(1) (5) 
2,6 12.1 11.1 
(13) (15) 
2,7 7.5 5.2 
(8) (7) 
2,8 0.9 0.0 
(1) (0) 
2,9 0.0 0.7 
(0) (I) 
2,10 6.5 8.1 
(7) ( 11) 
2,11 9.3 7.4 
(10) (10) 
3,6 0.9 0.0 
(1) (0) 
4,4 0.9 0.7 
(1) (I) 
4,5 0.0 2.2 
(0) (3) 
4,6 0.9 3.0 
(1) (4) 
4,7 1.9 1.5 
(2) (2) 
4,8 0.0 0.7 
(0) (1) 
4,9 0.0 0.7 
(0) (1) 
4,10 0.9 0.7 
(1) (1) 
4,11 4.7 1.5 
5 2 
Table 6.14 Genotypes at the TNFa microsatellite locus in normal control and 
patient groups (continued .... ) 
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TNFa genotype 
Controls Study patients 
n=107 n=135 
% o;o 
4,13 0.9 0.0 
(I) (0) 
5,6 0.0 1.5 
(0) (2) 
5,10 0.9 0.7 
(I) (1) 
5,11 1.9 1.5 
(2) (2) 
6,6 1.9 3.0 
(2) (4) 
6,7 1.9 0.7 
(2) (1) 
6,10 1.9 6.7 
(2) (9) 
6,11 9.3 7.4 
(I 0) (I 0) 
7,7 0.9 1.5 
(I) (2) 
7,8 0.9 0.0 
(1) (0) 
7,11 0.9 3.0 
(I) (4) 
7,13 0.9 0.0 
(I) (0) 
7,14 0.0 0.7 
(0) (I) 
8,10 0.9 0.7 
(1) (1) 
8,11 0.0 3.7 
(0) (5) 
9,10 0.9 0.0 
(!) (0) 
9,11 0.9 0.0 
(I) (0) 
10,10 0.9 0.0 
(1) (0) 
10,11 4.7 2.2 
(5) (3) 
11,11 0.9 3.7 
(1) (5) 
11,12 0.0 1.5 
(0) (2) 
Total, n 107 135 
Table 6.14 Genotypes at the TNFa microsatellite locus in normal control and 
patient groups 
This table displays TNFa microsatellite genotype frequencies in control and patient subjects 
For each genotype the % frequency and the actual number of genotypes (in brackets) is 
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' . 
given! Comparisons were made for each genotype(betweell pati~llt im9 cqntroJ,groups;using 
2x,2:conti!lg~ncy t_aoles;and;the l ;test. p values:were corrected for the j'jt.Jriiher. of . 
comp!lrisons made. Nmsignificant differences were ;seeri :in genotypeJres:~uencie!l betWeen; 
patient and control rgroups, · · 
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TNFb genotype Controls Study patients 
n=107 n=l35 
0/o 0/o 
1,1 1.9 1.5 
(2) (2) 
1,2 0.0 0.7 
(0) (1) 
1,3 4.7 4.4 
(5) (6) 
1,4 17.8 6.7 I 
( 19) (9) 
1,5 7.5 10.4 
(8) (14) 
1,6 0.0 0.7 
(0) (1) 
1,7 0.0 2.2 
(0) (3) 
3,3 2.8 0.0 
(3) (0) 
3,4 12.1 8.1 
(13) ( 11) 
3,5 11.2 ll.l 
(12) (IS) 
3,7 0.9 0.0 
(1) (0) 
4,4 7.5 15.6 
(8) (21) 
4,5 25.2 24.4 
(27) (33) 
4,6 0.0 0.7 
(0) (1) 
4,7 2.8 3.0 
(3) (4) 
5,5 5.6 8.9 
(6) ( 12) 
5,7 0.0 1.5 
(0) (2) 
Total 107 135 
Table 6.15 Genotypes at the TNFb microsatellite locus in normal control and 
patient groups 
This table displays TNFb microsatellite genotype frequencies in control and patient subjects. 
For each genotype the % frequency and the actual number of genotypes (in brackets) is 
g1ven. 
Comparisons were made for each genotype between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. 
No significant differences were seen in genotype frequencies between patient and control 
groups. 
1. Control VS. patient groups, X2 =7.18, p=0.007, Pc=O.I2. 
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Table 6.16 
Controls Study patients 
TNFc genotype n=107 n=135 
0/o % 
1,1 52.3 53.3 
(56) (72) 
1,2 42.1 39.3 
(45) (53) 
2,2 5.6 7.4 
(6) (10) 
Total 107 135 
Genotypes at the TNFc microsatellite locus in normal control and 
patient groups 
This table displays TNFc microsatellite genotype frequencies in control and patient subjects. 
For each genotype the % frequency and the actual number of genotypes (in brackets) is 
g1ven. 
Comparisons were made for each genotype between patient and control groups using 2x2 
contingency tables and the l test. P values were corrected for the number of comparisons 
made. 
No significant differences were seen in genotype frequencies between patient and control 
groups. 
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Controls Mild Severe Local TNFa genotype complication 
n=l07 n=97 n=38 n=21 
0/o % 0/o 0/o 
1,2 0.9 0.0 0.0 0.0 
(I) (0) (0) (0) 
1,7 0.0 1.0 0.0 0.0 
(0) (1) (0) (0) 
1,11 0.0 0.0 2.6 4.8 
(0) (0) (I) (1) 
2,2 13.1 5.2 7.9 9.5 
(14) (5) (3) (2) 
2,3 0.9 0.0 0.0 0.0 
(I) (0) (0) (0) 
2,4 5.6 6.2 7.9 4.8 
(6) (6) (3) (l) 
2,5 0.9 4.1 2.6 0.0 
(I) (4) (I) (0) 
2,6 12.1 10.3 13.2 14.3 
(13) (I 0) (5) (3) 
2,7 7.5 5.2 5.3 4.8 
(8) (5) (2) (I) 
2,8 0.9 0.0 0.0 0.0 
(I) (0) (0) (0) 
2,9 0.0 1.0 0.0 0.0 
(0) (1) (0) (0) 
2,10 6.5 6.2 13.2 4.8 
(7) (6) (5) (I) 
2,11 9.3 8.2 5.3 9.5 
(10) (8) (2) (2) 
3,6 0.9 0.0 0.0 0.0 
(I) (0) (0) (0) 
4,4 0.9 1.0 0.0 0.0 
(!) (1) (0) (0) 
4,5 0.0 1.0 5.3 9.5 
(0) (1) (2) (2) 
4,6 0.9 4.1 0.0 0.0 
( 1) (4) (0) (0) 
4,7 1.9 1.0 2.6 4.8 
(2) (1) (l) (1) 
4,8 0.0 1.0 0.0 0.0 
(0) (l) (0) (0) 
4,9 0.0 1.0 0.0 0.0 
(0) ( 1) (0) (0) 
4,10 0.9 1.0 0.0 0.0 
(I) (1) (0) (0) 
4,11 4.7 1.0 2.6 0.0 
~5~ ~12 ~12 ~02 
Table 6.17 Genotypes at the TNFa microsatellite locus in normal control and acute 
pancreatitis patients grouped according to (local and systemic) disease 
severity (cont. .......... ) 
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Controls Mild Severe Local 
TNFa genotype complication 
n=107 n=97 n=38 n=21 
% o;o o;o o;o 
4,13 0.9 0.0 0.0 0.0 
(I) (0) (0) (0) 
5,6 0.0 1.0 2.6 4.8 
(0) (I) (I) (I) 
5,10 0.9 1.0 0.0 0.0 
(I) (I) (0) (0) 
5,11 1.9 2.1 0.0 0.0 
(2) (2) (0) (0) 
6,6 1.9 3.1 2.6 4.8 
(2) (3) (I) (I) 
6,7 1.9 1.0 0.0 0.0 
(2) (l) (0) (0) 
6,10 1.9 5.2 10.5 9.5 
(2) (5) (4) (2) 
6,11 9.3 9.3 2.6 4.8 
(I 0) (9) (I) (I) 
7,7 0.9 1.0 2.6 0.0 
(1) (I) (I) (0) 
7,8 0.9 0.0 0.0 0.0 
(1) (0) (0) (0) 
7,11 0.9 4.1 0.0 0.0 
(1) (4) (0) (0) 
7,13 0.9 0.0 0.0 0.0 
(1) (0) (0) (0) 
7,14 0.0 1.0 0.0 0.0 
(0) (I) (0) (0) 
8,10 0.9 1.0 0.0 0.0 
(l) (l) (0) (0) 
8,11 0.0 2.1 7.9 9.5 
(0) (2) (3) (2) 
9,10 0.9 0.0 0.0 0.0 
(I) (0) (0) (0) 
9,11 0.9 0.0 0.0 0.0 
(I) (0) (0) (0) 
10,10 0.9 0.0 0.0 0.0 
(I) (0) (0) (0) 
10,11 4.7 2.1 2.6 0.0 
(5) (2) (1) (0) 
11,11 0.9 5.2 0.0 0.0 
(l) (5) (0) (0) 
11,12 0.0 2.1 0.0 0.0 
(0) (2) (0) (0) 
Total 107 97 38 21 
Table 6.17 Genotypes at the TNFa microsatellite locus in normal control and acute 
pancreatitis patients grouped according to (local and systemic) disease 
severity 
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Table 6.17 Genotypes at the TNFa microsatellite locus in normal control and acute 
pancreatitis patients grouped according to (local and systemic) disease severity 
This table displays TNFa microsatellite genotype frequencies in control and patient groups. 
For each genotype the% frequency and the actual number of genotypes (in brackets) is 
given. 
Mild and severe disease severity groups are according to the Atlanta convention 
classification (Bradley, 1993), described in section 5.1.4. 
Local complication is defined as occurrence of pancreatic necrosis, abscess or pseudocyst. 
Comparisons were made for each genotype between patient and control groups using 2x2 
contingency tables and the X2 test. P values were corrected for the number of comparisons 
made. 
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Controls Mild Severe Local TNFb genotype complication 
n=107 n=97 n=38 n=21 
% % % 0/o 
1,1 1.9 2.1 0.0 0.0 
(2) (2) (0) (0) 
1,2 0.0 1 0.0 0.0 
(0) (I) (0) (0) 
1,3 4.7 4.1 5.3 0.0 
(5) (4) (2) (0) 
1,4 17.8 5.2 10.5 9.5 
(19) (5) (4) (2) 
1,5 7.5 11.3 7.9 14.3 
(8) (11) (3) (3) 
1,6 0.0 1.0 0.0 0.0 
(0) (I) (0) (0) 
1,7 0.0 1.0 5.3 0.0 
(0) (I) (2) (0) 
3,3 2.8 0.0 0.0 0.0 
(3) (0) (0) (0) 
3,4 12.1 9.3 5.3 9.5 
(13) (9) (2) (2) 
3,5 11.2 11.3 10.5 9.5 
(12) ( 11) (4) (2) 
3,7 0.9 0.0 0.0 0.0 
(I) (0) (0) (0) 
4,4 7.5 15.5 15.8 9.5 
(8) (IS) (6) (2) 
4,5 25.2 25.8 21.1 23.8 
(27) (25) (8) (5) 
4,6 0.0 1.0 0.0 0.0 
(0) (I) (0) (0) 
4,7 2.8 3.1 2.6 4.8 
(3) (3) (I) (I) 
5,5 5.6 7.2 13.2 19.0 
(6) (7) (5) (4) 
5,7 0.0 1.0 2.6 0.0 
(0) (I) (I} (0) 
Total 107 97 38 135 
Table 6.18 Genotypes at the TNFb microsatellite locus in normal control and acute 
pancreatitis patients grouped according to (local and systemic) disease 
severity 
This table displays TNFb microsatellite genotype frequencies in control and patient groups. 
For each genotype the %frequency and the number of genotypes (in brackets) is given 
Mild and severe disease severity groups are according to the Atlanta convention 
classification (Bradley, 1993), described in section 5.1.4. 
Local complication is defined as occurrence of pancreatic necrosis, abscess or pseudocyst. 
Comparisons were made for each genotype between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. No significant differences were seen. 
223 
Controls Mild Severe Local 
TNFc genotype complication 
n=107 n=97 n=38 n=21 
% 0/o 0/o 0/o 
I, I 52.3 57.7 42.1 42.9 
(56) (56) (16) (9) 
1,2 42.1 35.1 50.0 52.4 
(45) (34) (19) ( 11) 
2,2 5.6 7.2 7.9 4.8 
(6) (7) (3) (I) 
Total 107 97 38 21 
Table 6.19 Genotypes at the TNFc microsatellite locus in normal control and acute 
pancreatitis patients grouped according to (local and systemic) disease 
severity 
This table displays TNFc microsatellite genotype frequencies in control and patient groups. 
For each genotype the % frequency and the number of genotypes (in brackets) is given. 
Mild and severe disease severity groups are according to the Atlanta convention 
classification (Bradley, 1993), described in section 5.1.4. 
Local complication is defined as occurrence of pancreatic necrosis, abscess or pseudocyst. 
Comparisons were made for each genotype between patient and control groups using 2x2 
contingency tables and the l test. P values were corrected for the number of comparisons 
made. No significant differences were seen. 
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Controls OFS~2 OFS~3 OFS~4 
TNFa genotype n=107 n=35 n=18 n=12 
o;o o;o o/o o;o 
---·-···---····---·······---------------------------------------------------------------------·--·············· 
1,2 0.9 0.0 0.0 0.0 
(1) (0) (0) (0) 
2,2 13.1 8.6 16.7 25.0 
(14) (3) (3) (3) 
2,3 0.9 0.0 0.0 0.0 
(1) (0) (0) (0) 
2,4 5.6 5.7 5.6 0.0 
(6) (2) (1) (0) 
2,5 0.9 2.9 0.0 0.0 
(l) (1) (0) (0) 
2,6 12.1 17.1 11.1 16.7 
(13) (6) (2) (2) 
2,7 7.5 5.7 11.1 8.3 
(8) (2) (2) (1) 
2,8 0.9 0.0 0.0 0.0 
(1) (0) (0) (l) 
2,9 0.0 0.0 0.0 0.0 
(0) (0) (0) (0) 
2,10 6.5 14.3 11.1 0.0 
(7) (5) (0) (0) 
2,11 9.3 2.9 0.0 0.0 
(10) (l) (0) (0) 
3,6 0.9 0.0 0.0 0.0 
(1) (0) (0) (0) 
4,4 0.9 0.0 0.0 0.0 
(l) (0) (0) (0) 
4,5 0.0 5.7 5.6 8.3 
(0) (2) (1) (1) 
4,6 0.9 2.9 0.0 0.0 
(1) (1) (0) (0) 
4,7 1.9 0.0 0.0 0.0 
(2) (0) (0) (0) 
4,8 0.0 0.0 0.0 0.0 
(0) (0) (0) (0) 
4,9 0.0 0.0 0.0 0.0 
(0) (0) (0) (0) 
4,10 0.9 0.0 0.0 0.0 
(l) (0) (0) (0) 
4,11 4.7 2.9 5.6 8.3 
(5) (1) (1) (1) 
4,13 0.9 0.0 0.0 0.0 
(1) (0) (1) (0) 
Table 6.20 TNFa genotype frequencies in normal controls and acute pancreatitis 
patients grouped according to (systemic) disease severity as assessed by 
organ failure score (continued .... ) 
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TNFa genotype 
Controls OFS~2 OFS~3 OFS~4 
n=107 n=35 n=18 n=12 
o;o o;o o;o o;o 
-------------------------------------------·····--·--·············--------------------------------------------------········-····----------------------·· 
5,6 0.0 2.9 5.6 8.3 
(0) (1) (1) (1) 
5,10 0.9 0.0 0.0 0.0 
(1) (0) (0) (0) 
5,11 1.9 2.9 0.0 0.0 
(2) (1) (0) (0) 
6,6 1.9 0.0 0.0 0.0 
(2) (0) (0) (0) 
6,7 1.9 0.0 0.0 0.0 
(2) (0) (0) (0) 
6,10 1.9 8.6 16.7 16.7 
(2) (3) (3) (2) 
6,11 9.3 0.0 0.0 0.0 
(1 0) (0) (0) (0) 
7,7 0.9 2.9 5.6 0.0 
(1) (1) (1) (0) 
7,8 0.9 0.0 0.0 0.0 
(1) (0) (0) (0) 
7,11 0.9 0.0 0.0 0.0 
(1) (0) (0) (0) 
7,13 0.9 0.0 0.0 0.0 
(1) (0) (0) (0) 
7,14 0.0 0.0 0.0 0.0 
(0) (0) (0) (0) 
8,10 0.9 0.0 0.0 0.0 
(1) (0) (0) (0) 
8,11 0.0 8.6 0.0 0.0 
(0) (3) (0) (0) 
9,10 0.9 0.0 0.0 0.0 
(1) (0) (0) (0) 
9,11 0.9 0.0 0.0 0.0 
(1) (0) (0) (0) 
10,10 0.9 0.0 0.0 0.0 
(1) (0) (0) (0) 
10,11 4.7 2.9 5.6 8.3 
(5) (1) (1) (1) 
11,11 0.9 2.9 0.0 0.0 
(1) (1) (0) (0) 
Total 107 35 18 12 
Table 6.20 TNFa genotype frequencies in normal controls and acute pancreatitis 
patients grouped according to (systemic) disease severity as assessed by 
organ failure score 
This table displays TNFa microsatellite genotype frequencies in control and patient groups. 
For each genotype the% frequency and the number of genotypes (in brackets) is given 
OFS Organ failure score 
OFS calculated according to method described in section 5.1.4 (Kingsnorth et al, 1995) 
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TNFb genotype Controls OFS;e:2 OFS;e:3 OFS;e:4 
n=107 n=35 n=18 n=12 
% % 0/o 0/o 
---------------·------------------·--·····--------------- . ------------------------
1,1 1.9 0.0 0.0 0.0 
(2) (0) (0) (0) 
1,2 0.0 0.0 0.0 0.0 
(0) (0) (0) (0) 
1,3 4.7 5.7 5.6 8.3 
(5) (2) (1) (I) 
1,4 17.8 8.6 16.7 8.3 
( 19) (3) (3) (I) 
1,5 7.5 11.4 16.7 25.0 
(8) (4) (3) (3) 
1,6 0.0 0.0 0.0 0.0 
(0) (0) (0) (0) 
1,7 0.0 5.7 0.0 0.0 
(0) (2) (0) (0) 
3,3 2.8 0.0 0.0 0.0 
(3) (0) (0) (0) 
3,4 12.1 5.7 11.1 8.3 
(13) (2) (2) (I) 
3,5 11.2 11.4 11.1 8.3 
(12) (4) (2) (I) 
3,7 0.9 0.0 0.0 0.0 
(I) (0) (0) (0) 
4,4 7.5 20.0 5.6 0.0 
(8) (7) (I) (0) 
4,5 25.2 17.1 27.8 33.3 
(27) (6) (5) (4) 
4,6 0.0 0.0 0.0 0.0 
(0) (0) (0) (0) 
4,7 2.8 0.0 0.0 0.0 
(3) (0) (0) (0) 
5,5 5.6 11.4 5.6 8.3 
(6) (4) (I) (I) 
5,7 0.0 2.9 0.0 0.0 
(0) (I) (0) (0) 
Total 107 35 18 12 
Table 6.21 TNFb genotype frequencies in normal controls and acute pancreatitis 
patients grouped according to (systemic) disease severity as assessed by 
organ failure score 
This table displays TNFb microsatellite genotype frequencies in control and patient groups. 
For each genotype the %frequency and the number of genotypes (in brackets) is given. 
OFS Organ failure score 
OFS calculated according to method described in section 5.1.4 (Kingsnorth et al, 1995). 
Comparisons were made for each genotype between patient and control groups using 2x2 
contingency tables and the l test. P values were corrected for the number of comparisons 
made. No significant differences were seen 
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TNFc genotype 
Controls OFS~2 OFS~3 OFS~4 
n=l07 n=35 n=18 n=l2 
0/o 0/o % 0/o 
-----·-··-···--·· ---------·-·····------------------------------------------------
1,1 52.3 42.9 44.4 25.0 
(56) ( 15) (8) (3) 
1,2 42.1 48.6 50.0 66.7 
(45) (17} (9) (8) 
2,2 5.6 8.6 5.6 8.3 
(6) (3) (I) (I) 
Total 107 35 18 12 
Table 6.22 TNFc genotype frequencies in normal controls and acute pancreatitis 
patients grouped according to (systemic) disease severity as assessed by 
organ failure score 
This table displays TNFc microsatellite genotype frequencies in control and patient groups. 
For each genotype the% frequency and the number of genotypes (in brackets) is given. 
OFS Organ failure score 
OFS calculated according to method described in section 51.4 (Kingsnorth et a!, 1995). 
Comparisons were made for each genotype between patient and control groups using 2x2 
contingency tables and the X,2 test. P values were corrected for the number of comparisons 
made. No significant differences were seen 
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TNFa genotype Controls Alcohol 
Idiopathic Gallstones 
n=107 n=21 n=37 n=77 
0/o 0/o 0/o % 
1,2 0.9 0.0 0.0 0.0 
(1) (0) (0) (0) 
1,7 0.0 4.8 0.0 0.0 
(0) (1) (0) (0) 
1,11 0.0 0.0 2.7 0.0 
(0) (0) (1) (0) 
2,2 13.1 0.0 5.4 7.8 
(14) (0) (2) (6) 
2,3 0.9 0.0 0.0 0.0 
(1) (0) (0) (0) 
2,4 5.6 0.0 8.1 7.8 
(6) (0) (3) (6) 
2,5 0.9 4.8 0.0 5.2 
(1) (1) (0) (4) 
2,6 12.1 14.3 13.5 9.1 
(13) (3) (5) (7) 
2,7 7.5 0.0 8.1 5.2 
(8) (0) (3) (4) 
2,8 0.9 0.0 0.0 0.0 
(1) (0) (0) (0) 
2,9 0.0 4.8 0.0 0.0 
(0) (1) (0) (0) 
2,10 6.5 4.8 10.8 7.8 
(7) (1) (4) (6) 
2,11 9.3 0.0 2.7 11.7 
(10) (0) (1) (9) 
3,6 0.9 0.0 0.0 0.0 
(I) (0) (0) (0) 
4,4 0.9 0.0 0.0 1.3 
(1) (0) (0) (1) 
4,5 0.0 0.0 2.7 2.6 
(0) (0) (I) (2) 
4,6 0.9 0.0 5.4 2.6 
(I) (0) (2) (2) 
4,7 1.9 0.0 2.7 1.3 
(2) (0) (1) (1) 
4,8 0.0 0.0 0.0 1.3 
(0) (0) (0) (1) 
4,9 0.0 0.0 2.7 0.0 
(0) (0) (1) (0) 
4,10 0.9 0.0 0.0 1.3 
(1) (0) (0) (1) 
4,11 4.7 0.0 2.7 1.3 
(5) (0) (1) (1) 
4,13 0.9 0.0 0.0 0.0 
~1 ~ ~0~ (0~ (0) 
Table 6.23 Genotypes at the TNFa microsatellite locus in normal control and acute 
pancreatitis patients grouped according to aetiology (continued ... ) 
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TNFa genotype 
Controls Alcohol Idiopathic Gallstones 
n=107 n=21 n=37 n=77 
o;o o;o o/o % 
5,6 0.0 0.0 2.7 1.3 
(0) (0) (I) (1) 
5,10 0.9 0.0 0.0 1.3 
{I) (0) (0) {I) 
5,11 1.9 0.0 2.7 1.3 
(2) (0) {I) ( l) 
6,6 1.9 4.8 0.0 3.9 
(2) (I) (0) (3) 
6,7 1.9 4.8 0.0 0.0 
(2) (I) (0) (0) 
6,10 1.9 9.5 5.4 6.5 
(2) (2) (2) (S) 
6,11 9.3 19.0 5.4 5.2 
(10) (4) (2) (4) 
7,7 0.9 0.0 2.7 1.3 
(I) (0) (I) (1) 
7,8 0.9 0.0 0.0 0.0 
(I) (0) (0) (0) 
7,11 0.9 9.5 2.7 1.3 
(I) (2) (I) (I) 
7,13 0.9 0.0 0.0 0.0 
(I) (0) (0) (0) 
7,14 0.0 0.0 2.7 0.0 
(0) (0) (I) (0) 
8,10 0.9 0.0 0.0 1.3 
(I) (0) (0) (I) 
8,11 0.0 9.5 2.7 2.6 
(0) (2) (I) (2) 
9,10 0.9 0.0 0.0 0.0 
(I) (0) (0) (0) 
9,11 0.9 0.0 0.0 0.0 
(I) (0) (0) (0) 
10,10 0.9 0.0 0.0 0.0 
(I) (0) (0) (0) 
10,11 4.7 0.0 2.7 2.6 
(S) (0) (1) (2) 
11,11 0.9 4.8 2.7 3.9 
{I) (I) (I) (3) 
11,12 0.0 4.8 0.0 1.3 
(0) (1) (0) (l) 
Total 107 21 37 77 
Table 6.23 Genotypes at the TNFa microsatellite locus in normal control and acute 
pancreatitis patients grouped according to aetiology 
This table displays TNFa microsatellite genotype frequencies in control and patient groups. 
For each genotype the % frequency and the number of genotypes (in brackets) is given. 
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I 
*lc6h_olic1pJm<;_r~~Htis iif·daily, consumption· cif·~ 80g alcohoi da/ 
tQaiis~ones-ifradiological o~ ERCP evidence1of choielitlii3:sis 
Idio(>athiciifno: identifiabie,aetiolbgy 
tCompaiisons,weretmade fotceach;gerio~ype. betWeen! Pl!tient and: control groups using;2x2 
iCOnting~ncttaoies and. the X2 it est. P values were.cor(ected[or the number of:compafisons 
made, .No significant 'differences were seen 
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TNFb 
Controls Alcohol Idiopathic Gallstones 
genotype n=107 n=21 n=37 n=77 
o;o o;o o;o 0/o 
1,1 1.9 0.0 2.7 1.3 
(2) (0) (I) (I) 
1,2 0.0 0.0 0.0 0.0 
(0) (0) (0) (0) 
1,3 4.7 0.0 5.4 5.2 
(5) (0) (2) (4) 
1,4 17.8 0.0 16.2 5.2 
(19) (0) (6) (4) 
1,5 7.5 9.5 13.5 9.1 
(8) (2) (5) (7) 
1,6 0.0 0.0 0.0 1.3 
(0) (0) (0) (1) 
1,7 0.0 0.0 0.0 3.9 
(0) (0) (0) (3) 
3,3 2.8 0.0 0.0 0.0 
(3) (0) (0) (0) 
3,4 12.1 9.5 8.1 9.1 
(13) (2) (3) (7) 
3,5 11.2 14.3 8.1 11.7 
(12) (3) (3) (9) 
3,7 0.9 0.0 0.0 0.0 
(I) (0) (0) (0) 
4,4 7.5 19.0 10.8 15.6 
(8) (4) (4) (12) 
4,5 25.2 38.1 27.0 18.2 
(27) (8) {10) (14) 
4,6 0.0 4.8 0.0 0.0 
(0} (1) (0) (0) 
4,7 2.8 0.0 2.7 3.9 
(3) (0) (1) (3) 
5,5 5.6 4.8 5.4 13.0 
(6) (I) (2) (1 0) 
5,7 0.0 0.0 0.0 2.6 
(0) (0) (0) (2) 
Total 107 21 35 77 
Table 6.24 Genotypes at the TNFb microsatellite locus in normal control and acute 
pancreatitis patients grouped according to aetiology 
This table displays TNFb microsatellite genotype frequencies in control and patient groups. 
For each genotype the % frequency and the number of genotypes (in brackets) is given. 
Alcoholic pancreatitis if daily consumption of;::: 80g alcohol da/ 
Gallstones if radiological or ERCP evidence of cholelithiasis 
Idiopathic if no identifiable aetiology 
Comparisons were made for each genotype between patient and control groups using 2x2 
contingency tables and the r! test. P values were corrected for the number of comparisons 
made. No significant differences were seen 
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TNFc genotype 
Controls Alcohol Idiopathic Gallstones 
n=107 n=21 n=37 n=77 
0/o 0/o % 0/o 
1,1 52.3 76.2 43.2 51.9 
(56) (16) (16) (40) 
1,2 42.1 23.8 51.4 37.7 
(45) (5) (19) (29) 
2,2 5.6 0.0 5.4 10.4 
(6) (0) (2) (8) 
Total 107 21 37 77 
Table 6.25 Genotypes at the TNFc microsatellite locus in normal control and acute 
pancreatitis patients grouped according to aetiology 
This table displays TNFc microsatellite genotype frequencies in control and patient groups. 
For each genotype the %frequency and the number of genotypes (in brackets) is given. 
Alcoholic pancreatitis if daily consumption of~ 80g alcohol dai1 
Gallstones if radiological or ERCP evidence of cholelithiasis 
Idiopathic if no identifiable aetiology 
Comparisons were made for each genotype between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. No significant differences were seen. 
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Controls Alcohol Alcohol Not alcohol TNFa genotype 'controls' 
n=107 n=33 n=21 n=ll4 
o/o o/o o/o % 
1,2 0.9 0.0 0.0 0.0 
(I) (0) (0) (0) 
1,7 0.0 0.0 4.8 0.0 
(0) (0) (I) (0) 
1,11 0.0 0.0 0.0 0.9 
(0) (0) (0) (I) 
2,2 13.1 18.2 0.0 7.0 
(14) (6) (0) (8) 
2,3 0.9 0.0 0.0 0.0 
(I) (0) (0) (0) 
2,4 5.6 6.1 0.0 7.9 
(6) (2) (0) (9) 
2,5 0.9 0.0 4.8 3.5 
(1) (0) (I) (4) 
2,6 12.1 9.1 14.3 10.5 
(13) (3) (3) ( 12) 
2,7 7.5 6.1 0.0 6.1 
(8) (2) (0) (7) 
2,8 0.9 3.0 0.0 0.0 
(1) (1) (0) (0) 
2,9 0.0 0.0 4.8 0.0 
(0) (0) (I) (0) 
2,10 6.5 15.2 4.8 8.8 
(7) (5) (1) (10) 
2,11 9.3 6.1 0.0 8.8 
(10) (2) (0) (10) 
3,6 0.9 0.0 0.0 0.0 
(1) (0) (0) (0) 
3,7 0.0 3.0 0.0 0.0 
(0) (I) (0) (0) 
4,4 0.9 0.0 0.0 0.9 
(I) (0) (0) (I) 
4,5 0.0 3.0 0.0 2.6 
(0) (1) (0) (3) 
4,6 0.9 3.0 0.0 3.5 
(l) (1) (0) (4) 
4,7 1.9 0.0 0.0 1.8 
(2) (0) (0) (2) 
4,8 0.0 0.0 0.0 0.9 
(0) (0) (0) (1) 
4,9 0.0 0.0 0.0 0.9 
(0) (0) (0) (1) 
4,10 0.9 0.0 0.0 0.9 
~I) ~0) {02 (12 
Table 6.26 Genotypes at the TNFa microsatellite locus in normal controls, alcohol-
induced and non alcohol-induced acute pancreatitis patients, and 
alcoholic 'controls' (continued ... ) 
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Controls Alcohol Alcohol Not alcohol 
TNFa genotype 'controls' 
n=107 n=33 n=21 n=114 
0/o 0/o 0/o 0/o 
4,11 4.7 3.0 0.0 1.8 
(5) (1) (0) (2) 
4,13 0.9 0.0 0.0 0.0 
(I) (0) (0) (0) 
5,6 0.0 0.0 0.0 1.8 
(0) (0) (0) (2) 
5,10 0.9 0.0 0.0 0.9 
(I) (0) (0) (I) 
5,11 1.9 3.0 0.0 1.8 
(2) (l) (0) (2) 
6,6 1.9 0.0 4.8 2.6 
(2) (0) (1) (3) 
6,7 1.9 0.0 4.8 0.0 
(2) (0) (I) (0) 
6,10 1.9 6.1 9.5 6.1 
(2) (2) (2) (7) 
6,11 9.3 6.1 19.0 5.3 
(I 0) (2) (4) (6) 
7,7 0.9 0.0 0.0 1.8 
(I) (0) (0) (2) 
7,8 0.9 0.0 0.0 0.0 
(I) (0) (0) (0) 
7,10 0.0 3.0 0.0 0.0 
(0) (I) (0) (0) 
7,11 0.9 3.0 9.5 1.8 
(I) (I) (2) (2) 
7,13 0.9 0.0 0.0 0.0 
(I) (0) (0) (0) 
7,14 0.0 0.0 0.0 0.9 
(0) (0) (0) (I) 
8,10 0.9 0.0 0.0 0.9 
(I) (0) (0) (I) 
8,11 0.0 0.0 9.5 2.6 
(0) (0) (2) (3) 
9,10 0.9 0.0 0.0 0.0 
(I) (0) (0) (0) 
9,11 0.9 0.0 0.0 0.0 
(I) (0) (0) (0) 
10,10 0.9 0.0 0.0 0.0 
(I) (0) (0) (0) 
10,11 4.7 0.0 0.0 2.6 
(5) (0) (0) (3) 
ll,ll 0.9 3.0 4.8 3.5 
(I) ( 1) (1) (4) 
11,12 0.0 0.0 4.8 0.9 
(0) (0) (I) (I) 
Total 107 33 21 114 
Table 6.26 Genotypes at the TNFa microsatellite locus in normal controls, alcohol-
induced and non alcohol-induced acute pancreatitis patients, and 
alcoholic 'controls' (footnotes next page ... ) 
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Table 6.26 Genotypes at the TNFa microsatellite locus in normal controls, alcohol-
induced and non alcohol-induced acute pancreatitis patients, and 
alcoholic 'controls' 
This table displays TNFa microsatellite genotype frequencies in control and patient groups. 
For each genotype the% frequency and the number of genotypes (in brackets) is given. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
Alcoholic pancreatitis if daily consumption of~ 80g alcohol dai1 
Non-alcohol induced pancreatitis includes: 
• Gallstones if radiological or ERCP evidence of cholelithiasis 
• Idiopathic if no identifiable aetiology 
Comparisons were made for each genotype between patient and control groups using 2x2 
contingency tables and the y} test. P values were corrected for the number of comparisons 
made. No significant differences were seen. 
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Controls Alcohol Alcohol Not alcohol 
TNFb 'controls' 
genotype n=107 n=33 n=21 n=114 
o;o o;o o;o o;o 
1,1 1.9 0.0 0.0 1.8 
(2) (0) (0) (2) 
1,3 4.7 6.1 0.0 5.3 
(5) (2) (0) (6) 
1,4 17.8 15.2 0.0 8.8 
(19) (5) (0) (I 0) 
1,5 7.5 0.0 9.5 10.5 
(8) (0) (2) (12) 
1,6 0.0 0.0 0.0 0.9 
(0) (0) (0) (1) 
1,7 0.0 0.0 0.0 2.6 
(0) (0) (0) (3) 
3,3 2.8 9.1 0.0 0.0 
(3) (3) (0) (0) 
3,4 12.1 9.1 9.5 8.8 
(13) (3) (2) (10) 
3,5 11.2 6.1 14.3 10.5 
(12) (2) (3) (12) 
3,7 0.9 0.0 0.0 0.0 
(1) (0) (0) (0) 
4,4 7.5 9.1 19.0 14.0 
(8) (3) (4) ( 16) 
4,5 25.2 21.2 38.1 21.1 
(27) (7) (8) (24) 
4,6 0.0 0.0 4.8 0.0 
(0) (0) (1) (0) 
4,7 2.8 0.0 0.0 3.5 
(3) (0) (0) (4) 
5,5 5.6 21.2 4.8 10.5 
(6) (7) (1) ( 12) 
5,7 0.0 3.0 0.0 1.8 
(0) (I) (0) (2) 
Total 107 33 21 114 
Table 6.27 Genotypes at the TNFb microsatellite locus in normal controls, alcohol-
induced and non alcohol-induced acute pancreatitis patients, and 
alcoholic 'controls' 
This table displays TNFb microsatellite genotype frequencies in control and patient groups. 
For each genotype the %frequency and the number of genotypes (in brackets) is given. 
Alcoholic pancreatitis if daily consumption of:?: 80g alcohol da/ 
Non-alcohol induced pancreatitis includes: 
• Gallstones if radiological or ERCP evidence of cholelithiasis 
• Idiopathic if no identifiable aetiology 
Comparisons were made for each genotype between patient and control groups using 2x2 
contingency tables and the l test P values were corrected for the number of comparisons 
made. No significant differences were seen. 
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TNFc genotype 
Controls Alcohol Alcohol Not alcohol 
'controls' 
n=107 n=33 n=21 n=l14 
% % % o/o 
1,1 52.3 45.5 76.2 49.1 
(56) (1 5) (16) (56) 
1,2 42.1 42.4 23.8 42.1 
(45) (14) (5) (48) 
2,2 5.6 12.1 0.0 8.8 
(6) (4) (0) (10) 
Total 107 33 21 114 
Table 6.28 Genotypes at the TNFc microsatellite locus in normal controls, alcohol-
induced and non alcohol-induced acute pancreatitis patients, and 
alcoholic 'controls' 
This table displays TNFc microsatellite genotype frequencies in control and patient groups. 
For each genotype the % frequency and the number of genotypes (in brackets) is given. 
Alcoholic pancreatitis if daily consumption of 2 80g alcohol day" 1 
Non-alcohol induced pancreatitis includes 
• Gallstones if radiological or ERCP evidence of cholelithiasis 
• Idiopathic if no identifiable aetiology 
Comparisons were made for each genotype between patient and control groups using 2x2 
contingency tables and the X) test. P values were corrected for the number of comparisons 
made. No significant differences were seen. 
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6.5 TNF microsatellite 3-Iocus haplotypes 
Haplotypes, alleles combining in non-random association across the TNF 3 locus 
microsatellite system, have been characterised by maximum likelihood estimates in previous 
population based and family studies (Jongeneel et al., 1991; Nedaspasov et al., 1991; 
Crouau-Roy et al., 1993) and their existence has been confirmed in homozygous cell lines 
(Weissensteiner and Lanchbury, 1997; Udalova et at, 1993). TNF haplotype analysis was 
performed using all 11 haplotypes described in European populations (Crouau-Roy et al., 
1993; Weissensteiner and Lanchbury, 1997). 
There were no significant differences in haplotype frequencies between patients and healthy 
controls (Table 6.29), or between any of the patient groups stratified according to disease 
severity classified according to the Atlanta classification and the occurrence of a local 
complication (Table 6.30). 
Table 6.31 shows haplotype frequencies in patient groups stratified according to organ 
failure score. No significant differences were seen between controls and patient groups or 
between patient groups. 
Table 6.32 shows TNFabc 3-locus haplotype frequency in normal controls and subjects 
grouped according to disease aetiology, and Table 6.33 also shows haplotype frequency in 
the alcoholic 'controls'. The TNF a2b I c2 haplotype shows a strong trend toward reduced 
frequency in the alcohol induced acute pancreatitis group compared to the two other 
aetiologies. This is not statistically significant after correction for multiple comparisons, 
however. Alcoholic pancreatitis group vs. non-alcoholic pancreatitis group (2.4 vs. 
15.8%,X2 =5.39, p=0.02, pc=0.22), alcoholic pancreatitis group vs. normal controls (24 vs. 
13.1%, X2 =4.59,p=0.032, Pc=0.38). 
When compared with the alcohol 'control' group however, the difference in frequency is 
even less marked, alcoholic pancreatitis group vs. alcoholic 'controls', (2.4 vs. 9.1 %, 
Fisher's exact test, p=0.16). 
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The TNF a2b5c2 haplotype is present at higher frequency in the alcoholic 'control' group 
compared to all other groups. This is not statistically significant after correction for multiple 
comparisons, however. Alcoholic pancreatitis group vs. 'alcoholic controls' (0.0 vs. 13.6%, 
Fisher's exact test, p=0.0095, Pc=O.l 05), non-alcoholic pancreatitis group vs. alcoholic 
'controls' (4.4 vs. 13.6%, Fisher's exact test, p=O.OI2, Pc=O.J32), normal control group vs. 
'alcoholic controls' ( 4. 7 vs. 13 .6%, Fisher's exact test, p=O.O 16, Pc=O. 176). 
240 
TNFabc haplotype 
a2b1c2 
a2b3cl 
a2b5c2 
a5b5c2 
a1b5c2 
a4b7c2 
a6b5c1 
a7b4cl 
a11b4cl 
a10b4cl 
a4b5bcl 
X 
Total chromosomes 
n 
Controls 
n=107 
% 
13.1 
(28) 
15.4 
(33) 
4.7 
(10) 
1.4 
(3) 
0.5 
(I) 
1.4 
(3) 
14.5 
(31) 
6.5 
(14) 
16.4 
(35) 
8.4 
(18) 
6.1 
(13) 
11.7 
(25) 
214 
Study patients 
n=135 
13.7 
(37) 
9.6 
(26) 
3.7 
(10) 
3.3 
(9) 
0.7 
(2) 
2.2 
(6) 
17.4 
(47) 
6.3 
(17) 
18.1 
(49) 
7.8 
(21) 
7.4 
(20) 
9.6 
(26) 
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Table 6.29 TNFabc haplotype frequency in control and patient groups 
Table shows TNFabc 3-locus haplotype frequency in normal controls and patient subjects. 
Haplotype analysis using 11 putative haplotypes previously characterised in Caucasian 
populations and confirmed in homozygous cell lines. 
For each haplotype the % frequency and the actual number of haplotypes (in brackets) is 
given. 
n represents the number of subjects in each group 
(n) represents the number of chromosomes in each group. 
X denotes unable to determine haplotype 
Comparisons were made for each haplotype between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. No significant differences were seen. 
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Local 
TNFabc 
Controls Mild Severe 
complication 
haplotype n=107 n=97 n=38 n=21 
0/o 0/o 0/o 0/o 
a2b1c2 13.1 13.4 14.5 11.9 
(28) (26) ( 11) (5) 
a2b3cl 15.4 9.8 9.2 9.5 
(33) (19) (7) (4) 
a2b5c2 4.7 3.1 5.3 7.1 
(10) (6) (4) (3) 
a5b5c2 1.4 2.6 5.3 7.1 
(3) (5) (4) (3) 
a1b5c2 0.5 0.5 1.3 2.4 
(1) (I) (1) (1) 
a4b7c2 1.4 2.1 2.6 2.4 
(3) (4) (2) (I) 
a6b5cl 14.5 18.0 15.8 21.4 
(31) (35) ( 12) (9) 
a7b4cl 6.5 6.2 6.6 4.8 
(14) ( 12) (5) (2) 
allb4c1 16.4 20.6 11.8 14.3 
(35) (40) (9) (6) 
a10b4c1 8.4 6.7 10.5 7.1 
(18) (13) (8) (3) 
a4b5bc1 6.1 7.7 6.6 7.1 
(13) ( 15) (5) (3) 
X 11.7 9.3 10.5 4.8 
(25) (18) (8) (2) 
Total 
chromosomes 214 194 76 42 
n 
Table 6.30 TNFabc haplotype frequency in control and acute pancreatitis patients 
grouped according to (local and systemic) disease severity 
Table shows TNFabc 3-locus haplotype frequency in normal controls and patient subjects 
grouped according to disease severity. 
Mild and severe disease severity groups are according to the Atlanta convention 
classification (Bradley, 1993), described in section 5. 1.4. 
Local complication is defined as occurrence of pancreatic necrosis, abscess or pseudocyst 
Haplotype analysis using 11 putative haplotypes previously characterised in Caucasian 
populations and confirmed in homozygous cell lines. 
For each haplotype the % frequency and the actual number of haplotypes (in brackets) is 
g1ven. 
n represents the number of subjects in each group 
(n) represents the number of chromosomes in each group. 
X denotes unable to determine haplotype 
Comparisons were made for each genotype between patient and control groups using 2x2 
contingency tables and the X 2 test. P values were corrected for the number of comparisons 
made. No significant differences were seen. 
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TNFabc 
Controls OFS~2 OFS~3 OFS~4 
haplotype n=107 n=35 n=18 n=12 
o;o o;o o;o o;o 
a2blc2 13.1 15.7 19.4 20.8 
(28) (11) {7) (5) 
a2b3cl 15.4 10.0 11.1 8.3 
(33) {7) (4) (2) 
a2b5c2 4.7 4.3 5.6 8.3 
{10) {3) (2) (2) 
a5b5c2 1.4 7.1 5.6 8.3 
(3) (5) (2) {2) 
alb5c2 0.5 0.0 0.0 0.0 
(1) (0) (0) {0) 
a4b7c2 1.4 1.4 0.0 0.0 
(3) (1) (0) (0) 
a6b5cl 14.5 14.3 16.7 20.8 
(31) (I 0) (6) (5) 
a7b4cl 6.5 5.7 11.1 4.2 
(14) (4) (4) (1) 
a11b4cl 16.4 12.9 5.6 8.3 
(35) (9) (2) (2) 
a10b4cl 8.4 10.0 16.7 12.5 
(18) (7) (6) (3) 
a4b5bcl 6.1 7.1 8.3 8.3 
(13) (5) (3) (2) 
X 11.7 11.4 0.0 0.0 
(25) {8) (0) (0) 
Total 
chromosomes 214 70 36 24 
n) 
Table 6.31 TNFabc 3-locus haplotype frequency in control and acute pancreatitis 
patients grouped according to (systemic) disease severity as assessed by 
organ failure score 
Table shows TNFabc 3-locus haplotype frequency in normal controls and subjects grouped 
according to maximal organ failure score for the disease episode. 
Haplotype analysis using 11 putative haplotypes previously characterised in Caucasian 
populations and confirmed in homozygous cell lines. 
For each haplotype the % frequency and the actual number of haplotypes (in brackets) is 
given. 
n represents the number of subjects in each group 
(n) represents the number of chromosomes in each group. 
X denotes unable to determine haplotype 
OFS Organ failure score 
OFS calculated according to method described in section 5.1.4 (Kingsnorth et al, 1995) 
Comparisons were made for each genotype between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. No significant differences were seen. 
243 
TNFabc 
haplotype 
a2b1c2 
a2b3c1 
a2b5c2 
a5b5c2 
a1b5c2 
a4b7c2 
a6b5cl 
a7b4cl 
allb4cl 
a10b4cl 
a4b5bc1 
X 
Total 
chromosomes 
n 
Controls 
n=l07 
o;o 
13.1 
(28) 
15.4 
(33) 
4.7 
(I 0) 
1.4 
(3) 
0.5 
(1) 
1.4 
(3) 
14.5 
(31) 
6.5 
( 14) 
16.4 
(35) 
8.4 
( 18) 
6.1 
(13) 
11.7 
(25) 
214 
Alcohol 
n=21 
o;o 
2.4 I 
(I) 
11.9 
(5) 
0.0 
(0) 
2.4 
(1) 
2.4 
(1) 
0.0 
(0) 
28.6 
(12) 
7.1 
(3) 
26.2 
(11) 
7.1 
(3) 
0.0 
(0) 
11.9 
(5) 
42 
Idiopathic Gallstones 
n=37 n=77 
o;o o;o 
20.3 13.6 
(IS) (21) 
6.8 10.4 
(5) ( 16) 
0.0 6.5 
(0) (I 0) 
4.1 3.2 
(3) (5) 
1.4 0.0 
(1) (0) 
1.4 3.2 
(1) (5) 
16.2 14.9 
( 12) (23) 
10.8 3.9 
(8) (6) 
14.9 17.5 
(!I) (27) 
8.1 7.8 
(6) ( 12) 
10.8 7.8 
(8) (12) 
5.4 11.0 
(4) (17) 
74 154 
Table 6.32 TNFabc 3-locus haplotype frequency in control and acute pancreatitis 
patients grouped according to aetiology of acute pancreatitis 
Table shows TNFabc 3-locus haplotype frequency in normal controls and subjects grouped 
according to disease aetiology. 
Haplotype analysis using 11 putative haplotypes previously characterised in Caucasian 
populations and confirmed in homozygous cell lines. 
For each haplotype the% frequency and actual number ofhaplotypes (brackets) is given. 
n represents the number of subjects in each group 
(n) represents the number of chromosomes in each group. 
X denotes unable to determine haplotype 
Alcoholic pancreatitis if daily consumption of~ 80g alcohol day"1 
Gallstones if radiological or ERCP evidence of cholelithiasis 
Idiopathic if no identifiable aetiology 
1. The TNF a2b 1 c2 haplotype shows a strong trend toward reduced frequency in the 
alcohol induced acute pancreatitis group compared to the two other aetiologies. This is 
not statistically significant after correction for multiple comparisons, however. 
Alcohol group vs. other aetiology, / =6.41, p=O.O 11, pc=0.13 
Alcohol group vs. normal controls, x2 =4.59,p=0.032, Pc=0.38 
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TNFabc 
haplotype 
a2b1c2 
a2b3c1 
a2b5c2 
a5b5c2 
a1b5c2 
a4b7c2 
a6b5cl 
a7b4cl 
allb4cl 
a10b4cl 
a4b5bcl 
X 
Total 
chromosomes 
n 
Controls 
n=l07 
% 
13.1 
(28) 
15.4 
(33) 
4.7 
(10) 
1.4 
(3) 
0.5 
(1) 
1.4 
(3) 
14.5 
(31) 
6.5 
(14) 
16.4 
(35) 
8.4 
(18) 
6.1 
(13) 
11.7 
(25) 
214 
Alcohol 
'controls' 
n=33 
% 
9.1 
(6) 
16.7 
(I) 
13.6 2 
(9) 
4.5 
(3) 
0.0 
(0) 
1.5 
(1) 
12.1 
(8) 
7.6 
(5) 
13.6 
(9) 
9.1 
(6) 
6.1 
(4) 
6.1 
(4) 
33 
Alcohol Not alcohol 
n=21 n=l14 
0/o o;o 
2.4 I 15.8 
(1) (36) 
11.9 9.2 
(5) (21) 
0.0 4.4 
(0) (I 0) 
2.4 3.5 
(1) (8) 
2.4 0.4 
(1) (1) 
0.0 2.6 
(0) (6) 
28.6 15.4 
( 12) (35) 
7.1 6.1 
(3) (14) 
26.2 16.7 
(11) (38) 
7.1 7.9 
(3) ( 18) 
0.0 8.8 
(0) (20) 
11.9 9.2 
(5) (21) 
42 228 
Table 6.33 TNFabc 3-locus haplotype frequency in normal controls, alcohol-
induced and non alcohol-induced acute pancreatitis patients, and 
alcoholic 'controls' 
Table shows TNFabc 3-locus haplotype frequency in normal controls and subjects groups. 
Haplotype analysis using 11 putative haplotypes previously characterised in Caucasian 
populations and confirmed in homozygous cell lines. 
For each haplotype the% frequency and the actual number ofhaplotypes (in brackets) is 
g1ven. 
n represents the number of subjects in each group 
(n) represents the number of chromosomes in each group. 
X denotes unable to determine haplotype. 
Alcoholic pancreatitis if daily consumption of~ 80g alcohol da/ 
Non-alcohol induced pancreatitis includes: 
• Gallstones if radiological or ERCP evidence of cholelithiasis 
• Idiopathic if no identifiable aetiology 
Comparisons were made for each genotype between patient and control groups using 2x2 
contingency tables and the x2 test, or Fisher's exact test if expected cell values were less 
than 5. P values were corrected for the number of comparisons made. 
I. The TNF a2b I c2 haplotype shows a strong trend toward reduced frequency in the 
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alcohol induced acute pancreatitis group compared to the two other aetiologies. This is 
not statistically significant after correction for multiple comparisons, however. 
Alcohol group vs. other non-alcoholic pancreatitis group, y} =5.39, p=0.02, Pc=0.22. 
Alcohol group vs. normal controls, X2 =4.59,p=0.032, Pc=0.38. 
When compared with the alcohol 'control' group however, the difference in frequency is 
much less marked. 
Alcohol group vs. 'alcoholic controls', Fisher's exact test, p=O.l6. 
2. The TNF a2b5c2 haplotype is present at higher frequency in the alcoholic 'control' 
group compared to all other groups. This is not statistically significant after correction 
for multiple comparisons, however. 
Alcohol group vs. 'alcoholic controls', Fisher's exact test, p=0.0095, Pc=O.l OS. 
Non-alcoholic pancreatitis group vs. 'alcoholic controls', Fisher's exact test, p=0.012, 
Pc=O.IJ2. 
Normal control group vs. 'alcoholic controls', Fisher's exact test, p=0.016, Pc=0.176. 
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6.5 TNF microsatellite 3-locus haplotypes (continued) 
When haplotype analysis is performed according to the ffequency of patients with at least 
one copy of a particular haplotype, a similar pattern is seen. Table 6.34 shows the ffequency 
(number) of patients with at least one copy of putative TNFabc 3-locus haplotype in normal 
controls, alcoholic 'controls', study patients, patients grouped according to severity of 
disease as assessed by the Atlanta classification, severity of disease as assessed by organ 
failure score, occurrence of a local complication, and aetiology of acute pancreatitis. 
Again, the TNF a2b 1 c2 haplotype shows a strong trend toward reduced frequency in the 
alcohol induced acute pancreatitis group compared to the two other aetiologies, and normal 
control groups. This is not statistically significant after correction for multiple comparisons, 
however. 
Alcoholic pancreatitis group vs. other aetiology (4.8 vs. 29.8%, ·l =6.76, p=0.009, 
pc=O.Il), alcoholic pancreatitis group vs. normal controls (4.8 vs. 24.3%, x2 =4.03, 
p=0.04S, Pc>O.S). When compared with the alcohol 'control' group however, the difference 
in ffequency is much less marked. Alcoholic pancreatitis group vs. 'alcoholic controls' (4.8 
vs 18.2%, Fisher's exact test, p=O. I SS). This is graphically represented in Fig 6.1. 
These differences in the a2 allele containing haplotype frequencies discussed above reflect 
the reduced carriage of the a2 allele in the alcoholic pancreatitis group. 
No significant differences were seen between controls and patient groups or between patient 
groups for any other haplotype. 
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Controls Study Mild Severe Local OFS;::: 2 OFS;::: 3 OFS;::: 4 Alcohol Idiopath. G\stones Alcoholic 
TNFabc patients complicn controls 
haplotype n=107 n=135 n=97 n=38 n=21 n=35 n=18 n=l2 n=21 n=37 n=77 n=33 
% % o/o 0/o o/o 0/o 0/o o/o 0/o 0/o 0/o % 
a2b1c2 24.3 25.9 24.7 28.9 23.8 31.4 38.9 41.7 4.8 I 37.8 26.0 18.2 
(26) (35) (24) (11) (5) ( 11) (7) (5) (I) (14) (20) (6) 
a2b3cl 29.0 20.0 20.6 18.4 19.0 20.0 22.2 16.7 23.8 13.5 22.1 24.2 
(3I) (27) (20) (7) (4) (7) (4) (2) (5) (5) ( 17) (8) 
a2b5c2 9.3 7.4 6.2 10.5 14.3 8.6 11.1 16.7 0.0 0.0 13.0 21.2 
(10) (10) (6) (4) (3) (3) (2) (2) (0) (0) (I 0) (7) 
a5b5c2 2.8 6.7 5.2 10.5 14.3 14.3 11.1 16.7 4.8 8.1 6.5 9.1 
(3) (9) (5) (4) (3) (5) (2) (2) (1) (3) (5) (3) 
a1b5c2 0.9 1.5 1.0 2.6 4.8 0.0 0.0 0.0 4.8 2.7 0.0 0.0 
(I) (2) (I) (1) (I) (0) (0) ()0 (I) (1) (0) (0) 
a4b7c2 1.9 4.4 4.1 5.3 4.8 2.9 0.0 0.0 0.0 2.7 6.5 3.0 
(2) (6) (4) (2) (1) (1) (0) (0) (0) (I) (5) (I) 
a6b5c1 27.1 32.6 34.0 28.9 38.1 28.6 33.3 41.7 52.4 32.4 27.3 24.2 
(29) (44) (33) ( II) (8) (10) (6) (5) (11) (I2) (21) (8) 
a7b4cl 13.1 11.1 11.3 10.5 9.5 8.6 16.7 8.3 14.3 18.9 6.5 15.2 
(I4) (IS) (11) (4) (2) (3) (3) (1) (3) (7) (5) (5) 
allb4c1 31.8 32.6 36.1 23.7 28.6 22.9 11.1 16.7 47.6 27.0 31.2 24.2 
(34) (44) (35) (9) (6) (8) (2) (2) (IO) (IO) (24) (8) 
a10b4cl 15.9 15.6 13.4 21.1 14.3 20.0 33.3 25.0 14.3 16.2 15.6 18.2 
(I7) (2I) (13) (8) (3) (7) (6) (3) (3) (6) (12) (6) 
a4b5bc1 11.2 14.8 15.5 13.2 14.3 14.3 16.7 16.7 4.8 21.6 14.3 12.1 
(I2) (20) (I 5) (5) (3) (5) (3) (2) (1) (8) ( II) (4) 
X 20.6 19.3 18.6 21.1 9.5 22.9 0.0 0.0 23.8 10.8 22.1 12.1 
(22) (26~ (I8) (8) ~2~ (8) (0) (0) ~5) (4) (17) (4~ 
Table 6.34 Frequency (number) of patients with at least one copy of putative TNFabc 3-locus haplotype (footnotes continued .... ) 
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Table 6.34 Frequency (number) of patients with at least one copy of putative TNFabc 3-locus haplotype 
Shows the frequency ofpossession of at least one copy of specific (putative) TNFabc 3-locus haplotype in 
• normal controls 
• study patients 
• patients grouped according to severity of disease as assessed by the Atlanta classification 
• severity of disease as assessed by organ failure score 
• occurrence of a local complication 
• aetiology of acute pancreatitis. 
Local complic" Local complication 
G/stones Gallstones 
OFS Organ failure score, calculated according to method described in section 5. 1.4 (Kingsnorth et al, 1995). 
Mild and severe disease severity groups are according to the Atlanta convention classification (Bradley, 1993), described in section 5 .1.4. 
Local complication is defined as occurrence of pancreatic necrosis, abscess or pseudocyst 
n represents the number of subjects in each group 
X denotes unable to determine haplotype 
Alcoholic pancreatitis if daily consumption of;:: 80g alcohol dai1 
Gallstones if radiological or ERCP evidence of cholelithiasis 
Idiopathic if no identifiable aetiology 
Haplotype analysis using 11 putative haplotypes previously characterised in Caucasian populations and confirmed in homozygous cell lines. 
For each haplotype the% frequency and the actual number ofhaplotypes (in brackets) is given. 
1 . Again, the TNF a2b 1 c2 haplotype shows a strong trend toward reduced frequency in the alcohol induced acute pancreatitis group compared to the two 
other aetiologies, and both control groups. This is not statistically significant after correction for multiple comparisons, however. 
Alcoholic pancreatitis group vs. other aetiology, l =6. 76, p=0.009, pc=0.11 
Alcoholic pancreatitis group vs. normal controls, l =4.03, p=0.045, Pc>0.5 
When compared with the alcohol 'control' group however, the difference in frequency is much less marked. 
Alcoholic pancreatitis group vs. 'alcoholic controls', Fisher's exact test, p=0.155 
This is graphically represented in Fig. 6.4. 
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Fig 6.4 Frequency(%) of individuals with the 3-locus TNFa2blc2 haplotype 
The TNF a2b 1 c2 haplotype shows a strong trend toward reduced frequency in the alcohol 
induced acute pancreatitis group compared to the two other aetiologies, and normal control 
groups. This is not statistically significant after correction fo r multiple comparisons, 
however. 
Alcoholic pancreatitis group vs. other aetiology, X2 =6.76, p=0.009, Pc=O. 11 
Alcoholic pancreatitis group vs. normal controls, x2 =4.03, p=0.045, Pc>0.5 
When compared with the alcohol 'control ' group however, the difference in frequency is 
much less marked. 
Alcoholic pancreatitis group vs. 'alcoholic controls', Fisher's exact test, p=O. 155 
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6.6 TNF microsatellite 3-locus genotypes 
Haplotypes, like individual alleles, combine in individuals to form haplotype 'genotypes. 
Table 6.35 shows TNFabc 3-locus genotypes in normal control and patient groups. Due to 
the number of possible different combinations, analysis of 3-locus genotypes is limited 
because of the small numbers of each combination present. No differences in 3-locus 
genotype numbers are seen between patient and normal control groups. Data showing 3-
locus genotypes for all the different patient subgroups is displayed in appendix I. 
251 
TNFabc haplotype 
combinations 
a2blc2- a2blc2 
a2blc2- all b4cl 
a2blc2- a6b5cl 
a2blc2- a10b4cl 
a2blc2- a2b3cl 
a2blc2- a7b4cl 
a2blc2- a2b5c2 
a2blc2- a5b5c2 
a2blc2- alb5c2 
a2blc2- a4b5cl 
a2blc2- a4b7c2 
a2blc2- X 
a2b3cl- a2b3cl 
a2b3cl- a7b4cl 
a2b3cl- a2b5b2 
a2b3cl- a5b5c2 
a2b3cl- a4b5cl 
a2b3cl- a4b7c2 
a2b3cl- X 
a2b5b2 - a4b5cl 
a2b5b2- X 
a5b5c2-a4b5cl 
a5b5c2- X 
a6b5cl- a6b5cl 
a6b5cl- a10b4cl 
a6b5cl- -a2b3cl 
a6b5cl- a7b4cl 
a6b5cl- a2b5c2 
a6b5cl- a5b5c2 
a6b5cl- a4b5cl 
a6b5cl- X 
a7b4cl- a7b4cl 
a7b4cl- a2b5c2 
Controls 
n=107 
n 
2 
4 
4 
4 
5 
2 
0 
1 
2 
0 
2 
5 
2 
3 
0 
0 
2 
2 
7 
2 
0 
0 
2 
0 
Study patients 
n=135 
n 
2 
3 
7 
3 
3 
4 
3 
1 
0 
2 
6 
0 
0 
3 
0 
3 
2 
0 
2 
3 
8 
6 
0 
2 
4 
3 
2 
Table 6.35 Number ofTNFabc 3-locus haplotype combinations in control 
and acute pancreatitis patient groups (continued ... ) 
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TNFabc haplotype 
combinations 
a7b4cl- alb5c2 
a7b4cl-alb5c2 
a7b4cl a4b5cl 
a7b4cl-a4b7c2 
a7b4cl- X 
allb4cl-allb4cl 
allb4cl-a6b5cl 
allb4cl-a10b4cl 
allb4cl-a2b3cl 
allb4cl-a7b4cl 
a 11 b4cl-a2b5c2 
a11b4c1-a5b5c2 
a 11 b4cl-a 1 b5c2 
a 11 b4cl-a4b5cl 
allb4cl-a4b7c2 
allb4cl-X 
a10b4c1-al0b4cl 
a10b4cl-a2b3cl 
a10b4cl-a2b5c2 
a10b4cl-a5b5c2 
a 1 Ob4cl-a4b5cl 
a10b4cl-X 
a4b5cl-a4b5cl 
a4b5c 1-a4b7 c2 
a4b5cl-X 
X-X 
0 
2 
3 
3 
0 
Table 6.35 Number of TNFabc 3-locus haplotype combinations in control 
and acute pancreatitis patient groups 
Table displays actual number ofTNFabc microsatellite 3-locus haplotype 
combinations in control and patient groups. 
Haplotype analysis using 11 putative haplotypes previously characterised in 
Caucasian populations and confirmed in homozygous cell lines. 
As can be seen, the numbers are too small for meaningful comparison, this is 
especially so between the patient groups. The data relating to haplotype combination 
frequency in the patient groups is therefore shown in appendix I. 
X unable to determine haplotype. 
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6. 7 Putative secretor status of TNFabc 3-locus microsatellite haplotypes 
Data concerning genetic variability in the TNF region affecting TNFa secretion levels by in 
vitro LPS stimulated monocytes has been extensively reviewed, re-evaluated and 
investigated by Weissensteiner and Lanchbury (1997). They have proposed associations 
between frequent Caucasian extended haplotypes involving the TNFabc microsatellite 
system and TNFa response. Combined experimental data was used to infer putative 
secretor status of extended haplotypes involving the TNFabc microsatellites from 
associations ofMHC markers in cell line and population studies. 
Table 6.36 details haplotypes determined by these authors as having a high, intermediate, or 
low TNFa secretor status. TNFa responses refer to experimental data in LPS stimulated 
monocytes. 
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TNFa. response 
phenotype in LPS 
stimulated monocytes 
Intermediate 
TNFabc 3-locus haplotype 
a2blc2 
a2b3cl 
a2b5c2 
a5b5c2 
alb5c2 
a4b7c2 
aSbScl 
a7b4cl 
allb4cl 
a10b4cl 
a4b5cl 
Table 6.36 Proposed associations between TNFabc 3-locus haplotypes and TNFa. 
secretor response 
Details proposed associations between TNFabc 3-locus haplotypes and TNFa. secretor 
response in LPS stimulated monocytes 
Weissensteiner and Lanchbury (1997) have proposed associations between frequent 
Caucasian extended haplotypes involving the TNFabc microsatellite system and TNFa. 
response. Combined experimental data was used to infer putative secretor status of 
extended haplotypes involving the TNFabc microsatellites from associations ofMHC 
markers in cell line and population studies. 
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6. 7 Putative secretor status of TNFabc 3-locus microsatellite haplotypes (continued) 
The proposed associations detailed in Table 6.36 have been used to analyse the populations 
of controls and acute pancreatitis patients. Table 6.37 details frequencies ofhaplotype 
groups proposed as high, low, or intermediate putative secretor status in control and patient 
subjects and patients groups according to disease severity according to the Atlanta 
classification and organ failure scores. No significant differences between patient and 
control groups are seen with regard to frequency of high, intermediate, or low secretor 
status. This type of analysis has it's limitations, as it does not consider what an individual's 
other haplotype is, or what effect it may have upon TNFa secretor phenotype. 
Table 6.38 shows frequencies of combinations of haplotype groups proposed as high, low, 
or intermediate putative secretor status in control and patient subjects and patients groups 
according to disease severity according to the Atlanta classification and organ failure scores. 
No significant differences between patient and control groups are seen with regard to 
frequency of high, intermediate, or low secretor status combinations. This type of analysis 
also has limitations, as no data exists as to whether there are dominant functional 
haplotypes, and what they may be. 
Table 6 39 shows frequencies of haplotype groups proposed as high, low, or intermediate 
putative secret or status in normal control, alcoholic 'control', and patient according to 
aetiology. There was a trend towards reduced frequency of the high secretor phenotype 
frequency in the alcoholic pancreatitis group. This only achieved conventional statistical 
significance when comparison was made with the alcoholic 'control' group. Alcoholic 
pancreatitis vs. normal control ( 19 vs. 35.5%, x2 =4.32, p=0,038, pc=0.15), alcoholic 
pancreatitis VS. other aetiology (19 VS. 36.0%, X2 =5.32, p=0,017, Pc=0.068), alcoholic 
pancreatitis VS. alcoholic 'controls' (19 VS. 45.5%, x2=7.85, p=0.0051, Pc=0.02). This 
mirrors the negative association of the a2 allele with alcoholic pancreatitis, as the a2 allele is 
classified as having high secretor status. 
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As mentioned above, this type of analysis has it's limitations, as it does not consider what an 
individual's other haplotype is, or what effect it may have upon TNFa secretor phenotype. 
Table 6. 38 shows frequencies of combinations of haplotype groups proposed as high, low, 
or intermediate putative secretor status in normal control, alcoholic 'control', and patient 
according to aetiology. 
There was a trend toward reduction in frequency of the High-Low secretor status 
combination in alcoholic pancreatitis patients. It does not achieve statistical significance. 
Alcoholic pancreatitis vs. normal controls (4.8 vs. 23.4%, Fishers exact test, p=0.04, 
p,=0.44), alcoholic pancreatitis vs. other aetiology (4 8 vs. 25.4%, Fishers exact test, 
p=0.026, p,=0.25), alcoholic pancreatitis vs. alcoholic 'controls' (4.8 vs. 27 3%, Fishers 
exact test, p=0.038, p,=0.38). 
As mentioned above this type of analysis has it's limitations as no data exists as to whether 
there are dominant functional haplotypes, and what they may be. 
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Controls Study Mild Severe Local OFS;;::2 OFS;;::3 OFS;;::4 
Putative patients complication 
haplotype n=107 n=135 n=97 n=38 n=21 n=35 n=18 n=12 
secretor status o;o % % % % o;o o;o o;o 
High (H) 35.5 33.3 31.4 38.2 38.1 37.1 41.7 45.8 
(76) (90) (61) (29) (I 6) (26) (15) ( 11) 
Intermediate (I) 22.0 23.3 24.2 21.1 26.2 20.0 27.8 25.0 (47) (63) (47) (I 6) (1 I) (14) (10) (6) 
Low (L) 31.8 32.6 33.5 30.3 31.0 30.0 30.6 29.2 (68) (88) (65) (23) (13) (21) (I I) (7) 
Undetermined (X) 10.7 10.7 10.8 10.5 4.8 12.9 0.0 0.0 (23) (29) (2 I) (8) (2) (9) (0) (0) 
Total number of 
chromosomes 214 270 194 76 42 70 36 24 
Table 6.37 Frequency of putative haplotype secretor status in controls and acute pancreatitis patients grouped according to disease severity 
Table shows putative haplotype secretor status frequency in controls and patients, and patients grouped according to disease severity as: 
• Mild or Severe (Atlanta classification) 
• Occurrence of a local complication (pancreatic necrosis, abscess or pseudocyst) 
• Organ failure scores (OFS), calculated according to method outlined in section 5 .1.4 (Kingsnorth et al, 1995). 
Haplotype analysis using 11 putative haplotypes previously characterised in Caucasian populations and confirmed in homozygous cell lines. Haplotypes have 
been determined as having high, low, or intermediate (TNFa) secretor phenotypes in response to LPS stimulation (Weissensteiner and Lanchbury 1997). An 
undetermined secretor status is due to being unable to assign a putative haplotype. 
For each haplotype the% frequency and the actual number ofhaplotypes in each specific secretor group (in brackets) is given. 
Comparisons were made for each secretor phenotype between patient and control groups using 2x2 contingency tables and the/ test. P values were corrected 
for the number of comparisons made. No significant differences between patient and control groups are seen. 
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Putative Controls Study patients Mild Severe Local OFS 2:2 OFS <:: 3 OFS 2:4 
haplotype complication 
secretor status n=107 n=135 n=97 n=38 n=21 n=35 n=18 n=12 
combination o/o 0/o o/o o;o 0/o 0/o 0/o 0/o 
H-H 13.1 9.6 9.3 10.5 4.8 8.6 16.7 25.0 
(14) (13) (9) (4) (1) (3) (3) (3) 
H-I 16.8 17.8 17.5 18.4 28.6 22.9 27.8 33.3 
(18) (24) ( 17) (7) (6) (8) (5) (4) 
H-L 23.4 22.2 20.6 26.3 38.1 20.0 22.2 8.3 
(25) (13) (20) (10) (8) (7) (4) (1) 
H-X 4.7 7.4 6.2 10.5 0.0 14.3 0.0 0.0 
(5) (1 0) (6) (4) (0) (5) (0) (0) 
I-I 3.7 3.7 3.1 5.3 4.8 2.9 5.6 0.0 
(4) (5) (3) (2) (1) (I) (1) (0) 
I-L 15.0 17.8 19.6 13.2 14.3 11.4 16.7 16.7 
(16) (24) (19) (5) (3) (4) (3) (2) 
I-X 4.7 3.7 5.2 0.0 0.0 0.0 0.0 0.0 
(5) (5) (5) (0) (0) (0) (0) (0) 
L-L 9.3 7.4 8.2 5.3 0.0 8.6 11.1 16.7 
(10) (10) (8) (2) (0) (3) (1) (2) 
L-X 6.5 10.4 10.3 10.5 9.5 11.4 0.0 0.0 
(7) (14) (1 0) (4) (2) (4) (0) (0) 
X-X 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
(3) (0) (0) (0) (0) (0) (0) (0) 
Table 6.38 Frequency of putative haplotype secretor status combination in controls and acute pancreatitis patients grouped 
according to disease severity 
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Table shows putative haplotype secretor status combination frequency in controls and patients, and patients grouped according to disease severity as: 
• Mild or Severe (Atlanta classification) 
• Occurrence of a local complication (pancreatic necrosis, abscess or pseudocyst) 
• Organ failure scores (OFS), calculated according to method outlined in section 5. 1.4, (Kingsnorth et al, 1995). 
Haplotype analysis using 11 putative haplotypes previously characterised in Caucasian populations and confirmed in homozygous cell lines. Haplotypes have 
been determined as having high, low, or intermediate (TNFa) secretor status in response to LPS stimulation (Weissensteiner and Lanchbury 1997). 
For each 'secretor status' haplotype combination the % frequency and the actual number in each specific secretor group (in brackets) is given. 
An undetermined secretor status is due to being unable to assign a putative haplotype. 
H- High TNFa secretor status 
L- Low TNFa secretor status 
I- Intermediate TNFa secretor status 
X-Undetermined TNFa secretor status 
Comparisons were made for each secretor group between patient and control groups using 2x2 contingency tables and the x2 test. P values were corrected for 
the number of comparisons made. No significant differences between patient and control groups are seen. 
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Controls Study patients 
n=135 Alcohol Idiopathic Gallstones 
Alcoholic 'controls' 
Putative 
haplotype 
secretor status 
High (H) 
Intermediate (I) 
Low (L) 
Undetermined (X) 
Total number of 
chromosomes 
n=l07 
35.5 
(76) 
22.0 
(47) 
31.8 
(68) 
10.7 
(23) 
214 
% 
33.3 
(90) 
23.3 
(63) 
32.6 
(88) 
10.7 
(29) 
270 
n=21 
0/o 
19.0 I 
(8) 
33.3 
(14) 
33.3 
(14) 
14.3 
(6) 
42 
n=37 n=77 n=33 
0/o 0/o % 
33.8 37.0 45.5 
(25) (57) (30) 
27.0 18.8 19.7 
(20) (29) (13) 
32.4 32.5 28.8 
(24) (50) (19) 
6.8 11.7 6.1 
(5) (18) (4) 
74 154 66 
Table 6.39 Frequency of putative haplotype secretor status in controls and patients grouped according to disease aetiology of acute pancreatitis 
Table shows putative haplotype secretor status frequency in controls, alcoholic 'controls', and patients, and patients grouped disease aetiology 
Alcoholic pancreatitis if daily consumption of~ 80g alcohol dai1 
Gallstones if radiological or ERCP evidence of cholelithiasis 
Idiopathic if no identifiable aetiology 
Haplotype analysis using 11 putative haplotypes previously characterised in Caucasian populations and confirmed in homozygous cell lines. Haplotypes have 
been determined as having high, low, or intermediate (TNFa) secretor phenotypes in response to LPS stimulation (Weissensteiner and Lanchbury 1997). 
For each group the % frequency and the actual number of haplotypes in each specific secretor group (in brackets) is given. 
An undetermined secretor status is due to being unable to assign a putative haplotype. 
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Comparisons were made for each secretor group between patient and control groups using 2x2 contingency tables and the x2 test. P values were corrected for 
the number of comparisons made. 
1. There was a trend towards reduced frequency of the high secretor status frequency in the alcoholic pancreatitis group. This only achieved statistical 
significance when comparison was made with the alcoholic 'control' group. 
Alcoholic pancreatitis vs. normal control, x2 =4.32, p=0,038, pc=0.15 
Alcoholic pancreatitis VS. other aetiology, X2 =5.32, p=O,Ol7, Pc=0.068 
Alcoholic pancreatitis vs. alcoholic 'controls', x2=7.85, p=0.005l, Pc=0.02 
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Putative Controls Study patients Alcohol Idiopathic Gallstones Alcoholic 'controls' 
haplotype 
secretor status n=107 n=135 n=21 n=37 n=77 n=33 
combination o/o o;o o;o o;o o;o % 
------------------------------------------------------------·--··········-----------------------------------------········-·----------------- --·---------------------------------
H-H 13.1 9.6 4.8 5.4 13.0 21.2 
(14) (13) (I) (2) (I 0) (7) 
H-1 16.8 17.8 19.0 27.0 13.0 15.2 
(18) (24) (4) (10) (I 0) (5) 
H-L 23.4 22.2 4,8 I 27.0 24.7 27.3 
(25) (13) (1) (10) (19) (9) 
H-X 4.7 7.4 4.8 2.7 10.4 6.1 
(5) (I 0) (1) (1) (8) (2) 
1-I 3.7 3.7 4.8 2.7 3.9 0.0 
(4) (5) (1) (!) (3) (0) 
1-L 15.0 17.8 33.3 16.2 14.3 18.2 
(16) (24) (7) (6) (11) (6) 
1-X 4.7 3.7 4.8 5.4 2.6 6.1 
(5) (5) (1) (2) (2) (2) 
L-L 9.3 7.4 4.8 8.1 7.8 6.1 
(10) (10) (1) (3) (6) (2) 
L-X 6.5 10.4 19.0 5.4 10.4 0.0 
(7) (14) (4) (2) (8) (0) 
X-X 2.8 0.0 0.0 0.0 0.0 0.0 
(3) ~0~ (0) (0) ~0~ (0) 
Table 6.40 Frequency of putative haplotype secretor status combination in controls and acute pancreatitis patients grouped according to disease 
severity 
(Footnotes next page ... ) 
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Table 6.40 Frequency of putative haplotype secretor status combination in controls and acute pancreatitis patients grouped according to disease 
severity 
Table shows putative haplotype secretor status combination frequency in controls and patients, and patients grouped disease aetiology 
Alcoholic pancreatitis if daily consumption of~ 80g alcohol day" 1 
Gallstones if radiological or ERCP evidence of cholelithiasis 
Idiopathic if no identifiable aetiology 
Haplotype analysis using 11 putative haplotypes previously characterised in Caucasian populations and confirmed in homozygous cell lines. Haplotypes have 
been determined as having high, low, or intermediate (TNFa) secretor status in response to LPS stimulation (Weissensteiner and Lanchbury 1997). 
For each 'secretor status' haplotype combination the% frequency and the actual number in each specific secretor group (in brackets) is given. 
An undetermined secretor status is due to being unable to assign a putative haplotype. 
H- High TNFa secretor status 
L- Low TNFa secretor status 
1- Intermediate TNFa secretor status 
X-Undetermined TNFa secretor status 
1. Trend toward reduction in frequency ofH-L combination in alcoholic pancreatitis patients. Does not achieve statistical significance 
Alcohol group vs. normal controls, Fishers exact test, p=0.04, pc=0.44 
Alcohol group vs. other aetiology, Fishers exact test, p=0.026, pc=0.25 
Alcoholic pancreatitis vs. alcoholic 'controls', Fishers exact test, p=0.038, Pc=0.38 
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6.8 TNF -308 locus typing 
Allelic and genotype frequencies at the TNF -308 locus within the TNFa. promoter were 
measured in 99 controls and 131 (97.0%) of patients. A PCR-SSP assay is shown in Figure 
6.5. 
Table 6.41 shows allelic frequencies of the -308 locus in patient and normal control 
subjects. No significant differences between patient and control groups are seen. 
Table 6.42 shows genotype frequencies of the -308 locus in patient and normal control 
subjects. No significant differences between patient and control groups are seen. 
The expected frequencies for TNF -308 genotypes were calculated. A 2 x n analysis 
showed that frequencies of heterozygotes and homozygotes in both study and normal 
control populations were in Hardy Weinberg equlilibrium. This is shown in Table 6.43. 
Tables 6.44 and 6.45 show allelic and genotype frequencies at the -308 locus in patient 
groups stratified according to disease severity classified according to the Atlanta 
classification and the occurrence of a local complication Tables 6.46 and 6.47 show allelic 
and genotype frequencies at the -308 locus in patient groups stratified according to organ 
failure score. 
There are no significant differences in the allelic or genotype frequencies of the TNF -308 
locus between the above patient groups. 
Tables 6.48 and 6.49 show allelic and genotype frequencies at the -308 locus in patient 
groups according to the aetiology of their disease. Tables 6.49 and 6.51 also show allelic 
and genotype frequencies at the -308 locus in patient groups according to the aetiology of 
their disease and alcoholic 'controls'. Again, there are no significant differences in the allelic 
or genotype frequencies of the TNF -3081ocus between the groups. 
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DirectiOn of 
n11grat10n 
Figure 6.5 PCR-SSP typing of the TNF-308 polymorphism 
PCR-SSP for 
-108TNF G 
PCR-SSP for 
-10&TI\F A 
Amplification of an 836 base pair (bp) fragment ofthe TNF promoter region was performed 
in two PCR-SSP reactions 
Primers for a 256 bp control amplicon from exon 15 of the adenomatous polyposis coli gene 
was included in the same reaction. Gels were electrophoresed for 20 minutes at 200V The 
gels were then photographed under UV light (320nm) and scored for the presence or 
absence of an allele specific band providing a PCR control band was present 
Lanes 1-9 show 9 samples each typed for both the -308 TNF.G and the -308T FA allele 
Lane I T F AA 
Lane 2 T F GA 
Lane 3 T F GG 
Lane 4: TNF.GG 
Lane 5: TNF.AA 
Lane 6 TNF GA 
Lane 7 TNF GG 
Lane 8: TNF.GA 
Lane 9 T F GA 
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TNF -308 allele 
Controls Study patients 
n=99 n=l31 
0/o % 
G 78.3 84.4 
(155) (221) 
A 21.7 15.6 
(43) ( 41) 
Total alleles (n) 198 262 
Table 6.41 TNF -308 allele frequencies in normal controls and acute pancreatitis 
patients 
This table displays TNF -308 allele frequencies in control and patient subjects. For each 
allele the % frequency and the actual number of alleles (in brackets) is given. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. 
No significant differences between patient and control groups are seen. 
TNF -308 genotype 
Controls 
n=99 
Study patients 
n=131 
0/o 0/o 
··--------·----------------- ------
GG 63.6 71.0 
(63) (93) 
GA 29.3 26.7 
(29) (35) 
AA 7.1 2.3 
(7) (3) 
Total 99 131 
Table 6.42 TNF -308 genotype frequencies in normal controls and acute 
pancreatitis patients 
This table displays TNF-308 genotype frequencies in control and patient subjects For each 
genotype the % frequency and their actual number (in brackets) is given 
n represents the number of subjects in each group 
Comparisons were made for each genotype between patient and control groups using 2x2 
contingency tables and the l test. P values were corrected for the number of comparisons 
made. No significant differences between patient and control groups are seen. 
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Expected Observed 
-308 Genotype 
n Freq. n Freq. 1..2 
Controls 
GG 60.7 61.3 63 63.6 0.1 
GA 33.6 34.0 29 29.3 0.6 
AA 4.7 4.7 7 7.1 n/a I 
Patients 
GG 93.3 71.2 93 73.3 0.0 
GA 34.5 26.3 35 26.7 0.0 
AA 3.2 2.4 3 2.3 n/a I 
Table 6.43 Frequency (%) of TNF -308 genotypes in patient and control subjects 
Showing expected and observed frequencies ofTNF -308 genotypes in patient and normal 
control subjects. Demonstrates that distribution conforms to Hardy-Weinberg equilibrium. 
1. Note that as expected value is less than 5, l test is not valid. 
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Local 
TNF-308 
Controls Mild Severe 
complication 
allele n=99 n=94 n=37 n=21 
o;o o;o % % 
G 78.3 84.6 83.8 83.3 
(155) ( 159) (62) (35) 
A 21.7 15.4 16.2 16.7 
(43) (29) ( 12) (7) 
Total alleles (n) 198 188 74 42 
Table 6.44 TNF -308 allele frequencies in normal controls and acute pancreatitis 
patients grouped according to (local and systemic) disease severity 
This table displays TNF -308 allele frequencies in control and patient sub-groups. For each 
allele the% frequency and the actual number of alleles (in brackets) is given. 
n represents the number of subjects in each group 
(n) represents the number ofalleles in each group. 
Mild and severe disease severity groups are according to the Atlanta convention 
classification (Bradley, 1993), described in section 5.1.4. 
Local complication is defined as occurrence of pancreatic necrosis, abscess or pseudocyst. 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the X2 test. P values were corrected for the number of comparisons 
made. 
No significant differences between patient and control groups are seen. 
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Controls Mild Severe Local 
TNF-308 complication 
genotype n=99 n=94 n=37 n=21 
o;o % o;o % 
GG 63.6 71.3 70.3 71.4 
(63) (67) (26) (IS) 
GA 29.3 26.6 27.0 23.8 
(29) (25) (10) (5) 
AA 7.1 2.1 2.7 4.8 
(7) (2) (1) (1) 
Total 99 37 74 21 
Table 6.45 TNF -308 genotype frequencies in normal controls and acute 
pancreatitis patients grouped according to (local and systemic) disease 
severity 
This table displays TNF -308 genotype frequencies in control and patient sub-groups. For 
each genotype the % frequency and their actual number (in brackets) is given. 
n represents the number of subjects in each group 
Mild and severe disease severity groups are according to the Atlanta convention 
classification (Bradley, 1993), described in section 5.1.4. 
Local complication is defined as occurrence of pancreatic necrosis, abscess or pseudocyst. 
Comparisons were made between patient and control groups using 2x2 contingency tables 
and the x2 test. P values were corrected for the number of comparisons made. 
No significant differences between patient and control groups are seen. 
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TNF-308 
Controls OFS;::>:2 OFS;::>:3 OFS;::>:4 
allele n=99 n=33 n=18 n=l2 
o;o % 0/o o;o 
G 78.3 84.8 86.1 83.3 
(155) (56) (31) (20) 
A 21.7 15.2 13.9 16.7 
(43) (I 0) (5) (4) 
Total alleles (n) 198 66 36 24 
Table 6.46 TNF -308 allele frequencies in normal controls and acute pancreatitis 
patients grouped according to (systemic) disease severity as assessed by 
organ failure score 
This table displays TNF -308 allele frequencies in control and patient group subjects. For 
each allele the % frequency and the actual number of alleles (in brackets) is given. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
OFS Organ failure score 
OFS calculated according to method described in section 5.1 A (Kingsnorth et al, 1995). 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. 
No differences are seen in the frequency of individual alleles between patient groups or 
between patient groups and controls. 
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TNF-308 
Controls OFS~2 OFS~3 OFS~4 
genotype n=99 n=33 n=l8 n=l2 
o;o % % o;o 
GG 63.6 72.7 77.8 75.0 
(63) (24) ( 14) (9) 
GA 29.3 24.2 16.7 16.7 
(29) (8) (3) (2) 
AA 7.1 3.0 5.6 8.3 
(7) (1) (1) (I) 
Total 99 33 18 12 
Table 6.47 TNF -308 genotype frequencies in normal controls and acute 
pancreatitis patients grouped according to (systemic) disease severity as 
assessed by organ failure score 
This table displays TNF-308 genotype frequencies in control and patient group subjects. For 
each genotype the % frequency and their actual number (in brackets) is given. 
n represents the number of subjects in each group 
OFS Organ failure score 
OFS calculated according to method described in section 5.1.4 (Kingsnorth et al, 1995). 
Comparisons were made between patient and control groups using 2x2 contingency tables 
and the x2 test. P values were corrected for the number of comparisons made. 
No differences are seen in the gene frequency between patient groups or between patient 
groups and controls. 
272 
TNF-308 Controls Alcohol Idiopathic Gallstones 
allele n=99 n=21 n=36 n=74 
% % o;o % 
G 78.3 88.1 88.9 81.1 
(!55) {37) (64) (120) 
A 21.7 11.9 11.1 18.9 
(43) (5) (8) (28) 
Total alleles (n) 198 42 72 148 
Table 6.48 TNF -308 allele frequencies in normal controls and acute pancreatitis 
patients grouped according to aetiology of acute pancreatitis 
This table displays TNF -308 allele ffequencies in control and patient group subjects. For 
each allele the % frequency and the actual number of alleles (in brackets) is given. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
Alcoholic pancreatitis if daily consumption of~ 80g alcohol da/ 
Gallstones if radiological or ERCP evidence of cholelithiasis 
Idiopathic if no identifiable aetiology 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. 
No differences are seen in the ffequency of individual alleles between patient groups or 
between patient groups and controls. 
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Controls Alcohol Idiopathic Gallstones 
TNF-308 
genotype n=99 n=21 n=36 
0/o % % 
GG 63.6 76.2 77.8 
(63) (16) (28) 
GA 29.3 23.8 22.2 
(29) (5) (8) 
AA 7.1 0.0 0.0 
(7) (0) (0) 
Total 99 21 36 
Table 6.49 TNF -308 genotype frequencies in normal controls and acute 
pancreatitis patients grouped according to aetiology of acute 
pancreatitis 
n=74 
% 
66.2 
(49) 
29.7 
(22) 
4.1 
(3) 
74 
This table displays TNF -308 genotype frequencies in control and patient group subjects. 
For each genotype the % frequency and their actual number (in brackets) is given. 
n represents the number of subjects in each group 
Alcoholic pancreatitis if daily consumption of:? 80g alcohol day" 1 
Gallstones if radiological or ERCP evidence of cholelithiasis 
Idiopathic if no identifiable aetiology 
Comparisons were made between patient and control groups using 2x2 contingency tables 
and the x2 test. P values were corrected for the number of comparisons made. 
No differences are seen in gene frequency between patient groups or between patient 
groups and controls. 
274 
Controls Alcohol Alcohol Not alcohol 
TNF-308 'controls' 
allele n=99 n=33 n=21 n=llO 
0/o 0/o 0/o % 
G 78.3 78.8 88.1 83.6 
(155) (52) (37) (184) 
A 21.7 21.2 11.9 16.4 
(43) (14) (5) (36) 
Total alleles (n) 198 66 42 220 
Table 6.50 TNF -308 allele frequencies in normal controls, alcohol-induced and 
non alcohol-induced acute pancreatitis patients, and alcoholic 'controls' 
This table displays TNF -308 allele frequencies in both control and patient group subjects. 
For each allele the % frequency and the actual number of alleles (in brackets) is given. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
Alcoholic pancreatitis if daily consumption of~ 80g alcohol da/ 
Non-alcohol induced pancreatitis includes: 
• Gallstones if radiological or ERCP evidence of cholelithiasis 
• Idiopathic if no identifiable aetiology 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the x.2 test. P values were corrected for the number of comparisons 
made. 
No differences are seen in the frequency of individual alleles between patient groups or 
between patient groups and controls. 
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Controls Alcohol Alcohol Not alcohol 
TNF-308 'controls' 
genotype n=99 n=33 n=21 n=llO 
0/o % 0/o 0/o 
GG 63.6 66.7 76.2 70.0 
(63) (22) (16) (77) 
GA 29.3 24.2 23.8 27.3 
(29) (8) (5) (30) 
AA 7.1 9.1 0.0 2.7 
(7) (3) (0) (3) 
Total 99 33 21 110 
Table 6.51 TNF -308 genotype frequencies in normal controls, alcohol-induced 
and non alcohol-induced acute pancreatitis patients, and alcoholic 
'controls' 
This table displays TNF -308 genotype frequencies in both control and patient group 
subjects. For each genotype the % frequency and their actual number (in brackets) is 
gtven. 
n represents the number of subjects in each group 
Alcoholic pancreatitis if daily consumption of~ 80g alcohol da/ 
Non-alcohol induced pancreatitis includes: 
• Gallstones if radiological or ERCP evidence of cholelithiasis 
• Idiopathic if no identifiable aetiology 
Comparisons were made between patient and control groups using 2x2 contingency tables 
and the X,2 test. P values were corrected for the number of comparisons made. 
No differences are seen in gene frequency between patient groups or between patient 
groups and controls. 
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6.9 TNF -308 I TNFabc microsatellite haplotypes. 
Alleles at the -308 locus have been shown to be in linkage disequilibrium with TNFabc 3-
locus microsatellite haplotypes. This has been discussed in section 4.1.4.3 (TNF region 
linkage and extended MHC haplotypes) and detailed in table 4.3. 
Analysis of patient and normal control populations in this study was also undertaken in this 
regard. 
Table 6.52 shows expected and observed frequencies ofTNF -308 I TNFabc microsatellite 
haplotypes in normal controls. Only associations with the -308.G allele are shown in this 
table. There was a negative association between allele -308.G and the a2b3cl haplotype Cl 
= 8.84, p=0.003). There was an association between allele -308.G and the a6b5cl 
haplotype Cl= 8.20, p=0.004). There was also a weaker association between allele -308.G 
and the allb4cl haplotype (x2=4.02, p=0.045). 
These associations were also present in the patient group, shown in table 6.53. Again, there 
was a negative association between the-308. G allele and the a2b3c 1 haplotype (x2 = 13. I, 
p=0.0003), and associations between the -308.G allele and a6b5cl (x2=6.0, p=O.Ol4), and 
allb4cl (x2 = 8.3, p=0.004). There was also an association between -308.G and the 
a2blc2 haplotype Cl=5.8, p=O.Ol6), and a negative association between the -308.G allele 
and the a4b5c I haplotype (x~=54, p=0.02). Both these latter two were not seen in the 
normal controls. All but two of these associations have been previously reported in 
Caucasian populations, as detailed in table 4.3, in section 4.1.4.3 (TNF region linkage and 
extended MHC haplotypes). The a6b5c I and a4b5c I associations are not reported in the 
literature reviewed in this work. 
It was not possible to determine haplotypes involving the -308.A allele, as not enough 
homozygotes were present. 
The issue ofhaplotypes involving the -308 A allele is addressed in tables 6.54 and 6.55 
(controls) and 6.56 and 6.57 (patients) As the majority of genotypes with the -308.A allele 
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(frequency 21. 7%) are heterozygotes, these tables demonstrate the association of an -308.A 
allele containing genotype with a TNFabc genotype containing the microsatellite haplotype 
TNFa2b3c1 or a4b5cl in normal controls and patients. These associations were tested 
because of the reported associations between allele -308.A and TNFa2b3c1, and due to the 
negative association found in this study of the -308.G allele with the haplotype a4b5cl. 
In normal controls a -308.GA or -308.AA genotype was associated with a 3-locus 
microsatellite genotype containing an a2b3c1 haplotype (X2 =19.2, p<O.OOOl). A weaker, 
non significant, association was found between -308.GA and -308.AA genotypes and a 3-
locus microsatellite genotype containing an a4b5c1 haplotype (Fisher's exact test, p=0.08). 
Likewise in the patient group, a -308.GA or -308.AA genotype was associated with a 3-
locus microsatellite genotype containing an a2b3c1 haplotype (X2 =35.4, p<O.OOO I). The 
association between -308.GA and -308.AA genotypes and a 3-locus microsatellite 
genotype containing an a4b5c I haplotype was significant in the patient group (x2 =23 J, 
p<0.0001 ). Although these finding do not prove allelic associations, because they involve 
genotypes, it strongly suggests allelic linkage. 
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-308.G I TNFabc Expected Observed 
haplotype 
n Freq. n Freq. "1.2 
G- a2blc2 14.8 10.3 19 13.2 1.19 
G- a2b3cl 17.4 12.1 5 3.5 8.84 I 
G- a2b5c2 5.2 3.6 8 5.6 1. 5 I 
G- a6b5cl 16.4 11.4 28 19.4 8.20 2 
G- a7b4cl 6.8 4.7 8 5.6 0.18 
G- allb4cl 18.4 12.8 27 18.8 4.02 3 
G- a10b4cl 9.5 6.6 15 10.4 3.18 
G- a4b5bcl 6.9 4.8 4 2.8 1.20 
G- other 3.6 2.5 3 2.1 0.10 
G-X 13.2 9.2 15 10.4 0.25 
Table 6.52 Frequency (%) of TNF -308.G I TNFabc microsatellite haplotypes in 
normal controls 
Table showing expected and observed frequencies ofTNF -308 I TNFabc microsatellite 
haplotypes. 
X - unable to determine haplotype 
1. x2 = 8.84, p=0.003, (negative association) 
2. x2 = 8.20, p=o.oo4 
3. x2=4.02, p=0.045 
Haplotype combinations able to be determined in 144/214 chromosomes (67.3%) 
It was not possible to determine haplotypes involving the -308.A allele, as not enough 
homozygotes were present. 
The issue ofhaplotypes involving the -308.A allele is addressed in tables 6.54 and 6.55. 
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-308.G I TNFabc Expected Observed 
haplotype 
n Freq. n Freq. x: 
-------------------·--·-·····-···-·-···-------------···-··--------------------------------··········-····--------------
G-a2blc2 21.0 10.5 32 16 5.8 I 
G- a2b3cl 15.0 7.5 0 5 13.1 2 
G- a2b5c2 6.0 3.0 7 3.5 0.7 
G- a6b5cl 25.6 12.8 38 19.0 6.0 3 
G- a7b4cl 9.0 45 17 8.5 3.8 
G- allb4cl 27.0 13.5 42 21.0 8.3 4 
G- a10b4cl 12.0 6.0 18 9.0 3.0 
G- a4b5bcl 10.6 5.3 3 1.5 5.4 5 
G- other 7.6 3.8 11 5.5 1.5 
G-X 16.6 8.3 22 11.0 1.8 
Table 6.53 Frequency(%) ofTNF -308.G I TNFabc microsatellite haplotypes in 
study patients 
Table showing expected and observed frequencies ofTNF -308 I TNFabc microsatellite 
haplotypes in study patients. 
X -unable to determine haplotype 
1. x2=5.8, p=O.Ol6 
2. x2 = 13.1, p=0.0003 (negative association) 
3. x2=6.o, p=0.014 
4. x2 = 8.3, p=0.004 
5. x"=5.4, p=0.02 (negative association) 
Haplotype combinations able to be determined in 2001270 chromosomes (74.1%) 
Patient subgroups are too small for meaningful analysis, as expected frequencies are less 
than 5 with most haplotypes. The exception is the group with gallstone -induced acute 
pancreatitis, but analysis gives very similar results to those seen with the study group as a 
whole, so data is not presented. 
It was not possible to determine haplotypes involving the -308.A allele, as not enough 
homozygotes were present. 
The issue ofhaplotypes involving the -308.A allele is addressed in tables 6.56 and 6.57. 
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-308.A I TNFabc Expected Observed 
genotype 
n Freq. n Freq. ·l 
-··-·--··· -----------·-·-· 
GIA. A- x. a2b3cl 9.5 I 0. I 23 24.5 19.20 I 
Gl A . A - x . other 24.0 26.0 17 18.1 2.04 
Table 6.54 Frequency(%) of -308.A allele occurring with a TNFabc genotype with 
at least one copy of the a2b3cl haplotype in normal controls 
As the majority of genotypes with the -308.A allele (frequency 21.7%) are heterozygotes, 
this table demonstrates the association of an -308.A allele with a TNFabc genotype 
containing the microsatellite haplotype TNFa2b3c I in normal controls. 
x/other - any genotype not containing a2b31 c 1 
I. x2 =19.2, p<O.OOOI 
-308.A I TNFabc Expected Observed 
genotype 
n Freq. n Freq. x2 
·-····--·-··--·-
G/A. A- x. a4b5cl 4.0 4.0 10 10.1 9.3 I 
G/A. A- x. other 31.7 32.0 26 26.3 1.0 
Table 6.55 Frequency(%) of -308.A allele occurring with a TNFabc genotype with 
at least one copy of the a4b5cl haplotype in normal controls 
As the majority of genotypes with the -308.A allele (frequency 21. 7%) are heterozygotes, 
this table demonstrates the association of an -308.A allele with a TNFabc genotype 
containing the microsatellite haplotype TNFa4b5cl in normal controls. 
x/other- any genotype not containing a4b5c I 
1. x2 =9.3, p=o.oo2 
It must be noted that as the expected value is <5, the ·l statistic is not valid. 
Fisher's exact test, p=0.08. 
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-308.A I TNFabc Expected Observed 
genotype 
n Freq. n Freq. ·l 
-------·-··--···--· ·---------· 
GIA. A- x. a2b3cl 7.6 5.8 24 18.3 35.4 I 
GIA. A- x. other 30.4 23.2 IS 11.4 7.8 2 
Table 6.56 Frequency(%) of -308.A allele occurring with a TNFabc genotype with 
at least one copy of the a2b3cl haplotype in study patients 
As the majority of genotypes with the -308.A allele (frequency 21.7%) are heterozygotes, 
this table demonstrates the association of an -308.A allele with a TNFabc genotype 
containing the microsatellite haplotype TNFa2b3c2 in study patients. 
x/other - any genotype not containing a2b31 c I 
I. x2 =35.4, p<O.OOOI 
2. X,2 =7.8, p=O.OOS (Negative association) 
-308.A I TNFabc 
genotype 
GIA. A- x. a4b5cl 
Gl A . A - x . other 
Expected 
n 
5.1 
32.9 
Freq. 
3.9 
25.1 
Observed 
n Freq. 
16 12.2 23.3 I 
23 17.5 3.0 
Table 6.57 Frequency(%) of -308.A allele occurring with a TNFabc genotype with 
at least one copy of the a4b5cl haplotype in study patients 
As the majority of genotypes with the -308.A allele (frequency 21. 7%) are heterozygotes, 
this table demonstrates the association of an -308.A allele with a TNFabc genotype 
containing the microsatellite haplotype TNFa4bSc I in study patients. 
xlother- any genotype not containing a4b5c I 
I. x2 =23.3, p<O.OOOI 
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6.10 TNF locus I HLA-DQBl associations 
As discussed in section 4.1.4.3 (TNF region linkage and extended MHC haplotypes) and 
detailed in table 4.3, alleles at the TNF loci are in linkage disequilibrium with MHC class I 
and II alleles. As HLA-DQB I typing was available in 70/107 (65.4%) of controls, 
associations between the -308 and TNFabc microsatellite loci were tested. 
Table 6.58 and 6.59 show that no associations were found between HLA-DQBI alleles and 
-308.G alleles. It was not possible to determine haplotypes involving the -308.A allele, as 
not enough homozygotes were present. 
Because oft he reported linkage between the -308.G allele and the HLA-DQB I *02 allelic 
group and the *020 I allele and the TNFb3 allele, the association between the 3-locus 
haplotype a2b3c I, and the 020 I allele was tested (a2b3c I associated with -308.A in this 
population). Because of the predominance ofheterozygotes at both loci, it was only 
possible to do this by looking for associations between genotypes occurring in individuals. 
As discussed above this does not prove allelic associations, but does strongly suggest them. 
Table 6.60 shows that there is an association between HLA-DQB I *0201 containing 
genotypes and 3 -locus TNFa2b3c I containing genotypes (Fisher's exact test, p=O. 00 I 5). 
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-308.G I HLA-DQB1 
haplotype 
G-"' 0201 
G-"' 0301 
G- * 0302 
G- * 0501 
G-" 0601 
Expected 
n 
16.3 
12.3 
9.4 
7.8 
7.4 
Freq. 
18.5 
14.0 
10.6 
8.9 
8.4 
Observed 
n Freq. 
16 18.2 0.0 
11 12.5 0.2 
10 11.4 0.0 
8 9.1 0.0 
10 11.4 1.6 
Table 6.58 Frequency(%) ofTNF -308.G I HLA-DQBl haplotypes in normal 
controls 
Table showing expected and observed frequencies ofTNF -308.G I HLA-DQB I 
haplotypes. No associations are seen. It was possible to determine haplotypes between the 
two loci in 88 chromosomes. 
It was not possible to determine haplotypes involving the -308.A allele, as not enough 
homozygotes were present. 
-308.G I HLA-DQBl 
haplotype 
n 
Expected 
Freq. 
Observed 
n Freq. 
-···-··-···-·· .. -· .. -···-··········-·--·--·-·-·-···--··---·---------·-·----------------
G- * 02 16.3 18.5 16 18.2 0.0 
G- * 03 26.6 30.2 28 31.8 0.1 
G- "05 9.9 11.2 11 12.5 0.1 
G- * 06 10.8 12.3 15 17.0 1.6 
G- * 011"04 5.5 6.3 10 11.4 
Table 6.59 Frequency(%) ofTNF -308.G I HLA-DQB1 allelic group haplotypes in 
normal controls 
Table showing expected and observed frequencies ofTNF -308.G I HLA-DQBlallelic 
group haplotypes. No associations are seen. It was possible to determine haplotypes 
between the two loci in 88 chromosomes. 
1. r! = 3.7, p=0.054. 
It was not possible to determine haplotypes involving the -308.A allele, as not enough 
homozygotes were present. 
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HLA-DQB1 I TNFabc Expected Observed 
genotype 
n Freq. n Freq. ·l 
X ."'0201- x. a2b3cl 4.5 6.4 I9 27.I 46.7 I 
X ."'0201- x. other II.6 16.5 14 20.0 0.5 
Table 6.60 Frequency (%) of a TNFabc genotype with at least one copy of the 
a2b3cl haplotype occurring with HLA-DQB1 genotype with a copy of 
the "'0201 allele in normal controls 
As the majority of genotypes at both loci are heterozygotes, this table demonstrates the 
association of an lll..A-DQBI *0201 allele containing genotype with a TNFabc genotype 
containing the microsatellite haplotype TNFa2b3cl in normal controls. It was possible to 
determine genotype combinations between the 2 loci in 70 individuals. 
xlother- any TNF haplotype except a2b3ci 
X - any lll..A-DQB I allele except *020 I 
I. x2 =46.7, 2 d.f, p<O.OOOI 
It must be noted that as the expected value is <5, the x2 statistic is not valid. 
Fisher's exact test (rounding expected value up to 5.0), p=0.0015. 
This strongly suggests linkage between lll..A-DQB 1 *020 I and TNFa2b3c I. 
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6.11 IL-lO.G microsatellite alleles 
Allelic frequencies of the IL-10.G microsatellite were measured in 100% of patients and a 
group of 136 normal controls. 11 of 15 previously described alleles were observed in the 
population studied (Figure 6.6). Table 6.61 shows the allelic frequencies in normal control 
and acute pancreatitis subjects. Table 6.62 shows allelic frequencies in patient groups 
stratified according to disease severity classified according to the Atlanta classification and 
the occurrence of a local complication. Tables 6.63 shows alleles inpatient groups stratified 
according to organ failure score. 
There are no statistically significant differences in the allelic frequencies IL-l 0. G locus when 
comparing all acute pancreatitis patients with controls or when patients grouped according 
to disease course (mild vs. severe, mild vs. OFS2:2, mild vs. OFS2:3, mild vs. OFS2:4) were 
compared. There was a slight increased frequency of IL-l 0. G 13 in the severe group 
compared to those patients with mild acute pancreatitis, however the difference does not 
reach statistical significance (26.3 vs. 17%, x2 =3 .0, p=0.08). This was mirrored by an 
increased frequency (23 .8%) of the IL-l O.G allele in the group who had a local 
complication. 
The distribution of all alleles between controls and patients was also not different (analysis 
excluding alleles with control frequencies less than 5), x2=8.04, 10 d. f., p=0.625. 
Patients were stratified according to aetiology of acute pancreatitis comparing between 
groups and with normal controls and alcoholic 'controls', and allelic frequencies are shown 
in tables 6.64 and 6.65. There was a reduction in the frequency ofthe IL-10.G13 allele in 
patients with alcoholic pancreatitis compared to normal controls (4.8 vs 21.3%, x2 =6.46, 
p=O.O 11, Pc=O.l2), non-alcoholic pancreatitis (4.8 vs. 22.2%, x2 =6.97, p= .008,pc=0.088), 
and the group of alcoholic 'controls' (4.8 VS. 22.8%, x2=6.25, p=O.Ol2, Pc=O.l3). None of 
these remained significant after correction for multiple comparisons. 
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Direction 
of 
migration 
' Liln.~: 1. 
::·.·.-::.-:·:·:· ..... 
Figure 6.6 IL-lO.G microsatellite autoradiograph 
··--IL-IO.Gl 5 
--IL-IO.Gl3 
--1L- IO.G9 
Amplification of a region containing the microsatellite was performed as described in 
section 5.5. Amplification products (6J..LI) mixed with 3J..LI of Stop solution containing 
Formamide (Amersham Life Science, Buckinghamshire, UK) are separated on a 6% 
polyacrylamide gel with 8M urea at 1700V for 2.5 hours, and alleles revealed with 
autoradiography. 
IL- l 0. G has 15 previously descibed alleles. Alleles were assigned by the identification of the 
most common allele in Europid populations, allele 9. Identification of alleles was also 
confirmed by running with a radiolabelled 123 base pair ladder, as allele 4 amplified using 
this assay is 123 bp in length. Individual alleles differ by one base pair repeat. 
Alleles IL-10.G9, IL- lO.GlJ , and IL-10.Gl 5 are labelled in this figure. Genotypes for each 
of the samples shown in lanes 1-9 are as follows: 
Lanel : 10, 13 
Lane2: 9, 12 
LaneJ : 9,10 
Lane4: 10, I I 
LaneS: 9, 15 
Lane6: 9,14 
Lane7: 9, 11 
Lane8: 9,13 
Lane9: 9,9 
LaneiO: 9,9 
Lane 11 : 9, 13 
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IL-10.G allele 
Controls Study patients 
n=136 n=135 
o;o % 
4 0.4 0.0 
(I) (0) 
5 0.0 0.4 
(0) (1) 
7 2.9 1.1 
(8) (3) 
8 1.8 3.3 
(5) (9) 
9 43.8 41.9 
(119) ( 113) 
10 7.7 7.4 
(21) (20) 
11 8.1 11.1 
(22) (30) 
12 4.8 7.4 
(13) (20) 
13 21.3 19.6 
(58) (53) 
14 8.8 6.3 
(24) (17) 
15 0.4 1.5 
(1) (4) 
Total alleles(n) 272 270 
Table 6.61 IL-lO.G microsatellite allele frequencies in normal controls and 
acute pancreatitis patients 
This table displays IL-10.G microsatellite allele frequencies in control and patient 
subjects. For each allele the % frequency and the actual number of alleles (in 
brackets) is given. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the / test. P values were corrected for the number of 
comparisons made. 
No statistically different differences in individual alleles are seen between the control 
and patient subjects. 
The distribution of all alleles between controls and patients was also not different 
(analysis excluding alleles with control frequencies less than 5), x2=8.04, I 0 d.f., 
p=0.625. 
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Local 
IL-lO.G allele Controls Mild Severe complication 
n=l36 n=97 n=38 n=21 
% o;o o;o o;o 
4 0.4 0.0 0.0 0.0 
(1) (0) (0) (0) 
5 0.0 0.5 0.0 0.0 
(0) (I) (0) (0) 
7 2.9 1.0 1.3 2.4 
(8) (2) (1) (1) 
8 1.8 4.1 1.3 2.4 
(S) {8) (1) (I) 
9 43.8 41.8 42.1 40.5 
( 119) {73) (32) ( 17) 
10 7.7 8.8 3.9 4.8 
(21) (17) (3) (2) 
11 8.1 12.4 7.9 7.1 
(22) (24) (6) (3) 
12 4.8 8.2 5.3 7.1 
(13) {16) (4) (3) 
13 21.3 17.0 26.3 I 23.8 
(58) (33) (20) (I 0) 
14 8.8 5.2 9.2 7.1 
{24) {I 0) (7) (3) 
15 0.4 1.0 2.6 4.8 
{I) (2) (2) (2) 
Total alleles( n) 272 194 76 42 
Table 6.62 IL-10.G microsatellite allele frequencies in normal controls and acute 
pancreatitis patients grouped according to (local and systemic) disease 
severity 
This table displays IL-IO.G microsatellite allele frequencies in control and patient group 
subjects. For each allele the % frequency and the actual number of alleles (in brackets) is 
gtven. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
Mild and severe disease severity groups are according to the Atlanta convention 
classification (Bradley, 1993), described in section 5.1.4. 
Local complication is defined as occurrence of pancreatic necrosis, abscess or pseudocyst. 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the x2 test P values were corrected for the number of comparisons. 
I. Increased frequency of IL-l O.G 13 in severe vs. mild group, however does not reach 
statistical significance, x2 =3.0, p=0.08 
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IL-10.G allele 
Controls OFS ~2 OFS~3 OFS~4 
n=136 n=35 n=18 n=12 
0/o 0/o 0/o 0/o 
4 0.4 0.0 0.0 0.0 
(I) (0) (0) (0) 
5 0.0 0.0 0.0 0.0 
(0) (0) (0) (0) 
7 2.9 0.0 0.0 0.0 
(8) (0) (0) (0) 
8 1.8 1.4 0.0 0.0 
(5) (1) (0) (0) 
9 43.8 41.4 50.0 50.0 
( 119) (29) (18) ( 12) 
10 7.7 2.9 2.8 4.2 
(21) (2) (1) (1) 
11 8.1 11.4 5.6 4.2 
(22) (8) (2) (1) 
12 4.8 5.7 2.8 4.2 
(13) (4) (I) (I) 
13 21.3 27.1 25.0 25.0 
(58) (19) (9) (6) 
14 8.8 8.6 13.9 12.5 
(24) (6) (5) (3) 
15 0.4 1.4 0.0 0.0 
(1) (1) (0) (0) 
Total alleles(n) 272 70 36 24 
Table 6.63 ILl-.G microsatellite allele frequencies in normal controls and acute 
pancreatitis patients grouped according to (systemic) disease severity as 
assessed by organ failure score 
This table displays IL-l 0. G microsatellite allele frequencies in control and patient group 
subjects. For each allele the% frequency and the actual number of alleles (in brackets) is 
given. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
OFS Organ failure score 
OFS calculated according to method described in section 5.1 A (Kingsnorth et al, 1995). 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. 
No differences are seen in the frequency of individual alleles between patient groups or 
between patient groups and controls_ 
290 
IL-10.G allele Controls 
Alcohol Idiopathic Gallstones 
n=l36 n=21 n=37 n=77 
0/o 0/o 0/o % 
4 0.4 0.0 0.0 0.0 
(I) (0) (0) (0) 
5 0.0 0.0 0.0 0.6 
(0) (0) (0) (1) 
7 2.9 0.0 1.4 1.3 
(8) (0) (I) (2) 
8 1.8 9.5 4.1 1.3 
(5) (4) (3) (2) 
9 43.8 47.6 36.5 42.9 
( 119) (20) (27) (66) 
10 7.7 19.0 6.8 4.5 
(21) (8) (5) (7) 
11 8.1 11.9 12.2 10.4 
(22) (5) (9) ( 16) 
12 4.8 2.4 8.1 8.4 
(13) (1) (6) (13) 
13 21.3 4.8 I 21.6 22.7 
(58) (2) (16) (35) 
14 8.8 2.4 9.5 5.8 
(24) (1) (7) (9) 
15 0.4 2.4 0.0 1.9 
(1) (I) (0) (3) 
Total alleles(n) 272 42 74 154 
Table 6.64 IL-IO.G microsatellite allele frequencies in normal controls and acute 
pancreatitis patients grouped according to aetiology of acute 
pancreatitis 
This table displays 1L-10.G microsatellite allele frequencies in control and patient group 
subjects. For each allele the% frequency and the actual number of alleles (in brackets) is 
given. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
Alcoholic pancreatitis if daily consumption of~ 80g alcohol da/ 
Gallstones if radiological or ERCP evidence of cholelithiasis 
Idiopathic if no identifiable aetiology 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. 
1. There was a trend towards reduced frequency of the IL-l 0. G 13 allele in patients with 
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alcohol induced acute pancreatitis, although this did not achieve conventional statistical 
significance. 
Controls vs. alcohol group, X2 =6.46, p=O.O ll, Pc=O 12 
Alcohol vs. idiopathic and gallstone groups combined, X2 =6.97, p= 0 008, pc=0.088 
The reduction in the G 13 allele in the alcoholic group was not accounted for by an 
increase in any one allele. 
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Controls Alcohol Alcohol Not alcohol 
IL-1 O.G allele 'controls' 
n=136 n=52 n=21 n=114 
o/o 0/o % % 
4 0.4 0.0 0.0 0.0 
(1) (0) (0) (0) 
5 0.0 0.0 0.0 0.4 
(0) (0) (0) (I) 
7 2.9 1.5 0.0 1.3 
(8) (I) (0) (3) 
8 1.8 3.0 9.5 2.2 
(5) (2) (4) (5) 
9 43.8 40.9 47.6 40.8 
( II9) (27) (20) (93) 
10 7.7 9.1 19.0 5.3 
(2I) (6) (8) (12) 
11 8.1 1.3.6 11.9 11.0 
(22) (9) (5) (25) 
12 4.8 7.6 2.4 8.3 
(13) (5) (1) (19) 
13 21.3 22.7 4.8 I 22.4 
(58) ( 15) (2) (51) 
14 8.8 1.5 2.4 7.0 
(24) (1) (1) (16) 
15 0.4 0.0 2.4 1.3 
(1) (0) (I) (3) 
Total alleles(n) 272 66 42 228 
Table 6.65 IL-l O.G microsatellite allele frequencies in normal controls, alcohol-
induced and non alcohol-induced acute pancreatitis patients, and 
alcoholic 'controls' 
This table displays fL-1 O.G microsatellite allele frequencies in both control and patient 
group subjects. For each allele the% frequency and the actual number of alleles (in 
brackets) is given. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
Alcoholic pancreatitis if daily consumption of:?: 80g alcohol day" 1 
Non-alcohol induced pancreatitis includes: 
• Gallstones if radiological or ERCP evidence of cholelithiasis 
• ldiopathic if no identifiable aetiology 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. 
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1. There was a strong trend towards reduced frequency ofthe IL-10.G13 allele in patients 
with alcohol induced acute pancreatitis, although this did not achieve conventional 
statistical significance. 
Controls vs. alcohol group, l =6.46, p=0.011, Pc=0.12 
Alcohol vs. idiopathic and gallstone groups combined, l =6.97, p=0.008,pc=0.088 
Alcohol vs. 'alcohol controls', x2=6.25, p=0.012, Pc=0.13 
The reduction in the G 13 allele in the alcoholic group was not accounted for by an 
increase in any one allele. 
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6.12 IL-lO.G microsatellite genotypes 
Due to the number of alleles, there are many possible LL-1 0. G microsatellite genotypes. 
This limits analysis of genotype distribution because of very small numbers. IL-IO.G 
genotypes in normal control and patients are displayed in Tables 6.66. Genotypes in patient 
groups stratified according to disease severity classified according to the Atlanta 
classification and the occurrence of a local complication are shown in Tables 6.67. No 
significant differences were seen between controls and patient groups or between patient 
groups. 
Tables 6.68 show genotypes in patient groups stratified according to organ failure score. No 
significant differences were seen between controls and patient groups or between patient 
groups. 
Tables 6. 69 and 6. 70 show IL-l 0. G genotypes in patient groups stratified according 
aetiology of acute pancreatitis, and alcoholic 'controls'. No significant differences were seen 
between controls and patient groups or between patient groups. 
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IL-lO.G genotype 
4,9 
5,11 
7,9 
7,10 
7,11 
7,12 
7,13 
8,9 
8,10 
8,11 
8,12 
8,13 
8,14 
9,9 
9,10 
9,11 
Controls 
n=l36 
o;o 
0.7 
(1) 
0.0 
(0) 
1.5 
(2) 
0.7 
(1) 
1.5 
(2) 
1.5 
(2) 
0.7 
(1) 
2.2 
(3) 
0.0 
{0) 
0.0 
(0) 
0.0 
(0) 
1.5 
(2) 
0.0 
(0) 
17.6 
(24) 
5.9 
(8) 
5.9 
(8) 
Study patients 
n=135 
o;o 
0.0 
(0) 
0.7 
(1) 
0.7 
(1) 
0.0 
(0) 
0.0 
(0) 
1.5 
(2) 
0.0 
(0) 
1.5 
(0) 
2.2 
(3) 
0.7 
(1) 
1.5 
(2) 
0.0 
(0) 
0.7 
(1) 
15.6 
(21) 
4.4 
(6) 
12.6 
(17) 
Table 6.66 Genotypes at the IL-10.G microsatellite locus in normal control and 
patient groups 
(continued ..... ) 
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IL-IO.G genotype 
Controls Study patients 
n=l36 n=135 
% 0/o 
9,12 3.7 5.2 
(5) (7) 
9,13 25.0 20.7 
(34) (28) 
9,14 6.6 5.9 
(9) (8) 
9,15 0.7 1.5 
(1) (2) 
10,10 0.0 1.5 
(0) (2) 
10,11 3.7 0.0 
(5) (0) 
10,12 0.0 0.7 
(0) (I) 
10,13 2.9 2.2 
(4) (3) 
10,14 2.2 1.5 
(3) (2) 
10,15 0.0 0.7 
(0) (1) 
11,11 0.0 1.5 
(0) (2) 
11,12 1.5 0.7 
(2) (I) 
11,13 2.9 3.7 
(4) (5) 
11,14 0.7 0.7 
(1) (I) 
12,12 0.0 1.5 
(0) (2) 
12,13 0.7 1.5 
(1) (2) 
Table 6.66 Genotypes at the JL.IO.G microsatellite locus in normal control and 
patient groups 
(continued... ) 
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IL-IO.G genotype 
Controls Study patients 
n=136 n=135 
o;o o;o 
12,14 2.2 0.7 
(3) (1) 
13,13 2.2 4.4 
(3) (6) 
13,14 4.4 2.2 
(6) (3) 
14,14 0.7 0.0 
(1) (0) 
14,15 0.0 0.7 
(0) (1) 
Total 136 135 
Table 6.66 Genotypes at the IL-10.G microsatellite locus in normal control and 
patient groups 
This table displays IL-l 0. G microsatellite genotype frequencies in control and patient 
subjects. For each genotype the% frequency and the actual number of genotypes (in 
brackets) is given. 
Comparisons were made for each genotype between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. 
No significant differences were seen in genotype frequencies between patient and control 
groups. 
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Controls Mild Severe Local 
IL-IO.G complication 
genotype n=136 n=97 n=38 n=21 
0/o 0/o 0/o % 
4,9 0.7 0.0 0.0 0.0 
(I) (0) (0) (0) 
5,11 0.0 1.0 0.0 0.0 
(0) (1) (0) (0) 
7,9 1.5 0.0 2.6 4.8 
(2) (0) (1) (1) 
7,10 0.7 0.0 0.0 0.0 
(1) (0) (0) (0) 
7,11 1.5 0.0 0.0 0.0 
(2) (0) (0) (0) 
7,12 1.5 2.1 0.0 0.0 
(2) (2) (0) (0) 
7,13 0.7 0.0 0.0 0.0 
(1) (0) (0) (0) 
8,9 2.2 1.0 2.6 4.8 
(3) (1) (1) (1) 
8,10 0.0 3.1 0.0 0.0 
(0) (3) (0) (0) 
8,11 0.0 1.0 0.0 0.0 
(0) (1) (1) (0) 
8,12 0.0 2.1 0.0 0.0 
(0) (2) (0) (0) 
8,13 1.5 0.0 0.0 0.0 
(2) (0) (0) (0) 
8,14 0.0 1.0 0.0 0.0 
(0) (1) (0) (0) 
9,9 17.6 17.5 10.5 9.5 
(24) (17) (4) (2) 
9,10 5.9 6.2 0.0 0.0 
(8) (6) (0) (0) 
9,11 5.9 11.3 15.8 14.3 
(8) (11) (6) (3) 
Table 6.67 Genotypes at the IL-lO.G microsatellite locus in normal control and 
acute pancreatitis patients grouped according to (local and systemic) 
disease severity 
(continued ........ ) 
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Controls Mild Severe Local lL-10.G complication 
genotype n=136 n=97 n=38 n=21 
% o;o % % 
9,12 3.7 6.2 2.6 0.0 
(5) (6) (1) (0) 
9,13 25.0 18.6 26.3 23.8 
(34) (18) (10) (5) 
9,14 6.6 4.1 10.5 9.5 
(9) (4) (4) (2) 
9,15 0.7 1.0 2.6 4.8 
(1) {1) (1) (1) 
10,10 0.0 2.1 0.0 0.0 
(0) (2) (0) {0) 
10,11 3.7 0.0 0.0 0.0 
(5) (0) (0) (0) 
10,12 0.0 0.0 2.6 4.8 
(0) (0) (1) (1) 
10,13 2.9 3.1 0.0 0.0 
(4) (3) (0) (0) 
10,14 2.2 1.0 2.6 0.0 
(3) (I) (1) (0) 
10,15 0.0 0.0 2.6 4.8 
(0) (0) (1) (1) 
11,11 0.0 2.1 0.0 0.0 
(0) (2) (0) (0) 
11,12 1.5 1.0 0.0 0.0 
(2) (I) (0) (0) 
ll,13 2.9 5.2 0.0 0.0 
(4) (5) (0) (0) 
11,14 0.7 1.0 0.0 0.0 
(1) (I) {0) (0) 
12,12 0.0 2.1 0.0 0.0 
(0) (2) (0) (0) 
12,13 0.7 1.0 2.6 4.8 
(I) (I) (I) (I) 
Table 6.67 Genotypes at the IL-10.G microsatellite locus in normal control and 
acute pancreatitis patients grouped according to (local and systemic) 
disease severity 
(continued ......... ) 
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Local 
IL-lO.G 
Controls Mild Severe 
complication 
genotype n=136 n=97 n=38 n=21 
0/o 0/o % % 
12,14 2.2 0.0 2.6 4.8 
(3) (0) (1) (I) 
13,13 2.2 2.1 10.5 9.5 
(3) (2) (4) (2) 
13,14 4.4 2.1 2.6 0.0 
(6) (2) (1) (0) 
14,14 0.7 0.0 0.0 0.0 
(I) (0) (0) (0) 
14,15 0.0 1.0 0.0 0.0 
(0) (I) (0) (0) 
Total 136 97 38 21 
Table 6.67 Genotypes at the IL-10.G microsatellite locus in normal control and 
acute pancreatitis patients grouped according to (local and systemic) 
disease severity 
This table displays IL-l 0. G microsatellite genotype frequencies in control and patient 
groups. For each genotype the % frequency and the actual number of genotypes (in 
brackets) is given. 
Mild and severe disease severity groups are according to the Atlanta convention 
classification (Bradley, 1993), described in section 5.1.4. 
Local complication is defined as occurrence of pancreatic necrosis, abscess or pseudocyst. 
Comparisons were made for each genotype between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. 
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IL-IO.G 
Controls OFS~2 OFS~3 OFS~4 
genotype n=136 n=35 n=18 n=12 
o;o o/o o;o o/o 
4,9 0.7 0.0 0.0 0.0 
(I) (0) (0) (0) 
5,11 0.0 0.0 0.0 0.0 
(0) (0) (0) (0) 
7,9 1.5 0.0 0.0 0.0 
(2) (0) (0) (0) 
7,10 0.7 0.0 0.0 0.0 
(1) (0) (0) (0) 
7,11 1.5 0.0 0.0 0.0 
(2) (0) (0) (0) 
7,12 1.5 0.0 0.0 0.0 
(2) (0) (0) (0) 
7,13 0.7 0.0 0.0 0.0 
(1) (0) (0) (0) 
8,9 2.2 2.9 0.0 0.0 
(3) (1) (0) (0) 
8,10 0.0 0.0 0.0 0.0 
(0) (0) (0) (0) 
8,11 0.0 0.0 0.0 0.0 
(0) (0) (0) (0) 
8,12 0.0 0.0 0.0 0.0 
(0) (0) (0) (0) 
8,13 1.5 0.0 0.0 0.0 
(2) (0) (0) (0) 
8,14 0.0 0.0 0.0 0.0 
(0) (0) (0) (0) 
9,9 17.6 8.6 16.7 16.7 
(24) (3) (3) (2) 
9,10 5.9 0.0 0.0 0.0 
(8) (0) (0) (0) 
9,ll 5.9 17.1 11.1 8.3 
(8) (6) (2) (I) 
Table 6.68 IL-lO.G genotype frequencies in normal controls and acute pancreatitis 
patients grouped according to (systemic) disease severity as assessed by 
organ failure score 
(continued ....... ) 
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IL-10.G 
Controls OFS;::: 2 OFS<=:3 OFS <=: 4 
genotype n=136 n=35 n=18 n=12 
o;o % o;o o;o 
···-···--------------------------------------·--·-············-·-········------·········-···--------------------------------·-----
9,12 3.7 2.9 0.0 0.0 
(5) (I) (0) (0) 
9,13 25.0 28.6 33.3 41.7 
(34) (I 0) (6) (5) 
9,14 6.6 11.4 22.2 16.7 
(9) (4) (4) (2) 
9,15 0.7 2.9 0.0 0.0 
(1) (I) (0) (0) 
10,10 0.0 0.0 0.0 0.0 
(0) (0) (0) (0) 
10,11 3.7 0.0 0.0 0.0 
(5) (0) (0) (0) 
10,12 0.0 2.9 0.0 0.0 
(0) (I) (0) (0) 
10,13 2.9 0.0 0.0 0.0 
(4) (0) (0) (0) 
10,14 2.2 2.9 5.6 8.3 
(3) (1) (I) (I) 
10,15 0.0 0.0 0.0 0.0 
(0) (0) (0) (0) 
11,11 0.0 0.0 0.0 0.0 
(0) (0) (0) (0) 
11,12 1.5 2.9 0.0 0.0 
(2) (I) (0) (0) 
11,13 2.9 2.9 0.0 0.0 
(4) (I) (0) (0) 
11,14 0.7 0.0 0.0 0.0 
(I) (0) (0) (0) 
12,12 0.0 0.0 0.0 0.0 
(0) (0) (0) (0) 
12,13 0.7 2.9 5.6 8.3 
(I) (I) (I) (I) 
Table 6.68 IL-lO.G genotype frequencies in normal controls and acute pancreatitis 
patients grouped according to (systemic) disease severity as assessed by 
organ failure score 
(continued ....... ) 
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IL-IO.G 
Controls OFS~2 OFS~3 OFS ~4 
genotype n=l36 n=35 n=l8 n=l2 
o/o % % % 
12,14 2.2 0.0 0.0 0.0 
(3) (0) (0) (0) 
13,13 2.2 8.6 5.6 0.0 
(3) (3) (I) (0) 
13,14 4.4 2.9 0.0 0.0 
(6) (I) (0) (0) 
14,14 0.7 0.0 0.0 0.0 
(1) (0) (0) (0) 
14,15 0.0 0.0 0.0 0.0 
(0) (0) (0) (0) 
Total 136 35 18 12 
Table 6.68 IL-10.G genotype frequencies in normal controls and acute pancreatitis 
patients grouped according to (systemic) disease severity as assessed by 
organ failure score 
This table displays IL-l 0. G microsatellite genotype frequencies in control and patient 
groups. For each genotype the % frequency and the number of genotypes (in brackets) is 
given. 
OFS Organ failure score 
OFS calculated according to method described in section 5.1.4 (Kingsnorth et al, 1995). 
Comparisons were made for each genotype between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. 
No significant differences were seen 
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IL-lO.G Controls Alcohol Idiopathic Gallstones 
genotype n=l36 n=21 n=37 n=77 
% % o;o o;o 
4,9 0.7 0.0 0.0 0.0 
(1) (0) (0) (0) 
5,11 0.0 0.0 0.0 1.3 (0) (0) (0) (0) 
7,9 1.5 0.0 2.7 0.0 (2) (0) (1) (0) 
7,10 0.7 0.0 0.0 o.o 
(1) (0) (0) (0) 
7,11 1.5 0.0 0.0 0.0 (2) (0) (0) (0) 
7,12 1.5 0.0 0.0 2.6 (2) (0) (0) (2) 
7,13 0.7 0.0 0.0 0.0 (I) (0) (0) (0) 
8,9 2.2 4.8 2.7 0.0 
(3) (I) (I) (0) 
8,10 0.0 4.8 5.4 0.0 (0) (I) (2) (0) 
8,ll 0.0 4.8 0.0 0.0 (0) (I) (0) (0) 
8,12 0.0 0.0 0.0 2.6 (0) (0) (0) (2) 
8,13 1.5 0.0 0.0 0.0 
(2) (0) (0) (0) 
8,14 0.0 4.8 0.0 0.0 (0) (I) (0) (0) 
9,9 17.6 23.8 5.4 18.2 (24) (5) (2) ( 14) 
9,10 5.9 9.5 5.4 2.6 
(8) (2) (2) (2) 
9,11 5.9 19.0 16.2 9.1 
(8) (4) (6) (7) 
Table 6.69 Genotypes at the IL-10.G microsatellite locus in normal control and 
acute pancreatitis patients grouped according to aetiology 
(continued ... . ) 
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IL-10.G 
Controls Alcohol Idiopathic Gallstones 
genotype n=136 n=21 n=37 n=77 
0/o 0/o % 0/o 
9,12 3.7 4.8 8.1 3.9 
(5) (I) (3) (3) 
9,13 25.0 4.8 18.9 26.0 
(34) (1) (7) (20) 
9,14 6.6 0.0 8.1 6.5 
(9) (0) (3) (5) 
9,15 0.7 4.8 0.0 1.3 
(I) (1) (0) (I) 
10,10 0.0 9.5 0.0 0.0 
(0) (2) (0) (0) 
10,11 3.7 0.0 0.0 0.0 
(5) (0) (0) (0) 
10,12 0.0 0.0 0.0 1.3 
(0) (0) (0) (I) 
10,13 2.9 4.8 0.0 2.6 
(4) (I) (0) (2) 
10,14 2.2 0.0 2.7 1.3 
(3) (0) (l) (I) 
10,15 0.0 0.0 0.0 1.3 
(0) (0) (0) (I) 
11,11 0.0 0.0 0.0 2.6 
(0) (0) (0) (2) 
11,12 1.5 0.0 0.0 1.3 
(2) (0) (0) (I) 
11,13 2.9 0.0 5.4 3.9 
(4) (0) (2) (3) 
11,14 0.7 0.0 2.7 0.0 
(I) (0) (I) (0) 
12,12 0.0 0.0 0.0 2.6 
(0) (0) (0) (2) 
12,13 0.7 0.0 5.4 0.0 
(I) (0) (2) (0) 
Table 6.69 Genotypes at the IL-10.G microsatellite locus in normal control and 
acute pancreatitis patients grouped according to aetiology 
(continued .. . ) 
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IL-10.G 
Controls Alcohol Idiopathic Gallstones 
genotype n=136 n=21 n=37 n=77 
% % % o;o 
-········------------ -----------
12,14 2.2 0.0 2.7 0.0 
(3) (0) (I) (0) 
13,13 2.2 0.0 5.4 5.2 
(3) (0) (2) (4) 
13,14 4.4 0.0 2.7 2.6 
(6) (0) (I) (2) 
14,14 0.7 0.0 0.0 0.0 
(I) (0) (0) (0) 
14,15 0.0 0.0 0.0 1.3 
(0) (0) (0) (I) 
Total 136 2I 37 77 
Table 6.69 Genotypes at the IL-10.G microsatellite locus in normal control and 
acute pancreatitis patients grouped according to aetiology 
This table displays TNFb microsatellite genotype frequencies in control and patient groups. 
For each genotype the % frequency and the number of genotypes (in brackets) is given. 
Alcoholic pancreatitis if daily consumption of~ 80g alcohol day" 1 
Gallstones if radiological or ERCP evidence of cholelithiasis 
Idiopathic if no identifiable aetiology 
Comparisons were made for each genotype between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. No significant differences were seen 
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Controls Alcohol Alcohol Not alcohol 
IL-lO.G 'controls' 
genotype n=136 n=33 n=21 n=ll4 
% o;o o;o o;o 
4,9 0.7 0.0 0.0 0.0 
(I) (0) (0) (0) 
5,11 0.0 0.0 0.0 0.9 
(0) (0) (0) (I) 
7,9 1.5 3.0 0.0 0.9 
(2) (I) (0) (I) 
7,10 0.7 0.0 0.0 0.0 
(I) (0) (0) (0) 
7,11 1.5 0.0 0.0 0.0 
(2) (0) (0) (0) 
7,12 1.5 0.0 0.0 1.8 
(2) (0) (0) (2) 
7,13 0.7 0.0 0.0 0.0 
(I) (0) (0) (0) 
8,9 2.2 3.0 4.8 0.9 
(3) (I) (I) (I) 
8,10 0.0 3.0 4.8 1.8 
(0) (1) (I) (2) 
8,11 0.0 0.0 4.8 0.0 
(0) (0) (1) (0) 
8,12 0.0 0.0 0.0 1.8 
(0) (0) (0) (2) 
8,13 1.5 0.0 0.0 0.0 
(2) (0) (0) (0) 
8,14 0.0 0.0 4.8 0.0 
(0) (0) (I) (0) 
9,9 17.6 18.2 23.8 14.0 
(24) (6) (5) (I6) 
9,10 5.9 12.1 9.5 3.5 
(8) (4) (2) (4) 
9,11 5.9 12.1 19.0 11.4 
(8) (4) (4) (13) 
Table 6.70 Genotypes at the IL-10.G microsatellite locus in normal controls, 
alcohol-induced and non alcohol-induced acute pancreatitis patients, 
and alcoholic 'controls' 
(continued .. . ) 
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Controls Alcohol Alcohol Not alcohol 
IL-10.G 'controls' 
genotype n=l36 n=33 n=21 n=ll4 
% 0/o % o;o 
9,12 3.7 6.1 4.8 5.3 
(5) (2) (1) (6) 
9,13 25.0 9.1 4.8 23.7 
(34) (3) (1) (27) 
9,14 6.6 0.0 0.0 7.0 
(9) (0) (0) (8) 
9,15 0.7 0.0 4.8 0.9 
(I) (0) (1) (1) 
10,10 0.0 0.0 9.5 0.0 
(0) (0) (2) (0) 
10,11 3.7 0.0 0.0 0.0 
(5) (0) (0) (0) 
10,12 0.0 0.0 0.0 0.9 
(0) (0) (0) (1) 
10,13 2.9 3.0 4.8 1.8 
(4) (1) (1) (2) 
10,14 2.2 0.0 0.0 1.8 
(3) (0) (0) (2) 
10,15 0.0 0.0 0.0 0.9 
(0) (0) (0) (1) 
11,11 0.0 0.0 0.0 1.8 
(0) (0) (0) (2) 
11,12 1.5 0.0 0.0 0.9 
(2) (0) (0) (1) 
11,13 2.9 15.2 0.0 4.4 
(4) (5) (0) (5) 
11,14 0.7 0.0 0.0 0.9 
(1) (0) (0) (1) 
12,12 0.0 0.0 0.0 1.8 
(0) (0) (0) (2) 
12,13 0.7 6.1 0.0 1.8 
(I) (2) (0) (2) 
Table 6.70 Genotypes at the IL-10.G microsatellite locus in normal controls, 
alcohol-induced and non alcohol-induced acute pancreatitis patients, 
and alcoholic 'controls' 
(continued ..... ) 
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Controls Alcohol Alcohol Not alcohol 
IL-10.G 'controls' 
genotype n=136 n=33 n=21 n=I14 
o;o % o;o % 
12,14 2.2 3.0 0.0 0.9 
(3) (I) (0) (I) 
13,13 2.2 6.1 0.0 5.3 
(3) (2) (0) (6) 
13,14 4.4 0.0 0.0 2.6 
(6) (0) (0) {3) 
14,14 0.7 0.0 0.0 0.0 
(1) (0) (0) (0) 
14,15 0.0 0.0 0.0 0.9 
(0) (0) (0) {I) 
Total 136 33 21 114 
Table 6.70 Genotypes at the IL-10.G microsatellite locus in normal controls, 
alcohol-induced and non alcohol-induced acute pancreatitis patients, 
and alcoholic 'controls' 
This table displays ll.,-IO.G microsatellite genotype frequencies in control and patient 
groups. For each genotype the % frequency and the number of genotypes (in brackets) is 
g1ven. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
Alcoholic pancreatitis if daily consumption of 2:: 80g alcohol daf1 
Non-alcohol induced pancreatitis includes: 
• Gallstones if radiological or ERCP evidence of cholelithiasis 
• Idiopathic if no identifiable aetiology 
Comparisons were made for each genotype between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. No significant differences were seen. 
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6.13 IL-10 -1117 locus typing 
JL-1 0 -1117 allelic and genotype frequencies were measured in 127 normal controls and 
124 acute pancreatitis patients (92% ). They were not measured in the group of alcoholic 
'controls'. Figure 6. 7 is a PCR-SSOP autoradiograph of the -1117 assay. 
Table 6. 71 shows allelic frequencies of the -1117 locus in patient and normal control 
subjects. No significant differences between patient and control groups are seen. 
Table 6. 72 shows genotype frequencies of the -1117 locus in patient and normal control 
subjects. No significant differences between patient and control groups are seen. 
The expected frequencies for IL-l 0 -1117 genotypes were calculated. A 2 x n analysis 
showed that frequencies of heterozygotes and homozygotes in both study and normal 
control populations were in Hardy Weinberg equlilibrium This is shown in Table 6. 73. 
Tables 6.74 and 6.75 show allelic and genotype frequencies at the -1117locus in patient 
groups stratified according to disease severity classified according to the Atlanta 
classification and the occurrence of a local complication. Tables 6. 76 and 6. 77 show allelic 
and genotype frequencies at the -1117 locus in patient groups stratified according to organ 
failure score. 
There are no significant differences in the allelic or genotype frequencies of the IL-l 0 -
1117 locus between the above patient groups. 
Tables 6. 78 and 6. 79 show allelic and genotype frequencies at the -1117 locus in patient 
groups according to the aetiology of their disease. Again, there are no significant differences 
in the allelic or genotype frequencies of the JL-1 0 -1117 locus between the groups. 
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Figure 6. 7 PCR-SSOP autoradiograph of the -1117 assay 
T;t<. 8·· 
·. rL-10 .-
11 17 r. 
Detection of the two alleles by PCR-SSOP is descibed in 5.7. Specific probes were used to 
detect either allele. AJleles were scored on the presence of bound probe detected by 
chemoluminescence. The genotypes of lanes 1-8 are scored as fo llows: 
Lane 1: - 111 7.AA 
Lane 2: - 111 7.AA 
Lane 3: - 111 7.GA 
Lane 4: - li1 7.AA 
Lane 5: - l 117.AA 
Lane 6: - 11 17.AA 
Lane 7: -lii 7.GG 
Lane 8: -1117.GA 
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IL-10 -1117 allele 
Controls Study patients 
n=127 n=124 
o;o o;o 
G 53.0 56.0 
(135) (138) 
A 47.0 44.0 
(119) (110) 
Total alleles (n) 257 248 
Table 6. 71 IL-10 -1117 allele frequencies in normal controls and acute pancreatitis 
patients 
This table displays IL-l 0 -1117 allele frequencies in control and patient subjects. For each 
allele the % frequency and the actual number of alleles (in brackets) is given. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. 
No significant differences between patient and control groups are seen. 
IL-10 -1117 genotype 
Controls Study patients 
n=127 n=124 
o;o o;o 
GG 29.1 29.8 
(37) (37) 
GA 48.0 51.6 
(61) (64) 
AA 22.8 18.5 
(29) (23) 
Total 127 124 
Table 6. 72 IL-10 -1117 genotype frequencies in normal controls and acute 
pancreatitis patients 
This table displays IL-10 -1117 genotype frequencies in control and patient subjects. For 
each genotype the % frequency and their actual number (in brackets) is given. 
n represents the number of subjects in each group 
Comparisons were made for each genotype between patient and control groups using 2x2 
contingency tables and the l test. P values were corrected for the number of comparisons 
made. No significant differences between patient and control groups are seen. 
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Expected Observed 
-1117 Genotype 
n Freq. n Freq. 
Controls 
GG 35.6 28.0 37 29.1 
GA 63.5 50.0 61 49.2 
AA 27.9 22.0 29 22.8 
Patients 
GG 38.9 31.4 37 29.8 
GA 61.1 49.3 64 51.6 
AA 24.0 19.4 23 18.5 
Table 6. 73 Frequency (%) of IL-l 0 -1117 genotypes in patient and control 
subjects 
x2 
0.1 
0.0 
0.0 
O.l 
0.1 
00 
Showing expected and observed frequencies of IL-l 0 -1117 genotypes in patient and 
nonnal control subjects. This demonstrates that the distribution conforms to Hardy-
Weinberg equilibrium. 
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Local 
IL-10-1117 
Controls Mild Severe 
complication 
allele n=127 n=90 n=34 n=l8 
o/o o/o o/o % 
G 53.0 56.0 56.0 53.0 
(135) (lOO) (38) (19) 
A 47.0 44.0 44.0 47.0 
(119) (80) {30) (17) 
Total alleles (n) 257 180 68 36 
Table 6.74 IL-10 -1117 allele frequencies in normal controls and acute pancreatitis 
patients grouped according to (local and systemic) disease severity 
This table displays IL-l 0 -1117 allele frequencies in control and patient sub-groups. For 
each allele the % frequency and the actual number of alleles (in brackets) is given. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
Mild and severe disease severity groups are according to the Atlanta convention 
classification (Bradley, 1993), described in section 5.1.4. 
Local complication is defined as occurrence of pancreatic necrosis, abscess or pseudocyst. 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. 
No significant differences between patient and control groups are seen. 
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Controls Local 
IL-10 -1117 Mild Severe complication 
genotype n=127 n=90 n=34 n=18 
o;o o;o 0/o u;o 
GG 29.1 30.0 29.4 22.2 
(37) (27) (10) (4) 
GA 48.0 51.1 52.9 61.1 
(61) (46) (18) ( 11) 
AA 22.8 18.9 17.6 16.7 
(29) (17) (6) (3) 
Total 127 90 34 18 
Table 6. 75 IL-10 -1117 genotype frequencies in normal controls and acute 
pancreatitis patients grouped according to (local and systemic) disease 
severity 
This table displays IL-10 -1117 genotype frequencies in control and patient sub-groups. For 
each genotype the % frequency and their actual number (in brackets) is given. 
n represents the number of subjects in each group 
Mild and severe disease severity groups are according to the Atlanta convention 
classification (Bradley, 1993), described in section 5.1.4. 
Local complication is defined as occurrence of pancreatic necrosis, abscess or pseudocyst 
Comparisons were made between patient and control groups using 2x2 contingency tables 
and the X2 test P values were corrected for the number of comparisons made. 
No significant differences between patient and control groups are seen. 
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IL-10-1117 
Controls OFS~2 OFS~3 OFS~4 
allele n=127 n=34 n=18 n=12 
o;o o;o o/o % 
G 53.0 57.0 67.0 62.5 
(135) (39) (24) (15) 
A 47.0 43.0 33.0 37.5 
(119) (29) ( 12) (9) 
Total alleles (n) 257 68 36 24 
Table 6.76 IL-10 -1117 allele frequencies in normal controls and acute pancreatitis 
patients grouped according to (systemic) disease severity as assessed by 
organ failure score 
This table displays IL-l 0 -1117 allele frequencies in control and patient group subjects. For 
each allele the % frequency and the actual number of alleles (in brackets) is given. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
OFS Organ failure score 
OFS calculated according to method described in section 5.1.4 (Kingsnorth et a!, 1995). 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. 
No differences are seen in the frequency of individual alleles between patient groups or 
between patient groups and controls. 
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IL-10 -1117 Controls OFS:? 2 OFS:? 3 OFS:? 4 
genotype n=127 n=34 n=18 n=12 
% o;o o;o o;o 
GG 29.1 35.3 50.0 41.7 
(37) {12) (9) (5) 
GA 48.0 44.1 33.3 41.7 
(61) (15) (6) (5) 
AA 22.8 20.6 16.7 16.7 
(29) (7) (3) (2) 
Total 127 33 18 12 
Table 6.77 IL-10 -1117 genotype frequencies in normal controls and acute 
pancreatitis patients grouped according to (systemic) disease severity as 
assessed by organ failure score 
This table displays IL-l 0 -1117 genotype frequencies in control and patient group subjects. 
For each genotype the % frequency and their actual number (in brackets) is given. 
n represents the number of subjects in each group 
OFS Organ failure score 
OFS calculated according to method described in section 5.1.4 (Kingsnorth et al, 1995). 
Comparisons were made between patient and control groups using 2x2 contingency tables 
and the x2 test. P values were corrected for the number of comparisons made. 
No differences are seen in the gene frequency between patient groups or between patient 
groups and controls. 
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IL-10 -1117 
Controls Alcohol Idiopathic Gallstones 
allele n=127 n=21 n=33 n=70 
% % 0/o 0/o 
--------··-··------···--·------ -----------------------------···· 
G 53.0 57.0 58.0 55.0 
(135) (24) (37) (72) 
A 47.0 43.0 42.0 45.0 
(119) ( 18) (27) (60) 
Total alleles (n) 257 42 64 132 
Table 6.78 IL-10 -1117 allele frequencies in normal controls and acute pancreatitis 
patients grouped according to aetiology of acute pancreatitis 
This table displays IL-l 0 -1117 allele frequencies in control and patient group subjects. For 
each allele the % frequency and the actual number of alleles (in brackets) is given. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
Alcoholic pancreatitis if daily consumption of~ 80g alcohol da/ 
Gallstones if radiological or ERCP evidence of cholelithiasis 
Idiopathic if no identifiable aetiology 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the l test. P values were corrected for the number of comparisons 
made. 
No differences are seen in the frequency of individual alleles between patient groups or 
between patient groups and controls. 
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IL-10 -1117 Controls Alcohol Idiopathic Gallstones 
genotype n=127 n=21 n=33 n=70 
% o;o % % 
GG 29.1 33.3 34.4 28.8 
(37) (7) ( 11) (19) 
GA 48.0 47.6 46.9 51.5 
(61) (I 0) (15) (34) 
AA 22.8 19.0 18.8 19.7 
(29) (4) (6) (13) 
Total 127 21 32 66 
Table 6. 79 IL-10 -1117 genotype frequencies in normal controls and acute 
pancreatitis patients grouped according to aetiology of acute 
pancreatitis 
This table displays IL-l 0 -1117 genotype frequencies in control and patient group subjects. 
For each genotype the %frequency and their actual number (in brackets) is given. 
n represents the number of subjects in each group 
Alcoholic pancreatitis if daily consumption of:?: 80g alcohol day" 1 
Gallstones if radiological or ERCP evidence of cholelithiasis 
Idiopathic if no identifiable aetiology 
Comparisons were made between patient and control groups using 2x2 contingency tables 
and the l test. P values were corrected for the number of comparisons made. 
No differences are seen in gene frequency between patient groups or between patient 
groups and controls. 
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6.14 IL-10 -854Iocus typing 
IL-l 0 -854 allelic and genotype frequencies were measured in 133 normal controls and 127 
acute pancreatitis patients (94.1 %). They were not measured in the group of alcoholic 
'controls'. 
Table 6.80 shows allelic frequencies of the -854locus in patient and normal control 
subjects. No significant differences between patient and control groups are seen. 
Table 6.81 shows genotype frequencies of the -854locus in patient and normal control 
subjects. No significant differences between patient and control groups are seen. 
The expected frequencies for IL-l 0 -854 genotypes were calculated. A 2 x n analysis 
showed that frequencies of heterozygotes and homozygotes in both study and normal 
control populations were in Hardy Weinberg equlilibrium. This is shown in Table 6.82. 
Tables 6.83 and 6.84 show allelic and genotype frequencies at the -854locus in patient 
groups stratified according to disease severity classified according to the Atlanta 
classification and the occurrence of a local complication. Tables 6.85 and 6.86 show allelic 
and genotype frequencies at the -854 locus in patient groups stratified according to organ 
failure score. 
There are no significant differences in the allelic or genotype frequencies ofthe IL-10 -854 
locus between the above patient groups. 
Tables 6.87 and 6.88 show allelic and genotype frequencies at the -854 locus in patient 
groups according to the aetiology of their disease. Again, there are no significant differences 
in the allelic or genotype frequencies of the IL-l 0 -854 locus between the groups. 
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IL-l 0 -854 allele 
Controls Study patients 
n=l33 n=127 
o;o % 
c 74.0 75.0 
(196) (191) 
T 26.0 25.0 
(70) (63) 
Total alleles (n) 266 254 
Table 6.80 IL-10 -854 allele frequencies in normal controls and acute pancreatitis 
patients 
This table displays IL-10 -854 allele frequencies in control and patient subjects. For each 
allele the % frequency and the actual number of alleles (in brackets) is given. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. 
No significant differences between patient and control groups are seen. 
IL-10 -854 genotype 
Controls Study patients 
n=133 n=127 
o;o % 
cc 57.1 58.3 
(76) (74) 
CT 33.1 33.9 
(44) (43) 
TT 9.8 7.9 
(13) (I 0) 
Total 127 124 
Table 6.81 IL-10 -854 genotype frequencies in normal controls and acute 
pancreatitis patients 
This table displays IL-10 -854 genotype frequencies in control and patient subjects. For 
each genotype the % frequency and their actual number (in brackets) is given. 
n represents the number of subjects in each group 
Comparisons were made for each genotype between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. No significant differences between patient and control groups are seen. 
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Expected Observed 
-854 Genotype 
n Freq. n Freq. 
----------------------------------------------------
Controls 
cc 72.8 54.7 76 57.1 0.1 
CT 51.2 38.5 44 33.1 1.0 
TT 9 6.7 13 9.8 1.8 
Patients 
cc 71.4 56.3 74 58.3 0.1 
CT 47.6 37.5 43 33.9 0.4 
TT 7.9 6.3 10 7.9 0.6 
Table 6.82 Frequency(%) of IL-10 -854 genotypes in patient and control subjects 
Showing expected and observed frequencies ofiL-1 0 -854 genotypes in patient and normal 
control subjects. Demonstrates that distribution conforms to Hardy-Weinberg equilibrium. 
Local 
IL-10 -854 
Controls Mild Severe 
complication 
allele n=l33 n=91 n=36 n=l9 
0/o o;o o/o % 
c 74.0 77.0 71.0 66.0 
(196) (140) (51) (25) 
T 26.0 23.0 29.0 34.0 
(70) (42) {21) (13) 
Total alleles (n) 266 182 72 38 
Table 6.83 IL-10 -854 allele frequencies in normal controls and acute pancreatitis 
patients grouped according to (local and systemic) disease severity 
This table displays IL-10 -854 allele frequencies in control and patient sub-groups. For each 
allele the% frequency and the actual number of alleles (in brackets) is given. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
Mild and severe disease severity groups are according to the Atlanta convention 
classification (Bradley, 1993), described in section 5.1.4. 
Local complication is defined as occurrence of pancreatic necrosis, abscess or pseudocyst. 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. 
No significant differences between patient and control groups are seen. 
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Local 
IL-10 -854 Controls Mild 
Severe 
complication 
genotype n=133 n=91 n=36 n=19 
% % o;o o;o 
cc 57.1 60.4 52.8 52.6 
(76) (55) (19) (10) 
CT 33.1 33.0 36.1 26.3 
(44) (30) (13) (5) 
TT 9.8 6.6 11.1 21.1 
(13) (6) (4) (4) 
Total 133 91 36 19 
Table 6.84 IL-10 -854 genotype frequencies in normal controls and acute 
pancreatitis patients grouped according to (local and systemic) disease 
severity 
This table displays TL-1 0 -854 genotype frequencies in control and patient sub-groups. For 
each genotype the %frequency and their actual number (in brackets) is given. 
n represents the number of subjects in each group 
Mild and severe disease severity groups are according to the Atlanta convention 
classification (Bradley, 1993), described in section 5.1.4. 
Local complication is defined as occurrence of pancreatic necrosis, abscess or pseudocyst. 
Comparisons were made between patient and control groups using 2x2 contingency tables 
and the x2 test. P values were corrected for the number of comparisons made. 
No significant differences between patient and control groups are seen. 
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IL-10 -854 Controls OFS;e:2 OFS ;e: 3 OFS ;e: 4 
allele n=133 n=34 n=18 n=12 
0/o 0/o o;o 0/o 
c 74.0 74.0 75.0 79.2 
(196) (SO) (27) (19) 
T 26.0 26.0 25.0 20.8 
(70) (18) (9) (5) 
Total alleles (n) 266 68 36 24 
Table 6.85 IL-10 -854 allele frequencies in normal controls and acute pancreatitis 
patients grouped according to (systemic) disease severity as assessed by 
organ failure score 
This table displays IL-l 0 -854 allele frequencies in control and patient group subjects. For 
each allele the % frequency and the actual number of alleles (in brackets) is given. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
OFS Organ failure score 
OFS calculated according to method described in section 5.1.4 (Kingsnorth et al, 1995). 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the r! test. P values were corrected for the number of comparisons 
made 
No differences are seen in the frequency of individual alleles between patient groups or 
between patient groups and controls. 
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IL-10 -854 Controls OFS~2 OFS~3 OFS~4 
genotype n=133 n=34 n=18 n=12 
% % o;o 0/o 
cc 57.1 52.9 55.6 58.3 
(76) (18) (10) (7) 
CT 33.1 41.2 38.9 41.7 
(44) (14) (7) (5) 
TT 9.8 5.9 5.6 0.0 
(13) (2) (1) (0) 
Total 133 33 18 12 
Table 6.86 IL-10 -854 genotype frequencies in normal controls and acute 
pancreatitis patients grouped according to (systemic) disease severity as 
assessed by organ failure score 
This table displays IL-l 0 -854 genotype frequencies in control and patient group subjects. 
For each genotype the % frequency and their actual number (in brackets) is given. 
n represents the number of subjects in each group 
OFS Organ failure score 
OFS calculated according to method described in section 5. 1.4 (K.ingsnorth et al, 1995). 
Comparisons were made between patient and control groups using 2x2 contingency tables 
and the ·l test. P values were corrected for the number of comparisons made. 
No differences are seen in the gene frequency between patient groups or between patient 
groups and controls. 
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IL-10 -854 
allele 
c 
T 
Total alleles (n) 
Controls 
n=133 
74.0 
(196) 
26.0 
(70) 
266 
Alcohol 
n=21 
76.0 
(32) 
24.0 
(I 0) 
42 
Idiopathic 
n=35 
% 
68.0 
(45) 
32.0 
(21) 
66 
Gallstones 
n=71 
% 
78.0 
(105) 
22.0 
(29) 
134 
Table 6.87 IL-10 -854 allele frequencies in normal controls and acute pancreatitis 
patients grouped according to aetiology of acute pancreatitis 
This table displays IL-l 0 -854 allele frequencies in control and patient group subjects. For 
each allele the % frequency and the actual number of alleles (in brackets) is given. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
Alcoholic pancreatitis if daily consumption of~ 80g alcohol day" 1 
Gallstones if radiological or ERCP evidence of cholelithiasis 
Idiopathic if no identifiable aetiology 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made 
No differences are seen in the frequency of individual alleles between patient groups or 
between patient groups and controls. 
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IL-10-854 
genotype 
Controls 
n=133 
Alcohol 
n=21 
Idiopathic 
n=35 
Gallstones 
n=71 
cc 57.1 61.9 51.5 
(76) (13) (17) 
CT 33.1 28.6 33.3 
(44) (6) (11) 
TT 9.8 9.5 15.2 
(13) (2) (5) 
Total 133 21 33 
Table 6.88 IL-10 -854 genotype frequencies in normal controls and acute 
pancreatitis patients grouped according to aetiology of acute 
pancreatitis 
61.2 
(41) 
34.3 
(23) 
4.5 
(3) 
67 
This table displays IL-l 0 -854 genotype frequencies in control and patient group subjects. 
For each genotype the % frequency and their actual number (in brackets) is given. 
n represents the number of subjects in each group 
Alcoholic pancreatitis if daily consumption of~ 80g alcohol day" 1 
Gallstones if radiological or ERCP evidence of cholelithiasis 
Idiopathic if no identifiable aetiology 
Comparisons were made between patient and control groups using 2x2 contingency tables 
and the·/ test. P values were corrected for the number of comparisons made. 
No differences are seen in gene frequency between patient groups or between patient 
groups and controls. 
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6.151L-10 -627 locus typing 
IL-1 0 -627 allelic and genotype frequencies were measured in 127 normal controls and 124 
acute pancreatitis patients (92%). They were not measured in the group of alcoholic 
'controls'. 
Table 6.89 shows allelic frequencies of the -6271ocus in patient and normal control 
subjects. No significant differences between patient and control groups are seen. 
Table 6.90 shows genotype frequencies of the -627 locus in patient and normal control 
subjects. No significant differences between patient and control groups are seen. 
The expected frequencies for IL-l 0 -627 genotypes were calculated. A 2 x n analysis 
showed that frequencies of heterozygotes and homozygotes in both study and normal 
control populations were in Hardy Weinberg equlilibrium. This is shown in Table 6.91. 
Tables 6.92 and 6.93 show allelic and genotype frequencies at the -627 locus in patient 
groups stratified according to disease severity classified according to the Atlanta 
classification and the occurrence of a local complication. Tables 6.94 and 6.95 show allelic 
and genotype frequencies at the -627 locus in patient groups stratified according to organ 
failure score. 
There are no significant differences in the allelic or genotype frequencies of the IL-l 0 -627 
locus between the above patient groups. 
Tables 6.96 and 6.97 show allelic and genotype frequencies at the -627 locus in patient 
groups according to the aetiology of their disease. Again, there are no significant differences 
in the allelic or genotype frequencies of the IL-l 0 -627 locus between the groups. 
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IL-10 -627 allele 
Controls Study patients 
n=134 n=125 
% 0/o 
c 63.8 67.0 
( 171) (167) 
A 36.2 33.2 
(97) (83) 
Total alleles (n) 268 250 
Table 6.89 IL-10 -627 allele frequencies in normal controls and acute pancreatitis 
patients 
This table displays IL-l 0 -627 allele frequencies in control and patient subjects. For each 
allele the %frequency and the actual number of alleles (in brackets) is given. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. 
No significant differences between patient and control groups are seen. 
IL-l 0 -627 genotype 
Controls Study patients 
n=l34 n=125 
o;o % 
cc 41.0 47.2 
(SS) (59) 
CA 45.5 39.2 
(61) (49) 
AA 13.4 13.6 
(18) ( 17) 
Total 134 125 
Table 6.90 IL-10 -627 genotype frequencies in normal controls and acute 
pancreatitis patients 
This table displays IL-l 0 -627 genotype frequencies in control and patient subjects. For 
each genotype the % frequency and their actual number (in brackets) is given. 
n represents the number of subjects in each group 
Comparisons were made for each genotype between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. 
No significant differences between patient and control groups are seen. 
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Expected Observed 
-627Genotype 
n Freq. n Freq. ·l 
Controls 
cc 54.9 41.0 ss 41.0 0.0 
CA 61.7 46.0 61 45.6 00 
AA 17.4 13.0 18 13.4 0.0 
Patients 
cc 56.1 44.9 59 47.2 0.1 
CA 55.3 44.2 49 39.2 0.7 
AA 13.6 10.9 17 13.6 0.9 
Table 6.91 Frequency(%) of IL-10 -627 genotypes in patient and control subjects 
Showing expected and observed frequencies of IL-1 0 -627genotypes in patient and normal 
control subjects. Demonstrates that distribution conforms to Hardy-Weinberg equilibrium. 
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Local 
IL-10 -627 
Controls Mild Severe 
complication 
allele n=134 n=91 n=34 n=18 
o;o o;o % o;o 
c 63.8 68.0 63.0 56.0 
(171) (124) (43) (20) 
A 36.2 32.0 36.8 44.0 
(97) {58) (25) {16) 
Total alleles (n) 268 182 68 36 
Table 6.92 IL-10 -627 allele frequencies in normal controls and acute pancreatitis 
patients grouped according to (local and systemic) disease severity 
This table displays IL-10 -62 7 allele frequencies in control and patient sub-groups. For each 
allele the % frequency and the actual number of alleles (in brackets) is given. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
Mild and severe disease severity groups are according to the Atlanta convention 
classification (Bradley, 1993), described in section 5.1 A. 
Local complication is defined as occurrence of pancreatic necrosis, abscess or pseudocyst. 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the/ test. P values were corrected for the number of comparisons 
made. 
No significant differences between patient and control groups are seen. 
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Local 
IL-10 -627 Controls Mild Severe complication 
genotype n=134 n=91 n=34 n=18 
% o/o % o;o 
cc 41.0 49.5 41.2 33.3 
(55) (45) (14) (6) 
CA 45.5 37.4 44.1 44.4 
(61) (34) (15) (8) 
AA 13.4 13.2 14.7 22.2 
(18) (12) (5) (4) 
Total 134 91 34 18 
Table 6.93 IL-10 -627 genotype frequencies in normal controls and acute 
pancreatitis patients grouped according to (local and systemic) disease 
severity 
This table displays JL-1 0 -627 genotype frequencies in control and patient sub-groups. For 
each genotype the % frequency and their actual number (in brackets) is given. 
n represents the number of subjects in each group 
Mild and severe disease severity groups are according to the Atlanta convention 
classification (Bradley, 1993), described in section 5.1.4. 
Local complication is defined as occurrence of pancreatic necrosis, abscess or pseudocyst. 
Comparisons were made between patient and control groups using 2x2 contingency tables 
and the / test. P values were corrected for the number of comparisons made. 
No significant differences between patient and control groups are seen. 
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IL-10 -627 Controls OFS~2 OFS~3 OFS~4 
allele n=l34 n=33 n=l8 n=l2 
o/o 0/o % 0/o 
c 63.8 68.0 72.0 70.8 
( 171) (45) (26) (17) 
A 36.2 32.0 28.0 29.2 
(97) (21) (I 0) (7) 
Total alleles (n) 268 66 36 24 
Table 6.94 IL-10 -627 allele frequencies in normal controls and acute pancreatitis 
patients grouped according to (systemic) disease severity as assessed by 
organ failure score 
This table displays IL-l 0 -627 allele frequencies in control and patient group subjects. For 
each allele the % frequency and the actual number of alleles (in brackets) is given. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
OFS Organ failure score 
OFS calculated according to method described in section 5.1.4 (Kingsnorth et al, 1995). 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the / test. P values were corrected for the number of comparisons 
made. 
No differences are seen in the frequency of individual alleles between patient groups or 
between patient groups and controls. 
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IL-10 -627 
Controls OFS~2 OFS~3 OFS~4 
genotype n=134 n=33 n=18 n=12 
0/o % % o;o 
cc 41.0 45.5 50.0 50.0 
(55) (15) (9) (6) 
CA 45.5 45.5 44.4 41.7 
(61) (15) (8) (5) 
AA 13.4 9.1 5.6 8.3 
(18) (3) (I) (I) 
Total 134 33 18 12 
Table 6.95 IL-10 -627 genotype frequencies in normal controls and acute 
pancreatitis patients grouped according to (systemic) disease severity as 
assessed by organ failure score 
This table displays IL-l 0 -627 genotype frequencies in control and patient group subjects. 
For each genotype the % frequency and their actual number (in brackets) is given. 
n represents the number of subjects in each group 
OFS Organ failure score 
OFS calculated according to method described in section 5.1.4 (Kingsnorth et al, 1995). 
Comparisons were made between patient and control groups using 2x2 contingency tables 
and the x2 test. P values were corrected for the number of comparisons made. 
No differences are seen in the gene frequency between patient groups or between patient 
groups and controls. 
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IL-10 -627 Controls Alcohol 
Idiopathic Gallstones 
allele n=l34 n=21 n=34 n=71 
% % % % 
c 63.8 69.0 63.0 68.0 
(171) (29) (39) (90) 
A 36.2 31.0 37.0 32.0 
(97) (13) (23) (42) 
Total alleles (n) 268 42 62 132 
Table 6.96 IL-10 -fJ27 allele frequencies in normal controls and acute pancreatitis 
patients grouped according to aetiology of acute pancreatitis 
This table displays IL-l 0 -627 allele frequencies in control and patient group subjects. For 
each allele the% frequency and the actual number of alleles (in brackets) is given. 
n represents the number of subjects in each group 
(n) represents the number of alleles in each group. 
Alcoholic pancreatitis if daily consumption of~ 80g alcohol dai1 
Gallstones if radiological or ERCP evidence of cholelithiasis 
Idiopathic if no identifiable aetiology 
Comparisons were made for each allele between patient and control groups using 2x2 
contingency tables and the x2 test. P values were corrected for the number of comparisons 
made. 
No differences are seen in the frequency of individual alleles between patient groups or 
between patient groups and controls. 
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IL-10 -627 
Controls Alcohol Idiopathic Gallstones 
genotype n=134 n=21 n=31 n=66 
% % % 
cc 41.0 47.6 41.9 
(55) (1 0) (13) 
CA 45.5 42.9 41.9 
(61) (9) (13) 
AA 13.4 9.5 16.1 
(18) (2) (5) 
Total 134 21 31 
Table 6.97 IL-10 -627 genotype frequencies in normal controls and acute 
pancreatitis patients grouped according to aetiology of acute 
pancreatitis 
o;o 
50.0 
(33) 
36.4 
(24) 
13.6 
(9) 
66 
This table displays IL-10 -627 genotype frequencies in control and patient group subjects. 
For each genotype the % frequency and their actual number (in brackets) is given. 
n represents the number of subjects in each group 
Alcoholic pancreatitis if daily consumption of~ 80g alcohol day" 1 
Gallstones if radiological or ERCP evidence of cholelithiasis 
Idiopathic if no identifiable aetiology 
Comparisons were made between patient and control groups using 2x2 contingency tables 
and the x2 test. P values were corrected for the number of comparisons made. 
No differences are seen in gene frequency between patient groups or between patient 
groups and controls. 
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6.16 IL-10 -1117 I 854 I 627 2 and 3-locus haplotypes 
The -1117, -854, and -627 loci are situated close together within a 490 bp region in the 5' 
(promoter) region of the IL-10 gene. They can be expected to associate with each other in a 
non-random fashion forming 2 and 3-locus haplotypes. The evidence for this occurring in 
the study populations is detailed in Table 6.1 06, and discussed in section 6.17. 
Table 6.98 shows frequencies of -1117 I -854 I -627 3-locus haplotypes in normal control 
and patient subjects. 
3-locus haplotypes were assigned when an individual was homozygous at two or more loci. 
This was not possible in all subjects due to the high frequency of heterozygocity at all three 
loci. The number of subjects in the control group to whom 3-locus haplotypes could be 
assigned was 68 out of 127 (53.5%) in whom all3 loci had been typed. The number of 
subjects in the patient group to whom 3-locus haplotypes could be assigned was 71 out of 
124 (57.3%) in whom all 3 loci had been typed 
A greater number of g-e-e haplotypes were able to be assigned in patient as compared to the 
control group, X2 =7.58, p=O.OOS9, Pc=0.047. This however, assumes less significance than 
at first sight, as haplotypes were able to be assigned in only just over half of patient and 
control subjects due to the high number ofheterozygotes seen. The higher figure seen in the 
patient group is not confirmed on analysis of the 2-locus haplotypes (tables 6.100-1 02). 
A greater number of a-c-a haplotypes were able to be assigned in the control as compared 
to the study group, X2 =9.8, p=O.OO 17, pc=O.O 14. This however, assumes less significance 
than at first sight, as haplotypes were able to be assigned in only c. SO% of patient and 
control subjects due to the high number of heterozygotes seen. The higher figure seen in the 
patient group is not confirmed on analysis of the 2-locus haplotypes (tables 6.100-6.1 02). 
Table 6.99 shows IL-l 0 -1117 I 854 I 627 3-locus haplotype frequencies in normal control 
and patient subjects, and patients grouped according to disease severity and aetiology as 
previously. 
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3-locus haplotypes were assigned when an individual was homozygous at two or more loci. 
This was not possible in all subjects so comparison between groups is of limited value due 
to not being to assign haplotypes in individuals heterozygous at more than one locus, so 
resulting in small numbers. Also the frequency of haplotypes that have been able to be 
assigned may not give a true estimate of actual frequencies. There is no significant 
difference in comparison between all subject groups beyond that discussed above and shown 
in Table 6.98. 
Table 6.100 shows IL-l 0 -1117 I 854 2- locus haplotypes in normal control and patient 
subjects. 2-locus haplotypes were assigned when an individual was homozygous at one or 
more loci. This was possible in 98 of 127 (77.2%) of controls and 99 of 124 (79.8%) of 
patients. 
No differences are seen in haplotype frequency between control and patient groups. 
Table 6.10 I shows IL-l 0 -1117 I 627 2- locus haplotypes in normal control and patient 
subjects. 2-locus haplotypes were assigned when an individual was homozygous at one or 
more loci. This was possible in 86 of 127 (67.7%) of controls and 92 of 124 (74.2%) of 
patients. 
No differences are seen in haplotype frequency between control and patient groups. 
Table 6. I 02 shows IL-l 0 -854 I 627 2- locus haplotypes in normal control and patient 
subjects. 2-locus haplotypes were assigned when an individual was homozygous at one or 
more loci. This was possible in 92 of 127 (72.4%) of controls and 96 of 124 (77.4%) of 
patients. 
No differences are seen in haplotype frequency between control and patient groups. 
Table 6.103 shows IL-l 0 -1117 I 854 2-locus haplotype frequencies in normal control and 
patient subjects, and patients grouped according to disease severity and aetiology as 
previously. Comparison between groups is of limited value due to not being to assign 
haplotypes in individuals heterozygous at more than one locus, so resulting in small 
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numbers. Also the frequency ofhaplotypes that have been able to be assigned may not give 
a true estimate of actual frequencies. 
No differences are seen in gene frequency between control and patient groups. 
Table 6.104 shows IL-l 0 -1117 I 627 2-locus haplotype frequencies in normal control and 
patient subjects, and patients grouped according to disease severity and aetiology as 
previously Comparison between groups is of limited value due to not being to assign 
haplotypes in individuals heterozygous at more than one locus, so resulting in small 
numbers. Also the frequency of haplotypes that have been able to be assigned may not give 
a true estimate of actual frequencies. 
No differences are seen in gene frequency between control and patient groups. 
Table 6.105 shows IL-l 0 -854 I 627 2-locus haplotype frequencies in normal control and 
patient subjects, and patients grouped according to disease severity and aetiology as 
previously. Comparison between groups is of limited value due to not being to assign 
haplotypes in individuals heterozygous at more than one locus, so resulting in small 
numbers. Also the frequency of haplotypes that have been able to be assigned may not give 
a true estimate of actual frequencies. 
No differences are seen in gene frequency between control and patient groups. 
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IL-10-1117 /854/627 
3-locus haplotype 
Controls Study patients 
g-e-e 
a-c-c 
a-t-a 
a-c-a 
g-t-c 
g-c-a 
a-t-e 
g-t-a 
Total number of 
chromosomes 
n=681127 
o;o 
·---·-------
42.6 
(58) 
24.3 
(33) 
12.5 
( 17) 
11.0 
(IS) 
2.2 
(3) 
3.7 
(5) 
2.2 
(3) 
1.5 
(2) 
136 
n=711124 
% 
··---·-·-······ 
59,2 I 
(84) 
23.2 
(33) 
9.2 
(13) 
2.1 2 
(3) 
0.7 
(I) 
1.4 
(2) 
2.8 
(4) 
1.4 
(2) 
142 
Table 6.98 IL-10 -1117 I 854 I 627 3-locus haplotype frequencies in normal control 
and patient subjects 
Frequencies(%) and actual number (in brackets) ofiL-1 0 -1117 I 854 I 627 3-locus 
haplotypes able to be determined in each group are shown. 
n number of patients 
(n) number of chromosomes 
3-locus haplotypes were assigned when an individual was homozygous at two or more loci. 
This was not possible in all subjects so the total number of subjects is also given (nln). 
1. A greater number of g-e-e haplotypes were able to be assigned in patient as compared 
to the control group, X2 =7 58, p=0.0059, Pc=0.047. This however, assumes less 
significance than at first sight, as haplotypes were able to be assigned in only c. 50% of 
patient and control subjects due to the high number of heterozygotes seen. The higher 
figure seen in the patient group is not confirmed on analysis of the 2-locus haplotypes 
(tables 6.1 00-102). 
2. A greater number of a-c-a haplotypes were able to be assigned in the control as 
compared to the study group, x2 =9.8, p=0.0017, pc=0.014. This however, assumes less 
significance than at first sight, as haplotypes were able to be assigned in only c 50% of 
patient and control subjects due to the high number of heterozygotes seen. The higher 
figure seen in the patient group is not confirmed on analysis of the 2-locus haplotypes 
(tables 6.100-1 02). 
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IL-10 Controls Study Mild Severe Local OFS::::2 OFS::::3 OFS::::4 Alcohol Idiopath G\stones 
-1117/854/627 patients complicll 
3-locus haplotype n=68 o=71 o=52 n=19 n=9 n=20 n=12 o=7 n=13 n=19 n=36 
% % % % o;o u;o o;o o;o o;o % o;o 
g-e-e 42.6 59.2 60.6 55.3 50.0 60.0 62.5 50.0 57.7 55.3 65.3 
(58) (84) (63) (21) (9) (24) (15) (7) (15) (21) (47) 
a-c-c 24.3 23.2 25.0 18.4 5.6 20.0 12.5 21.4 19.2 21.1 25.0 
(33) (33) (26) (7) (I) (8) (3) (3) (5) (8) (18) 
a-t-a 12.5 9.2 6.7 15.8 27.8 5.0 4.2 7.1 11.5 13.2 5.6 
(17) (13) (7) (6) (5) (2) (I) (1) (3) (5) (4) 
a-c-a 11.0 2.1 1.9 2.6 0.0 2.5 4.2 7.1 0.0 5.3 1.4 
(15) (3) (2) (l) (0) (1) (1) (1) (0) (2) (1) 
g-t-c 2.2 0.7 1.0 0.0 0.0 2.5 4.2 0.0 0.0 2.6 0.0 
(3) (1) (1) (0) (0) (1) (1) (0) (0) (1) (0) 
g-c-a 3.7 1.4 1.0 2.6 5.6 2.5 4.2 7.1 3.8 0.0 1.4 
(5) (2) (1) (1) (1) (1) (1) (1) (1) (0) (I) 
a-t-e 2.2 2.8 2.9 2.6 5.6 2.5 4.2 7.1 7.7 0.0 1.4 
(3) (4) (3) (I) (I) (1) (1) (1) (2) (0) (1) 
g-t-a 1.5 1.4 1.0 2.6 5.6 5.0 4.2 0.0 0.0 2.6 0.0 
(2) (2) (I) (1) (I) (2) (I) (0) (0) (1) (0) 
Total number of 136 142 104 38 18 40 24 14 26 38 72 
chromosomes 
Table 6.99 IL-10 -1117/854/627 3-locus haplotype frequencies in normal control and patient subjects, and patients grouped according to 
disease severity and aetiology as previously. 
Frequencies (%) and actual number (in brackets) of IL-l 0 -1117 I 854 I 627 3-locus haplotypes able to be detennined in each group are shown. 
3-locus haplotypes were assigned when an individual was homozygous at two or more loci. This was not possible in all subjects so the total number of patients 
is also given (nln). The difference between control and patient groups as previously noted in Table 6.96 is shown, but comparison between groups is limited 
due to the small number in each group. 
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IL-10 -1117 I 854 Controls Study patients 
2-locus haplotype n=981127 n=991124 
% % 
g-c 42.9 51.0 
(84) (101) 
a-c 36.7 30.3 
(72) (60) 
a-t 15.8 14.1 
(3 1) (28) 
g-t 4.6 4.5 
(9) (9) 
Total number of 196 198 
chromosomes 
Table 6.100 IL-10 -1117 I 854 2-locus haplotypes in normal control and patient 
subjects 
Frequencies(%) and actual number (in brackets) ofiL-1 0 -1117 I 854 2-locus haplotypes 
able to be determined in each group are shown. 
n number of patients 
(n) number of chromosomes 
2-locus haplotypes were assigned when an individual was homozygous at one or more loci. 
This was not possible in all subjects so the total number of patients is also given (n/n). 
Comparisons were made between patient and control groups using 2x2 contingency tables 
and the x2 test. P values were corrected for the number of comparisons made. 
No differences are seen in gene frequency between control and patient groups. 
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IlrlO -1117 I 627 Controls Study patients 
2-locus haplotype n=861127 n=92/124 
o;o o;o 
··--·--··--·--·----
g-c 43.0 48.9 
(74) (90) 
a-a 27.9 17.9 
(48) (33) 
a-c 23.3 24.5 
(40) (45) 
g-a 5.8 8.7 
( 10) (16) 
Total number of 172 184 
chromosomes 
Table 6.101 IL-10 -1117 I 627 2-locus haplotypes in normal control and patient 
subjects 
Frequencies (%) and actual number (in brackets) of IL-l 0 -1117 I 854 2-locus haplotypes 
able to be determined in each group are shown. 
n number of patients 
(n) number of chromosomes 
2-locus haplotypes were assigned when an individual was homozygous at one or more loci. 
This was not possible in all subjects so the total number of patients is also given (nln). 
Comparisons were made between patient and control groups using 2x2 contingency tables 
and the x2 test. P values were corrected for the number of comparisons made. 
No differences are seen in gene frequency between control and patient groups. 
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IL-10 -854 I 627 Controls Study patients 
2-locus haplotype n=921127 n=961124 
o;o 0/o 
c-c 64.1 67.7 
( 118) (130) 
e-a 17.9 14.6 
(33) (28) 
t-a 13.6 13.5 
(24) (26) 
t-c 4.9 4.2 
(9) (8) 
Total number of 184 192 
chromosomes 
Table 6.102 IL-l 0 -854 I 627 2- locus haplotypes in normal control and patient 
subjects 
Frequencies (%) and actual number (in brackets) of IL-l 0 -1 117 I 854 2-locus haplotypes 
able to be determined in each group are shown. 
n number of patients 
(n) number of chromosomes 
2-locus haplotypes were assigned when an individual was homozygous at one or more loci. 
This was not possible in all subjects so the total number of patients is also given (n/n). 
Comparisons were made between patient and control groups using 2x2 contingency tables 
and the l test. P values were corrected for the number of comparisons made. 
No differences are seen in gene rrequency between control and patient groups. 
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Controls Study Mild Severe Local OFS;:o:2 OFS;:o:3 OFS;:o:4 Alcohol ldiopath G\stones IL-l 0 -1117 I 854 patients complic!! 
2-locus haplotype n=98 n=99 n=52 n=l9 n=9 n=20 n=l2 n=7 n=13 n=l9 n=36 
0/o o;o o;o o/o 0/o 0/o o/o o;o Dfo % % 
g-c 42.9 51.0 51.4 50.0 50.0 50.0 60.0 55.6 55.6 54.8 49.1 
(84) {101) (74) (27) (13) (25) (18) (I 0) (20) (23) (55) 
a-c 36.7 30.3 31.3 27.8 23.1 32.0 20.0 27.8 25.0 21.4 32.1 
(72) (60) {45) (15) (6) (16) (6) (5) (9) (9) (36) 
a-t 15.8 14.1 13.2 16.7 23.1 10.0 10.0 11.1 16.7 14.3 15.2 
(31) (28) (19) (9) (6) (5) (3) (2) (6) (6) (17) 
g-t 4.6 4.5 4.2 5.6 3.8 8.0 10.0 5.6 2.8 9.5 3.6 
(9) (9) (6) (3) (1) (4) (3) (I) (I) {4) (4) 
Total number of 196 198 144 54 26 50 30 18 36 42 112 
chromosomes 
Table 6.103 IL-l 0 -1117 I 854 2-locus haplotype frequencies in normal control and patient subjects, and patients grouped according to disease 
severity and aetiology as previously. 
Frequencies (%) and actual number (in brackets) of IL-l 0 -Ill 7 I 854 2-locus haplotypes able to be determined in each group are shown. 
n number of patients 
(n) number of chromosomes 
2-locus haplotypes were assigned when an individual was homozygous at one or more loci. This was not possible in all subjects . 
Comparisons were made between patient and control groups using 2x2 contingency tables and the x2 test. P values were corrected for the number of 
comparisons made. 
No differences are seen in gene frequency between control and patient groups. 
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Controls Study Mild Severe Local OFS;:?:2 OFS;:?:3 OFS;:?:4 Alcohol ldiopath G\stones IL-10-1117 1627 patients J' n comp •c-
2-locus haplotype n=86 n=92 n=52 n=19 n=9 n=20 n=12 n=7 n=13 n=19 n=36 
0/o 0/o % % 0/o 0/o % 0/o 0/o % 0/o 
g-c 43.0 48.9 49.3 47.8 50.0 55.6 60.7 50.0 50.0 54.8 49.0 
(74) (90) (68) (22) (9) (25) (17) (8) (16) (23) (51) 
a-a 27.9 17.9 16.7 21.7 11.1 15.6 10.7 12.5 15.6 16.7 17.3 
(48) (33) (23) (10) (2) (7) (3) (2) (5) (7) (18) 
a-c 23.3 24.5 26.1 19.6 22.2 15.6 17.9 25.0 25.0 19.0 26.0 
(40) (45) (36) (9) (4) (7) (5) (4) (8) (8) (27) 
g-a 5.8 8.7 8.0 10.9 16.7 13.3 10.7 12.5 9.4 9.5 7.7 
(1 0) (16) ( 11) (5) (3) (6) (3) (2) (3) (4) (8) 
Total number of 172 184 138 46 18 45 28 16 32 42 104 
chromosomes 
Table 6.104 IL-10 -1117 I 627 2-locus haplotype frequencies in normal control and patient subjects, and patients grouped according to disease 
severity and aetiology as previously. 
Frequencies (%) and actual number (in brackets) of IL-10 -1117 I 627 2-locus haplotypes able to be determined in each group are shown. 
n number of patients 
(n) number of chromosomes 
2-locus haplotypes were assigned when an individual was homozygous at one or more loci. This was not possible in all subjects. 
Comparisons were made between patient and control groups using 2x2 contingency tables and the x2 test. P values were corrected for the number of 
comparisons made. 
No differences are seen in gene frequency between control and patient groups. 
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Controls Study Mild Severe Local OFS~2 OFS~3 OFS~4 Alcohol Idiopath G\stones IL-10 -854 I 627 patients complic" 
2-locus haplotype n=92 n=96 n=52 n=19 n=9 n=20 n=12 n=7 n=13 n=19 n=36 
o;o o;o o;o o;o o;o o;o % % o;o o;o % 
c-c 64.1 67.7 68.8 64.6 50.0 72.7 73.1 68.8 67.6 62.5 72.0 
( 118) (130) (99) (31) (15) (32) (19) ( 11) (23) (30) (72) 
e-a 17.9 14.6 15.3 12.5 16.7 11.4 11.5 18.8 11.8 10.4 15.0 
(33) (28) (22) (6) (5) (5) (3) (3) (4) (5) (15) 
t-a 13.6 13.5 11.8 18.8 26.7 11.4 7.7 6.3 17.6 20.8 11.0 
(24) (26) (17) (9) (8) (5) (3) (I) (6) (10) ( 11) 
t-c 4.9 4.2 4.2 4.2 6.7 4.5 7.7 6.3 2.9 6.3 2.0 
(9) (8) (6) (2) (2) (2) (2) (1) (1) (3) (2) 
Total number of 184 192 144 48 30 44 26 16 34 48 100 
chromosomes 
Table 6.105 IL-10 -854 I 627 2-locus haplotype frequencies in normal control and patient subjects, and patients grouped according to disease 
severity and aetiology as previously. 
Frequencies (%) and actual number (in brackets) of ll...-1 0 -854 I 627 2-locus haplotypes able to be determined in each group are shown. 
n number of patients 
(n) number of chromosomes 
2-locus haplotypes were assigned when an individual was homozygous at one or more loci. This was not possible in all subjects. 
Comparisons were made between patient and control groups using 2x2 contingency tables and the x2 test. P values were corrected for the number of 
comparisons made. 
No differences are seen in gene frequency between control and patient groups 
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6.17 IL-lO.G /-1117 I -854 I -627 haplotypes 
The IT__- I O.G locus is also close to the 3 hi-allelic polymorphisms at -1117, -854, and -627. 
It starts only c. 34 bp from the -1117 locus. Haplotypes can also be expected to exist 
between the 4 loci. Table 6. I 06 shows frequencies of the 3 locus (3 hi-allelic 
polymorphisms), and 4-locus haplotypes (3 bi-allelic polymorphisms and IT__-IO.G locus) in 
normal controls and provides evidence that allelic associations occur. 
It was possible to determine IT__- I 0 G I -11 I 7 2-locus haplotypes in 7 5/124 ( 60. 5%) of 
subjects, -1117 I 854 I 627 3-locus haplotypes in 71/124 subjects (57.3%), and ll__-10.G I -
1117 I 854 I 627 3-locus haplotypes in 43/124 subjects (34. 7%). 
An allelic association (haplotype) is seen to occur between IL-l O.G9 and -1117.A Cl =9.5, 
p=0.002). 
The -1117 I -854 I -627 3-locus haplotype G-C-C is confirmed to exist at higher frequency 
than could be expected by non-random association ofalleles (X2 =16.9, p<O.OOOI), as is the 
A-T -A haplotype (X2 =20.2, p<O.OOOO I). The haplotypes A-C-C and A-C-A occur as 
frequently as expected from random association, whilst the 3-locus combinations G-T -C 
(l=6.8, p=0.009), G-C-A Cl =10.3, p=O.OOl), A-T-C (x2=5.5, p=0.0!9), and G-T-A 
(x2=3.3, p=0.067) occur much less frequently than can be expected from random 
association confirming that linkage disequilibrium occurs between the 3 loci to produce the 
increased frequency of the haplotypes G-C-C and A-T -A. 
Haplotypes also exist between ll__-IO.G and the 3 hi-allelic loci. ll__-IO.G9 is seen to 
associate with the 3-locus haplotype A-T-A (Fishers exact test, p<O.OOOI). 
In the patient group (Table 6.1 07), similar associations are seen. However, no association is 
seen between IT__- I O.G9 and -1117.A. The 3-locus haplotype A-C-A is seen at a lower 
frequency than is expected (x2=10.2, p=O.OOI), and the ll___G9 association with the 3-locus 
haplotype A-T -A, although present at slightly higher frequency, does not approach 
statistical significance (Fishers exact test, p=O. 19). The A-T -A haplotype is present at lower 
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,l 
I' I 
ffequency:iri:,sttidy:patients compa~edi to coritrois;.which may accourit for this. 
H iis not: possible to compare.·i'~lbctiS associatiorHi· oetween ·patient groups, as: numbers1are 
too small. 
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IL-10.G I -1117 I -854 I -627 Expected Observed 
haplotypes 
IL-10.G "l 
-1117 -854 -627 n Freq. n Freq. 
9 A 27.0 20.6 43 32.8 9.5 I 
9 G 30.4 23.2 27 20.6 0.4 
13 A 13.0 10.0 12 9.2 0.1 
13 G 14.8 11.3 18 13.7 0.7 
X A 21.5 16.4 30 22 9 3.4 
X G 24.2 18.5 11 8.4 7.2 
G c c 34.0 25.0 58 42.6 16.9 2 
A c c 30.3 22.3 33 24.3 0.3 
A T A 6.0 4.4 17 12.5 20.2 J 
A c A 17.0 12.5 15 11.0 0.2 
G T c 12.0 8.8 3 2.2 6.8 4 
G c A 19.0 14.0 5 3.7 IOJ 5 
A T c 10.6 8.0 3 2.2 5.5 6 
G T A 6.7 4.9 2 1.5 3J 
9 G c c 11.6 18.7 13 19.7 0.2 
9 A c c 66 10 6 0 0.0 6.5 7 
9 A T A 3.4 5.5 15 22.7 p<0.003 H 
9 Other haplotype 5.9 9.0 5 7.6 0.15 
13 G c c 5.6 9.1 10 15.2 3.46 
13 Other haplotype 8.0 12.2 5 7.6 1.1 
X G c c 9.8 14.9 7 10.6 0.8 
X Other haplotype 13.2 20.0 8 12.1 2.0 
Table 6.106 IL-lO.G I -1117 I -854 I -627 haplotype frequencies(%) in normal 
controls 
Shows frequency (%) ofiL-1 0. G I -1117 I -854 I -627 haplotype in the 5' flanking region of 
the IL-l 0 gene on chromosome I in normal controls. 
X -IL-IO.G allele, not G9 or GI3 
I. x2 =9.5, p=o.oo2 
2. x2 =16.9, p<O.OOOI 
3. X2 =20.2, p<O.OOOOI 
4. l=6.8, p=0.009 (negative association) 
5. x2 =I 0.3, p=O.OO I (negative association) 
6. x2=5.5, p=O.O 19 (negative association) 
7. x2=6.5, p=O.Ol (negative association) 
8. As cell value is <5, x2 statistic not valid. Fishers exact test, p<0.003 
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Able to determine 11L-I O•G ,f. -1!;!1!i7 2"locus haplotypes in 65/127 subjects 
Able to determine -I 117/854 / 627 3-locus haplotypes in 68/l27 subjects 
Able. to .determine i:f> 101G I "I 1'1 7 I 854/'627 3~locus haplotypes in JJI/'127 subjects 
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JL..IO.G I -1117 I -854 I -627 Expected Observed 
haplotypes 
··!! 
IL-lO.G 
-1117 -854 -627 n Freq. n Freq. 
9 A 27.6 18.4 29 19.3 0.1 
9 G 35.3 23.5 42 28.0 1.3 
13 A 12.9 8.6 11 7.3 0.3 
13 G 16.5 11.0 18 12.0 0.1 
X A 25.4 16.9 23 15.3 0.2 
X G 32.4 21.6 27 18.0 0.9 
G c c 39.9 28.1 84 59.2 48.7 I 
A c c 31.4 22.1 33 23.2 0.1 
A T A 5.3 3.7 13 9.2 11.2 2 
A c A 15.6 11.0 3 2.1 10.2 3 
G T c 13.9 9.8 0.7 12.0 4 
G c A 19.7 13.9 2 1.4 15.9 5 
A T c 10.5 7.4 4 2.8 4.0 
G T A 6.5 4.6 2 1.4 3.1 
9 G c c 21.3 24.8 28 32.2 2.1 
9 A c c 8.4 9.7 2 2.3 4.9 6 
9 A T A 3.3 3.9 7 8.0 p=O 167 
9 Other haplotype 3.0 3.5 2 2.3 n/a 
13 G c c 10 11.6 12 13.8 0.4 
13 Other haplotype 6.8 7.9 5 5.7 0.5 
X G c c 19.6 22.8 26 29.9 2.1 
X Other haplotype 13.5 15.7 5 5.7 5.35 
Table 6.107 JL..lO.G I -1117 I -854 I -627 haplotype frequencies(%) in patients 
Shows frequency(%) ofiL-1 O.G I -1117 I -854 I -627 haplotype in the 5' flanking region of 
the LL-1 0 gene on chromosome I in patients. 
X -IL-IO.G allele, not G9 or Gl3 
I. x2=48.7, p<l0"5 
2. x2=II.2, p=o.ooo8 
3. x2=10.2, p=O.OOI4 
4. x2=12.0, p=0.00053 
5. /=15.9, p=0.00007 
6. x2=4.9, p=0.27 (negative association) 
7. Expected cell value <5, x2 statistic not valid. Fishers exact test, p=O.l9 
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Able, to deterrriinelLlO.G f: -1.117:2-l_ocu~ h!lplotypes in: 7~/1~4 subjects' 
A'bleito determine -)1)1)17/:ss4· / 627"3-locus !naplotypes in· 71/124 subj~cts 
.A:ble:to deiermineJb I O.G I -:Ji!,li7 t854 /627 3-locuslhaplotypes in,43/124 subjects 
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6.18 TNF locus and IL-10 locus genotype associations 
Because the functions of IL-l 0 and TNF can be considered counter -regulatory with respect 
to the regulation of inflammation, it is of import to consider whether certain alleles or 
genotypes of each locus, which may have functional relevance by affecting TNF and IL-l 0 
protein levels, occur in particular association in individuals. In this study, the analysis of 
associations of genotypes of the two cytokine genes is limited, as many loci are multi-allelic, 
producing many possible genotypes, so numbers of associations will be small. 
6.18.1 IL-IO.G microsatellite and TNFabc microsatellite 3-locus haplotype 
associations. 
Table 6.108 shows that there is no association between IL-l 0. G genotypes containing allele 
G9 and TNFabc 3-locus genotypes containing certain haplotypes. Likewise Table 6.109 
shows no association between IL-l O.G genotypes containing allele G 13 and TNFabc 3-
locus genotypes. It is not possible to analyse individual genotype associations as most 
subjects are heterozygous at all 4 microsatellite loci. Furthermore it is pertinent to mention 
that the IL-IO.G genotype G9,13 is present in 25% of control subjects, so there is some 
crossover between these two analyses. 
The same analysis was done for the acute pancreatitis patients, IL-l 0. G genotypes 
containing allele G9 are shown in table 6. 110 for patients classified as having mild 
pancreatitis. It was not possible to ascertain associations involving the G 13 allele because of 
the small numbers involved. Likewise analysis of patients with severe disease was not 
possible due to the small numbers involved. 
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IL-10.G9 containing Expected Observed 
genotype I TNFabc 
xl 
association n Freq. n Freq. 
G 9- a2blc2 19.1 9.2 20 9.6 0.0 
G 9- a2b3cl 22.4 10.8 21 10.1 0.1 
G 9- a2b5c2 6.9 3.3 8 3.9 0.2 
G 9- a6b5cl 21.0 10.1 18 8.7 0.4 
G 9x- a7b4cl 9.4 4.5 9 4.3 0.0 
G 9x- allb4cl 23.9 11.5 23 11.1 0.0 
G 9x- al0b4cl 12.3 5.9 12 5.8 0.0 
G 9x- a4b5cl 8.9 4.3 9 4.3 0.0 
G9x- X 17. I 8.2 19 9.1 0.5 
Table 6.108 Association of IL-lO.G microsatellite genotype containing allele G9 with 
TNFabc haplotype in normal controls 
Shows a lack of an association between possession of genotype containing allele 9 of 
IL-l O.G and possession of a copy of the TNFabc 3-locus haplotype in normal controls. 
X -undetermined TNFabc haplotype 
Only those combinations with an expected number of>5 are included. 
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lL-1 O.G 13 containing Expected Observed 
genotype I TNFabc 
·l association n Freq. n Freq. 
---------·-··----·-···--·· --··-··-----·--
G 13x- a2blc2 11.0 5.6 13 6.6 0.4 
G 13x- a2b3cl 13.0 6.6 13 6.6 0.0 
G 13x- a6b5cl 12.2 6.2 13 6.6 0.1 
G 13x- allb4cl 13.9 7.1 11 5.6 0.6 
G 13x- a10b4cl 7.1 3.6 8 4.1 0.1 
G 13x- a4b5cl 5.1 2.6 6 3.0 0.2 
G 13x- X 9.9 5.0 10 5.1 0.0 
Table 6.109 Association of IL-lO.G microsatellite genotype containing allele G 13 
with TNFabc haplotype in normal controls 
Shows a lack of an association between possession of genotype containing allele 13 of 
IL-10.G and possession of a copy ofthe TNFabc 3-locus haplotype in nonnal controls. 
X -undetermined TNFabc haplotype 
Only those combinations with an expected number of>S are included. 
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IL-l O.G9 containing Expected Observed 
genotype I TNFabc 
xz 
association n Freq. n Freq. 
G 9- a2blc2 14.7 7.8 20 10.6 1.9 
G 9- a2b3cl 10.5 5.6 13 6.9 0.6 
G 9- a6b5cl 19.8 10.5 23 12.2 0.5 
G 9x- a7b4cl 6.8 3.6 4 2.1 1.2 
G 9x- all b4cl 22.6 12.0 24 12.8 0.1 
G 9x- a10b4cl 7.3 3.9 8 4.3 0.1 
G 9x- a4b5cl 8.5 4.5 10 5.3 0.3 
G 9x-X 10.1 5.4 11 5.9 0.1 
Table 6.110 Association of IL-IO.G microsatellite genotype containing allele G9 with 
TNFabc haplotype in patients classified as having mild pancreatitis 
Shows a lack of an association between possession of genotype containing allele 9 of 
IL-JO.G and possession of a copy of the TNFabc 3-locus haplotype in patients classified as 
having mild pancreatitis. 
X - undetermined TNFabc haplotype 
Only those combinations with an expected number of>5 are included. 
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" I. I. ;6;18.21Ik lO.G microsat'ellite and ;J'NF -308'genotype associations. 
A: similar:a1111Wsis wai{tlnder:takeri to ilookfor•an 'association ibetv.(een ifL-1 O!G,genotypes 
confaining aiieJeiG9: or'Gl3 and.:rNF ~3Q8 igel}otypes., Table 6,111 shows a clack ofany 
such:association in 1normaJ :control! subjects; Whilst tao)e,(), fl2 sl10Wsi the same in patient 
subjects. 
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IL-10.G9 or GI3 Expected Observed 
containing genotype I 
·l TNF-308 genotype n Freq. n Freq. 
association 
IL-lO.G 9x- GG 41.4 44.5 40 43.0 0.0 
IL-IO.G 9x- GA 18.8 20.3 20 21.5 0.1 
IL-lO.G 9x- GA\AA 23.6 25.4 24 25.8 0.0 
IL-lO.G 13x- GG 23.9 25.7 25 26.9 0.1 
IL-lO.G 13x- GA 11.0 11.8 IS 16.1 1.5 
IL-lO.G 13x- GA\AA 13.7 14.7 16 17.2 0.4 
Table 6.111 Association between IL-10.G9 and .G13 containing genotype and TNF 
-308 genotypes in normal controls 
Shows lack of any association between IL-IO.G9 and .Gl3 containing genotypes with TNF 
-308 genotypes in normal controls 
IL-10.G9 or G13 Expected Observed 
containing genotype I 
·l TNF-308 genotype n Freq. n Freq. 
association 
lL-lO.G 9x- GG 62.9 48.4 61 46.9 0.1 
IL-lO.G 9x- GA 23.7 18.2 24 18.5 0.0 
IL-lO.G 9x- GA\AA 25.6 19.7 26 20.0 00 
IL-IO.G 13x- GG 32.1 24.7 31 23.8 0.0 
IL-lO.G 13x- GA 12.1 9.3 !I 8.5 0.1 
IL-IO.G 13x- GA\AA 13.1 10.1 13 10.0 0.0 
Table 6.112 Association between IL-IO.G9 and .Gl3 containing genotype and TNF 
-308 genotypes in study patients 
Shows frequency(%) ofiL-IO.G9 and IL-IO.Gl3 containing genotypes occurring with 
TNF -308 genotypes. 
There is no association between IL-l 0. G9 and. G 13 containing genotypes and TNF-308 
genotypes in study patients. 
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6.18.3 TNFabc microsatellite putative secretor status combinations and IL-lO.G 
microsatellite genotype association. 
Because it is possible to assign a smaller number of putative secretor status 'genotypes' to 
the TNFabc 3-locus genotypes instead of using the 3-locus genotype itself (which has many 
different genotypes), an association was looked for between putative secretor 'genotypes' 
and ll...-1 0. G genotypes containing allele 9 or 13. Tables 6.113 and 6.114 show there is no 
such association in normal controls, and tables 6.115 and 6.116 show the same in the 
patient subjects It was not possible to do this analysis in patient subgroups as numbers were 
too small. 
361 
TNFabc putative Expected Observed 
secretor genotypes and 
1..2 IL-10.G9 containing n Freq. n Freq. 
___g!!!_~~-s -· 
---·-·-----· 
HH- IL-10.G9x 8.9 9.2 9 9.3 0.0 
HI- IL-10.G9x 11 .3 11.7 8 8.2 1.0 
HL- IL-10.G9x 15.9 16.4 21 21.6 1.6 
IL- IL-10.G9x 10.2 10.5 9 9.3 0.1 
LL- ll...-10.G9x 6.3 6.5 5 5.2 0.3 
Other- IL-IO.G9x 13.3 13.7 17 17.5 1.0 
Table 6.113 Association between TNFabc microsatellite 'putative secretor' 
combinations and IL-IO.G microsatellite genotypes containing allele G9 
in normal controls 
Shows the frequency(%) of genotype combinations occurring in normal controls and 
demonstrates an absence of any association. 
Haplotype analysis using 11 putative haplotypes previously characterised in Caucasian 
populations and confirmed in homozygous cell lines. Haplotypes have been determined as 
having high, low, or intermediate (TNFa) secretor phenotypes in response to LPS 
stimulation (Weissensteiner and Lanchbury 1997). 
H- High TNFa secretor phenotype 
L- Low TNFa secretor phenotype 
1- Intermediate TNFa secretor phenotype 
X-Undetermined TNFa secretor phenotype 
Other - HX, Il, IX, and LX 
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TNFabc putative Expected Observed 
secretor genotypes and 
·l IL-lO .. GlJ containing n Freq. n Freq. 
_g_~notypt:~----
--------·-····-----·-·---··-·---- ------------
HH- IL-lO.GlJx 5. I 5.3 3 3.1 0.9 
m- IL-tO.GlJx 6.6 6.8 6 6.2 0.1 
HL- IL-lO.GlJx 9.2 9.5 14 14.4 2.5 
IL- IL-lO.GlJx 5.9 6.1 8 8.2 0.7 
Other- IL-lO.GlJx 11.3 11.6 10 10.3 0.1 
Table 6.114 Association between TNFabc microsatellite 'putative secretor' 
haplotypes and IL-IO.G microsatellite genotypes containing allele GtJ 
in normal controls 
Shows the frequency(%) of genotype combinations occurring in normal controls and 
demonstrates an absence of any association. 
Haplotype analysis using 11 putative haplotypes previously characterised in Caucasian 
populations and confirmed in homozygous cell lines. Haplotypes have been determined as 
having high, low, or intermediate (TNFa) secretor phenotypes in response to LPS 
stimulation (Weissensteiner and Lanchbury 1997). 
H- High TNFa secretor phenotype 
L- Low TNFa secretor phenotype 
1- Intermediate TNFa secretor phenotype 
X-Undetermined TNFa secretor phenotype 
Other- HX, II, IX, LL, and LX 
363 
TNFabc putative Expected Observed 
secretor genotypes and 
·t IL-lO.G9 containing n Freq. n Freq. 
genotypes 
HH- IL-lO.G9x 8.3 6.5 12 9.4 1.6 
HI - IL-l O.G9x 15.4 12.1 14 11.0 0.1 
HL- IL-lO.G9x 19.2 15.1 21 16.5 0.2 
HX- IL-10.G9x 6.4 5.0 5 3.9 0.3 
IL- IL-10.G9x 15.4 12.1 17 13.4 0.2 
LL - IL-l O.G9x 6.4 5.0 8 6.3 0.4 
LX- IL-10.G9x 9.0 7.1 8 6.3 0.1 
Other- IL-10.G9x 6.4 5.0 5 3.9 OJ 
Table 6.115 Association between TNFabc microsatellite 'putative secretor' 
haplotypes and IL-lO.G microsatellite genotypes containing allele G9 in 
study patients 
Shows the frequency(%) of genotype combinations occurring in normal controls and 
demonstrates an absence of any association. 
Haplotype analysis using 11 putative haplotypes previously characterised in Caucasian 
populations and confirmed in homozygous cell lines. Haplotypes have been determined as 
having high, low, or intermediate (TNFa) secretor phenotypes in response to LPS 
stimulation (Weissensteiner and Lanchbury 1997). 
H- High TNFa secretor phenotype 
L- Low TNFa secretor phenotype 
I- Intermediate TNFa secretor phenotype 
X-Undetermined TNFa secretor phenotype 
Other -IT and IX 
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TNFabc putative Expected Observed 
secretor genotypes and 
1.2 IL-lO.GlJ containing n Freq. n Freq. 
_genotypes 
----·------------···-·· 
HI- IL-lO.GlJx 7.9 6.2 lO 7.9 0.6 
HL- IL-lO.GIJx 9.8 7.7 10 7.9 00 
IL- IL-10.G13x 7.9 6.2 4 3.1 1.9 
Other- IL-lO.GlJx 18.8 14.8 23 18.1 0.9 
Table 6.116 Association between TNFabc microsatellite 'putative secretor' 
haplotypes and IL-l O.G microsatellite genotypes containing allele G 13 
in study patients 
Shows the frequency(%) of genotype combinations occurring in normal controls and 
demonstrates an absence of any association. 
Haplotype analysis using 11 putative haplotypes previously characterised in Caucasian 
populations and confirmed in homozygous cell lines. Haplotypes have been determined as 
having high, low, or intermediate (TNFa) secretor phenotypes in response to LPS 
stimulation (Weissensteiner and Lanchbury 1997). 
H- High TNFa secretor phenotype 
L- Low TNFa secretor phenotype 
1- Intermediate TNFa secretor phenotype 
X-Undetermined TNFa secretor phenotype 
Other- BB, BX, IJ, IX, LL, and LX 
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,6.}8.4 l'_NF -~OII~genocype arid IL-l 0 -11,,17, -854\ and -627 genotype asso~iatioJ~s., 
Anrassociation was 'looked for !between 1]\IG -3 68\geiiotypes and genotypes :occurfing!at 
;the 3 ibi-ailelic iloci:whhin ,the It-1'0 promoterregitm:. 
'Fables '6. l ~it 6, j 18, and.i6.111.9 showlthere' is no 'SUch:association:in ;nofm!ll !CO[ltt()Is; <l!ld 
tables,,6.120, ~6121, .andi6: ]22 show there is!no~.such association in, study subj~cts: It was 
not possible-to do<this analysis i_n P!ltie~t st}bgtoups:as' numbers.are too small. 
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TNF -308 genotype I Expected Observed 
IL-l 0 -1117 genotype 
n Freq. n Freq. ·l 
GG-GG 13.6 14.5 IS 16.0 0.1 
GG-GA 27 30.5 30 31.9 0.1 
GG-AA 17.4 18.5 18 19.1 0.0 
GA-GG 6.3 6.7 3 3.2 1.7 
GA-GA 13.3 14.1 16 17.0 0.5 
GA-AA 8.0 8.5 6 6.4 0.5 
AA-GGIGA/AA 6 6.4 n!a 
Table 6.117 Association between TNF -308 and IL-10. -1117 genotypes in normal 
controls 
Shows a lack of any association between genotypes of the TNF -3 08 and IL-10 -I 117 loci. 
Expected frequencies for individual TNF.AA associations are not shown as they are <5. 
TNF -308 genotype I 
IL-l 0 -854 genotype 
GG-CC 
GG-CT 
GG-TT 
GA-CC 
GA-CT 
GA-TT 
AA - CC I CT I TT 
Expected 
n Freq. 
33.9 36.4 
19.6 21.1 
5.6 6.0 
I 5.5 16.7 
9.0 9.7 
2.7 2.9 
Observed 
n Freq. 
36 38.7 0.1 
17 18.3 0.4 
5 5.4 0.1 
14 I 5.1 0.2 
10 10.8 0.1 
2 2.2 n!a 
6 6.4 nla 
Table 6.118 Association between TNF -308 and [L-10. -854 genotypes in normal 
controls 
Shows a lack of any association between genotypes of the TNF -308 and IL-l 0 -854 loci. 
Expected frequencies for individual TNF.AA associations are not shown as they are <5. 
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TNF -308 genotype I Expected Observed 
IL-10 -627 genotype 
n Freq. n Freq. ·i 
----------------------·----·--·------------------------------------------------------------------
GG-CC 24.0 26.1 27 29.3 0.4 
GG-CA 26.7 29.0 27 29.3 0.0 
GG-AA 7.8 8.5 6 6.5 0.4 
GA-CC 11.0 12.0 10 10.9 0.1 
GA-CA 12.2 13.3 11 12.0 0.1 
GA-AA 3.7 4.0 5 5.4 n/a 
AA-CC/CA/AA 6 6.4 n/a 
Table 6.119 Association between TNF -308 and IL-10. -627 genotypes in normal 
controls 
Shows a lack of any association between genotypes of the TNF -3 08 and lL-1 0 -62 7 loci. 
Expected frequencies for individual TNF.AA associations are not shown as they are <5. 
TNF -308 genotype I Expected Observed 
IL-10 -1117 genotype 
n Freq. n Freq. ·i 
-----------
GG-GG 23.3 21.2 24 21.8 0.0 
GG-GA 40.3 36.6 39 35.5 00 
GG-AA 14.4 13.1 15 13.6 0.0 
GA-GG 8.8 8.0 8 7.3 0.1 
GA-GA 15.2 13.8 18 16.4 0.5 
GA-AA 5.4 4.9 4 3.6 04 
AA-GG/GA/AA 2 1.8 n/a 
Table 6.120 Association between TNF -308 and IL-l 0. -1117 genotypes in study 
patients 
Shows a lack of any association between genotypes of the TNF -308 and IL-l 0 -1117 loci. 
Expected frequencies for individual TNF.AA associations are not shown as they are <5. 
This type of analysis is not possible for the patient subgroups as expected numbers are 
small. 
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TNF -308 genotype I Expected Observed 
IL-l 0 -854 genotype 
n Freq. n Freq. -t 
---------·-···--···--·-·················· .. ······-------··----··-·········-···-···-····----·············----------- --------
GG-CC 46.0 41.4 51 45.9 0.5 
GG-CT 31.4 28.3 21 18.9 3.4 
GG-TT 6.2 5.6 7 6.3 0.1 
GA-CC 17.3 15.6 11 9.9 2.3 
GA-CT 11.9 10.7 16 14.5 1.4 
GA-TT 2.3 2.1 3 2.7 n/a 
AA - CC I CT I TT 6 6.4 n/a 
Table 6.121 Association between TNF -308 and fL-10. -854 genotypes in study 
patients 
Shows a lack of an association between genotypes of the TNF -308 and IL-10 -854 loci. 
Expected frequencies for individual TNF.AA associations are not shown as they are <5. 
This type of analysis is not possible for the patient subgroups as expected numbers are 
small. 
TNF -308 genotype I 
IL-10 -627 genotype 
GG-CC 
GG-CA 
GG-AA 
GA-CC 
GA-CA 
GA-AA 
AA-CC/CA/AA 
Expected 
n Freq. 
33 5 33.5 
27.8 27.8 
97 9.7 
12.6 12.6 
10.4 10.4 
3.6 3.6 
Observed 
n Freq. 
41 41.0 1.3 
17 17.0 4.2 
10 10.0 0.0 
11 11.0 0.2 
14 14.0 1.2 
5 5.0 n/a 
2 2.0 n/a 
Table 6.122 Association between TNF -308 and IL-10. -627 genotypes in study 
patients 
Shows a lack of an association between genotypes ofthe TNF -308 and IL-10 -854loci. 
Expected frequencies for individual TNF.AA associations are not shown as they are <5. 
This type of analysis is not possible for patient subgroups as expected numbers are small. 
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6.18.5 TNFabc microsatellite putative secretor status combinations and IL-l 0 -1117, 
-854, and -627 genotype associations 
Because it is possible to assign a smaller number of putative secretor status 'genotypes' to 
the TNFabc 3-locus genotypes instead of using the 3-locus genotype itself(which has many 
different genotypes), an association was looked for between putative secretor 'genotypes' 
and IL-l 0 -1117, -854, and -627 genotypes. Even by assigning putative secret or status 
'genotypes' numbers are too small for meaningful comparison. Therefore an association was 
looked for between high, intermediate, and low secretor status containing 'genotypes and 
IL-l 0 -1117, -854, and -627 genotypes. This type of analysis has it's limitations, as it does 
not consider what an individual's other haplotype is, or what effect it may have upon TNFa 
secretor phenotype. Also no data exists as to whether there are dominant functional 
haplotypes, and what they may be. Table 6.123 shows there is no association between 
putative secretor status 'genotypes' containing copies of haplotypes assigned as having a 
high secretor status and any of the genotypes at the -1117, -854, and -627 loci in normal 
controls. Similarly no association is seen with putative secretor status 'genotypes' 
containing copies of haplotypes assigned as having a intermediate or low secretor status and 
any of the three IL-l 0 hi-allelic loci (tables 6.124 and 6.125). Tables 6.126, 6.127, and 
6. 128 show similar findings in study patient subjects. 
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TNFabc 'high secretor' Expected Observed 
containing genotypes and 
x2 IL-10 -1117- 854, and- n Freq. 11 Freq. 
627 genotypes 
- 1117 
Hx-GG 13.9 7.8 8 4.4 2.5 
Hx-GA 29.4 16.3 35 19.4 1.1 
Hx-AA 17.8 9.9 18 10.0 0.0 
-854 
Hx-CC 36.1 19.4 40 21.5 0.4 
Hx-CT 11.9 6.4 18 9.7 3.1 
Hx-TT 6.1 3.3 5.0 2.7 0.2 
-627 
Hx-CC 26.8 14.0 27 14.1 0.0 
Hx-CA 29.7 15.5 36 18.8 1.3 
Hx-AA 8.8 4.6 16 8.3 5.9 
Table 6.123 Showing frequency (%)of the association of TNFabc 'putative secretor' 
containing genotypes with IL-10 -1117 genotypes in normal controls 
Shows a lack of any association between TNFabc ' high putative secretor' containing 
genotypes and IL-l 0 -1117, - 854, and- 627 genotypes. It was not possible to compare 
putative secretor 'genotypes' as expected numbers are too small. The total X2 = 11.0, 
p=0.2, (8 d. f), indicating normal distribution in this analysis, so it is unlikely an association 
is seen with H-1-L 'genotypes'. 
Haplotype analysis using 11 putative haplotypes previously characterised in Caucasian 
populations and confirmed in homozygous cell lines. Haplotypes have been determined as 
having high, low, or intermediate (TNFa) secretor phenotypes in response to LPS 
stimulation (Weissensteiner and Lanchbury 1997). 
Hx- High secretor haplotype with any other haplotype 
Lx- Low secretor haplotype with any other haplotype 
Ix- Intermediate secretor haplotype with any other haplotype 
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TNFabc 'intermediate Expected Observed 
secretor' containing 
·l genotypes and IL-10 -1117, n Freq. n Freq. 
- 854, and - 627 geno~_ 
- 1117 
Ix- GG 8.6 4.8 7 3.9 0.3 
Ix- GA 18.8 10.0 21 11.7 0.3 
lx-AA 11.0 6.1 11 6.1 0.0 
-854 
Ix- cc 21.0 11.6 19 0.6 0.2 
Ix- CT 12.5 6.9 13 7.2 00 
Ix- TT 3.8 2.1 4 2.2 n/a 
-627 
Ix-CC 16.5 8.6 18 9.4 0.1 
Ix- CA 18.3 9.6 18 9.4 0.0 
Ix- AA 5.4 2.8 6 3.1 0.1 
Table 6.124 Showing frequency(%) of the association ofTNFabc intermediate 
putative secretor containing genotypes with IL-10- 1117 genotypes in 
normal controls 
Shows a lack of any association between TNFabc ' intermediate putative secret or' 
containing genotypes and IL-10 -1117,- 854, and- 627 genotypes. It was not possible to 
compare putative secretor 'genotypes' as expected numbers are too smalL The total x2 = 
1.0, p>0.9, (8 d.t), indicating normal distribution in this analysis, so it is unlikely an 
association is seen with H-I-L 'genotypes'. 
Haplotype analysis using 11 putative haplotypes previously characterised in Caucasian 
populations and confirmed in homozygous cell lines. Haplotypes have been determined as 
having high, low, or intermediate (TNFa) secretor phenotypes in response to LPS 
stimulation (Weissensteiner and Lanchbury 1997). 
Hx- High secretor haplotype with any other haplotype 
Lx- Low secretor haplotype with any other haplotype 
Ix- Intermediate secretor haplotype with any other haplotype 
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TNFabc 'low secretor' Expected Observed 
containing genotypes and 
x2 fL-10 -1117,- 854, and - n Freq. n Freq. 
627 geno~-------
- 1117 
Lx-GG 12.7 7.1 13 7.2 0.0 
Lx-GA 26.8 14.9 29 16.1 0.2 
Lx-AA 16.2 9.0 16 8.9 0.0 
-854 
Lx-CC 31.9 17.7 32 17.8 0.0 
Lx-CT 18.5 10.3 26 14.4 3.0 
Lx-TT 5.5 3.1 7 3.9 0.4 
-627 
Lx-CC 24.4 12.7 22 11.5 0.2 
Lx-CA 27.1 14.1 21 I 0.9 1.4 
Lx-AA 8.1 4.2 6 3.1 0.5 
Table 6.125 Showing frequency(%) of the association ofTNFabc low putative 
secretor containing genotypes with IL-10- 1117 genotypes in normal 
controls 
Shows a lack of any association between TNF abc ' low putative secret or' containing 
genotypes and IL-l 0 -I 1 17, - 854, and- 627 genotypes. It was not possible to compare 
putative secretor 'genotypes' as expected numbers are too smalL The total x2 = 5.7, p>0.6, 
(8 d t), indicating normal distribution in this analysis, so it is unlikely an association is seen 
with H-1-L 'genotypes'. 
Haplotype analysis using 11 putative haplotypes previously characterised in Caucasian 
populations and confirmed in homozygous cell lines. Haplotypes have been determined as 
having high, low, or intermediate (TNFa) secretor phenotypes in response to LPS 
stimulation (Weissensteiner and Lanchbury 1997). 
Hx- High secretor haplotype with any other haplotype 
Lx- Low secretor haplotype with any other haplotype 
lx- Intermediate secretor haplotype with any other haplotype 
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7 Discussion 
This study is the first to characterise TNF and fL-1 0 polymorphisms in patients with acute 
pancreatitis. It also documents allelic, gene, and haplotype frequencies across the 
polymorphic TNF and IL-l 0 loci, and provides description of linkage in the IL-l 0 promoter 
region between haplotypes of the 3 locus bi-allelic system and alleles 9 and 13 of the IL-
IO.G microsatellite. 
In addition it provides considerable demographic data upon a group of 13 5 patients with 
acute pancreatitis and enables the examination of this data in relation to aetiology and 
disease outcome. 
7.1 TNF loci 
Allele and gene frequencies of the TNFabc microsatellite loci and the -308 locus in the 
population ofEuropids studied are similar to those in previously published work (Crouau-
Roy et al., 1993). TNF microsatellite 3-locus haplotype analysis was performed using all 11 
haplotypes described in European populations (see section 4.1.4.3), and haplotype 
frequencies are also similar to those previously published (Crouau-Roy et al., 1993). 
As previously discussed, alleles at the TNF loci are in linkage disequilibrium with each other 
and with class I and IJ alleles. Various previously described associations are seen in the 
normal population studied in this work. These include the negative association of the TNF 
-308.G allele with the TNF a2b3cl haplotype and the association of the -308.G allele with 
the TNFall b4cl haplotype. A new association, not previously reported, was seen between 
the -308.G allele and the TNFa6b5c I haplotype in the normal population. 
This work also shows that there is an association between HLA-DQB I *0201 containing 
genotypes and 3-locus TNFa2b3cl containing genotypes in normal controls. As the analysis 
was performed using genotypes it does not prove linkage, but does strongly suggest it. 
7.2 IL-10 loci 
Allelic frequencies at the three bi-allelic loci ( -1117, -854, and -627) and the IL-l O.G 
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microsatellite allele frequencies were in the main comparable with the previously published 
frequencies (Turner et al, 1997; Eskdale et al, 1997). Only the allele frequencies at position 
-627 were significantly different from these, 627*C and 627* A occurring in 62% and 38% 
of the study population compared to 79%and 21% of the previously characterised 
population (x} = 16.2, p < 0.001 ). However, the observed gene frequencies in the study 
population did not significantly differ from the expected, so Hardy-Weinberg equilibrium 
was established. Heterozygotes and homozygotes were detected at all 4 loci. 
Eight three locus haplotypes of the hi-allelic polymorphisms at positions -1117, -854, and 
-627 were identified, in comparison to previously published work which only identified 3 
haplotypes (Turner et al, 1997). The 4 most common haplotypes accounted for 91% oftotal 
haplotypes. 
The -11 17 I -854 I -627 3-locus haplotype G-C-C has been confirmed to exist at higher 
frequency than could be expected by non-random association of alleles, as is the A-T -A 
haplotype. The haplotypes A-C-C and A-C-A occur as frequently as expected from random 
association, whilst the 3-locus combinations G-T -C, G-C-A, A-T -C, and G-T-A occur 
much less frequently than can be expected from random association confirming that linkage 
disequilibrium occurs between the 3 loci to produce the increased frequency of the 
haplotypes G-C-C and A-T -A 
Haplotypes also exist between IL-IO.G and the 3 bi-allelic loci. IL-IO.G9 is seen to 
associate with the 3-locus haplotype A-T -A No associations are seen with the IL-l O.G 13 
allele. 
This study has provided the first evidence of linkage in the IL-l 0 promoter region between 
haplotypes ofthe 3 locus hi-allelic system and alleles 9 and 13 of the IL-IO.G microsatellite. 
The study of cytokine gene polymorphisms in autoimmune and inflammatory diseases is 
used to identify useful disease associated genetic markers, and to provide insight into 
pathogenic mechanisms of disease at the molecular level. To ensure that all possible genetic 
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markers are studied for a particular gene locus the accurate characterisation of allelic, 
genotypic, and haplotype distribution within normal healthy populations is a prerequisite for 
studies of this type. 
The characterisation of more haplotypes and linkage across the four polymorphic sites in the 
IL-l 0 locus described in this work will aid the analysis of disease in relation to the human 
IL-l 0 promoter, as it identifies increased sequence polymorphism, so providing a more 
powerful tool for population genetic analysis. 
7.3 IL-10 and TNF locus associations 
The analysis of associations of genotypes of the two cytokine genes was limited in this 
study, as many of the loci studied are multi-allelic. This produces many possible genotypes, 
so numbers of associations will be small. 
As expected no associations were seen between loci in the region of the TNF gene and loci 
of IL-l 0 in normal controls. 
7.4 Acute pancreatitis patients 
Two recognised systems for classification of disease outcome were used in this study. The 
Atlanta convention classification (Bradley., 1993) and an organ failure scoring system were 
both used to stratify patients, as not all those classified under the Atlanta system as having 
severe disease have organ failure, and it also does not distinguish between differing severity 
of organ failure. 
Age distribution has been shown to be different in those classified as having severe disease 
(Atlanta) compared to those with mild disease. The same was true for those with an OFS:?:2, 
which is comparable with published data (de Beaux et al., 1995) showing morbidity and 
mortality is related to age. However, no difference in distribution of age was seen between 
patients with mild disease and those with higher degrees of organ failure as evidenced by an 
OFS :?:3 or :?:4. This may be due to relatively small numbers in the latter two groups. 
The proportion of patients in this study with gallstone associated acute pancreatitis is 57%, 
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which is slightly higher than previously reported in UK populations, although wide variation 
has been shown in studies, from 30 to 50% (Thompson et al., 1987; Corfield et al., 1985; 
Mann et al., 1994; De Beaux et al., 1995). There is also wide variability in reported 
incidence of alcohol induced acute pancreatitis in the UK, from 11 to 3 8% (Thompson et 
al., 1987; Corfield et al., 1985; De Beaux et al., 1995; Mann et al., 1994). The incidence of 
15.6% found in the population studied in this work falls within this range, although one 
cannot directly compare studies, as different epidemiological studies have no common 
defining criteria for when alcohol is considered the main aetiology . Only one published 
study has set an alcohol consumption level (consumption of:e:80 g da/) at which subjects 
were defined as having alcoholic acute pancreatitis (Wilson et al., 1985). This criteria has 
been adopted in this study. Furthermore, no mention is made in other published studies of 
any attempts to distinguish those with alcohol induced chronic pancreatitis from those with 
alcohol induced acute disease. 
In the population studied idiopathic pancreatitis accounted for 27.4% of patients, which is 
high compared to other studies (14% and 23% of cases of acute pancreatitis (Mann et al., 
1994; Thompson et al., 1987; De Beaux et al., 1995; Corfield et al., 1985)). ln this study 
the exclusion of subjects from the alcohol-induced group who consumed less than 80g day" 1 
but had no evidence of gallstones helped increase the proportion in the idiopathic group. 
In this study greater numbers of patients with idiopathic disease were seen than expected in 
the groups with severe disease (Atlanta) and an OFS:e:3 . 17 of 38 patients with severe 
disease had idiopathic disease, as did ll of 18 patients with an OFS:e:J. The group with 
idiopathic disease only accounted for 27.4% of all patients. Although this was only a trend, 
as the difference did not approach statistical significance, it is of interest to note that a 
previous study reports mortality rates as being higher in those with idiopathic disease (de 
Beaux et al., 1995) compared to gallstone associated disease (3 vs. 15%, p=0.03). 
Subjects with alcohol induced pancreatitis are shown to have a significantly younger 
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distribution of age than those with idiopathic and gallstone. The alcohol induced pancreatitis 
group were also predominantly male. The reasons for this difference in age and sex 
distribution are unclear. It cannot just be due to the fact that young men start excessive 
drinking behaviour (and therefore develop alcohol associated diseases) early in life as 
patients with alcoholic pancreatitis were also significantly younger than the group of 
alcoholic 'controls', and there was also a significant difference in sex distribution between 
these two latter groups. However, there was a significant difference in sex distribution 
between the alcohol 'control' group and the normal controls, indicating that alcohol induced 
liver and pancreatic disease is more prevalent in males. This may only mean that alcoholism 
is more prevalent in the male sex, which cannot be tested in this study, as no group of 
disease free alcoholics was available for comparison. Previously published data, however, 
confirms that alcoholism is more prevalent in males compared to females (77 vs. 33%), 
although the incidence in women in the Western world is increasing (Sherlock and Dooley, 
1993) 
7.5 Immunogenetic studies in acute pancreatitis patients 
The importance of both pro-inflammatory and regulatory cytokines in the pathogenesis of 
acute pancreatitis is well established. 
Animal models have shown that TNF plays an important role in the early disease 
pathogenesis. Increased TNF expression has been demonstrated in these animal models 
(Gukovskaya et al, 1997; Norman et al, 1995a; Fu et al, 1997), and TNF antagonism is 
known to ameliorate local and systemic markers of disease (Gukovskaya et al, 1997; 
Hughes et al, 1996; Norman et al, 1996b ). Since TNF production in individuals has been 
shown to be genetically influenced (Poicot et al, 1993 ), it was hypothesised that 
polymorphism of the TNF gene locus may influence disease susceptibility and course in 
acute pancreatitis. 
The regulatory cytokine, IL-l 0, is undoubtedly important in the pathogenesis of acute 
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pancreatitis. Unlike TNF, it acts to reduce inflammation, and as a part of this reduces 
macrophage secretion of TNF (Fiorentino et al, 1991 ). As could be expected, experimental 
data with animals suggests that IL-l 0 acts to suppress the inflammatory process associated 
with acute pancreatitis (Van Laethem et al., 1995; Rongione et al., 1997; Kusske et al., 
1996a). As a locus within the IL-l 0 promoter has been shown to influence IL-l 0 
production (Turner et al, 1997), it can be hypothesised that IL-l 0 promoter region 
polymorphisms may influence the development or severity of acute pancreatitis. 
This study shows that the TNF and IL-l 0 gene polymorphisms studied are not determinants 
of disease severity in acute pancreatitis. However, alleles of both TNF and IL-l 0 
microsatellite polymorphisms are differently distributed in patients with alcohol-induced 
acute pancreatitis compared to normal controls and a group of patients with alcoholic liver 
disease. These findings are independent of one another. 
In agreement with the findings of this study, characterisation of the TNF -308 
polymorphism in patients with severe post-operative sepsis, a condition thought to have a 
similar pathogenesis to acute pancreatitis, reveals no association with disease severity 
(Stuber et al, 1996b). There are many other studies, already reviewed in section 4.1.4.5 
(Table 4.4), that investigate associations between the TNF -308.G allele and susceptibility 
to and severity of various acute and chronic inflammatory and infective disorders in which 
TNF is thought to play an important role. As previously indicated, there is often no 
consistent finding between different studies of the same disease, and most associations were 
found to be due to linkage of the -308 locus with HLA types known to be linked with the 
disease in question. Where this wasn't the case HLA associations often were not 
investigated. 
TNF microsatellites have also been investigated in various inflammatory and infective 
disorders as detailed in section 5.1.4.5 (Table 4.5). No one allele or haplotype has been 
identified as being consistently associated with the development of severity of disease, and it 
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is interesting to note that it is also the case with TNF microsatellites that differences in 
allelic or haplotype frequency were not independent ofHLA associations, due to linkage 
between loci. 
Previous studies have demonstrated associations in various populations between 
serologically typed HLA-B and C antigens and chronic pancreatitis of alcoholic origin. 
These include HLA-Bw40, HLA-B 13, HLA-Bw39, and HLA-Cw52. Our results provide 
further evidence to suggest that the MHC is involved in the development of alcoholic 
pancreatitis. 
There are several possible explanations to explain the results reported. If the TNF locus is 
itself associated with the development of acute pancreatitis following excessive alcohol 
consumption, then specific alleles or haplotypes may be influencing TNF regulation. There 
is some evidence that certain microsatellite alleles in the TNF locus may have a functional 
role (Poicot et al, 1993). The a2 and c2 alleles are associated with higher TNF production 
from stimulated lymphocytes in vitro. The a2 allele is found at a markedly reduced 
frequency in the group of patients with alcohol-induced pancreatitis. Although this finding 
does not reach conventional statistical significance, it strongly suggests that the a2 allele is 
negatively associated with the development of pancreatic inflammation following excessive 
alcohol consumption. It appears that this negative association is specific to the pancreas, as 
the group of alcoholic liver disease patients also had different allelic frequencies compared 
to the alcoholics with pancreatic disease. The significance of these findings is unclear, as 
animal models suggest that TNF upregulates the inflammatory process that occurs in the 
development of pancreatitis, and the a2 allele that has been associated with higher TNF 
production is markedly reduced in frequency. 
It may be that TNF microsatellites are linked to as yet undefined genes within the MHC that 
play a major role in conferring protection from alcoholic pancreatitis than TNF itself As the 
MHC has a high degree oflinkage disequilibrium these genes may even be some distance 
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away from the TNF locus. The number of as yet undefined gene loci within the MHC upon 
chromosome 6 preclude speculation as to the which linked genes may be involved, as there 
are many genes within the MHC that are involved in a multitude of diverse immune 
processes, a lot of them immune. Within the TNF region itself are genes speculated to 
encode for inhibitors oftranscription factors, and others of unknown function including the 
LST-1 gene (Trowsdale and Campbell., 1998). 
We have shown that the bi-allelic polymorphisms of the IL-10 promoter have no association 
with susceptibility or severity of acute pancreatitis. We also investigated the potentially 
more informative microsatellite, IL-l O.G, and although no association reaches conventional 
statistical significance, it appears that the IL-IO.G 13 microsatellite allele, like the TNFa2 
allele, is present at reduced frequency in those with alcoholic acute pancreatitis. These 
findings are independent of one another. 
At present the importance of the fL-1 O.G microsatellite in regulating IL-l 0 production is 
under investigation, enabling limited interpretation of the results presented in this work. 
However, characterisation of the IL-l 0 promoter region in which the IL-l 0 polymorphisms 
described here occur, show that there are many transcription sites close to these 
polymorphisms, which may be influenced by them. For example, there are two potential 
NFKB/REL sites 60 and 80bp immediately upstream of IL I 0. G (Eskdale et al, 1997b ), 
which may be involved in cytokine mediated modulation of IL-l 0 expression, so influencing 
the pathogenesis of inflammatory disorders such as human acute pancreatitis 
Overall, because of the failure of the findings in this study to achieve conventional statistical 
significance, it appears that the associations demonstrated between these cytokine gene 
polymorphisms and alcoholic pancreatitis have some limitation. It may be that the loci 
themselves are not important determinants of disease susceptibility, but that sites close to or 
in linkage disequilibrium with them induce susceptibility to disease. Further studies are 
required to assess the functional importance of these polymorphisms and their effect upon 
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susceptibility to alcoholic pancreatitis. 
Should it be possible to identify loci that are more closely associated with alcoholic 
pancreatitis it may be possible to use genetic typing to predict clinical outcome in alcoholics 
and to use the infonnation to be able to give patients a more accurate assessment of risk of 
pancreatic disease in the event of continued excessive alcohol intake. 
Once the functional importance of any disease associated locus is fully identified then it may 
be possible to assess the effects of replacing deficient proteins, or antagonising excess 
proteins in the event of either being pivotal in disease pathogenesis, in individuals identified 
by genetic testing. 
7.6 Suggested further studies arising from this work 
I. In-vitro studies upon the functional relevance of the TNF and IL-10 polymorphisms. 
2. Characterisation of the TNF and IL-l 0 polymorphisms in a group of pancreatic and liver 
disease free alcoholics, and comparison with the group of alcohol-induced pancreatitis 
patients. 
3. Characterisation of the TNF and IL-l 0 polymorphisms in a group of patients with 
chronic pancreatitis. 
4. Characterisation of other pro-inflammatory cytokine polymorphisms in patients with 
acute pancreatitis. 
5. Search for other susceptibility genes involved in alcoholic acute pancreatitis These might 
include chemokine genes or alcohol metabolising enzyme genes. 
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APPENDICES 
AI TNF microsatellite 3-locus genotyges in gatient subgrougs 
TNFabc haplotype Controls Study Mild Severe Local combinations patients complieD 
n=107 n=l35 n=97 n=38 n=21 
a2blc2- a2blc2 2 2 2 0 0 
a2blc2- allb4cl 4 3 3 0 0 
a2blc2- a6b5cl 4 7 5 2 2 
a2blc2- al0b4cl 4 3 2 
a2blc2- a2b3cl 5 3 2 0 
a2blc2- a7b4cl I 4 2 2 
a2blc2- a2b5c2 2 3 2 
a2blc2- a5b5c2 0 0 0 
a2blc2- al b5c2 0 0 0 0 
a2blc2- a4b5cl 2 0 0 
a2blc2- a4b7c2 0 2 0 0 
a2blc2- X 6 4 3 0 
a2b3cl- a2b3cl 2 0 0 0 0 
a2b3cl- a7b4c1 5 0 0 0 0 
a2b3cl- a2b5b2 0 
a2b3cl- a5b5c2 0 0 
a2b3cl- a4b5cl 2 3 2 0 
a2b3cl- a4b7c2 0 0 0 0 
a2b3cl- X 3 3 2 0 
a2b5b2 - a4b5cl 2 
a2b5b2- X 0 0 0 0 
a5b5c2-a4b5cl 0 2 0 2 2 
a5b5c2- X 0 0 0 
a6b5cl- a6b5cl 2 3 2 
a6b5cl- al0b4cl 2 8 4 4 2 
a6b5c1- -a2b3cl 7 6 5 
a6b5cl- a7b4cl 2 0 0 0 0 
a6b5cl- a2b5c2 0 0 0 
Table AI Number ofTNFabc 3-locus haplotype combinations in control and 
acute pancreatitis patients grouped according to (local and systemic) 
disease severity 
(continued ... ) 
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TNFabc haplotype Controls Study Mild Severe Local 
combinations patients complic'l 
n=l07 n=lJS n=97 n=38 n=2l 
a6b5cl- a5b5c2 0 2 
a6b5cl- a4b5cl 4 4 0 0 
a6b5cl- X 2 3 3 0 0 
a7b4cl- a7b4cl 0 2 0 
a7b4cl- a2b5c2 0 0 
a 7 b4cl-a 1 b5c2 0 0 0 
a7b4cl a4b5cl 0 0 0 0 
a7b4cl-a4b7c2 0 1 0 0 
a7b4cl- X 3 2 
a 11 b4cl-a 11 b4cl s s 0 0 
allb4cl-a6b5cl 10 10 9 
allb4cl-al0b4cl 4 3 2 0 
a l1 b4cl-a2b3cl 3 s 3 2 2 
allb4cl-a7b4cl 4 4 0 0 
a 11 b4cl-a2b5c2 3 2 2 0 0 
a 11 b4cl-a5b5c2 2 2 0 0 
a l1 b4cl-a 1 b5c2 0 0 
allb4cl-a4b5cl 3 0 0 
allb4c1-a4b7c2 2 0 0 
allb4cl-X 2 7 4 3 2 
a10b4cl-a10b4cl 0 0 0 0 
a10b4cl-a2b3cl 2 4 4 0 0 
al0b4cl-a2b5c2 0 0 0 0 
a l Ob4cl-a5b5c2 0 0 0 0 
a 1 Ob4cl-a4b5cl 0 0 0 0 0 
al0b4cl-X 2 3 2 0 
a4b5cl-a4b5cl 0 0 
a4b5cl-a4b7c2 0 0 0 
a4b5cl-X 2 3 3 0 0 
X-X 3 0 0 0 0 
Table AI Number ofTNFabc 3-locus haplotype combinations in control and 
acute pancreatitis patients grouped according to (local and systemic) 
disease severity 
(footnotes continued .. ) 
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Table Al Number of TNFabc 3-locus haplotype combinations in control and 
acute pancreatitis patients grouped according to (local and systemic) 
disease severity 
Shows actual number ofTNFabc microsatellite 3-locus combinations in normal controls and 
study patients, patients grouped according to severity of disease as assessed by the Atlanta 
classification, and occurrence of a local complication. 
Local complic" Local complication 
Mild and severe disease severity groups are according to the Atlanta convention 
classification (Bradley, 1993), described in section 5.1.4. 
Local complication is defined as occurrence of pancreatic necrosis, abscess or pseudocyst 
n represents the number of subjects in each group 
X denotes unable to determine haplotype 
Haplotype analysis using 1 I putative haplotypes previously characterised in Caucasian 
populations and confirmed in homozygous cell lines. 
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TNFabc haplotype Controls Study OFS :::>: 2 OFS;::.: 3 OFS :::>: 4 
combinations patients 
n=107 n=135 n=35 n=l8 n=12 
a2blc2- a2blc2 2 2 0 0 0 
a2blc2- allb4cl 4 3 0 0 0 
a2blc2- a6b5cl 4 7 3 2 2 
a2blc2- a10b4cl 4 3 0 
a2blc2- a2b3cl 5 3 
a2blc2- a7b4cl 4 2 2 
a2blc2- a2b5c2 2 3 
a2blc2- a5b5c2 0 0 0 0 
a2blc2- alb5c2 I 0 0 0 0 
a2blc2- a4b5cl 2 0 0 0 
a2blc2- a4b7c2 0 2 0 0 
a2blc2- X 6 2 0 0 
a2b3cl- a2b3cl 2 0 0 0 0 
a2b3cl- a7b4cl 5 0 0 0 0 
a2b3cl- a2b5b2 
a2b3cl- a5b5c2 0 0 0 
a2b3cl- a4b5cl 2 3 0 
a2b3cl- a4b7c2 0 0 0 0 
a2b3cl- X 3 3 0 0 
a2b5b2 - a4b5cl 2 0 0 0 
a2b5b2- X 0 0 0 0 
a5b5c2-a4b5cl 0 2 2 
a5b5c2- X 0 0 0 
a6b5cl- a6b5cl 2 3 0 0 0 
a6b5cl- al0b4cl 2 8 3 3 2 
a6b5c 1- -a2b3cl 7 6 0 0 
a6b5cl- a7b4cl 2 0 0 0 0 
a6b5cl- a2b5c2 0 0 0 
a6b5cl- a5b5c2 0 2 
a6b5cl- a4b5cl 4 0 0 
Table A2 Number of TNFabc 3-locus haplotype combinations in normal controls 
and acute pancreatitis patients grouped according to (systemic) disease 
severity as assessed by organ failure score 
(continued ... ) 
386 
TNFabc haplotype Controls Study OFS~2 OFS~3 OFS~4 combinations patients n=107 n=35 n=18 n=12 
n=135 
a6b5c1- X 2 3 0 0 0 
a7b4cl- a7b4cl 0 2 0 
a7b4cl- a2b5c2 0 0 0 
a7b4cl-alb5c2 0 0 0 0 
a7b4cl a4b5cl 0 0 0 0 
a7b4cl-a4b7c2 0 0 0 0 
a7b4cl- X 3 2 0 0 0 
a 11 b4c 1-a 11 b4cl 5 0 0 
allb4cl-a6b5c1 10 10 0 0 0 
a11b4cl-a10b4cl 4 3 
allb4cl-a2b3cl 3 5 0 0 
allb4cl-a7b4cl 4 0 0 0 
allb4cl-a2b5c2 3 2 0 0 0 
a 11 b4cl-a5b5c2 2 0 0 
a 11 b4cl-a 1 b5c2 0 0 0 0 
allb4cl-a4b5cl 3 
allb4cl-a4b7c2 2 0 0 0 
allb4cl-X 2 7 3 0 0 
al Ob4cl-a l Ob4cl 0 0 0 0 
al0b4cl-a2b3cl 2 4 0 
a I Ob4c l-a2b5c2 0 0 0 0 
at Ob4cl-a5b5c2 0 0 0 0 
a10b4cl-a4b5cl 0 0 0 0 0 
al0b4ct-X 2 3 0 0 
a4b5c t-a4b5cl 0 0 0 
a4b5cl-a4b7c2 0 0 0 0 
a4b5cl-X 2 3 0 0 0 
X-X 3 0 0 0 0 
Table A2 Number of TNFabc 3-locus haplotype combinations in normal controls 
and acute pancreatitis patients grouped according to (systemic) disease 
severity as assessed by organ failure score 
(footnotes continued ... ) 
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Table A2 Number of TNFabc 3-locus haplotype combinations in normal 
controls and acute pancreatitis patients grouped according to 
(systemic) disease severity as assessed by organ failure score 
Shows actual number ofTNFabc microsatellite 3-locus combinations in normal controls and 
study patients, and patients grouped for severity of disease as assessed by organ failure 
score 
OFS Organ failure score, calculated according to method described in section 5.1.4 
(Kingsnorth 1995) 
n represents the number of subjects in each group 
X denotes unable to determine haplotype 
Haplotype analysis using 11 putative haplotypes previously characterised in Caucasian 
populations and confirmed in homozygous cell lines. 
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TNFabc haplotype Controls Alcohol Idiopath. G\stones Alcohol 
combinations controls 
n=107 n=21 n=37 n=77 n=33 
a2blc2- a2blc2 2 2 0 
a2blc2- allb4cl 4 3 0 2 
a2blc2- a6b5cl 4 7 4 2 
a2blc2- a10b4cl 4 3 0 2 
a2blc2- a2b3cl 5 3 0 2 
a2blc2- a7b4cl 4 0 3 
a2blc2- a2b5c2 2 3 0 0 3 
a2blc2- a5b5c2 0 0 0 
a2blc2- alb5c2 0 0 0 0 
a2blc2- a4b5cl 2 0 1 0 
a2blc2- a4b7c2 0 2 0 0 2 
a2blc2- X 6 0 5 
a2b3cl- a2b3cl 2 0 0 0 0 
a2b3cl- a7b4cl 5 0 0 0 0 
a2b3cl- a2b5b2 0 0 
a2b3cl- a5b5c2 0 0 
a2b3cl- a4b5cl 2 3 0 2 
a2b3cl- a4b7c2 0 0 0 0 
a2b3cl- X 3 3 0 2 
a2b5b2- a4b5cl 2 0 0 2 
a2b5b2- X 0 0 0 0 
a5b5c2-a4b5cl 0 2 0 
a5b5c2- X 0 0 0 
a6b5cl- a6b5cl 2 3 0 2 
a6b5cl- a10b4cl 2 8 2 2 4 
a6b5cl- -a2b3cl 7 6 2 3 
a6b5cl- a7b4cl 2 0 0 0 0 
a6b5cl- a2b5c2 0 0 0 
a6b5cl- a5b5c2 0 2 0 
a6b5cl- a4b5cl 4 0 2 2 
a6b5cl- X 2 3 0 2 
Table A3 Number ofTNFabc 3-locus haplotype combinations in normal controls 
and acute pancreatitis patients grouped according to aetiology of acute 
pancreatitis (continued ... ) 
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TNFabc haplotype Controls Alcohol Idiopath. G\stones Alcohol 
combinations controls 
n=107 n=21 n=37 n=77 n=33 
a7b4cl- a7b4cl 0 2 0 
a7b4cl- a2b5c2 0 0 
a 7b4cl-a 1 b5c2 0 0 0 
a7b4cl a4b5cl 0 0 0 0 
a7b4cl-a4b7c2 0 0 0 
a7b4cl- X 3 2 0 
allb4cl-allb4cl 5 3 
allb4c1-a6b5cl 10 10 4 2 4 
all b4cl-a I Ob4cl 4 3 0 2 
a 11 b4cl-a2 b3cl 3 5 0 0 5 
a 11 b4cl-a 7 b4cl 4 2 
a11b4cl-a2b5c2 3 2 0 0 2 
a 11 b4c1-a5b5c2 2 0 
a11b4cl-al b5c2 0 0 0 
all b4cl-a4b5cl 3 0 0 
allb4c1-a4b7c2 2 0 0 
allb4c1-X 2 7 3 3 
al0b4cl-a10b4c1 0 0 0 0 
a10b4cl-a2b3c1 2 4 2 
a 10b4cl-a2b5c2 0 0 0 0 
a 1 Ob4cl-a5b5c2 0 0 0 0 
a10b4cl-a4b5c1 0 0 0 0 0 
al0b4cl-X 2 3 0 0 3 
a4b5c l-a4b5c I 0 0 
a4b5c1-a4b7c2 0 0 0 
a4b5c1-X 2 3 0 2 
X-X 3 0 0 0 0 
Table A3 Number ofTNFabc 3-locus haplotype combinations in normal 
controls and acute pancreatitis patients grouped according to 
aetiology of acute pancreatitis 
Shows actual number ofTNFabc microsatellite 3-locus combinations in normal controls, 
'alcoholic controls', and patients grouped according to aetiology of acute pancreatitis. 
G/stones Gallstones 
X denotes unable to determine haplotype 
Alcoholic pancreatitis if daily consumption of~ 80g alcohol da/ 
Gallstones if radiological or ERCP evidence of cholelithiasis 
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ldiopathic:ifno identifiable. aetiology 
'Haplotype analysis;i,lsillg 1:1 putative haplotypes previously chl!ra<;terisedl in· Caucasian 
,pqpuiations •andi conflrm~d in homozygous cell lines. · 
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LIST OF ABBREVIATIONS 
ACh Acetylcholine (ACh) 
ADH Alcohol dehydrogenase 
AIDS Aquired immune deficiency syndrome 
ALDH Aldehyde dehydrogenase 
APACHE II Acute Physiology and Chronic Health Evaluation 11 
APC Antigen presenting cell 
APP Acute phase proteins 
ARDS Adult respiratory distress syndrome 
ARMS Amplification refractory mutation system 
A TP Adenosine tri-phophate 
bp Base pairs 
cAMP Cyclic AMP 
CCK Cholecystokinin (CCK) 
CD Cluster of differentiation I Crohn's disease 
CDE Choline-deficient ethionine-supplemented (diet) 
cDNA Complimentary deoxyribonucleic acid 
CMI Cell mediated immunity 
CRP C-reactive protein 
CT Computerised tomography 
CTL Cytotoxic T lymphocyte 
DIC Disseminated Intravascular Coagulation 
DIG Digoxygenin 
DNA Deoxyribonucleic acid 
EDT A Ethylene diamine tetra-acetic acid 
ER Endoplasmic reticulum 
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ERt:P 
FM!Es 
dMcCSF" 
GllP 
m A 
HP 
Hsp 
1IAPP 
11CE 
IDE>M. 
IFN 
lg 
lli-'IOR 
l.UAra 
KDa 
KlR 
KPa 
LT 
LMP 
LPS 
MAC 
MBP 
MHt: 
mmHg 
E_J'Idoscopic ret(ograde choiangio-pancreatography 
Fatty acid ethyl esr~rs 
Granulocytecmacrophage col()n}' stirnuhitirig 'factor 
iGiycerine•tri~phosphate 
Human leu«ocyte antigen 
Hereditary tpancreati!is 
iHeat shock· protein 
'islet celli amyloid polypeptide 
JnflarrntUttOJY boweli disease 
Interh!ukiil-l converting enzyme 
:r11sulin dependent>diabetes mellitus 
Interferon, 
Iinml.JJ1oglobulin 
lnterlel!kin 
'IL-i]O ft!Ceptor 
'IL-·1 rec~ptor antagonist-
Kilodalton 
Killer cell inhibitory re:ce)Jtor 
Kilopascal. 
Lymphotoxin. 
Large ;multifunctipna.l iprotease 
Lipopolysaccharicte 
Membrane att11ck complex 
Mann()setbi11cli11g ,protein. 
Major hi_sJQcompatibility complex 
Millirnetresi of mercury 
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MODS 
mRNA 
MSOF 
NFKB 
NIDDM 
NK 
NO 
NOS 
OFR 
PAF 
PaOz 
PBMC's 
PCR 
PNK 
pp 
PSP 
PSTI 
RER 
RAG 
RF 
RING 
RFLP 
RNA 
SIRS 
SLE 
ssc 
Multiple organ dysfunction syndrome 
Messenger ribonucleic acid 
Multisytem organ failure 
Nuclear factor kappa beta 
Non-insulin dependant diabetes mellitus 
Natural killer (cell) 
Nitric oxide 
Nitric oxide synthase 
Oxygen free radicals 
Platelet activating factor 
Partial pressure of oxygen 
Peripheral blood mononuclear cells 
Polymerase chain reaction 
Polynucleotide kinase 
Pancreatic polypeptide 
pancreatic stone protein 
Pancreatic secretory trypsin inhibitor 
Rough endoplasmic reticulum 
Recombination-activation-genes 
Rheumatoid factor 
Really interesting new gene 
Restriction fragment length polymorphism 
Ribonucleic acid 
Systemic inflammatory response syndrome 
Systemic lupus erythamatosus 
Sodium chloride & sodium citrate 
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SSOP 
SSP· 
TA:P 
If BE 
iliCR' 
f:GF 
TMAC 
TNF 
TNFR. 
u.c 
rtJSS. 
VIP 
VNTR 
Seqpence speCific· oligonucleotide: probing 
Sequence specific; ~rimers 
illrypsinogen activation peptide I 7franspor'ter associated' with: antigen presentation 
1]ris~ boric,_addL :ethylene diamine tetra~acetic acid 
T':cell' recepto_li' 
Transforming growth facto~ 
.t :helper,( cell) 
Tetra:-fnethyl-ammonium chloride 
rftjmour necrosis factor 
'FNF· receptof 
rtJicera,tive colitis! 
llJltrasouncl scah 
Vasoactive irttestiflall polypeptide {VIP) 
VariablenUflipetoftandem:repeats 
395. 
REFERENCES 
Abraham, L.A, Marley, J.V., Nedaspasov, S.A., Cambon-Thomsen, A, Crouau-Roy, B., 
Dawkins, RL., and Giphart, M.J. (1993). Microsatellite, Restriction-Fragment-Length 
Polymorphism, and sequence-Specific Oligonucleotide Typing of the Tumour Necrosis 
Factor Region. Human Immunology 38, I 7-23. 
Acioli, J.M., Isobe, M., and Kawasaki, S. (1997). Early complement system activation and 
neutrophil priming in acute pancreatitis: participation of trypsin. Surgery 122, 909-917. 
Acosta, J.M. and Ledesma, C.L. (1974). Gallstone migration as a cause of acute 
pancreatitis. New England Journal of Medicine 290, 484-487. 
Acosta, J.M., Pellegrini, C.A., and Skinner, D.B. (1980). Etiology and pathogenesis of 
acute biliary pancreatitis. Surgery 118-125. 
Adler, G., Beglinger, C., Braun, U., Reinshagen, M., Koop, I., Schafmeyer, A., Rovati, L., 
and Arnold, R. (1991). Interaction ofthe cholinergic system and cholecystokinin in the 
regulation of endogenous and exogenous stimulation of pancreatic secretion in humans. 
Gastroenterology 100, 537-543. 
Adler, G., Nelson, D.K., Katchinski, M., and Beglinger, C. (1995). Neurohormonal control 
ofhuman pancreatic exocrine secretion. Pancreas 10, 1-13. 
Agematsu, K., Nagumo, H., Oguchi, Y, and et al (1998). Generation ofplama cells from 
peripheral blood memory cells: synergistic effect ofinterleukin 10 and CD27/Cd70 
interaction. Blood 91, I 73-180. 
Alexander, HR .. , Sheppard, B.C., Jensen, J.C., and et al (1991). Treatment with 
recombinant human tumor necrosis factor-alpaha protects rats against the lethality, 
hypotension, and hypothermia of gram-negative sepsis. J Cl in Invest 88, 34-39. 
Alien, J.E. and Maizels, RM. ( 1997). Th 1-Th2: reliable paradigm or dangerous dogma? 
Immunology Today 18, 387-392. 
Allison, JP., Mclntyre, B.W., and Bloch, D. (1982). Tumor-specific antigen of murine T 
lymphoma defined with monoclonal antibody. Journal oflmmunology 129, 2293-2299. 
Andersson, R, Deng, X. M., and Wang, X. D. (1997). Role of macrophage overactivation in 
the development of acute pancreatitic injury in rats. Br 1 Surg 84, 775-780. 
Apte, M., Norton, I., Haber, P., Applegate, T., Korsten, M., McCaughan, G., Pirola, R., 
and Wilson, J. ( 1998). The effect of ethanol on pancreatic enzymes-a dietary artifact? 
Biochim Biophys Acta 1379,314-324. 
Apte, M.V., Norton, I.D., Haber, P.S., McCaughan, GW., Korsten, M.A., Pirola, RC., 
and Wilson, J.S. (1996). Both ethanol and protein deficiency increase messenger RNA 
levels for pancreatic lithostathine. Life Sciences 58, 485-492. 
Arai, T., Hiromatsu, K., Nishimura, H., and et al (1995). Endogenous interleukin I 0 
prevents apoptosis in macrophages during salmonella infection Biochem Biophys Res 
Commun 213, 600-607. 
Arias, AI., Giles, B., Eiermann, T.H., Sterry, W., and Pandey, J.P. (1997). Tumor necrosis 
factor-alpha polymorphism in psoriasis. Exp Clin Immunogenet 14, 226-233. 
Arias, AI., Giles, B., Eiermann, T.H., Sterry, W., and Pandey, J.P. (I997). Tumor necrosis 
factor-alpha polymorphism in psoriasis. Exp Clin Immunogenet 14, 226-233. 
Arnon, R, Espoti, S.D., and Zern, M.A. (I995). Molecular biological aspects ofalcohol-
induced liver disease. Alcoholism Clin Exp Res 19, 247-256. 
Asano, H., Kobayashi, T., Uchida, K., Hayashi, S., Yokoyama, I., Inoko, H., and Takagi, 
396 
H. ( 1997). Significance oftumor necrosis factor microsatellite polymorphism in renal 
transplantation. Tissue Antigens 50, 484-488. 
Assuma, R., Oates, T., Cochran, D., Amar, S., and Graves, D.T. (1998). ll...-1 and TNF 
antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. J 
lmmunol160, 403-409. 
Baeuerle, P.A. and Henkel, T. (1994). Function and activation ofNFkB in the immune 
system. AnnuRevlmrnunol 12,141-179. 
Banerjee, A.K., Galloway, S.W., and Kingsnorth, AN. (1994). Experimental models of 
acute pancreatitis. Br J Surg 81, 1096-1103. 
Banks, P.A. (1997). Practice guidlines in acute pancreatitis. The American Journal of 
Gastroenterology 92, 377-386. 
Banks, P.A., Tenner, S., Noordhoek, E. C., Sica, G., Feng, S., and Zinner, M. ( 1996). Does 
pancreatic necrosis predict severity in patients with acute pancreatitis? Digestion 57, 
218(Abstract) 
Bannister, L.H. (1995). Alimentary System. In Gray's Anatomy. P. Williams, R. Warwick, 
M. Dyson, and L. Bannister, eds. (New York: Churchill Livingstone}, pp. 1790-1794. 
Barie, P.S., Tahamont, M. V., and Malik, AB. (1982}. Prevention of increased pulmonary 
vascular permeability after pancreatitis by granulocyte depletion in sheep. Am rev Respir 
Dis 126, 904-908. 
Baumann, H. and Gauldie, J. (1994). The acute phase response. Immunology Today 15, 74-
79. 
Bazzoni, F. and Beutler, B. (1996). The tumor necrosis factor ligand and receptor families 
New England Journal of Medicine 334, 1717-1725. 
Bazzoni, F., Alejos, E., and Beutler, B. (1995). Chimeric tumor necrosis factor receptors 
with constitutive signaling activity. Proc. Natl. Acad. Sci. USA 92, 5376-5380. 
Bean, AG., Freiburg, R.A., Andrade, s., Menon, S., and Zlotnik, A (1993). lnterleukin-10 
protects mice against staphylococcal enterotoxin B-induced lethal shock. Infection and 
immunity 61, 4937-4939. 
Beutler, B., Milsark, I.W., and Cerami, AC. (1985). Passive immunisation against 
cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 2 29, 
869-871. 
Bianchi, E., Bender, J.R., Blasi, F, and Pardi, R. (I 997). Through and beyond the wall: late 
steps in leukocyte transendothelial migration. Immunology Today 18, 586-591. 
Biragyn, A and Nedaspasov, S.A. (I 995 ). Lipopolysaccharide induced expression ofTNF-
alpha gene in the macrophage cell line ANA-l regulated at the levels of transcriptional 
processivity. 1 lmmunol155, 674-683. 
Bird, G.L.A., Sheron, N., and Goka, A.K.J. (I 990). Increased plasma tumor necrosis factor 
in severe alcoholic hepatitis. Ann Intern Med 112, 91 7-922. 
Blakemore, A.I.F., Cox, A., Gonzalez, A., Makill, J.K., Hughes, M.E., Wilson, R.M., 
Ward, J.D., and Duff, G.W. (I 996). Interleukin-1 receptor antagonist allele (IL 1RN*2) 
associated with nephropathy in diabetes mellitus. Hum Genet 97, 369-374. 
Bone, RC. (1998). Toward a theory regarding the pathogenesis ofthe systemic 
inflammatory response syndrome: what we do and do not know about cytokine regulation. 
Crit Care Med 24, 163-172. 
Bouma, G., Xia, B., Crusius, J.B.A., Bioque, G., Koutroubakis, I., V on Blomberg, B.M.E., 
397 
Meuwissen, S. G.M., and Pena, AS. (1996). Distribution of four polymorphisms in the 
tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). 
Clin Exp Immunol103, 391-396. 
Bouma, G., Xia, B., Crusius, J.B.A., Bioque, G., Koutroubak.is, 1., V on Blomberg, B.M.E, 
Meuwissen, S.G.M., and Pena, AS. (1996). Distribution of four polymorphisms in the 
tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). 
Clin Exp 1mmunol103, 391-396. 
Bradley, E.L. (1993). A clinically based classification system for acute pancreatitis. Arch 
Surg 128, 586-590. 
Braganza, J.M. (1991). Evolution ofpancreatitis.ln The pathogenesis ofpancreatitis. J.M. 
Braganza, ed. (Manchester-New York: Manchester University Press), pp. 19-33. 
Braganza, J.M., Scott, P., Bilton, D., and et al (1995). Evidence for early oxidative stress in 
acute pancreatitis. lnt J Pancreatol 17, 69-81. 
Braquet, P., Touqui, L., and Phen, T. Y. (I 987). Perspectives in Platelet Activating Factor 
research. Pharmacal Rev 39, 97-145. 
Braud, V.M., Allan, D.S.J., O'Callaghan, C.A., Soderstrom, K., D'Andrea, A, Ogg, G.S., 
Lazetic, S., Young, N.T., Bell, J.l., Phillips, J.H., Lanier, L.L., and McMichael, A.J. (1998). 
HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 
Braunstein, J., Qiao, L., Autschbach, F., Schurmann, G., and Meuer, S. (1997). T cells of 
the human intestinal lamina propria are high producers of interleukin-1 0. Gut 41, 215-220. 
Brinkman, B.M.N, Huizinga, T.W.J., Kurban, S.S., Velde, E.A., Schreuder, G.M., Hazes, 
J.M., Breedveld, F.C., and Verweij, CL. (1997). Tumour necrosis factor alpha gene 
polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, 
disease? Br 1 Rheumatol 36, 516-521. 
Brinkman, B.M.N., Zuijdgeest, D., Kaijel, E.L., Breedveld, F.C., and Verweij, C.L. {1996). 
Relevance of the TNF? -308 promoter polymorphism in TNF? gene regulation. 1 lnflamm 
46, 32-41. 
Bunce, M, O'Neill, C.M., Barnado, M.C.M.N., Krausa, P., Browning, M.J., Morris, P.J., 
and Welsh, K.l. (1995). Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB I, 
DRB3, DRB4, DRB5, & DQB I BY PCR with 144 primer mixes utilizing sequence-specific 
primers (PCR-SSP). Tissue Antigens 46, 355-367. 
Bussolati, B , Mariano, F., Montrucchio, G., Piccoli, C., and Camussi, G. (1997). 
Modulatory effect of interleukin-1 0 on the production of platelet activating factor and super 
oxide anions by humnan leukocytes. Immunology 90, 440-447. 
Cabrera, M., Shaw, M.A., Sharpes, C., Willaims, H., Castes, M., Convit, J., and Blackwell, 
J.M. (1995). Polymorphism in tumor necrosis factor genes associated with mucocutaneous 
leishmaniasis. 1 Exp Med 182, 1259-1264. 
Cabrera, M., Shaw, M.A., Sharpes, C., Willaims, H, Castes, M., Convit, J., and Blackwell, 
J.M. (1995). Polymorphism in tumor necrosis factor genes associated with mucocutaneous 
leishmaniasis. J Exp Med 182, 1259-1264. 
Carroll, M.C., Katzman, P., and Alicot, E.M. (1987) Linkage map of the human major 
histocompatibility complex including the tumor necrosis factor genes. Proc. Natl. Acad. 
Sci. 84, 8535-8539. 
Carswell, E.A., Old, L.J., Kassel, R.L., Green, S., Foire, N., and Williamson, B. (1975). An 
endotoxin-induced serum factor that causes necrosis oftumors. Proc. Natl. Acad. Sci. 
USA 72, 3666-3670. 
398 
Cassatella, M. A. and Meda, L. (1994). J Exp Med 179, 1695-1699. 
Chao, W. and Olson, M.S. (1993). Platelet activating factor: receptors and signal 
transduction. Biochem J 292, 617-629. 
Chesney, J., Metz, C., Stavitsky, AB., Bacher, M., and Bucala, R. (I 998). Regulated 
production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J 
Immunol/60, 419-425. 
Chiari, H. (1896). Ueber selbstverdaung des Menschlichen Pancreas. Zeitschrift fur 
Heilkunde 17, 69-96. 
Chouchane, L., Ahmed, S.B., Baccouche, S., and Remadi, S. (1997). Polymorphism in the 
tunor necrosis factor-a promoter region and in the heat shock protein 70 genes associated 
with malignant tumors. Cancer 80, 1489-1496. 
Chouchane, L., Ahmed, S.B., Baccouche, S., and Remadi, S. (1997). Polymorphism in the 
tunor necrosis factor-a promoter region and in the heat shock protein 70 genes associated 
with malignant tumors. Cancer 80, 1489-1496. 
Cohen, M.C. and Cohen, S. ( 1996). Cytokine function. A study in biologic diversity. Am J 
Clin Pathol 105, 589-598. 
Cohen, S.B.A., Crawley, J.B., Kahan, M.C., Feldmann, M., and Foxwell, B.M.J. (1997). 
lnterleukin-1 0 rescues T cells from apoptotic cell death. Immunology 92, 1-5. 
Colonna, M. and Samaridis, J. (I 995). Cloning of immunoglobulin-superfamily members 
associated with HLA-C and HLA-B recognition by human natural killer cells. Science 268, 
405-408 
Copekland, N. G., Silan, C., Kingsley, D., and et al (1991 ). Chromosomal location oflL-1 
receptor genes. Genomics 9, 44-50. 
Corfield, A.P., Cooper, M.J., and Williamson, R.C.N. (1985). Acute Pancreatitis: a lethal 
disease of increasing incidence Gut 26, 724-729. 
Cory S., Adams J.M. ( 1980). Delations are asssociated with somatic rearrangement of Ig 
heavy chain genes. Cell 19, 37-51. 
Couzigou, P., Fleury, B., Groppi, A., Iron, A., Coutelle, C., Cassaigne, A., and Begueret, J. 
( 1990). Role of alcohol dehydrogenase polymorphism in ethanol metabolism and alcohol 
related diseases. In Enzymology and Molecular Biology of Carbonyl Metabolism 3. H. 
Weiner, ed. (New York: Plenum Press), pp. 263-270. 
Crabb, D. W. ( 1995). Ethanol oxidising enzymes and liver disease. Progress in liver diseases 
13, 152-172. 
Crawley, J.B., Williams, L.M, Mander, T., Brennan, F.M., and Foxwell, B.M.J. (1996). 
Interleukin I 0 stimulation of phosphatidylinositol 3-kinase and p70 S6 kinase is required for 
the proliferative but not the antiintlammatory effects ofthe cytokine. J Bioi Chem 271, 
16357-16362. 
Crouau-Roy, B., Bouzekri, N., Carcassi, C., Clayton, J, Contu, L., and Cambon-Thomsen, 
A. ( 1996). Strong association between microsatellites and an HLA-B, DR haplotype (B 18-
DR3): implication for microsatellite evolution. Immunogenetics 43, 255-260. 
Crouau-Roy, B., Bouzekri, N., Carcassi, C., Clayton, J., Contu, L., and Cambon-Thomsen, 
A. (I 996). Strong association between microsatellites and an HLA-B, DR haplotype (B 18-
DR3): implication for microsatellite evolution. Immunogenetics 43, 255-260. 
Crouau-Roy, B., Briant, L., Bouissou, C., Stavropoulos, C., Poicot, F., Cambon-Thomsen, 
A, and Clayton, J. (I 993). Tumor necrosis factor microsatellites in four European 
399 
populations. Human Immunology 38, 213-216. 
Crowe, P.D., VanArsdale, T.L., Waiter, B.N., and et al (1994). A lymphotoxin-?-specific 
receptor. Science 264, 707-709. 
Curley, P.J. (1996). Endotoxin, cellular immune dysfunction and acute pancreatitis. Annals 
of the Royal College of Surgeons of England 78, 531-535. 
Curley, P.J., Nestor, M., Collins, K., Saporoschetz, 1., Mendez, M., Mannick, J.A., and 
Rod rick, M.L. ( 1996). Decreased Interleukin-2 production in murine acute pancreatitis: 
potential for immunomodulation. Gastroenterology 1/0, 583-588. 
Dabrowski, A. and Chwiecko, M. ( 1992). Oxidative stress: An early phenomenon 
characteristic of acute experimental pancreatitis. Int J Pancreatol I 2, 193-199. 
Dabrowski, A., Gabryelewicz, A, and Chyczewski, L. (1995). The effect of platelet 
activating factor antagonist (BN 52021) on acute experimental pancreatitis with reference 
to multiorgan oxidative stress. Int J Pancreatol 17, 173-180. 
Dale, J.B. and Beachey, E.H. {1985). Epitopes of streptococcal M protein shared with 
cardiac myosin J Exp Med /62, 583-591. 
D'Aifonso, S. and Momigliano Richiardi, P. (1994). A polymorphic variation in a putative 
regulation box of the TNF A promoter region. Immunogenetics 39, 150-154. 
D'Aifonso, S. and Momigliano, P. (1994). A new polymorphism in the TNFA gene. Hum 
Immunol 47, 65A(Abstract) 
Damas, P., Reuter, A, Gysen, P., Demonty, J., Lamy, M., and Franchimont, P ( 1989). 
Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit 
Care Med /7, 975-978. 
Danis, V. A., Millington, M., Hyland, V.J., and Grennan, D. (1995). Cytokine production by 
normal human monocytes: inter-subject variation and relationship to an lL-1 receptor 
antagonist (lL-1 ra) gene polymorphism. Clin Exp Immunol 99, 303-310. 
Davies, M.G. and Hagen, P. (1997). Systemic inflammatory response syndrome. Br J Surg 
84, 920-935. 
Day, C.P., Bashir, R, James, O.F.W., Bassendine, M.F., Crabb, D.W., Thomasson, HR., 
Li, T., and Edenberg, HJ. (1991). Investigation ofthr role ofpolymorphisms at the alcohol 
and aldehyde dehydrogenase loci in genetic predisposition to alcohol-related end-organ 
damage. Hepatology 14, 798-801. 
Day, C.P., Grove, l, Daly, A.K., Stewart, M.W., Avery, P.J., and Walker, M (1998). 
Tumour necrosis factor-alpha gene promoter polymorphism and decreased insulin 
resistance. Diabetologia 4/, 430-434. 
Day, C.P., Grove, J., Daly, AK., Stewart, M.W., Avery, P.J., and Walker, M. (1998). 
Tumour necrosis factor-alpha gene promoter polymorphism and decreased insulin 
resistance. Diabetologia 41, 430-434. 
De Beaux, A C., Goldie, A.S., Ross, JA., Carter, D.C., and Fearon, K.H.C. ( 1996). Serum 
concentrations of inflammatory mediators related to organ failure in patients with acute 
pancreatitis. British Journal of Surgery 83, 349-353. 
De Beaux, AC., Palmer, K.R., and Carter, D.C. {1995). Factors influencing morbidity and 
mortality in acute pancreatitis; an analysis of279 cases. Gut 37, 121-126. 
De Beaux, AC., Ross, J.A., Maingay, J.P., Fearon, K.H.C., and Carter, D. C. {1997). 
Proinflammatory cytokine release by peripheral blood mononuclear cells from patients with 
acute pancreatitis. British Journal of Surgery 83, 1071-1075. 
400 
De Togni, P., Goellner, J., Ruddle, N.H., Streeter, P.R., and et al (1994). Abnormal 
development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 264, 
703-707. 
de Waal Malefyt, R., Haanen, J., Spits, H., Roncarolo, M., Te Velde, A., Figdor, C., 
Johnson, K., Kastelein, R., Yssel, H., and de Vries, J.E. (1991). lnterleukin -I(IL-10) and 
virallL-1 0 strongly reduce antigen-specific human T -cell proliferation by diminishing the 
antigen-presenting capacity of monocytes via down regulation of class 11 major 
histocompatibility complex expression. Journal ofExperimental Medicine 174, 915-924. 
de Waal Malefyt, R., Yssel, H., Roncarolo, M., Spits, H., and de Vries, J.E. (1992). 
Interleukin-1 0. Current Opinion in Immunology 4, 314-320. 
Debets, J.M.I-1., Kampmeijer, R., Van Der Linden, M.P.M.H., Buurman, W.A., and Van 
Der Linden, C.J. (1989). Plasma tumor necrosis factor and mortality in critically ill septic 
patients. Crit Care Med 17, 489-494. 
Dejbakhsh-Jones, S., Jerabek, L., Weissman, I.L., and Strober, S. (1995). Journal of 
Immunology 155, 3338-3344. 
Dempsey, P.W., Allison, M.E.D., Akkaraju, S., Goodnow, C.C., and Fearon, D.T. (1996). 
C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. 
Science 271, 348-350. 
Deng, G.Y., McClaren, N.K, Huang, H.S., Zuang, J.P., and She, J.X. (1996). No primary 
association between the 308 polymorphism in the tumor necrosis factor alpha promoter 
region and insulin-dependent diabetes mellitus. Hum Immunol 45, 13 7-142. 
Denham, W., Fink, G.W., Yang, J., Ulrich, P., Tracey, K.J., and Norman, J.G. (1997a) 
Small molecule inhibition oftumor necrosis factor gene processing during acute pancreatitis 
prevents cytokine cascade progression and attenuates pancreatitis severity. Am Surg 63, 
I 045-1049. 
Denham, W., Yang, J., Fink, G.W., Denham, D., Carter, G, Ward, K., and Norman, J.G. 
( 1997b ). Gene targeting demonstrates additive detrimental effects of interleukin -I and 
tumor necrosis factor. Gastroenterology 113, 1741-1746. 
Derr, R.F., Porta, E.A., Larkin, E. C., and Arnanda Rao, G. (1990). Is ethanol per se 
hepatotoxic? J Hepatol 10, 381-386. 
Dickensheets, H.L., Freeman, S.L., Smith, M.F., and Donnelly, R.P. (1997). lnterleukin-10 
upregulates tumor necrosis factor receptor type 11 (p75) gene expression in endotoxin 
stimulated human monocytes. Blood 90, 4162-4171. 
Diehl, A.K., Holleman, D.R., Chapman, J.B., Schwesinger, W.H, and Kurtin, W.E. ( 1997). 
Gallstone size and risk of pancreatitis. Archives of Internal Medicine 157, 1674-1678. 
Dower, S.K., Fanslow, W., Jacobs, C., Waugh, S., Sims, J.E., and Widmer, M.B. (1994). 
Interleukin-1 antagonists. Therapeutic Immunology 1, 1 13-122. 
Dunham, I., Sargent, C.A., Trowsdale, J., and Campbell, R.D. (1987) Molecular mapping 
of the major histocompatibility complex by pulse-field gel electrophoresis. Proc. Natl 
Acad. Sci. 84, 7237-7241. 
Dunn, J.A., Li, C., Ha, T., Kao, R.L., and Browder, W. (1997). Therapeutic modification of 
nuclear factor kappa B biding activity and tumor necrosis factor-alpha gene expression 
during acute biliary pancreatitis. Am Surg 63, 1036-1043. 
Echtenacher, B., Falk, W., Mannel, D.N., and Krammer, P.H. (1990). Requirement of 
endogenous tumor necrosis factor/cahectin for recovery from experimental peritonitis. J 
Immunol145, 3762-3766. 
401 
Eigler, A., Sinha, B., Hartmann, G., and Endres, S. (1997). Taming TNF: strategies to 
restrain this pro-inflammatory cytokine. Immunology Today 18, 487-491. 
Emmanuelli, G., Montrucchio, G., Gaia, E., Dughera, L., Corvelli, G., and Gupetta, L. 
{1989). Experimental acute pancreatitis induced by platelet activating factor in rabbits. Am J 
Pathol 134, 315-326. 
Enk, A.H. and Katz, S.I. (1992). Identification and induction ofkeratinocyte derived IL-10. 
J Immunol 149, 92-95. 
Erickson, S.L., de Sauvage, F.J., Kikly, K., Carver-Moore, K., Pitts-Meek, S., Gillet, N., 
and et al ( 1994). decreased sensitivity to tumour necrosis factor but normal T -cell 
development in TNF receptor-2-deficient mice. Nature 372, 560-563. 
Eskdale, J. and Gallagher, G. ( 1995). A polymorphic dinucleotide repeat in the human IL-
l 0 promoter. Immunogenetics 42, 444-445. 
Eskdale, J., Kube, D., and Gallagher, G. ( 1996). A second polymorphic dinucleotide repeat 
in the 5' flanking region of the human IL-l 0 gene. Immunogenetics 45, 82-83. 
Eskdale, J., Kube, D., Tesch, H., and Gallagher, G. (1997a). Mapping ofthe human ILIO 
gene and further characterisation of the 5' flanking sequence. Immunogenetics 46, 120-128. 
Eskdale, J., Wordsworth, P., Bowman, S., Field, M., and Gallagher, G. (1997b). 
Association between polymorphisms of the human IL-l 0 locus and systemic lupus 
erythematosus. Tissue Antigens 49, 635-639. 
Exley, A.R., Leese, T., Holliday, M.P, Swann, R.A., and Cohen, J. ( 1992). Endotoxaemia 
and serum tomour necrosis factor as prognostic markers in severe acute pancreatitis. Gut 
33, 1126-1128. 
Fanning, G., Bunce, M., Black, C.M., and Welsh, KI. (1997). Polymerase chain reaction 
haplotyping using 3' mismatches in the forward and reverse primers: application to the hi-
allelic polymorphisms oftumor necrosis factor and lymphotoxin alpha Tissue Antigens 50, 
23-31. 
Genetet, B., Gosselin, M., and Gastard, J. (1979). HLA antigens in chronic alcoholic 
pancreatitis. Tissue Antigens 13, 163-166. 
Field, M., Gallagher, G., Eskdale, J., McGarry, F., Richards, S.D., Oh, HH., and Campbell, 
C. (1997). Tumour necrosis factor locus polymorphisms in rheumatoid arthritis. Tissue 
Antigens 50, 303-307. 
Fink, G.W. and Norman, J.G. (1996). Intrapancreatic Interleukin -I? gene expression by 
specific leukocyte populations during acute pancreatitis. J Surg Res 63, 369-373. 
Fink, G.W. and Norman, J.G. (1997). Specific changes in the pancreatic expression of the 
interleukin I family of genes during experimental acute pancreatitis. Cytokine 9, I 023-1027. 
Fink, G.W., Yang, J., Carter, G., and Norman, J.G. (1997). Acute pancreatitis-induced 
enzyme release and necrosis are attenuated by IL-l antagonism through an indirect 
mechanism. Journal of Surgical Research 67, 94-97. 
Fiorentino, D.F., Bond, M.W., and Mosmann, T.R. (1989). Two types ofhelper T cell. T 
cell clones secrete a factor that inhibits cytokine production Bh Th I clones. J Exp Med 170, 
2081-1095. 
Fiorentino, D.F., Zlotnik, A., Mosmann, T.R., Howard, M., and O'Garra, A. (1991). IL-10 
inhibits cytokine production by activated macrophages. Journal oflmmunology 147, 3815-
3822. 
Fitz, R. ( 1889). Acute pancreatitis: a consideration of pancreatic haemorrhage, 
402 
haemorrhagic, supperative, and gangerenous pancreatitis, and of disseminated fat necrosis 
Boston Medical and Surgical Journal 70, 181-187. 
Folsch, E., Closa, D., Prats, N., Gelpi, E., and Rosello-Catafau, J. (1998). Leukotreine 
generation and neutrophil infiltration after experimental acute pancreatitis. Inflammation 22, 
83-93. 
Forbes, A., Schwarz, G., Mirikian, R., Drummond, V., Chan, C., Cotton, P.B., and 
Bottazo, G.F. {1987). HLA antigens in chronic pancreatitis. Tissue Antigens 30, 176-183. 
Formela, L.J., Wood, L.M., Whittaker, M., and Kingsnorth, AN. (1994). Amelioration of 
acute pancreatitis in a rat model by a potent platelet activating factor antagonist. British 
Journal of Surgery 81, 1783-1785. 
Foulis, A.K., Murray, W.R., Galloway, D., McCartney, AC., Lang, E, and Veitch, J. 
(1992). Endotoxaemia and complement activation in acute pancreatitis in man. Gut 23, 656-
661. 
Frank, M.M. and Fries, L.F. (1991). The role of complement in inflammation and 
phagocytosis. Immunology Today 12, 322-326. 
Fraser, J.D., lrving, B.A., Crabtree, G.R., and Weiss, A (1991). Regulation oflnterleukin-2 
gene enhancer activity by the T cell accessory molecule CD28. Science 251, 313-316. 
Frick, T.W., Fernandez-del-castillo, C., Bimmler, D., and Warshaw, A.L. (1997). Elevated 
calcium and activation oftrypsinogen in rat pancreatic acini. Gut 41, 339-343. 
Fries, J.W., Williams, A.J., Atkins, RC., Newman, W., Liscomb, M.F., and Collins, T. 
(1993). Expression ofVCAM-1 and E-selectin in an in vivo model of endothelial cell 
activation. American Journal ofPathology 143, 725-737. 
Fu, K., Sarras, M.P., De Lisle, R.C., and Andrews, G.K. (1997). Expression ofoxidative 
stress responses genes and cytokine genes during caerulein induced acute pancreatitis. Am J 
Physiol273, G696-G705. 
Fujimoto, K., Hosotani, R., Doi, R., Wada, M., Lee, J.U., Koshiba, T., Miyamoto, Y., and 
Imamura, M. ( 1997). Role of neutrophils in cerulein induced pancreatitis in rats: possible 
involvement of apoptosis. Digestion 58, 421-430. 
Furukawa, M., Kimura, T., Yamaguchi, H., and et al {1994). Role of oxygen-derived free 
radicals in hemorrhagic pancreatitis induced by stress and cerulein in rats. Pancreas 9, 67-
72. 
Gallagher, G., Eskdale, J., Oh, H.H., Richards, S.D., Campbell, D.A., and Field, M. 
(1997a) Polymorphisms in the TNF gene cluster and MHC serotypes in the West of 
Scotland. Immunogenetics 45, 188-194. 
Gallagher, G., Lindemann, M., Oh, H.H., Ferencik, S., Waldz, M.K, Schmitz, A, Richards, 
S.D., Eskdale, J., Field, M., and Grosse-Wilde, H. (1997b). Association ofthe TNFa2 
microsatellite allel with the presence of colorectal cancer. Tissue Antigens 50, 47-51. 
Gallea-Robache, S., Morand, V., Millet, S., and et al ( 1997) A metalloproteinase inhibitor 
blocks the shedding of soluble cytokine receptors and processing of transmembrane 
cytokine precursors in human monocytic cells. Cytokine 9, 340-346. 
Galloway, S.W. and Kingsnorth, A.N. {1996). Lung injury in a microembolic model of 
acute pancreatitis. Pancreas 13, 140-146. 
Gamble, J.R., Harlan, J.M., Klebanoff, S.J., and Vadas, M.A. (1985). Stimulation ofthe 
adherence of neutrophils to umbilical vein endothelium by human recombinant tumor 
necrosis factor. Proc. Natl. Acad. Sci. USA 82, 8667-8671. 
403 
Garcia-Merino, A, Alper, C.A., Usuku, K., Marcus-Bagley, D., Lincoln, R., Awdeh, Z., 
Yunis, E.J., Eisenbarth, G.S., Brink, S.J., and Hauser, S.L. (1996). Tumor necrosis factor 
(TNF) microsatellite haplotypes in relation to extended haplotypes, susceptibility to diseases 
associated with the Major Histocompatibility Complex and TNF secretion. Human 
Immunology 50, 11-21. 
Garcia-Merino, A, Alper, C. A., Usuku, K., Marcus-Bagley, D., Lincoln, R., Awdeh, Z, 
Yunis, E.J., Eisenbarth, G.S., Brink, S.J., and Hauser, S.L. (1996). Tumor necrosis factor 
(TNF) microsatellite haplotypes in relation to extended haplotypes, susceptibility to diseases 
associated with the Major Histocompatibility Complex and TNF secretion. Human 
Immunology 50, 11-21. 
Georgopoulos, K. ( 1997). Transcription factors required for lymphoid lineage commitment. 
Current Opinion in Immunology 9, 222-227. 
Gerard, C., Bruyns, C., Marchant, A, and et al (1993). Interleukin I 0 reduces the relaeseof 
tumor necrosis factor and prevents Iethality in experimental endotoxaemia. 1 Exp Med 177, 
547-550. 
Gerard, C., Frossard, J., Bhatia, M., Saluja, A, Gerard, N.P., Lu, B., and Steer, M.L. 
(1997). Targeted disruption of the ?-chemokine receptor CCRI protects against 
pancrreatitis-associated lung injury. Journal of Clinical Investigation 100, 2022-2027. 
Gesser, B., Leffers, H., Jinquan, T., and et al (1997). Identification of functional domains on 
human interleukin I 0. Proc. Natl. Acad. Sci. USA 94, 14620-14625. 
Gjrup, I., Roikjaer, 0., and Amderven, B. (I 992). A double blinded multicenter trial of 
somatostatin in the treatment of acute pancreatitis. Surgery, Gynaecology, Obstetrics 175, 
397-400. 
Golf, J.S. (1993). The effect of ethanol on the pancreatic duct sphincter of Oddi. Am J 
Gastroenterol 88, 656-660. 
Goldfield, A.E., Doyle, C., and Maniatis, T. (1990). Human tumor necrosis factor? gene 
regulation by virud and lipopolysaccharide. Proc. Natl. Acad. Sci. USA 87, 9769-9772. 
Goris, R.J.A., te Boekhorst, T.P.A., Nuytinck, J.K.S., and Gimbrere, J.S.F. (1985) 
Multiple-organ failure. Arch Surg 120, 1109-1115. 
Goto, M., Matsuno, K., Yamaguchi, Y., Ezaki, T., and Ogawa, M. (1993). Proliferation 
kinetics of macrophage subpoulations in a rat experimental pancreatitis model. Arch Histol 
Cytol 56, 75-82. 
Grady, T., Liang, P., Ernst, S.A., and Logsdon, CD. (1997). Chemokine gene expression in 
rat pancreatic acinar cells is an early event associated with acute pancreatitis. 
Gastroenterology 113, 1966-1975 
Greenbaum, L.M. and Hirschkowitz, A ( 1961 ). Endogenous cathepsin activates 
trypsinogen in extracts of dog pancreas. Proc Soc Exp Bioi Med 107, 74-76. 
Grell, M., Douni, E., Wajant, H., Lohden, M., Clauss, M., Maxiener, B., and et al (I 995). 
The transmembrane form oftumor necrosis factor is the prime activating ligand oft he 
80kDa tumor necrosis factor receptor. Cell 83, 793-802. 
Grewal, H.P., Mohey el-Din, AB., Gaber, L.W., Kotb, M., and Gaber, AO. (1994). 
Amelioration of the physiologic and biochemical changes of acute pancreatitisusing an anti-
TNF-? polyclonal antibody. The American Journal of Surgery 167, 214-219. 
Griesbacher, T., Tiran, B., and Lembeck, F. (1993). Pathological events in experimental 
acute pancreatitis prevented by the bradykinin antagonist, Hoe 140. British Journal of 
Pharmacology 108, 405-411. 
404 
Grimsley, C. and Ober, C. (1997). population studies ofHLA-E. Evidence for selection. 
Hum Immunol 52, 33-40. 
Gross, V., Andreesen, R., Leser, H.G., Ceska, M., Liehl, E., Lausen, M., and et al (1992). 
Interleukin-8 and neutrophil activation in acute pancreatitis. European Journal of Clinical 
Investigation 22, 200-203. 
Grove, J., Daly, A.K., Bassendine, M. F., and Day, C.P. ( 1997). Association of a tumor 
necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis 
Hepatology 26, 143-146. 
Grove, J., Daly, A.K., Bassendine, M.F., and Day, C.P. (1997). Association of a tumor 
necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. 
Hepatology 26, 143-146. 
Guice, K.S., Oldham, KT., and Johnson, KS. (1988). Pancreatitis induced lung injury. 
Annals of Surgery 208, 71-77. 
Guice, KS., Oldham, K.T., Caty, M.C., Johnson, K.J., and Ward, P. (1989). Neutrophil 
dependant oxygen radical mediated lung injury associated with acute pancreatitis. Annals of 
Surgery 210, 740-747. 
Guice, KS., Oldham, KT., Remick, D.G., Kunkel, S.L., and Ward, P.A. (1991). Anti-
turner necrosis factor antibody augments edema formation in caerulein-induced pancreatitis. 
Journal of Surgical Research 51, 495-499. 
Gukovskaya, A.S., Gukovsky, 1., Zaninovic, V., Song, M., Sandoval, D, Gukovsky, S., 
and Pandol, S.J. (1997). Pancreatic acinar cells produce, release, and respond to tumour 
necrosis factor-a. The Journal of Clinical Investigation 100, 1853-1862. 
Gukovsky, I, Gukovskaya, A.S., and Pandol, S.J. (1998). Gastroenterology (Abstract 485) 
Gullo, L., Tabacchi, P.L., Corazza, GR, Calanca, F., Campione, 0., and Labo, G ( 1982). 
HLA-B 13 and chronic calcific pancreatitis. Dig Dis Sci 2 7, 214-216. 
Guy, 0., Robles-Diaz, G., Adrich, Z., Sahel, 1., and Sarles, H. (1983). Protein content of 
precipitates present in pancreatic juice of alcoholic subjects and patients with chronic 
calcifying pancreatitis. Gastroenterology 89, 102-107. 
Haber, P., Wilson, J., Apte, M., Korsten, M., and Pirola, R. (1995). Individual susceptibility 
to alcoholic pancreatitis: still an enigma. 1 Lab Cl in Med 125, 305-312. 
Hacker, U.T., Gomolka, M., Keller, E., Eigler, A., Folwaczny, C., Fricke, H., Albert, E., 
Loeschke, K., and Endres, S. (1997). Lack of association between an interleukin-1 receptor 
antagonist gene polymorphism and ulcerative colitis. Gut 40, 623-627. 
Hajeer, A. H., Lazarus, M., Turner, D.M., Mageed, R.A., Vencovsky, J., Sinnott, P.J., 
Hutchinson, I. V., and Oilier, W.E R. (1998). IL-10 gene promoter polymorphisms in 
rheumatoid arthritis. Scand J rheumatol27, 142-145. 
Hajeer, A.H., Worthington, J., Silman, A.J., and Oilier, W.E.R. (1996). Association of 
tumor necrosis factor microsatellite haplotypes with HLA-DRB I *04 bearing haplotypes in 
rheumatoid arthritis patients. Arthritis rheum 39, 1109-1114. 
Hale, K.K., Smith, C.G, Baker, S.L., Vanderslice, R.W., Squires, C.H., Gleason, T.M., 
Tucker, KK, Kohno, T., and Russell, D.A. (1995). Multifunctional regulation of the 
biological effects ofTNF-? by the soluble type I and type II receptors. Cytokine 7, 26-38. 
Hart, P.H., Ahern, M.J., Smith, M.D., and Finlay-Jones, J.J. (1995). Comparison ofthe 
supressive effects of interleukin I 0 and interleukin 4 on synovial fluid macro phages and 
blood monocytes from patients with inflammatory arthritis. Immunology 84, 536-542. 
405 
Hart, P.H., Hunt, E.K., Bonder, C.S., Watson, C.J., and Finlay-Jones, J.J. (1996). 
Regulation of surface and soluble TNF receptor expression on human monocytes and 
synovial fluid macrophages by IL-4 and IL-10. J Immunol/57, 3672-3680. 
Havell, E.A. ( 1989). Evidence that tumor necrosis factor has an important role in 
antibacterial resistance. The Journal oflmmunology 143, 2894-2899. 
Hawrami, K., Hitman, G.A., Rema, M., Snehalatha, C., Viswasathan, M., Ramachandran, 
A., and Mohan, V. (1996). An association in non-insulin dependent Diabetes Mellitus 
subjects between susceptibility to retinopathy and tumour necrosis factor polymorphism. 
Human Immunology 46, 49-54. 
Hawrami, K., Hitman, G.A., Rema, M., Snehalatha, C., Viswasathan, M., Ramachandran, 
A., and Mohan, V. ( 1996). An association in non-insulin dependent Diabetes Mellitus 
subjects between susceptibility to retinopathy and tumour necrosis factor polymorphism. 
Human Immunology 46, 49-54. 
Hendrick (1994). Nature 308, 149 
Heresbach, D., Alizadeh, M., Dabadie, A., Le Berre, N., Columbel, J.F., Yaouanq, J., 
Bretagne, J.F., and Semana, G. (1997). Significance ofinterleukin-1 beta and interleukin-1 
receptor antagonist genetic polymorphism in inflammatory bowel diseases. Am J 
Gastroenterol92, 1164-1169. 
Hermann, S.M., Rickard, S., Nicaud, V., Mallet, C., Arveiler, D., Evans, A., Ruidavets, 
J.B., Luc, G., Barra, L., Parra, H.J., Poinier, 0., and Cambien, F. (1998). Polymorphisms of 
the tumor necrosis factor-alpha gene, coronary heart disease and obesity. Eur 1 Clin Invest 
28, 59-66. 
Hershey, G.K., Friedrich, M.F., Esswein, L.A., Thomas, M.L., and Chatila, T.A. (1997) 
The association of atopy with a gain-of-function mutation in the alpha subunit of the 
interleukin-4 receptor. N Engl 1 Med 337, 1720-1725. 
Hibbs, J.B., Taintor, R.R., Vavrin, Z., and Rachlin, E. M. ( 1988). Nitric oxide: a cytotoxic 
activated macrophage effector molecule. Biochem Biophys Res Commun 157, 87-94. 
Hirano, T., Saluja, A., Ramarao, P., Lerch, M.M., Saluja, M., and Steer, M.L. (1991). 
Apical secretion of lysosomal enzymes in rabbit pancreas occurs via a secretagogue 
regulated pathway and is increased after pancreatic duct obstruction. Journal of Clinical 
Investigation 87, 865-869. 
Ho, A.S. and Moore, K.W. (1994). Interleukin-10 and its receptor. Therapeutic 
Immunology 1, 173-185. 
Hoffinann, T.F, Leiderer, R., Waldner, H., and Messmer, K. ( 1996a). Bradykinin 
antagonists HOE-140 and CP-0597 diminish microcirculatory injury after ischaemia-
reperfusion of the pancreas in rats. British Journal of Surgery 83, 189-195. 
Hoffmann, T.F, Waldner, H., and Messmer, K (1996b). The bradykinin antagonist CP-
0597 can limit the progression ofpostischaemic pancreatitis. Immunopharmacology 33, 
243-246. 
Hohler, T., Kruger, A., Gerken, G., Schneider, P.M., Meyer zum Buschenfelde, K.H., and 
Rittner, C. ( 1997). A tumor necrosis factor-alpha (TNF-alpha) polymorphism is associated 
with chronic hepatitis-B infection. Clin Exp Immunol/11, 579-582. 
Honda, Z. ( 1991 ). Cloning by functional expression of platelet activating factor from guinea 
pig lung. Nature 349, 342-346. 
Hotamisligil, G.S., Arner, P., Caro, J.F., Atkinson, R.L., and Spiegelman, BM. (1995). 
Increased adipose tissue expression oftumor necrosais factor in human obesity and insulin 
406 
resistance. Journal of Clinical Investigation 95, 2409-2415. 
Hotter, G., Closa, D., Gelpi, E., and et at (1995). Role ofXanthine oxidase and eicosanoids 
in development of pancreatic ischaemia-reperfusion injury. Inflammation 4, 469-478. 
Howard, M., Muchamuel, T., Andrade, s., and et al (1993). Interleukin-10 protects mice 
from lethal endotoxemia. J Exp Med 177, 1205-1209. 
Hughes, C.B., Gaber, L.W., Kotb, M., Mohey ei-Din, AB., Pabst, M., and Gaber, A.O. 
(1995). Induction of acute pancreatitis in germ-free rats: Evidence of a primary role for 
tumor necrosis factor-alpha. Surgery 117, 201-205. 
Hughes, C.B., Gaber, L.W., Mohey et-Din, A. B., Grewal, H.P., Kotb, M., Mann, L., and 
Gaber, A.O. (1996). Inhibition ofTNF-? improves survival in an experimental model of 
acute pancreatitis. The American Surgeon 62, 8-13. 
Huizinga, T.W.J., Westendorp, R.G.J., Bollen, E.L.E.M., ., Keijsers, V., Brinkrnan, 
B.M.N., Langermans, J.A.M., Breedveld, F.C., Verweij, C.L., Van de Gaer, L., Crusius, 
J.B.A., Garcia-Gonzalez, A., Van Oosten, B. W., Polman, C. H., and Pena, AS. (1997). 
TNF-? promoter polymorphisms, production and susceptibility to multiple sclerosis in 
different groups of patients. Journal ofNeuroimmunology 72, 149-153. 
Huizinga, T.W.J., Westendorp, R.G.J., Bollen, E.L.E.M., ., Keijsers, V., Brinkman, 
B.M.N., Langermans, J.A.M., Breedveld, F.C., Verweij, C.L., Van de Gaer, L., Crusius, 
J.B.A., Garcia-Gonzalez, A., Van Oosten, B.W., Polman, C.H., and Pena, AS. (1997). 
TNF-? promoter polymorphisms, production and susceptibility to multiple sclerosis in 
different groups ofpatients Journal ofNeuroimmunology 72, 149-153. 
Hunger, RE., Mueller, C., Z'Graggen, K., Friess, H, and Buchler, M.W. (1997) Cytotoxic 
cells are activated in cellular infiltrates of alcoholic chronic pancreatitis. Gastroenterology 
112, 1656-1663. 
Iimuro, Y., Bradford, B.U., Gao, W, Kadiiska, M., Mason, R.P, Stefanovic, B., Brenner, 
D.A., and Thurman, R.G. (1996). Detection ofalpha-hydroxyethyl free radical adducts in 
the pancreas after chronic exposure to alcohol in the rat. Molecular Pharmacology 50, 656-
661. 
Inoue, S., Nakao, A., Kishimoto, W., Murakami, H., Itoh, K., Itoh, T., Harada, A., 
Nonami, T., and Takagi, H. ( 1995). Anti-neutrophil antibody attenuates the severity of 
acute lung injury in rats with experimental acute pancreatitis. Arch Surg 130, 93-98. 
Isenmann, R. and Buchler, M.W. ( 1994). Infection and acute pancreatitis. British Journal of 
Surgery81, 1707-1708. 
Ishizaka, S , Saito, S , Yoshikawa, M., Kimoto, M., and Nishiyama, T. ( 1996). TL-1 0 
production in mouse hepatocytes augmented by TGF-8. Cytokine 8, 837-843. 
ltoh, K. and Hirohata, S. (1995) The role offL-10 in human B cell activation, proliferation, 
and differentiation. J lmmunol /54, 4341-4350. 
Jaakkola, M. and Nordback, I. (1993). Pancreatitis in Finland between 1970 and 1989. Gut 
34, 1255-1260. 
Jacob, C.O., Fronek, Z, Lewis, G.D, Koo, M., Hansen, J.A., and McDevitt, H.O. ( 1990). 
Hereditable major histocompatibility complex class II-associated differences in production 
oftumor necrosis factor? :Relevance to genetic predisposition to systemic lupus 
erythematosus. Proc. Natl. Acad. Sci. 87, 1233-1237. 
Jalleh, R.P., Gilbertson, J.A., Williamson, R.C.N., Slater, S.D., and Foster, C.S. (1993). 
Expression of major histocompatibility antigens in human chronic pancreatitis. Gut 34, 
1452-1457. 
407 
Janeway, C. and Travers, P. (1996). Antigen recognition by T lymphocytes. In 
lmmunobiology: the immune system in health and disease. New York: Current Biology 
Ltd), pp. 4:1-4:48. 
Joillet, P., Bulpa, P., and Ritz, M. (1997). Additive beneficial effects of the prone position, 
nitric oxide, and almatrine bismesylate on gas exchange and oxygen transport in acute 
respiratory distress syndrome. Critical Care Medicine 25, 786-794. 
Jones, E.Y., Stuart, DJ., and Walker, N.P.C. (1989). Structure of tumour necrosis factor. 
Nature 338, 225-228. 
Jongeneel, C. V., Briant, L., Udalova, I.A., Sevin, A., Nedaspasov, S.A, and Cambon-
Thomsen, A ( 1991 ). Extensive genetic polymorphism in the human tumour necrosis factor 
region and relation to extended HLA haplotypes. Proc. Natl. Acad. Sci. 88, 9717-9721. 
Jongeneel, C. V., Briant, L., Udalova, I.A, Sevin, A., Nedaspasov, S.A., and Cambon-
Thomsen, A ( 1991 ). Extensive genetic polymorphism in the human tumour necrosis factor 
region and relation to extended HLA haplotypes. Proc. Natl. Acad. Sci. 88, 9717-9721. 
Kanbe, T., Naruse, S., Kitagawa, M., Nakae, Y., and Hayakawa, T. ( 1996). Effects of a 
bradykinin receptor antagonist (HOEI40) on taurochlorate-induced acute pancreatitis in 
rats. Pancreas 13, 283-288. 
Karimgani, 1., Porter, K.A., Langevin, RE., and Banks, P.A. (1992). Prognostic factors in 
sterile pancreatic necrosis. Gastroenterology 103, 1636-1640. 
Karlson, L., Surh, C. D., Sprent, J., and Peterson, P.A. ( 1992). An unusual class 11 
molecule. Immunol Today 13, 269-270. 
Kazantse, GB., Hecht, D.W., Rao, R., Fedorak, I.J., Gattuso, P., Thompson, K., Djuricin, 
G., and Prinz, RA ( 1994). Plasmic labelling confirms bacterial translocation in pancreatitis. 
American Journal of Surgery 167, 201-207. 
Keel, M., Ungethum, U., Steckholzer, U, and et al (1997). lnterleukin 10 counterregulates 
prointlammatory cytokine induced inhibition of neutrophil apoptosis during severe sepsis. 
Blood 90, 3356-3363. 
Kellermeyer, R.W. and Graham, RC. (1968). Kinins-possible physiologic and pathologic 
roles in man. New England Journal of Medicine 279, 859-866. 
Khoo, S.H., Pepper, L., Snowden, N., Hajeer, A.H., Valelly, P., Wilkins, E.G., Mandal, 
B.K., and Oilier, W.E.R (1997). Tumour necrosis factor c2 rnicrosatellite allele is 
associated with rate ofHIV disease progression. AIDS 11, 423-428. 
Kim, J.M., Brannan, C.I., Copeland, N.G., Jenkins, N.A., Khan, T.A., and Moore, K.W. 
(1992). Structure ofthe mouse IL-10 gene and chromosomal localisation ofthe mouse and 
human genes. Journal of Immunology /46, 3 618-3623. 
Kim, S., Davis, M., Sinn, E., Patten, P., and Hood, L. ( 1981 ). Antibody diversity; Somatic 
hypermutation of rearranged Vh genes. Cell 27, 573-581. 
Kindler, V. and Zubler, R.H. (1997). Memory, but not naive B Lymphocytes differentiate 
into Ig secreting cells after Cd40 ligation and costimulation with Il-4 and the differentiation 
factors, IL-2,IL-10. J Immunol159, 2085-2090. 
Kingsnorth, A.N. (1996). Platelet-Activating factor. Scand J Gastroenterol 3/(.S'2), 28-31. 
Kingsnorth, A. N. (1997). Role of cytokines and their inhibitors in acute pancreatitis. Gut 
40, 1-4. 
Kingsnorth, A. N. and for the British Acute Pancreatitis Study Group ( 1997). early 
treatment with Lexipafant, a platelet activating factor antagonist reduces mortality in acute 
408 
pancreatitis: a double blind, randomised placebo controlled study. Gastroenterology I 12, 
453A 
Kingsnorth, A.N. and Sargen, K. (1998). The inflammatory response in acute pancreatitis. 
Current Opinion in Critical Care 4, 121-124. 
Kingsnorth, A.N., Galloway, S.W., and Formela, L.J. (1995). Randomised, double-blind 
phase II trial ofLexipafant, a platelet activating factor antagonist, in human acute 
pancreatitis. British Journal of Surgery 82, 1414-1420. 
Kleijmeer, M.J., Kelly, A., Geuze, H.J., Slot, J.W., Townsend, A., and Trowsdale, J. 
( 1992). Location of MHC-encoded transporters in the endoplasmic reticulum and cis-golgi. 
Nature 357, 342-344. 
Knolle, P., Schlaak, J., Uhrig, A., Kempf, P, and Gerken, G. (1995). human kupffer cells 
secrete lL-1 0 in response to lipopolysaccharide challenge. Journal ofHepatology 22, 226-
229. 
Knuchel, M.C, Spira, T.J., Neumann, A.U., Xiau, L., Rudolph, D.L., Phair, J., Wolinsky, 
S.M., Koup, R.A., Cohen, O.J., Folks, T.M., and Lal, R.B. (1998). Analysis ofbi-allelic 
polymorphism in the tumor necrosis factoralpha promoter and HJV type 1 disease 
progression. AIDS Res 14, 305-309. 
Kornfield, S. ( 1986). Trafficking of lysosomal enzymes in normal and disease states. Journal 
of Clinical Investigation 77, 1-6. 
Kube, D., Platzer, C, V on Knethen, A., Straub, H., Bohlen, H., Hafuer, M., and Tesch, H. 
(1995). Isolation of the human interleukin 10 promoter. Characterisation of the promoter 
activity in Burkitt's Lymphoma cell lines. Cytokine 7, 1-7. 
Kubes, P, Suzuki, M., and Granger, D.N. (1991 ). Nitric oxide: an endogenous modulator 
ofleukocyte adhesion. Proc. Natl. Acad. Sci. USA 88, 4651-4655. 
Kusske, A.M., Rongione, A.J., and Reber, H.A. (1996b). Cytokines and acute pancreatitis 
Gastroenterology 110, 639-642. 
Kusske, A. M., Rongione, A.J., Ashley, S.W., and et al ( 1996a). Interleukin-1 0 prevents 
death in lethal necrotizing pancreatitis in mice. Surgery 120, 284-289. 
Lankisch, P.G. and Banks, P.A. (1998a). Chronic pancreatitis: Complications. In 
Pancreatitis. P. Lanksich and P.A. Banks, eds. (Berlin: Springer-Verlag), pp. 115-143. 
Lankisch, P.G. and Banks, P.A. (1998b). General Considerations: Anatomy. In Pancreatitis. 
P. Lanksich and P.A. Banks, eds. (Berlin: Springer-Verlag), pp. 15-18. 
Lankisch, P.G. and Banks, P.A. (1998c). Acute pancreatitis:pathophysiology. In 
Pancreatitis. P. Lanksich and P.A. Banks, eds. (Berlin Springer-Verlag), pp. 161 
Lankisch, P.G. and Banks, P.A. ( 1998d) Chronic pancreatitis: Pathology. In Pancreatitis. P 
Lanksich and P.A. Banks, eds (Berlin: Springer-Verlag), pp. 215-217. 
Lankisch, P.G. and Banks, P.A. ( 1998e). Acute Pancreatitis: Complications. In Pancreatitis. 
P. Lanksich and P.A. Banks, eds. (Berlin: Springer-Verlag}, pp. 115-143. 
Lankisch, PG., Assmus, C, Pflichthofer, D., Maisonneuve, P., and Lowenfels, A.B. 
(1998). Risk factors for the developing chronic pancreatitis after a first attack of alcoholic 
acute pancreatitis. Gastroenterology A50l(Abstract) 
Lankisch, P.G., Droge, M., and Gottesleben, F. (1995). Drug induced acute pancreatitis: 
incidence and severity. Gut 37, 565-567. 
Lankisch, P.G., Pohl, U., and Otto, J. (1989). Xanthine oxidase inhibitor in acute 
experimental pancrreatitis in rats and mice. Pancreas 4, 436-440. 
409 
Larvin, M. and McMahon, M.J. (1989). Apache-11 score for assessment and monitoring of 
acute pancreatitis. Lancet ii, 201-205. 
Larvin, M., Alexander, D.J., Switala, S.F., and McMahon, M.J. ( 1993). impaired 
mononuclear phagocyte function in patients with severe acute pancreatitis. Digestive 
Diseases and Sciences 38, 18-27. 
Laster, S.M., Wood, J.G., and Goading, L.R. (1988). Tumor necrosis factor can induce 
both apoptic and necrotic forms of cell lysis. J Immunol 141, 2629-2634. 
Lazarus, M., Hajeer, A.H., Turner, D.M., Sinnott, P.J., Worth.ington, J., Oilier, W.E.R, and 
Hutchinson, I. V. ( 1997). Genetic variation in the lnterleukin-1 0 gene promoter and 
systemic lupus erythematosus. J Rheumatol 24, 2314-2317. 
Le Boutellier, P. (1994). HLA class l chromosomal region, genes, and products: facts and 
questions. Crit Rev lmmunol 14, 89-129. 
Leach, S.D., Gorelick, F.S., and Modlin, I.M. (1990). Acute pancreatitis at its centenary. 
Annals of Surgery 212, 109-113. 
Ledebur, H.C. and Parks, T.P. (1995). Transcriptional regulation of the intercellular 
adhesion molcule I gene by inflammatory cytokines in human endothelial cells:essential 
roles of a variant NFkB site and p65 homodimers. J Bioi Chem 270, 933-943. 
Lee, S.P., Nicholls, J., and Park, H.Z. (1992). Biliary sludge as a cause of acute 
pancreatitis. New England Journal of Medicine 326, 589-593. 
Lerch, M.M., Saluja, A, Dawra, R., Ramarao, P., Saluja, M., and Steer, M.L. (1992). acute 
necrotizing pancreatitis in the opossum: earliest morphological changes involve acinar cells. 
Gastroenterology 103, 205-213. 
Lerch, M.M., Weidenbach, H., Gress, T.M., and Adler, G. (1995). Effect ofkinin inhibition 
in experimental acute pancreatitis. American Journal of Physiology (Gl Liv Physiol 32}, 
G490-G499. 
Lerch, M.M., Weidenbach, H., Hernandez, C.A., Preclik, G., and Adler, G. (1994). 
Pancreatic outflow obstruction as the critical event in human gallstone induced pancreatitis. 
Gut 35, 1501-1503. 
Li, Y. and Owyang, C. (1994). Endogenous cholecystokininstimulates pancreatic exocrine 
secretion via vagal afferent pathway in rats. Gastroenterology 107, 525-531. 
List, S. and Gluuid, C. (1994). A meta-analysis ofHLA-antigen prevalences in alcoholics 
and alcoholic liver disease. Alcohol & Alcoholism 29, 757-764. 
Liu, Y, Wei, S., H-Y., Ho, A.S., de Waal Malefyt, R., and Moore, K.W. (1994). 
Expression cloning and characterisation of a human lL-10 receptor. J Immunol 152, 1821-
1826. 
Lloyd, A.R, Oppenheim, JJ., Kelvin, D.J., and Taub, D.D. (1996). Chemokines regulate T 
cell adherence to recombinant adhesion molecules and extracellular matrix proteins. J 
Immunol 156, 932-938. 
Louis, E., Satsangi, J., Roussomoustakaki, M., Parkes, M., Fanning, G., Welsh, K.l., and 
Jewell, D.P. (1996). Cytokine gene polymorphisms in inflammatory bowel disease. Gut 39, 
705-710. 
Lumeng, L. and Crabb, D.W. (1994). Genetic aspects and risk factors in alcoholism and 
alcoholic liver disease Gastroenterology 107, 572-578. 
Mann, D.V., Hershman, M.J., Hittinger, R., and Glazer, G. (1994). Multicentre audit of 
death from acute pancreatitis. British Journal of Surgery 81, 890-893. 
410 
Mansfield, J.A, Holden, H., Tarlow, J.K., McDowell, T.L., Wilson, A.G., di Giovine, FS., 
Holdsworth, C.D., and Duff, G.W. (1994). Novel genetic association between ulcerative 
colitis and the anti-inflammatory cytokine interleukin-1 receptor antagonist. 
Gastroenterology 106, 637-642. 
Mantovani, A., Bussolino, F., and Introna, M. (1997). Cytokine regulation of endothelial 
cell function. Immunology Today 18, 231-239. 
Manus, R.M., Wilson, A. G., Mansfield, J.A., Weir, D.W., Duff, G.W., and Kelleher, D. 
(1996). TNF2, a polymorphism of the tumour necrosis factor alpha gene promoter, is a 
component of the celiac disease major histocompatibility complex haplotype. Eur J Immunol 
29,2113-2118. 
Marchant, A., Deviere, J., Baudouin, B., De Groote, D., Vincent, J., and Goldman, M. 
( 1994). Interleukin-1 0 production during septicaemia. Lancet 343, 707-708. 
Mascher, B., Schmidt, W., Csemok, E., Tatsis, E., Reil, A., Gross, W.L., and Sayfarth, M. ( 
1996). Polymorphisms in the tumour necrosis factor genes and Wegener's granulomatosis 
Exp Clin Immunogenet 14, 226-233. 
Matsumoto, M., Takahashi, H., Murayama, K., Higuchi, S., Matsushita, S., Muramatsu, T., 
Okuyama, K., Yokoyama, A., Nanako, M., and Ishii, H. (1996). Genotypes of alcohol-
metabolising enzymes and the risk for alcoholic chronic pancreatits in Japanese alcoholics 
Alcoholism Clin Exp Res 20, 289A-292A. 
Matsushita, M., Endo, Y., Nonaka, A., and Fujita, T. (1998). Complement related serine 
proteases in vertebrates. Current Opinion in Immunology 10, 29-35. 
Maudsley, D.J. (1995). Modulation ofMHC expression by viruses. In Modulation ofMHC 
antigen expression and disease. G.E. Blair, C.R. Pringle, and D.J. Maudsley, eds. 
(Cambridge: Cambridge University Press), pp. 133-149. 
Me Dowell, P.L., Symonds, J.A., Ploski, R., Forre, 0., and Duff, G.W. (1995). A genetic 
association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha 
polymorphism. Arthritis rheum 38, 221-228. 
McArthur, K.E. ( 1996). Review article: drug-induced pancreatitis. Aliment Pharmacal Ther 
10, 23-38. 
McFadden, D. W. ( 1991) Organ failure and multiple organ system failure in pancreatitis. 
Pancreas 6, S37-S43. 
McGuire, W., Hill, A.V.S., Allsopp, C.E.M., Greenwood, B.M., and Kwiatkowski, D. 
( 1994 ). Variation in the TNF? promoter region associated with susceptibility to cerebral 
malaria. Nature 371, 508-511. 
McGuire, W., Hill, A.V.S., Allsopp, C.E.M., Greenwood, B.M., and Kwiatkowski, D. 
(1994). Variation in the TNF? promoter region associated with susceptibility to cerebral 
malaria. Nature 3 71, 508-511. 
McKay, C., Curran, F., Sharples, C., and lmrie, C. W. ( 1997). Lexipafant in severe acute 
pancreatitis: a prospective, placebo-controlled, randomised trial. British Journal of Surgery 
84, 
McKay, C.J., Gallagher, G., Brooks, 8., lmrie, C.W., and Baxter, J.N. (1996). Increased 
monocyte cytokine production in association with systemic complications in acute 
pancreatitis. British Journal of Surgery 83, 919-923. 
McLaughlin, P.J. and Davies, H. M. (I 990). Tumour necrosis factor in normal plasma 
Lancet ii, I 014-1015. 
411 
McManus, R., Moloney, M., Borton, M., Finch, A., Chaun, Y.T., Lawlor, E., Weir, D.G, 
and Kelleher, D. (1996). Association of celiac disease with microsatellite polymorphisms 
close to the tumor necrosis factor genes. Hum Immunol 45, 24-31. 
Medich, D.S., Lee, T.K., Melhem, M.F., Rowe, M.I., Schraut, W.H., and Lee, K.K.W. 
( 1993 ). Pathogenesis of pancreatic sepsis. American Journal of Surgery 165, 46-52. 
Mehrota, P.T., Donelly, R.P., Wong, S., and et al (1998). Production ofiL-10 by human 
NI< cells stimulated with IL-2 and/or 11-12. J Immunol 160, 2637-2344. 
Meier, P. (1995). Who gets and what causes pancreatitis. J Lab Clin Med 125, 298-300. 
Meldrum, D.R. (1998). Tumor necrosis factor in the heart. American Journal ofPhysiology 
274, R577-R595. 
Mergener, K. and Baillie, J. (1998). Acute Pancreatitis. British Medical Journal316, 44-48. 
Messer, G., Spengler, U., Jung, M.C., Honold, G., Blomer, K., Pape, G.R., Reithmuller, G., 
and Weiss, E.H. (1991). Polymorphic structure ofthe tumor necrosis factor (TNF) locus: 
an Ncol polymorphism in the first intron of the human TNF-b gene correlates with a variant 
amino acid in position 26 and a reduced level ofTNF-b production. J Exp Med 173, 209-
219. 
Moffatt, M.F. and Cookson, W.O. (1997). Tumour necrosis factor haplotypes and asthma. 
Hum Mol Genet 6, 551-554. 
Mok, C.C., Lanchbury, J.S., Chan, D.W., Lau, C.S. (1998). lnterleukin-10 promoter 
polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis & 
Rheumatism. 4, 1090-5. 
Molero, X., Guarner, F., and Salas, A. ( 1995). Nitric oxide modulates pancreatic basal 
secretion and response to cerulein in the rat: effects in acute pancreatitis. Gastroenterology 
108, 1855-1862. 
Monaco, J.J. (1992). Not so groovy after all? Curr Biol2, 433-435. 
Monos, D.S., Kamoun, M., Udalova, I.A., Czansky, E., Cizman, B, Turetskaya, R.L., 
Smirnova, JB., Zharkov, V.G., Gasser, D., and Zmijewski, C. M. ( 1995). Genetic 
polymorphism of the human tumor necrosis factor region in insulin-dependent diabetes 
mellitus.Linkage disequilibrium ofTNFab microsatellite alleles with HLA haplotypes Hum 
Immunol44, 70-79. 
Moore, KW., O'Garra, A., de Waal Malefyt, R., Vierra, P., and Mosmann, T.R. (1993). 
Annu Rev Immunol 11, 165-190. 
Mora, A., Perez-Mateo, M., Viedma, J.A., Carballo, F., Sanchez-Paya, J., and Liras, G. 
( 1997). Activation of cellular immune response in acute pancreatitis. Gut 40, 794-797. 
Moreau, J.A., Zinsmeister, A.R., Melton, L.J., and DiMagno, E.P (1988). Gallstone 
pancreatitis and the effect of cholecystectomy: a population-based cohort study. Mayo 
Clinic Proceedings 63, 466-473. 
More!, P.A., Dorman, JS., Todd, JA., McDevitt, H.O., and Trucco, M. (1988). Aspartic 
acid at position 57 of the HLA-DQB chain protects against type I diabetes: a family study. 
Proc. Natl. Acad. Sci. USA85,8111-8115. 
Mosmann, T.R., Cherwinski, H., Bond, M.W., Giedlin, M.A., Coffman, R.L., and Locksley, 
R.M. (1986). Journal oflmmunology 136, 2348-2357. 
Mullighan CG, Fanning G, Chapel HM, Welsh KI. (1997). TNF and lymphotoxin-alpha 
polymorphisms associated with common variable immune deficiency; role in the 
pathogenesis of granulomatous disease. J Tmmunol 159, 6236-41. 
412 
Multigener, L., Sarles, H., Lombardo, D., and De Caro, A. (1985). Pancreatic stone 
protein .I!. Implication in stone formation during the course of chronic calcifying 
pancreatitis. Gastroenterology 89, 387-391. 
Muncy, D.M., Haley-Russell, D., Stanislawka, M., Vakil, A., Rodriguez, L., and Moody, 
F.G. (1993). Bacterial translocation following acute pancreatitis in rats. Gastroenterology 
102, A490(Abstract) 
Murakami, H., Nakao, A., Kishimoto, W., and et al (1995). Detection of02- generation and 
neutrophil accumalation in rat lungs after acute necrotizing pancreatitis. Surgery 118, 547-
554. 
Nadel, S., Newport, M.J., Booy, R., and Levin, M. (1996). Variation in the tumour necrosis 
factor-a gene promotor region may be associated with death from meningococcal disease. 
Journal oflnfectious Diseases 174, 878-880. 
Nadel, S., Newport, M.J., Booy, R., and Levin, M. ( 1996). Variation in the tumour necrosis 
factor-a gene promotor region may be associated with death from meningococcal disease. 
Journal oflnfectious Diseases 174, 878-880. 
Nanako, M., Knowlton, AA., Dibbs, Z., and Mann, D.L. (1998). Turner necrosis factor-
alpha confers resistance to hypoxic injury in the adult mammalian cardiac myocyte. 
Circulation 14, 1392-1400. 
Napolitano, L.M., Buzdon, M.M., Shi, H.J., and Bass, B.L. ( 1997). Intestinal epithelial cell 
regulation of macrophage and lymphocyte interleukin-10 expression. Arch Surg 132, 1271-
1276. 
Nedaspasov, S.A., Udalova, I.A., Kuprash, D.V., and Turetskaya, R.L. (1991). DNA 
sequence polymorphism at the human turner necrosis factor (TNF) locus. J [mmunol 147, 
I 053-1059. 
Neiderau, C., Neiderau, M., Borchard, F., and et al (1992). Effects of antioxidants and free 
radical scavengers in three different models of acute pancrreatitis. Pancreas 7, 486-496. 
Neiderau, C., Neiderau, M., Luthen, R., Strohmeyer, G., Ferrell, L.D., and Grendell, J.H. 
( 1990). Pancreatic exocrine secretion in acute experimental pancreatitis Gastroenterology 
99,1120-1127. 
Newton, C.R., Graham, A., Heptinstall, L.E., Powell, S.J., Summers, C., Kalsheker, N, 
Smith, JC., and Markham, A.F. (1989). Analysis of any point mutation in DNA. The 
amplification refractory mutation system (ARMS). Nucleic Acids Research 17, 2503-25 16. 
Nicklin, M.J.H., Weith, A., and Duff, G.W. (1994). a physical map ofthe region 
encompassing the human interleukin I and IL-l receptor antagonist genes. Genomics 19, 
382-384. 
Nishizuka, Y (1984). Turnover of inositol phospholipids and signal transduction. Science 
225, 1365-1370. 
Nonaka, A., Manabe, T, and Tobe, T. (1991). Effect of a new synthetic ascorbic acid 
derivative as a free radical scavenger on the development of acute pancreatitis in mice. Gut 
32, 528-532. 
Nonaka, A., Manabe, T., Tamura, K., and et al (1989). Changes in lipid peroxide and 
oxygen radical scavengers in Cerulein induced pancreatitis. Digestion 43, 41-46. 
Norman, J.G., Fink, G.W., and Franz, M.G. (1995a). Acute pancreatitis induces 
intrapancreatic tumor necrosis factor gene expression. Arch Surg 130, 966-910. 
Norman, JG., Fink, G.W., Franz, M. G., Guffey, J, Carter, G., Davison, B., and Glaccum, 
413 
M. (1996a). Active Interleukin-1 receptor required for maximal progression of acute 
pancreatitis. Annals of Surgery 223, 163-169. 
Norman, J.G., Fink, G.W., Messina, J., Carter, G., and Franz, M.G. (1996b). Timing of 
tumor necrosis factor antagonism is critical in determining outcome in murine lethal acute 
pancreatitis. Surgery 120, 5 I 5-521. 
Norman, J.G., Franz, M.G., Fink, G.W., Messina, J., Fabri, P.J., Gower, W.R., and Carey, 
L.C. (1995b). Decreased mortality of severe acute pancreatitis after proximal cytokine 
blockade. Annals of Surgery 221, 625-634. 
Norman, J.G., Franz, M.G., Messina, J., Riker, A., Fabri, P.J., Rosemurgy, A.S., and 
Gower, W.R. ( 1995c). Interleukin-1 receptor antagonist decreases severity of experimental 
acute pancreatitis. Surgery 117, 648-655. 
Norman, J.G., Yang, J., Fink, G.W., Carter, G., Ku, G., Denham, W., and Livingston, D. 
( 1997) Severity and mortality of experimental pancreatitis are dependent on lnterleukin-1 
converting enzyme (ICE). Journal of Interferon and Cytokine Research /7, 113-118. 
O'Donovan, D.A., Kelly, C.J., Abdih, H., Bouchier-Hayes, D., Watson, R.W.G., Redmond, 
H.P., Burke, P.E., and Bouchier-Hayes, D.A. (1995). Role ofnitric oxide in lung injury 
associated with experimental acute pancreatitis. British Journal of Surgery 82, 1122-1126. 
Oettinger, M.A., Schatz, D.G., Gorka, C., and Baltimore, D. (1990). RAG-I and RAG-2, 
adjacent genes that synergistically activate V(D)J recombination. Science 248, I 5 17-1 523. 
O'Farrell, AM., Liu, Y., Moore, KW., and Mui, AL. (1998).IL-10 inhibits macrophage 
activation and proliferation by distinct signalling pathways. EMBO Journal 17, I 006-10 18. 
O'Garra, A., Chang, R., Hastings, R., Houghton, G., and Howard, M. (1992). B I cells are 
the main source of B cell derived IL-l 0. Eur J lmmunol 22, 711-717. 
Onozaki, K., Matsushima, K., Aggarwal, B. B., and Oppenheim, J.J. ( 1985). lnterleukin-1 as 
a cytocidal factor for several tumor cell lines. J lmmunol 135, 3962-3968. 
Opie, EL (190 I). The etiology of acute haemorrhagic pancreatitis. John Hopkins Hospital 
Bulletin 12, 182-188. 
Palade, G. (1975). Intracellular aspects of the process of protein synthesis. Science 189, 
347-358. 
Palmer, R.M.J., Ashton, D.S., and Moncada, S. (1988). Vascular endothelial cells 
synthesize nitric oxide from L-arginine. Nature 333, 664-646. 
Panes, J. and Granger, D .N. ( 1998). Leukocyte-endothelial cell interactions: Molecular 
mechanisms and implications in gastrointestinal disease. Gastroenterology 114, 1066-1090. 
Parenti, D.M., Steinberg, W., and Kang, P. (1996). Infectious causes of acute pancreatitis. 
Pancreas 13,356-371. 
Parham, P. ( 1990). Antigen processing. Transporters of delight. Nature 348, 674-675. 
Parham, P., Lomen, C.E., Lawlor, D.A., Ways, J.P., Holmes, N., Coppin, H.L., Salter, 
R.D., Wan, AM., and Ennis, P.D. (1988). nature ofpolymorphism ofHLA-A, -B, and -C 
molecules. Proc. Natl. Acad. Sci. USA 85, 4005-4009. 
Parillo, J.E. (1993). Pathogenetic mechanisms of septic shock. New England Journal of 
Medicine 328, 1471-1477. 
Pennica, D., Nedwin, G.E., Hayflick, J.S , Seeburg, P.H., Derynck, R., Palladino, M.A., 
Kohr, W.J., Aggarwal, B.B., and Goedel, D. V. (1984). Human tumor necrosis factor: 
precursorstructure, expression and homology to lymphotoxin. Nature 312, 724-729. 
414 
Petrone, W.F., English, D.K., Wong, K., and McCord, J.M. (1980). Free radicals and 
inflammation: Superoxide-dependent activation of a neutrophil chemotactic factor in 
plasma. Proc. Natl. Acad. Sci. USA 77, 1159-1163. 
Pezzilli, R., Billi, P., Beltrandi, E., Casedei Maldini, M., and Mancini, R. (1997a). Impaired 
lymphocyte proliferation in human acute pancreatitis. Digestion 58, 431-436. 
Pezzilli, R., Billi, P., Miniero, R., and Bakarat, B. (1997b). Serum Interleukin-1 0 in human 
acute pancreatitis. Digestive Diseases Science 42, 1469-1472. 
Platanias, L. C. and Vogelzang, N.J. (1990). Interleukin-l:Biology,pathophysiology,and 
clinical prospects. American Journal of Medicine 89, 621-629. 
Platzer, C., Meisel, C.H., Vogt, K., Platzer, K., and Volk, H.D. (1995). Up-regulation of 
monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs. Int 1mmunol 7, 
517-523. 
Plevy, S.E, Targan, S.R., Yang, H., Fernandez, D., Ratter, J.l., and Toyoda, H. (1996). 
Tumor Necrosis Factor Microsatellites defme a Crohn's Disease-Associated haplotype on 
Chromasome 6 Gastroenterology 110, I 053-1060. 
Pober, J.S., Lapierre, LA, Stolpen, A.H., and et al (1987). Activation of cultured human 
endothelial cells by recombinant lymphotoxin: comparison with tumor necrosis factor and 
Interleukin -I species. J lmmunol 138, 3319-3324. 
Poicot, F., Briant, L., Jongeneel, C. V., Molvig, J., Worsaae, H., Abbal, M., Thomsen, M., 
Nerup, J., and Cambon-Thomsen, A. (1993). Association oftumour necrosis factor (TNF) 
and class I1 major histocompatibility complex alleles with the secretion of TNF-? and TNF-? 
by human mononuclear cells : a possible link to insulin-dependent diabetes mellitus. Eur 1 
Immunol 23, 224-231. 
Poicot, F., Briant, L., Jongeneel, C. V., Molvig, J., Worsaae, H., Abbal, M., Thomsen, M., 
Nemp, J., and Cambon-Thomsen, A. (1993). Association oftumour necrosis factor (TNF) 
and class !I major histocompatibility complex alleles with the secretion ofTNF-? and TNF-? 
by human mononuclear cells : a possible link to insulin-dependent diabetes mellitus. Eur J 
Immunol 23, 224-231. 
Powis, S.H., Mockridge, I., Kelly, A., Kerr, LA, Glynne, R, Gileadi, U., Beck, S., and 
Trowsdale, J. (1992). Polymorphism in a second ABC transporter gene located within the 
class U region of the human major histocompatibility complex Proc. Natl. Acad. Sci. 
USA89, 1463-1467. 
Premack, B.A. and Schall, T.J. ( 1996). Chemokine receptors: Gateways to inflammation 
and infection. Nature Medicine 2, 1174-1178. 
Pretolani, M. and Goldman, M. (1997). IL-10: a potential therapy for allergic inflammation? 
Immunology Today 18, 277-283. 
Prins, J.B., Neisler, C.U., Winterford, C.M., and et al (1997). Tumor necrosis factor? 
induces apoptosis of human adipose cells Diabetes 46, 1939-1944. 
Pujol-Borrell, R., Todd, 1., Dos hi, M., and et al ( 1987). HLA class TI induction in human 
islet cells by interferon-gamma plus tumour necrosis factor or lymphotoxin. Nature 326, 
304-306. 
Pujol-Borrell R, Todd I, Londei M, Foul is AK, Feldmann M, Bottazo GF ( 1986). 
Innapropriate major histocompatibility complex class II expression by thyroid follicular cells 
in thyroid autoimmune disease and by pancreatic beta cells in type I diabetes Mol Bioi Med 
3, 159-65. 
Puolakkainen, P., Valtonen, V., Paananen, A, and Schroder, T. (1987). C-reactive protein 
415 
(CRP) and serum phospholipase A2 in the assesment of severity of acute pancreatitis. Gut 
28, 764-771. 
Radi, R., Beckman, J.S., Bush, KM., and Freeman, B.A. (1991). Peroxynitrite oxidation of 
sulfhydryls: the cytotoxic potential of superoxide and nitric oxide. J Bioi Chem 266, 244-
250. 
Ragoussis, J. (1995). Organization ofthe MHC. In Modulation ofMHC expression and 
disease. G.E. Blair, C.R. Pringle, and DJ. Maudsley, eds. (Cambridge: Cambridge 
University Press), pp. 27-42. 
Ranson, J.H.C., Rifkind, K.M., Roses, D.F., Fink, S.D., Eng, K., and Spencer, F.C. (1974). 
Prognostic signs and the role of operative management in acute pancreatitis. Surgery, 
Gynaecology, Obstetrics 139, 69-81.(Abstract) 
Reed, T., Page, W.F., Viken, R.J., and Christian, J.C. (1996). Genetic predisposition to 
organ-specific endpoints of alcoholism. Alcoholism Clin Exp Res 20, 1528-1533. 
Riche, F., Panis, Y., Laisne, M., Briard, C., Cholley, B., Bernard-Poenaru, 0., Graulet, A., 
Gueris, J., and Valleur, P. ( 1996). High tumor nrcrosis factor serum level is associated with 
increased survival in patients with abdominal septic shock: a prospective study in 59 
patients. Surgery 120, 801-807. 
Rinderknecht, H. ( 1988). Fatal pancreatitis, a consequence of excessive leukocyte 
stimulation? International Journal ofPancreatology 3, 105-112. 
Rinderknecht, H. (1993). Pancreatic secretory enzymes. In The pancreas: Biology, 
Pathobiology, and disease. V.L.W. Go, E.P. DiMagnio, J.D. Gardner, E. Lebenthal, H.A. 
Reber, and G.A. Scheele, eds. (New York: Raven Press), pp. 219-251. 
Rinderknecht, H. (1994). Genetic determinants ofmortality in acute necrotizing 
pancreatitis. International Journal ofPancreatology 16, 11-15. 
Rink, L. and Kirchner, H. ( 1996). Recent progress in the tumor necrosis factor-a field 
Allergy and Immunology 111, 199-209. 
Rongione, A.J., Kusske, AM., and Kwan, K. (1997). Interleukin-10 reduces the severity of 
acute pancreatitis in rats. Gastroenterology 112, 960-967. 
Ros, E., Navarro, S., Garcia-Puges, A., and Valderrama, R. (1991 ). Occult microlithiasis in 
'idiopathic' acute pancreatitis: prevention of relapses by cholecystectomy or ursodeoxycholic 
acid therapy. Gastroenterology 101, 1701-1709. 
Rosai, J. ( 1998). Pancreas and ampullary region. In Ackerman's Surgical Pathology. J. 
Rosai, ed. (St Louis: Mosby), pp. 969-970. 
Rothe, J., Lesslauer, W., Lotscher, H., Lang, Y., Koebel, P., Kontgen, F., Althage, A., 
Zinkernagel, R., Steinmetz, M., and Bluethrnann, H (1993). Mice lacking the tumour 
necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to 
infection by Listeria monocytogenes. Nature 364, 798-802. 
Rousset, F., Garcia, E., Defrance, T., Peronne, C., Vezzio, N., Hsu, D., Kastelein, R., 
Moore, KW., and Banchereau, J. (1992). lL-10 is a potent growth and differentiation 
factor for activated human B lyrnphocytes. Proc. Natl. Acad. Sci. USA 89, 1890-1893. 
Roussomoustakaki, M., Satsangi, J., Welsh, K.I., Louis, E., Fanning, G., Targan, S.R., 
Landers, C., and Jewell, D.P. (1997). Genetic markers may predict disease behavior in 
patients with Ulcerative colitis. Gastroenterology 112, 1845-1853. 
Rudlaweit, M., Tikly, M., Khamashta, M., Gibson, K., Klinke, J., Hughes, G., and 
Wordsworth, P. (1996) Interethnic differences in the association oftumor necrosis factor 
416 
promoter polymorphisms with systemic lupus erythematosus. J Rheumatol 23, 1725-1728. 
Rudlaweit, M., Tikly, M., Khamashta, M., Gibson, K., Klinke, J., Hughes, G., and 
Wordsworth, P. (1996). Jnterethnic differences in the association oftumor necrosis factor 
promoter polymorphisms with systemic lupus erythematosus. J Rheumatol 23, 1725-1728. 
Runkel, N. ( 1996). Bacterial translocation in acute pancreatitis. Digestive Surgery I 3, 269-
272. 
Runkel, N., Moody, F.G., Smith, G.S., Rodriguez, L., Chen, Y., LaRocco, M.T., and 
Miller, T.A. (1993). Alterations in rat intestinal transit by morphine promote bacterial 
translocation. Digestive Diseases and Sciences 38, 1530-1536. 
Runkel, N., Moody, F.G., Smith, G.S., Rodriguez, L., LaRocco, M.T., and Miller, T.A 
( 1991 ). The role of the gut in the development of sepsis in acute pancreatitis. Journal of 
Surgical Research 51, 18-23. 
Runkel, N., Rodriguez, L., and Moody, F.G. (1995). Mechanisms of sepsis in acute 
pancreatitis in opossums. American Journal of Surgery 169, 227-232. 
Runkel, N., Rodriguez, L., LaRocco, M.T., and Moody, F.G. (1990). Mechanisms of 
pancreatic infection in acute pancreatitis in opposums. Curr Surg 47, 460-462. 
Ryan, J.W., Moffat, J.G., and Thompson, A.G. (1964). Role of bradykinin in the 
development of acute pancreatitis. Nature 204, 1212-1213. 
Saghizadeh, M., Ong, J.M., Garvey, W.T., Henry, R.R., and Kern, P.A. (1996). The 
expression of TNF? by human muscle. Journal of Clinical Investigation 9 7, 1111-1116 
Saito, I, Hashimoto, S., Saluja, A, Steer, M.L., and Meldolosi, J. (1987). Intracellular 
transport of pancreatic zymogens during caerulein supramaximal stimulation. American 
Journal ofPhysiology (GI Liv Physio/16), G508-G516. 
Saluja, A., Sadmitsu, H., Saluja, M., Powers, R.E., Meldolosi, l, and Steer, M.L. (1987). 
Subcellular redistribution of lysosomal enzymes during caerulein induced pancreatitis. 
American Journal of Physiology 253, G508-G516. 
Saluja, A., Saluja, M., Villa, A., Leli, U., Rutledge, P, Meldolosi, l, and Steer, M.L. 
(1989). Pancreatic duct obstruction in rabbits causes digestive zymogen and lysosomal 
enzyme colocalisation. Journal ofCiinical Investigation 84, 1260-1266. 
Sandoval, D., Gukovskaya, AS, Reavey, P., Gukovsky, S, Sisk, A, Braquet, P., Pandol, 
SJ., and Pouceii-Hatton, S. (1996). The role ofneutrophils and platelet activating factor in 
mediating experimental pancreatitis. Gastroenterology I 11, I 081-1 091. 
Santamaria, P., Gehrz, R.C., Bryan, M.K., and Barbosa, J.J. (1989). Involvement of class II 
MHC molecules in the LPS-induction ofiL-1/TNF secretions by human monocytes. Journal 
oflmmunology 143, 913-922. 
Samer, M. and Cotton, PB. (1984). Classification of pancreatitis. Gut 25, 756-759. 
Satiani, B. and Stone, HH. (1979). Predictability of present outcome and future recurrence 
in acute pancreatitis. Archives of Surgery I 14, 711-716. 
Sato, M., Ishikawa, 0., Abe, M., and Miyachi, Y. ( 1998). Opposite effects of tumour 
necrosis factor-alpha on type I and 11 collagengene expression by human dermal fibroblasts 
in monolayer and three-dimensional cultures. Br J Dermatol 138, 118-121. 
Savolainen, V.T., Pajarinen, J., Perola, M., Pentilla, A., and Karhunen, P.l (1997). 
Polymorphism in the cytochrome P4 50 2E 1 gene and risk of alcoholic liver disease. J 
Hepatol 26, 55-61. 
Schilling, PJ., Murray, J.L., and Markowitz, AB. (1992). Novel tumor necrosis factor 
417 
toxic effects. Pulmonary haemorrhage and severe hepatic dysfunction. Cancer 69, 256-260. 
Schmidt, H.W. and Waiter, U. (1994). NO at work. Cell 78, 919-925. 
Schmiegel, W., Burchert, M., Kalthoff, H., Roeder, C., Butzow, G., Grimm, H., Kremer, 
B., Soehenra, N., Schreiber, H., Thiele, H., and Greten, H. (1990). Immunohistochemical 
characterization and quantitative distribution of pancreatic stone protein in sera and 
pancreatic secretions in pancreatic disorders. Gastroenterology 99, 1421-1430. 
Schoenberg, M.H., Birk, D., and Beger, H. G. (1995). Ox.idative stress in acute and chronic 
pancreatitis. Am J Clin Nutr 62, 1306-1314. 
Schoenberg, M.H., Buchler, M., and Younes, M. (1994). Effect of antioxidant treatment in 
rats with acute hemorrhagic pancreatitis. Dig Dis Sci 39, I 034-1040. 
Schoenberg, M.H., Buchler, M., Gaspar, M., and et al (1990). Oxygen free radicals in acute 
pancreatitis of the rat. Gut 31, 1138-1143. 
Schreiber, S, Heinig, T., Thiele, H., and Raedler, A. (1995). Immunoregulatory role of 
interleukin-1 0 in patients with inflammatory bowel disease. Gastroenterology 108, 1434-
1444. 
Schwaeble, W., Schaefer, M.K.H., Petry, F., Fink, T., Knebel, D., Weihe, E., and Loos, M. 
(1995). Follicular dendritic cells, interdigitating cells, and cells of the monocyte-macrophage 
lineage are the C I q-producing sources in the spleen. Journal oflmmunology 155, 4971-
4978. 
Seitzer, U., Swider, C., Stuber, F., Suchnicki, K., Lange, A., Richter, E., Zabel, P., Muller-
Quernheim, J., Flad, H. G., and Gerdes, J. (1997). Tumor necrosis factor-alpha gene 
polymorphism in sarcoidosis. Cytokine 9, 789-790. 
Selby, P., Hobbs, S., Viner, C., Jackson, E., Jones, A., Newell, D., Calvert, A.H., 
McElwain, T., Fearon, K.H.C., Humphreys, J., and Shiga, T. ( 1987). Tumour necrosis 
factor in man: Clinical and biological observations. British Journal of Cancer 56, 803-808. 
Senninger, N, Moody, F.G., Coelho, JC.U., and Van Buren, D.V. (1986). The role of 
biliary obstruction in the pathogenesis of acute pancreatitis in the opossum. Surgery 688-
693. 
Sherlock, S. and Dooley, J. (1993). Alcohol and the liver. In Diseases ofthe liver and biliary 
system. S. Sherlock and J. Dooley, eds. (Oxford: Blackwell Scientific Publications), pp. 
370-389. 
Singer, M.V., Gyr, K., and Sarles, H. (1985). Revised classification ofpancreatitis. 
Gastroenterology 89, 683-685. 
Singh, M. and Simsek, H. ( 1990). Ethanol and the pancreas: Current status. 
Gastroenterology 98, 1051-1062. 
Situnayake, R.D., Crump, B.J., and Thurnam, D.I. (1990). Lipid peroxidation and hepatic 
antioxidants in alcoholic liver disease. Gut 31, 1311-1316. 
Slater, T.F. ( 1984). Free radical mechanism in tissue injury. Biochem J 221, 1-15. 
Soiling, H. and Fest, W. ( 1986). Synthesis of platelet activating factor in exocrine glands 
and it's control by secretagogues. J Bioi Chem 261, 1316-1322. 
Soudah, H.C., Lu, Y., Hasler, W., L., and Owyang, C. (1992). Cholecystokinin at 
physiological levels evokes pancreatic exocrine secretion via a cholinergic pathway 
American Journal ofPhysiology 263, G102-Gl07. 
418 
Spies, T., Bresnahan, M., Bahram, S., Arnold, D., Blanck, G., Mellins, E., Pious, D., and 
DeMars, R. (1990). A gene in the human major histocompatibility complex class U region 
controlling the class I antigen presentation pathway. Nature 348, 744-747. 
Steer, M.L. and Meldolosi, J. ( 1987). The cell biology of experimental pancreatitis. N Engl 
J Med 316, 144-150. 
Steer, M.L., Rutledge, P.L., Powers, R.E., and et al (1991). The role of oxygen derived free 
radicals in two models of experimental acute pancreatitis:Etfects of catalase, superoxide 
dismutase, dimethylsulfoxide, and allopurinol. Klin Wochenschr 69, 1012-1017. 
Steinberg, W.M. and Schlesselmann, S.E. (1987). Treatment of acute pancreatitis: 
Comparison of animal and human studies. Gastroenterology 93, 1420-1427. 
Stephens, K.E., lshizaka, A., Larrick, J.W., and Raffin, T.A. (1988). Tumor necrosis factor 
causes increased pulmonary permeability and edema. American Review of Respiratory 
Diseases 13 7, 1364-13 70. 
Stevens, A. and Lowe, J.S. (1992). Digestive Tract. In Histology. London: (Gower), pp. 
169-170. 
Streb, H., lrvine, R.F, Berridge, M.J., and Schulz, I. ( 1983). Release ofCa2+ from a 
nonmitochondrial intracellular store in pancreatic acinar cells by inositol-1 ,4,5-triphosphate. 
Nature 306, 67-68. 
Stuber, F., Petersen, M , Bokelmann, F., and Schade, U_ ( 1996a). A genomic polymorphism 
within the tumor necrosis factor locus influences plasma tumor necrosis factor-a 
concentrations and outcome of patients with severe sepsis. Crit Care Med 24, 381-384. 
Stuber, F., Udalova, I.A., Book, M., Drutskaya, L.N., Kuprash, D. V., Turetskaya, R.L., 
Schade, U., and Nedaspasov, S.A. (1996b). -308 tumor necrosis factor (TNF) 
polymorphism is not associated with survival in severe sepsis and is unrelated to 
lipopolysaccharide inducibility of the human TNF promoter. Journal oflntlammation 46, 
42-50. 
Sullivan, K.E., Wooten, C., Schmeckpeper, B.J., Goldmann, D., and Petri, M.A. (1997). A 
promoter polymorphism oftumor necrosis factor alpha associated with systemic lupus 
erythematosus in African-Americans. Arthritis rheum 40, 2207-2211. 
Sullivan, K.E., Wooten, C., Schmeckpeper, B.J., Goldmann, D., and Petri, M.A. ( 1997). A 
promoter polymorphism oftumor necrosis factor alpha associated with systemic lupus 
erythematosus in African-Americans. Arthritis rheum 40, 2207-2211. 
Suzuki, K., Uchida, A., Yasuhiko, M, and Fukunaga, T. (1994). A study on ADH2 
gena typing by PCR-RFLP and SSCP analyses with description of allele and genotype 
frequencies in Japanese, Finn, and Lapp populations. Alcohol & Alcoholism 29, 21-27_ 
Sweiry, J.H. and Mann, G.E. (1996). Role of oxidative stress in the pathogenesis of acute 
pancreatitis. Scand J Gastroenterol S2 19, 10-15. 
Takahashi, A., Nanako, M., Mashiko, S., and lnaba, H. ( 1990)_ The first observation of 0 2-
generation in in situ lungs of rats treated with drugs to induce experimental acute 
respiratory distress syndrome. FEBS Lett 261, 369-3 72_ 
Talvik, R., Liigant, A, Sissak, H.M, and O'Konnel-Bronina, N. (1977). Respiratory failure 
in acute pancreatitis. Intensive Care Med 3, 97-98. 
Tan, J.C., Braun, S., Rang, H., and et al (1995). Characterisation ofrecombinant 
extracellular domain of human interleukin-1 0 receptor. J Bioi Chem 2 70, 12906-12911_ 
Tanaka, F., Shiratori, Y., Yokosuka, 0., Imazeki, F., Tsukada, Y., and Omata, M. (1996) 
419 
high incidence of ADH2 *I I ALDH2 * I genes among Japanese alcohol dependents and 
patients with alcoholic liver disease. Hepatology 23, 234-239. 
Tanaka, K., Murata, A., Uda, K., Toda, H., Kato, T., Hayashida, H., Matsuura, N., and 
Mori, T. (1995). lnterleukin-1 receptor antagonist modifies the changes in vital organs 
induced by acute necritizing pancreatitis. Critical Care Medicine 23, 901-908. 
Tarlow, J.K., Blakemore, A.I.F., Lennard, A., Solari, R., Hughes, H.N., Steinkassrer, A., 
and Duff, G. W. (1993). Polymorphism in human IL-l receptor antagonist gene intron 2 is 
caused by variable numbers of an 86-bp tandem repeat. Hum Genet 91, 403-404. 
Thompson, S.R., Hendry, W.S., McFarlane, G.A., and Davidson, A.I. (1987). 
Epidemiology and outcome of acute pancreatitis. British Journal of Surgery 74, 398-40 I. 
Thomson, B.M., Mundy, G.R., and Chambers, T.J. (1987). Turner necrosis factors? and? 
induce osteoblastic cells to stimulate osteoclastic bone resorption. J lmrnunol 138, 775-779. 
Tiwari, J.L. and Terasaki, P I. ( 1985}. Data and Statistical Analysis. In HLA and Disease 
Associations. J.L. Tiwari and P.I. Terasaki, eds. (New York: Springer Verlag), pp. 18-27. 
Todd, J.A, Bell, J.I., and McDevitt, H.O. (1987). HLA-DQB gene contributes to 
susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 329, 599-604. 
Tomaszwska, R., Dembiniski, A, Warzecha, Z., Banas, B., Konturek, S.J., and Stachura, J. 
(1992). Platelet activating factor inhibitor (TCV-309) reduces caerulin and PAF induced 
pancreatitis; a morphologic and functional study in the rat. J Physiol Pharmacal 4, 345-352. 
Toyama, M.T., Patel, A.G., Nguyen, T., Ashley, S.W., and Reber, H.A. (1997). Effect of 
ethanol on pancreatic interstitial pH and blood flow in cats with chrionic pancreatitis. 
Annals of Surgery 225, 223-228. 
Tracey, K.J., Beutler, B., Lowry, S.F., Merryweather, J., Wolpe, S., Milsark, l.W., Hariri, 
R.J., Fahey Ill, T., Zentella, A, Albert, J.D., Shires, G.T., and Cerami, A (1986). Shock 
and tissue injury induced by recombinant human cachectin. Science 234, 470-474. 
Tracey, K.J., Fong, Y., and Hesse, D.J. (1987). Ant-cachectin/TNF monoclonal antibodies 
prevent septic shock during lethal bacteraemia. Nature 330, 662-664. 
Tracey, K.J., Vlassara, H., and Cerami, A. (1989). Cachectin/Tumour necrosis factor. 
Lancet I 122-112 5. 
Trapnell, I.E. and Duncan, E.H.L. ( 1975). Patterns of incidence in acute pancreatitis. 
British Medical Journal 2, 179-183. 
Trinchieri, G. (1997). Cytokines acting on or secreted by macrophages during intracellular 
infection. Current Opinion in Immunology 9, 17-23. 
Trowsdale, 1. and Camp bell, R.D. ( 1998). The 12th International MHC map. In Genetic 
diversity ofHLA and functional and medical implication. D. Charron, ed. (Paris: EDK), pp. 
8-12. 
Tsukahara, Y., Horita, Y., Anan, K., Morisaki, T., Tanaka, M., and Torisu, M. (1996). 
Role of nitric oxide derived from alveolar macro phages in the early phase of acute 
pancreatitis. Journal of Surgical Research 66, 43-50. 
Tsutsumi, M., Takada, A, and Wang, J. ( 1994). Genetic polymorphisms of cytochrome 
P4502EI related to the development of alcoholic liver disease. Gastroenterology 107, 1430-
1435. 
Turner, D.M., Williams, D.M., Sankaran, D., Lazarus, M., Sinnott, P.J., and Hutchinson, 
I.V. (1997). An investigation ofpolymorphism in the Interleukin-10 gene promoter. 
European Journal oflmmunogenetics 24, 1-8. 
420 
Udalova, l.A., Nedaspasov, S.A., Webb, G.C., Chaplin, D.D., and Turetskaya, R.L. (1993). 
Highly informative typing of the human TNF locus using six adjacent polymorphic markers. 
Genomics 16, 180-186. 
Udalova, I.A., Nedaspasov, S.A., Webb, G.C., Chaplin, D.D., and Turetskaya, R.L. (1993). 
Highly informative typing of the human TNF locus using six adjacent polymorphic markers. 
Genomics 16, 180-186. 
Uhrberg, M., Valiante, N.M., Shum, B.P., Shilling, H.G., Lienert-Weidenbach, K., Corliss, 
B., Tyan, D., Lanier, L.L., and Parham, P. ( 1997). Human diversity in killer cell inhibitory 
receptor genes. Immunity 753-763. 
Van der Poll, T., Jansen, P.M., Montegut, W.J., and et al (1997). Effects oflnterleukin-1 0 
on systemic inflammatory responses during sublethal primate endotoxaemia. J Immunol 
158, 1971-1975. 
Van der Poll, T., Van Deventer, S.J.H., Hack, C.E., Wolbink, G.J., Aarden, L.A, Buller, 
H.R., and ten Cate, J.W. (1992). Effects on leukocytes following injection oftumor necrosis 
factor into healthy humans. Blood 79, 693-698. 
Van Deventer, S.J.H., Hart, M., Van der Poll, T., Hack, C.E., and Aarden, L.A. (1993). 
Endotoxin and TNF-induced IL-8 release in humans. Journal oflnfectious Diseases 167, 
461-464. 
van Dissel, J.T., van Langevelde, P., Westendorp, R.G.J., Kwappenberg, K., and Frolich, 
M. ( 1998). Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 351, 
950-953. 
Van Laethem, J., Marchant, A, Delvaux, A, and et al (I 995). Interleukin-1 0 prevents 
necrosis in murine experimental acte pancreatitis. Gastroenterology 108, 1917-1922. 
Vejans, G.M.G.M., Brinkman, B.M.N., Van Doomik, C.E.M., and Kijlstra, A (1994). 
Polymorphism of tumour necrosis factor-alpha (TNF-?) at position-308 in relation to 
ankylosing spondylitis. Clin Exp Immunol 97, 45-47. 
Vejans, G.M.G.M., Brinkman, B.M.N., Van Doornik, C.E.M, and Kijlstra, A. (1994). 
Polymorphism of tumour necrosis factor-alpha (TNF-?) at position-308 in relation to 
ankylosing spondylitis. Clin Exp lmmunol 97, 45-47. 
V enable, M.E., Zimmermann, G.A., Mclntyre, T.M, and Prescott, S.M. (1993). Platelet 
activating factor: a phospholipid autacoid with diverse actions. Journal of Lipid Research 
34, 691-702. 
Vinasco, J., Beraun, Y., Nieto, A, Fraile, A, Mataran, L., Pareja, E., and Martin, J. (1997). 
Polymorphism at the TNf loci in rheumatoid arthritis. Tissue Antigens 49, 74-78. 
Vinasco, J., Beraun, Y., Nieto, A., Fraile, A, Mataran, L., Pareja, E., and Martin, J. ( 1997). 
Polymorphism at the TNfloci in rheumatoid arthritis. Tissue Antigens 49, 74-78. 
Wang, N., O'Brien, L., and Brindley, D.N. (1998). Effects of cell-permeable ceramides and 
tumor necrosis factor-a on insulin signaling and glucose uptake in 3T3-Ll adipocytes 
Diabetes 47, 24-31. 
Wang, X.D., Deng, X.M., Haraldsen, R., and et al (1995) Antioxidant and calcium 
channnel blockers counteract endothelial barrier injury induced by acute pancreatitis in rats. 
Scand J Gastroenterol 30, 1129-1136. 
Ward, J.B., Peterson, O.H, Jenkins, S.A., and Sutton, R. (1995) Is an elevated 
concentration of acinar cytosolic free calcium the trigger for acute pancreatitis. Lancet 346, 
1016-1019. 
421 
Watanebe, 0., Baccino, F.M., Steer, M.L., and Meldolosi, J. (1984). Supramaximal 
caerulein stimulation of the ultrastructure of rat pancreatic acinar cell: early morphological 
changes during the development of experimental pancreatitis. American Journal of 
Physiology 246, G457-G467. 
Weber, J.L. and May, P.E. (1989). Abundant class ofhuman DNA polymorphisms which 
can be typed using the polymerase chain reaction. Am J Hum Genet 44, 388-386. 
Wedgwood, K.R, Adler, G., Kern, H., and Reber, H.A. (1986). Effects of oral agents on 
pancreatic duct permeability: a model of acute alcoholic pancreatitis. Dig Dis Sci 31, 1081-
1088. 
Weidenbach, H., Lersch, M.M., Gross, T.M., and et al (1995). Vasoactive mediators and 
the progression from oedematous to necrotising experimental acute pancreatitis. Gut 37, 
434-440. 
Weiser, M.R., Gibbs, S.A.L., Moore, F.D., and Hechtman, H.B. (1996). Complement 
inhibition by soluble complement receptor type I fails to moderate cerulein-induced 
pancreatitis in the rat. International Journal ofPancreatology 19, 129-134. 
Weissensteiner, T. and Lanchbury, J.S. (1997). TNFB polymorphisms characterize three 
lineages ofTNF region microsatellite haplotypes. Immunogenetics 47, 6-16. 
Weissensteiner, T. and Lanchbury, J.S. (1997). TNFB polymorphisms characterize three 
lineages ofTNF region microsatellite haplotypes. Immunogenetics 47, 6-16. 
Werner, J., Laposata, M., Fernandez-del-castillo, C., Saghir, M, Iozzo, RV., 
Lewandrowski, K.B., and Warshaw, A.L. (1997a). Pancreatic injury in rats induced by fatty 
acid ethyl ester, a nonoxidative metabolite of alcohol. Gastroenterology 113, 286-294. 
Werner, J., Rivera, J., and Fernandez-del-castillo, C. (1997b). Differing roles of nitric oxide 
in the pathogenesis of acute edematous versus necrotising pancreatitis. Surgery 121, 23-30. 
Westendorp, R.G.J., Langermans, J.A.M., Huizinga, T.W.J., and et al (1996). Genetic 
influence on cytokine production and fatal meningococcal disease. Lancet 349, 170-173. 
Westendorp, R G.J., Langermans, J.A.M., Huizinga, T.W.J., and et al (1996). Genetic 
influence on cytokine production and fatal meningococcal disease. Lancet 349, 170-173. 
Whitcomb, D. C., Gorry, M.C., Preston, R.A., Furey, W., Sossenheimer, M.J., Ulrich, CD., 
Martin, S.P., Gates, L.K., Arnann, S.T., Toskes, P.P., Liddle, R., McGrath, K., Uomo, G., 
Post, J.C., and Ehrlich, G.D. (1996a). Hereditary pancreatitis is caused by a mutation in the 
cationic trypsinogen gene. Nature Gen 14, 141-145. 
Whitcomb, D.C., Preston, R.A., Aston, C.E, Sossenheimer, M.J., Barua, P.S., Zhang, Y., 
Wong-Chong, A., White, G.J., Wood, P.G., Gates, LK, Ulrich, C.D., Martin, S P., Post, 
J.C., and Ehrlich, G.D. (1996b). A gene for herdeditary pancreatitis maps to chromosome 
7q35. Gastroenterology 110, 1975-1980. 
Widdison, A.L. and Cunningham, S. (1996). Immune function early in acute pancreatitis. Br 
J Surg 83, 633-636. 
Widdison, A.L., Karanjia, N.D., Alvarez, C., and Reber, H.A. (1992). Influence of 
levimasole on pancreatic infection in acute pancreatitis. American Journal of Surgery 163, 
I 00-104. 
Widdison, A.L., Karanjia, N.D., and Reber, H.A. (1994). Routes of spread of pathogens 
into the pancreas in a feline model of acute pancreatitis. Gut 35, 1306-1310. 
Wilson, A. G., de Vries, N., Poicot, F., di Giovine, F.S., van der Putte, L.B.A., and Duff, 
G.W. (1993). An allelic polymorphism within the human tumour necrosis factor? promoter 
422 
region is strongly associated with HLA AI, B8, and DR3 alleles. Journal ofExperimental 
Medicine 177, 557-560. 
Wilson, A.G., de Vries, N., Poicot, F., di Giovine, F.S., van der Putte, L.B.A., and Duff, 
G.W. (1993). An allelic polymorphism within the human tumour necrosis factor? promoter 
region is strongly associated with HLA A 1, B8, and DR3 alleles. Journal of Experimental 
Medicine 177, 557-560. 
Wilson, A. G., de Vries, N., van der Putte, L.B., and Duff, G.W. (1995). Atumour necrosis 
factor polymorphism is not associated with rheumatoid arthritis. Ann Rheum dis 54, 601-
603. 
Wilson, A. G., Symons, J.A., McDowell, T.L., McDevitt, HO., and Duff, GW. (1997). 
Effects of a polymorphism in the human tumor necrosis factor ? promoter on transcriptional 
activation. Proc. Natl. Acad. Sci. USA 94, 3195-3199. 
Wilson, C. and lmrie, C. W ( 1990). Changing patterns of incidence and mortality from 
acute pancreatitis in Scotland, 1961-1985. British Journal of Surgery 77, 731-734. 
Wilson, C., lmrie, C.W., and Carter, D.C. (1988). Fatal acute pancreatitis. Gut 29, 782-788. 
Wilson, J.S, Bernstein, L., McDonald, C., Tait, A., McNeil, D., and Pirola, R.C. (1985). 
Diet and drinking habits in relation to the development of alcoholic pancreatitis. Gut 26, 
882-887. 
Wilson, J.S., Gossat, D., Tait, A., Rouse, S., Jeng Juan, X, and Pirola, R.C. (1984). 
Evidence for an inherited predisposition to alcoholic pancreatitis; a controlled HLA typing 
study. Dig Dis Sci 29, 727-730. 
Wilson, J.S., Korsten, M.A., Leo, M.A., and Lieber, C.S. (1988). Combined effects of 
protein deficiency and chronic ethanol consumption on rat pancreas. Digestive Diseases and 
Sciences 33, 1250-1259. 
Wisner, 1. and Renner, I.G. (1988). Allopurinol attenuates caerulein induced acute 
pancreatitis in the rat. Gut 29, 926-929. 
Wisner, J., Green, D., Ferrell, L., and et al ( 1988). Evidence for a role of oxygen free 
radicals in the pathogenesis of caerulein induced acute pancreatitis in rats. Gut 29, I 5 16-
1523. 
Wolf, E., Spencer, KM., and Cudworth, A. G. ( 1983). The genetic susceptibility to type I 
(insulin-dependent) diabetes: analysis of the HLA-DR association. Diabetologia 24, 224-
230. 
Wucherpfennig, KW. and Strominger, J.L. (1995). Molecular mimicry in T cell mediated 
autoimmunity viral peptides activate human T cell clones specific for myelin basic protein. 
Cell 80, 695-705. 
Yamaguchi, H., Weidenbach, H., Luhrs, H., Lerch, M.M., Dickneite, G., and Adler, G. 
( 1997). Combined treatment with C I esterase inhibitor and antithrombin III improves 
survival in severe acute experimental pancreatitis. Gut 40, 531-535. 
Yamaguchi, M., Maezawa, Y., Toda, G., Suzuki, H., and Sakurai, S. (1995). Association of 
a restriction fragment length polymorphism in the alcohol dehydrogenase 2 gene with 
Japanese alcoholic cirrhosis. J Hepatol 23, 519-523. 
Yamanaka, K., Saluja, A., Brown, G.E., Yamaguchi, Y., Hofbauer, B., and Steer, M.L. 
( 1997). Protective effects of prostaqglandin E 1 on acute lung injury of caerulein induced 
acute pancreatitis in rats. Am J Physiol 272, G23-G30. 
Yotsumoto, F., Manabe, T., and Ohshio, G. (1993). Bradykinin involvement in the 
423 
aggravation of acute pancreatitis in rats. Digestion 54, 224-230. 
Yotsumoto, L, Manabe, T., Kyogoku, T., Hirano, T., Ohshio, G., Yamamoto, M., 
Imamura, T., and Yoshitomi, S. (1994). Platelet activating factor involvement in the 
aggrevation of acute pancreatitis in rabbits. Digestion 55, 260-267. 
Zemmour, J., Koller, B.H., Ennis, P.D., Geraghty, D.E., Lawlor, D.A., Orr, H.T., and 
Parham, P. (1990). HLA-AR, an inactivated antigen-presenting locus related to HLA-A. J 
Immunol 144, 3619-3629. 
Zhou, W., McCollum, M.O., Levine, B.A., and et al (1992). Role ofplatelet activating 
factor in pancreatitis associated lung injury in the rat. American Journal of Pathology 140, 
971-979. 
424 
